VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 18 (1-17 agosto/2025)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el ojetivo de serle útil.

Usted puede realizar sugerencias sobre los contenidos y de esa forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.
- Patentes más recientes en USPTO.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

Noticias en la Web

Pasteur Institute, Nagasaki University step up disease prevention collaboration

Aug 1. The Pasteur Institute in Ho Chi Minh City and Nagasaki University of Japan, both leading facilities in tropical medicine and infectious diseases in their respective countries, have signed a memorandum of understanding (MoU) to strengthen cooperation in key areas such as epidemiological surveillance capacity building, vaccine development, and response to both existing and emerging diseases.

Associate Professor Dr. Nguyen Vu Trung, Director of the Pasteur Institute, said that under the MoU, the two sides committed to promoting diverse and practical collaborative activities. These include joint conferences and workshops, exchanges of scholars, researchers and students, sharing academic materials, and the development of specific programmes and projects in scientific research, training, and epidemic prevention.

Witnessing the signing ceremony, Nguyen Ngo Quang, Director of the Administration of Science, Technology and Training under the Ministry of Health, suggested that the institute quickly draft a first-year action plan focused on readily implementable items such as short-term expert exchanges, bilateral workshops, and joint research group connections. Additionally, it should proactively seek and mobilise resources from international research support programmes and bilateral or multilateral funding organisations to ensure the financial sustainability of the cooperation.

Masuo Ono, Consul General of Japan in the southern metropolis, emphasised the importance of preventive medicine in preventing outbreaks and the transmission of infectious diseases. He highlighted its role in protecting lives, public health, and ensuring societal stability and prosperity. He expressed his hope that the agreement would strengthen efforts to control infectious diseases in Vietnam and around the world.

Notably, the two institutions have engaged in research and training cooperation since 2004.

Fuente: Vietnam Plus. Disponible en https://n9.cl/ifsx65

70% enrolment of participants for Phase III clinical trial of dengue vaccine completed: Centre

Aug 1. India achieves a milestone in dengue prevention. The DengiAll vaccine trial sees 70% participant enrollment. ICMR leads the multi-center study across 20 Indian sites. The budget is approximately Rs 1.3 to 1.5 crore per site. Dengue cases are rising, with over 5 lakh confirmed in 2024. The government monitors outbreaks and provides support to states.

"The trial involves over 10,000 participants, out of which more than 70 per cent enrolment has been completed. The trial has been implemented in 20 sites across India." Prataprao Jadhav

Seventy percent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, told Lok Sabha on Friday.

The Indian Council of Medical Research (ICMR) has undertaken a clinical trial titled phase III, multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy, immunogenicity and safety of the single-dose Dengue Tetravalent vaccine, live attenuated (Recombinant, Lyophilised) - 'DengiAll', Jadhav said in a written reply.

The sites are JSS Medical College and Hospital, Mysuru (Karnataka), Bangalore Medical College and Research Institute, and All India Institute of Medical Sciences, Bibinagar (Telangana).

The approximate budget for the trial is Rs 1.3 to 1.5 crore per site, Jadhav said.

According to ICMR, there is no specific antiviral treatment or licensed vaccines for dengue and the treatment is supportive in nature, Jadhav said.

A total of 5,73,563 laboratory confirmed dengue cases were reported through the Integrated Health Information Platform (IHIP) in 2024, according to information shared by the National Centre for Disease Control (NCDC).

According to ICMR, all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV -4) are known to circulate and co-circulate in India.

Multiple serotypes can be present in the same geographical region and can even infect the same individual at the same time.

Hence, participants have been enrolled in the ICMR vaccine trial from different zones where these four serotypes circulate in order to test the efficacy of the vaccine against all four serotypes, Jadhav said.

The minister also said that the Union Health Ministry, Director General of Health Services, and National Centre for Vector Borne Disease Control (NCVBDC) regularly monitor the situation of dengue outbreaks across the country for assessing the disease situation, preparedness, technical guidance and to sensitise and forewarn the states.

Under the National Health Mission, adequate budgetary support is provided to states and Union territories for dengue control activities such as epidemic preparedness, monitoring, case management, vector control (provision of domestic breeding checkers, ASHA involvement, insecticide, fogging machines), training, intersectoral convergence, awareness activities, etc.

For surveillance and free of cost diagnosis of dengue, Sentinel Surveillance Hospitals with laboratory facility and Apex Referral laboratories with advance diagnostic facilities have been identified across the country, Jadhav said.

The government of India has developed national guidelines on dengue treatment/management, in consultation with experts, which have been shared with all the states and UTs for implementation.

The guidelines emphasise the preparedness of hospitals for case treatment/management.

In addition, advisories have been issued from time to time to states/ UTs for prevention and control of dengue, including case management, the minister said.

Fuente: The Economic Times. Disponible en https://n9.cl/ldgvbq

RSV vaccine 82 per cent effective in preventing hospitalisation in older people

Aug 1. A study on the effectiveness of RSV vaccines published yesterday by the UK Health Security Agency (UKHSA) claims they are 82 per cent effective in preventing people aged 75 to 79 from being admitted to hospital with infection.

The study, conducted alongside Nottingham University Hospitals and other NHS trusts, also revealed RSV vaccines are “highly effective” in preventing older people with a chronic respiratory condition and those living with immunosuppression from hospitalisation.

In April, NHS England said it would increase the number of pharmacies taking part in its respiratory syncytial virus vaccines pilot from 50 to as many as 200 in 2025-26.

Twenty-five pharmacies in Mid and South Essex and North-East Essex integrated care boards were commissioned to provide the vaccine in August last year, shortly before two RSV vaccination schemes, one for older adults and a maternal programme, were introduced to the NHS vaccination schedule.

Under the scheme for older adults, people turning 75 can get vaccinated and there is a “one-off catch-up campaign” for adults aged 75 to 79.

The maternal vaccination programme is offered to women from 28 weeks of pregnancy to protect newborns at higher risk of severe illness from RSV.

Another study, Vaccination in Pregnancy and RSV Hospitalisation in Infants in the UK, published in *The Lancet Child and Adolescent Health*, found the maternal RSV vaccine was 72 per cent effective in preventing infants needing hospital treatment when their mothers were vaccinated over 14 days before delivery.

According to the UKHSA, the older adults programme reached 62.9 per cent of people as of 30 June 2025, an increase on 60.3 per cent in March, while 20,051 of 36,657 women who gave birth in March this year received an RSV vaccine.

The UKHSA said the highest vaccine maternal coverage was among the Chinese ethnic group at 73.3 per cent while the lowest was among black and black British Caribbean women at 26.4 per cent.

Fuente: Pharmacy Magazine. Disponible en https://n9.cl/0aita0

mRNA Technology Shows Early Progress in Developing HIV Vaccines Targeting Diverse Virus Variants

Aug 1. Recent studies have demonstrated early progress in the development of mRNA-based HIV vaccines, addressing longstanding challenges in targeting the virus. Researchers have focused on eliciting neutralizing antibodies capable of binding to and blocking diverse variants of HIV, a critical hurdle that has historically slowed vaccine development efforts.

Neutralizing antibodies are proteins produced by the immune system that play a key role in defending against pathogens such as viruses and bacteria.

The findings suggest that mRNA technology, which has gained prominence in recent years for its role in COVID-19 vaccines, may offer a promising approach to overcoming the complexities associated with HIV's variability. Scientists involved in these studies aim to refine this strategy further to improve its effectiveness across the wide range of HIV strains.

Fuente: GeneOnline. Disponible en https://n9.cl/f637k

Pfizer's Phase 3 Study: Evaluating Co-administration of RSV and Shingles Vaccines

Aug 2. Pfizer Inc. is conducting a Phase 3 study titled 'A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults.' This study aims to assess the safety, tolerability, and immune response of a Respiratory Syncytial Virus (RSV) prefusion F subunit vaccine when administered alongside a herpes zoster subunit vaccine in adults aged 50 and above. The significance of this study lies in its potential to enhance vaccine efficacy and convenience for older adults.

The study is testing two biological interventions: the RSV prefusion F subunit vaccine and the herpes zoster subunit (HZ/su) vaccine. Both are administered via intramuscular injection and are intended to prevent RSV and shingles, respectively.

This interventional study follows a randomized, parallel-group design with no masking, focusing primarily on prevention. Participants are divided into two groups: one receiving both vaccines simultaneously and the other receiving them sequentially.

The study began on April 4, 2025, with primary completion expected shortly thereafter. The latest update was submitted on July 30, 2025. These dates are crucial for tracking the study's progress and anticipating results.

Pfizer's ongoing study could influence its stock performance positively by showcasing its commitment to advancing adult vaccination. This could also impact investor sentiment, especially as the pharmaceutical industry remains competitive with ongoing innovations in vaccine development.

The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.

Fuente: THE GLOBE AND MAIL. Disponible en https://n9.cl/39nl9

Estudio global revela cuántas vidas salvaron las vacunas contra la COVID-19

2 ago. Las vacunas contra COVID-19 evitaron 2,5 millones de muertes, según un nuevo estudio de modelización global.

"Estudio internacional revela el verdadero impacto de las vacunas contra la COVID-19 y expone cifras sorprendentes sobre vidas salvadas en todo el mundo."

Entre diciembre de 2020 y finales de 2024 se administraron alrededor de 13.600 millones de dosis de vacunas contra COVID-19 en todo el mundo.

Es decir, por 5.400 dosis de vacunas administradas, se evitó una muerte, precisó en un artículo el doctor John Ioannidis, profesor de medicina y epidemiología de la Universidad de Stanford, y sus coautores. Se tomaron estimaciones de la tasa de mortalidad por COVID-19 y la eficacia de las vacunas contra la mortalidad y las introdujeron en modelos para tratar de averiguar cuántas muertes se evitaron gracias a la vacunación.

Los datos oficiales sobre el número de personas fallecidas a causa de la COVID-19 ascienden a más de siete millones de personas en el mundo (7.083.769 en informe de la OMS del 5 de enero de 2025), aunque la ONU habla de una cifra varias veces superior: al menos 20 millones.

La Organización Mundial de la Salud (OMS), lideró el extenso estudio que demuestra lo que por años han defendido los expertos: la vacunación es uno de los mayores avances en salud pública. Según el informe, entre 1974 y 2024, las vacunas salvaron al menos 154 millones de vidas en el mundo.

Esto equivale a seis vidas salvadas por minuto durante cinco décadas, una cifra que subraya el poder transformador de la inmunización, especialmente en los países en desarrollo.

Los más beneficiados con vacunas: niños menores de cinco años

Del total de vidas salvadas, la mayoría correspondió a niños menores de cinco años, el grupo más vulnerable a enfermedades prevenibles como el sarampión, la difteria o la tosferina.

El estudio destaca que, sin acceso a vacunas, millones de familias en todo el mundo habrían enfrentado tragedias evitables. La inmunización ha sido especialmente crítica en regiones de África, Asia y América Latina.

El sarampión, la vacuna con mayor impacto

Entre todas las vacunas, la que tuvo el mayor impacto fue la del sarampión, responsable de alrededor del 60% de las vidas salvadas, según el reporte. Esta enfermedad altamente contagiosa ha sido controlada en gran parte del mundo gracias a programas masivos de inmunización infantil.

"Las cifras hablan por sí solas. Vacunar no solo protege al individuo, sino que salva comunidades enteras", indicó un vocero de la OMS.

Riesgos sí existen, pero los beneficios superan con creces

El informe también reconoce que, como cualquier medicamento, las vacunas pueden tener efectos secundarios. Sin embargo, recalca que los beneficios superan ampliamente los riesgos, y que los sistemas de salud deben seguir fomentando la vacunación segura y equitativa.

Los expertos insisten en que los casos graves por reacciones adversas son extremadamente raros, y que evitar las vacunas puede poner en riesgo tanto al individuo como a su entorno.

Un llamado global a mantener y ampliar la cobertura en vacunación: OMS

La OMS hizo un llamado a mantener e incluso ampliar la cobertura de vacunación, especialmente en un

contexto en el que los movimientos antivacunas y la desinformación amenazan con revertir décadas de progreso.

"Invertir en vacunas es invertir en vida. Es la herramienta más efectiva, equitativa y económica para proteger la salud global", concluyó el estudio.

La OMS defiende el tratado antipandemias

Entre tanto, el tratado global recientemente alcanzado para luchar contra pandemias y las reformas de las regulaciones sanitarias internacionales acordados en 2024 se aprobaron por consenso de los miembros de la Organización Mundial de la Salud (OMS) y no quitan soberanía a los Estados, defendió el director general de la agencia, Tedros Adhanom Ghebreyesus, en respuesta a recientes críticas desde EE.UU. e Italia.

"La OMS no tiene autoridad para decir a los países lo que deben hacer, no podemos imponerles limitaciones a los viajes, confinamientos, vacunaciones o cualquier otra medida", aclaró el director general en rueda de prensa el pasado miércoles.

Fuente: Vanguardia. Disponible en https://n9.cl/5jqtg

Stanford Medicine: laboratorios con "científicos virtuales" diseñan soluciones biomédicas en días

Aug 2. Un equipo de investigadores de Stanford Medicine creó "científicos virtuales" que colaboran en laboratorios digitales para resolver desafíos biológicos, logrando en pocos días avances como el diseño de candidatos innovadores para vacunas contra variantes recientes de COVID-19. Anticipo del futuro en el que la IA acelera y multiplica los descubrimientos científicos.

La colaboración interdisciplinaria está en el corazón del progreso científico, pero organizar equipos de expertos, coordinar ideas y avanzar a gran escala sigue siendo un enorme reto. Ahora, investigadores de Stanford Medicine liderados por James Zou, PhD, han puesto a prueba una solución disruptiva: laboratorios virtuales impulsados por inteligencia artificial, capaces de simular la dinámica y el ingenio de los mejores equipos humanos, pero trabajando sin descanso ya una velocidad inalcanzable para las personas.

"Las grandes innovaciones ocurren cuando personas de diferentes disciplinas colaboran, pero forman esos equipos y consiguen sinergia es uno de los mayores cuellos de botella de la investigación", explicó Zou, quien se dirigió al estudio publicado el 29 de julio en *Nature*.

"Hemos visto enormes avances en los agentes de IA capaces de actuar proactivamente, colaborar entre sí y con humanos en lenguaje natural. Eso nos animó a entrenar estos modelos para pensar y debatir como científicos top, buscando soluciones novedosas a grandes problemas."

¿Cómo funciona el laboratorio virtual?

El laboratorio virtual de Stanford se modela como un auténtico grupo de investigación, con un investigador principal de IA (IA PI), que recibe un reto científico y decide qué otros "agentes científicos" de IA sumarán, asignando roles como inmunología, biología computacional, machine learning y un crítico encargado de identificar fallas o posibles sesgos.

A cada paso, los agentes pueden hacer uso de herramientas especializadas —como AlphaFold para modelado de proteínas— y hasta solicitar acceso a nuevos softwares, que los investigadores humanos incorporan de acuerdo a las necesidades del equipo virtual.. Las reuniones, en vez de durar horas, se resuelven en segundos; Además, el grupo realiza decenas de sesiones simultáneas. Sin microgestión, la intervención humana es mínima (alrededor de 1%), oscilando entre límites presupuestarios y validaciones iniciales del desafío. Todo el proceso queda automáticamente registrado, permitiendo a los investigadores monitorear el avance y redireccionar el trabajo cuando sea necesario.

Resultados: IA resuelve en días lo que antes tomaba meses

Para probar la eficacia del laboratorio virtual, el equipo de Stanford encargó el diseño de una estrategia para una vacuna contra las variantes recientes del SARS-CoV-2. Mientras la solución habitual habría sido anticuerpos tradicionales, el equipo de IA se sorprendió proponiendo nanocuerpos: fragmentos más pequeños, simples de modelar y potencialmente más fáciles de producir a escala.

“Desde el inicio, los científicos virtuales decidieron que los nanocuerpos eran más prometedores que los anticuerpos. Argumentaron que, al ser más pequeños, aumentaban la confianza en el modelado y diseño computacional de proteínas”, explicó Zou. El equipo diseñó 92 nuevos nanocuerpos; Tras su síntesis en el laboratorio real del coautor John Pak en Chan Zuckerberg Biohub, comprobaron que más del 90% eran funcionales y solubles. Dos de ellos sobresalieron al unirse con alta afinidad a cepas recientes del virus y también a la variante de Wuhan, clave para una vacuna de amplio espectro.

“Lo que era una idea de ciencia ficción ahora es real: los agentes de IA propusieron una estrategia creativa, razonable y muy rápida. Y los experimentos validaron su efectividad”, resaltó Pak.

Más allá de la COVID-19: ciencia acelerada, nuevas preguntas

La versatilidad del laboratorio virtual es enorme: tras el éxito con el SARS-CoV-2, los investigadores planean explorar otros desafíos biomédicos y crear agentes especializados en análisis de datos complejos, capaces de reevaluar investigaciones previas y formular nuevas hipótesis.

“Muchas veces la IA propone hallazgos más allá de lo publicado por humanos. Esto es tremendamente talentoso para toda la comunidad científica”, afirmó Zou.

Para Pak, lejos de reemplazar a los investigadores, la IA potenciará su productividad: “La IA nos dio más trabajo, porque sugirió más hipótesis para evaluar. Si puede proponer ideas testables, todos ganamos”.

El futuro de la investigación, hoy

El estudio, financiado por becas de la Knight-Hennessy y Stanford Bio-X, ilustra cómo los laboratorios virtuales —combinando IA generativa, modelado estructural y participación humana— pueden multiplicar la capacidad y velocidad de la ciencia moderna. Los responsables de la investigación prevén que esta metodología se expanda en áreas como el desarrollo de fármacos, medicina personalizada y análisis de nuevas enfermedades.

Los datos, los entrecomillados y los resultados experimentales ya hablan por sí mismos: la colaboración entre humanos e "investigadores virtuales" puede marcar un antes y un después en la carrera por los grandes descubrimientos de la biomedicina.

Fuente: CURE COMPASS. Disponible en https://n9.cl/zyotj

Seven more strains covered

Aug 3. Malaysians can now be protected against 20 strains of the bacteria *Streptococcus pneumoniae*, which causes pneumonia.

"As pneumococcal bacterial strains continue to evolve, scientists race to update vaccines for more protection."

This follows the recent announcement that the Health Ministry has approved the 20-valent pneumococcal conjugate vaccine (PCV20) by American pharmaceutical company Pfizer.

This new vaccine offers protection against an additional seven serotypes of *S. pneumoniae*, also known as pneumococcus, compared to its 13valent predecessor (PCV13).

These include newer strains associated with antibiotic resistance and high death rates.

Professor Dr Mark van der Linden, who heads the national reference centre for Streptococci in Germany, notes that scientists have been racing to keep up with the evolving strains of pneumococcus.

"There are currently 107 known serotypes.

"We're not creating new ones; they evolve naturally.

"Pneumococcus reproduces every 30 minutes, so it adapts far faster than humans," he shares.

The first conjugate vaccine, which was developed specifically for use in young children, targeted the seven serotypes that caused the majority of pneumococcal disease.

This 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in Malaysia over two decades ago.

As vaccination reduced these strains, others emerged – a process called serotype replacement.

"We saw a 40% drop in cases, but new strains emerged.

"That's why vaccines must continuously evolve.

"We can't cover all 107, but expanding coverage is essential, especially for high-risk groups," says Prof van der Linden.

Meanwhile, consultant clinical microbiology and infection physician Dr Teresa Wang Kin Fong from Hong Kong explains that based on data from the Chinese territory, invasive pneumococcal disease is now more common among adults than children.

"We used to give adults the polysaccharide vaccine PPV23, but it had limited effectiveness.

"Pfizer later developed PCV7, and at one point, we [in Hong Kong] implemented a combined adult programme using both PPV23 and PCV7.

"Now with PCV20, we can skip PPV23 entirely.

"PCV20 offers broader protection and simplifies the process to a single dose, making it more convenient for patients and doctors alike."

In Malaysia, vaccine uptake among adults remains low.

"This is largely due to the outdated perception that vaccines are only for children," notes Malaysian Society of Infectious Diseases and Chemotherapy past president Prof Dr Zamberi Sekawi.

Adults with chronic conditions like diabetes, high blood pressure and lung disease, are especially vulnerable

to developing severe pneumonia, which can be life-threatening.

Vaccinating adults not only protects individuals, but also reduces transmission within households.

“When one family member brings home an infection, the whole household is at risk.

“Vaccinating adults helps break that chain,” Prof Zamberi adds.

This is important as both young children and the elderly are also vulnerable to developing severe pneumonia.

“Children are born with immature immune systems.

“As we age, our immune system weakens – a process called immunosenescence.

“That’s why both groups need the most protection,” says consultant paediatrician Prof Datuk Dr Zulkifli Ismail.

Since the Covid-19 pandemic, parental concerns about vaccination have shifted from cultural or religious questions to fear of side effects.

“I’ve had parents who declined the pneumococcal vaccine, only to return later after their child was hospitalised.

“Sadly, by then it’s too late,” shares Prof Zulkifli.

PCV20 is approved for use in both children and adults starting from the age of six weeks onwards.

Fuente: Press Reader. Disponible en https://n9.cl/x9seh

Korea launches free 20-valent pneumococcal vaccine for children in October

Aug 4. The Korea Disease Control and Prevention Agency announced on 4th that it plans to implement free vaccinations for the 20-valent pneumococcal conjugate vaccine (PCV20) starting from Oct. 1.

The target group includes all infants aged 2 months to under 12 years and high-risk adolescents under 18 years; this is part of the national immunization program (NIP).

Pneumococcus is a major bacterial pathogen that causes various diseases such as otitis media, pneumonia, and meningitis in infants. It can cause invasive infections (Invasive Pneumococcal Disease, IPD) that threaten the lives of immunocompromised children, making vaccination very important.

So far, the national immunization program has supported vaccinations for children with the 13-valent conjugate vaccine (PCV13) and the 15-valent conjugate vaccine (PCV15).

The newly introduced PCV20 received approval from the Ministry of Food and Drug Safety last October. It includes an additional 5 serotypes (8, 10A, 11A, 12F, 15B) on top of the 15 serotypes included in the 15-valent vaccine (PCV15), allowing for protection against a total of 20 serotypes.

For healthy children, the vaccination schedule remains the same: a total of 3 vaccinations at 2, 4, and 6 months, followed by an additional vaccination at 12 to 15 months. Children who have already started vaccination with PCV13 can receive cross vaccination with PCV20. However, if vaccination was started with PCV15, it is recommended to complete the vaccination with the same vaccine.

High-risk children and adolescents who are vulnerable to infections due to immunodeficiency, chronic diseases, or cochlear implants are also eligible for PCV20 vaccination. For high-risk children and adolescents,

the vaccination schedule varies according to their age and previous vaccination history, so they should follow a vaccination schedule that fits their situation. The upper age limit for high-risk children eligible for PCV20 support has been raised from the previous 12 years to 18 years.

Fuente: Chosun Biz. Disponible en https://n9.cl/48c3mv

Co-Administering Dengue and HPV Vaccines Found Compatible

Aug 4. According to the World Health Organization (WHO), Dengue is a viral infection spread to humans by infected mosquitoes and is a leading cause of febrile illness among international travelers.

"Takeda second generation dengue vaccine Qdenga approved in various countries."

Based on the record-setting number of Dengue outbreaks in 2024, the WHO has classified Dengue as a grade 3 emergency, placing about four billion people at risk globally.

In recent years, the development of effective vaccines to prevent Dengue has been an essential factor in the global effort to reduce outbreaks.

Still, strategies to maximize second-generation vaccine coverage in endemic regions are needed.

According to a new study published in the journal Vaccines (Volume 62, August 30, 2025, 127558), dengue-endemic countries, such as the Kingdom of Thailand, have already initiated national Human Papillomavirus (HPV) school-based vaccination programs based on recommendations from the WHO.

These researchers wrote, 'Due to the overlapping age range targeted by many vaccines, including 9vHPV (Merck GARDASIL 9®) and TAK-003 (Takeda's QDENGA®), integration of Dengue vaccination into these existing programs could be a beneficial approach to increase vaccine coverage and reduce operational costs.'

This phase 3, multicenter clinical trial (NCT04313244) demonstrated the non-inferiority (NI) of the immune response to 9vHPV when co-administered with the live-attenuated dengue vaccine, TAK-003, compared with 9vHPV administered alone, with the primary objective was met.

There was no evidence of interaction caused by the live-attenuated vaccine on the virus-like particle-based 9vHPV immunogenicity and safety.

Similarly, these data suggest that co-administration of TAK-003 with HPV does not compromise TAK-003 immunogenicity or safety.

In the co-administration group, an immune response was elicited against each of the four dengue serotypes, with GMTs of anti-dengue NAbs increasing to 494–1691 at M4 post-vaccination.

Participants who had a previous exposure to Dengue (Dengue seropositive at baseline) showed higher post-vaccination GMTs, which can be explained by the presence of immune memory from their prior dengue infection.

As observed in previous studies with TAK-003, almost all participants (99.6%) had tetravalent seropositivity at M4, irrespective of baseline serostatus.

The co-administration of 9vHPV and TAK-003 was well-tolerated, and there was no clinically relevant adverse impact on the safety or reactogenicity, with no AEs leading to vaccine withdrawal or trial discontinuation.

A limitation of this trial is that a TAK-003-only arm was not included, meaning the NI of the TAK-003 immune response could not be directly evaluated after co-administration. One of the reasons behind this design was that the trial was only considered feasible in dengue-endemic regions.

As of August 4, 2025, Thailand's Food and Drug Administration has approved the QDENGA vaccine and over

30 other countries, but not the United States. Currently, the U.S. is evaluating the first-generation Dengue vaccine (Dengvaxia) in children in Puerto Rico.

Note: This phase 3 clinical trial was sponsored by Takeda Vaccines, Inc., Cambridge, MA, USA, the producer of the QDENGA vaccine.

Fuente: VAX-BEFORE-TRAVEL. Disponible en https://n9.cl/yl0d3

China makes significant progress in HIV vaccine development

Aug 4. China's National Center for AIDS/STD Control and Prevention, along with other research teams, has recently completed the Phase I clinical trial of China's first replication-competent Tiantan vaccinia-based AIDS vaccine, marking a major breakthrough in the country's HIV vaccine development efforts, Beijing Daily reported on Monday.

The study innovatively used the Tiantan strain of the vaccinia virus, which was widely used as a smallpox vaccine in China. The trial confirmed the vaccine's safety and its ability to elicit effective immune responses against HIV, according to the report.

AIDS remains one of the major public health challenges facing humanity. Despite progress in antiretroviral therapy and pre-exposure prophylaxis, there are still over a million new HIV infections globally each year.

The research team noted that the high variability of the HIV virus and its ability to attack the immune system pose significant challenges for vaccine development. Globally, over 300 HIV vaccine trials have been conducted, including 11 efficacy trials, most of which have failed to demonstrate protective immune effects.

Compared to replication-defective vectors that provide only transient antigen exposure, replication-competent viral vectors are considered a promising alternative for HIV antigen delivery. Replication-competent vectors, such as adenovirus, vaccinia virus, and cytomegalovirus, have been studied in preclinical and clinical trials.

Against this backdrop, teams from the AIDS Prevention and Control Center under the Chinese CDC, Peking Union Medical College Hospital, and other institutions used the vaccinia virus Tiantan, previously used to eradicate smallpox, as a vector to construct a recombinant vaccine. So far, they have completed a Phase I clinical trial evaluating safety and immunogenicity in 48 healthy participants, Beijing Daily reported.

The study results confirmed the safety of the replication-competent Tiantan vaccinia-based AIDS vaccine in healthy individuals and demonstrated its ability to induce sustained HIV-specific immune responses through this enhanced immunization strategy, laying the foundation for Phase II clinical trials.

Fuente: Global Times. Disponible en https://n9.cl/kd6ih2

Departamento de Salud de EEUU elimina $500 millones para desarrollo de vacunas

5 ago. El Departamento de Salud y Servicios Humanos de Estados Unidos (HHS, por sus siglas en inglés) cancelará contratos y retirará fondos para algunas vacunas en desarrollo contra virus respiratorios como la COVID-19 y la gripe.

El secretario de Salud, Robert F. Kennedy Jr., anunció en un comunicado que se detendrán 22 proyectos, por un valor de $500 millones de dólares, para desarrollar vacunas con tecnología de ARNm.

Es la última de una serie de decisiones que han cristalizado las dudas de RFK Jr. sobre las vacunas en el departamento de salud del país. Kennedy ha retirado recomendaciones sobre las vacunas contra la COVID-19, despidió al panel que hace recomendaciones de vacunas y se negó a ofrecer un respaldo enérgico a las vacunas mientras empeoraba un reciente brote de sarampión en el país.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during an event in the East Room of the White House, Wednesday, July 30, 2025, in Washington. AP Photo/Mark Schiefelbein

El secretario de Salud criticó las vacunas de ARNm en un video en sus cuentas de redes sociales en el que explica la decisión de cancelar proyectos liderados por las principales compañías farmacéuticas del país, incluidas Pfizer y Moderna, que ofrecen protección contra virus como la gripe, COVID-19 y H5N1.

"Para reemplazar los problemáticos programas de ARNm, estamos priorizando el desarrollo de estrategias de vacunas más seguras y amplias, como las vacunas de virus completo y plataformas novedosas que no colapsan cuando los virus mutan", dice Kennedy en el video.

Expertos en enfermedades infecciosas señalan que la tecnología de ARNm utilizada en las vacunas es segura, y atribuyen la ralentización de la pandemia de coronavirus de 2020 al desarrollo de dichas vacunas durante el primer mandato de Donald Trump. Advirtieron que futuras pandemias serán más difíciles de detener sin la ayuda del ARNm.

"No creo haber visto una decisión de salud pública más peligrosa en mis 50 años en el negocio", dijo Mike Osterholm, experto en enfermedades infecciosas y preparación para pandemias de la Universidad de Minnesota.

Señaló que la tecnología de ARNm ofrece ventajas potenciales como su rápida producción, que es crucial en caso de otra pandemia que requiera una nueva vacuna.

El abandono de los proyectos de ARNm es miope en el contexto de que aún hay preocupaciones sobre una pandemia de gripe aviar, dijo el doctor Paul Offit, experto en vacunas del Hospital Infantil de Filadelfia.

"Ciertamente ha salvado millones de vidas", dijo Offit sobre las vacunas de ARNm existentes.

Los científicos están utilizando el ARNm para más que vacunas contra enfermedades infecciosas, pues investigadores de todo el mundo exploran su uso para inmunoterapias contra el cáncer. Este año en la Casa Blanca, el multimillonario empresario tecnológico Larry Ellison elogió el ARNm por su potencial para tratar el cáncer.

Tradicionalmente, las vacunas han requerido cultivar fragmentos de virus, a menudo en huevos de gallina o grandes cubas de células, y luego purificar ese material. La estrategia de vacunas ARNm comienza con un fragmento de código genético que lleva instrucciones para fabricar proteínas. Los científicos eligen la proteína a atacar, inyectan esa instrucción y el cuerpo produce la suficiente para desencadenar la protección inmunitaria, produciendo su propia dosis de vacuna.

En un comunicado el martes, el HHS dijo que "otros usos de la tecnología de ARNm dentro del departamento no se ven afectados por este anuncio".

La tecnología de ARNm se utiliza en las vacunas aprobadas contra la COVID-19 y el VRS, pero aún no ha

sido aprobada para una vacuna contra la gripe. Moderna, que estaba estudiando una combinación de vacuna de ARNm contra la COVID-19 y la gripe, había dicho que creía que el ARNm podría acelerar la producción de vacunas contra la gripe en comparación con las vacunas tradicionales.

Los proyectos de ARNm abandonados son indicio de un "cambio en las prioridades de desarrollo de vacunas", dijo el departamento de salud en su comunicado, agregando que comenzará a "invertir en mejores soluciones". No se proporcionaron detalles sobre cuáles podrían ser esas otras tecnologías.

"Permítanme ser absolutamente claro, el HHS apoya vacunas seguras y efectivas para cada estadounidense que las desee", dijo Kennedy en el comunicado.

Fuente: Eye Witness News. Disponible en https://n9.cl/hi9zh

Identifying high risk "pathogen X" with potential to spark future pandemics

Aug 5. Announcing a new article publication for *Zoonoses* journal. In past decades, numerous emerging infectious diseases have markedly affected global health and social-economic development.

Consequently, the concept of "disease X" has been developed and lists of the pathogens with potential to cause future pandemics have been proposed and updated several times by the World Health Organization. This article analyses the major features of pathogens with high probability to cause future COVID-19-like pandemics, on the basis of their transmission routes, animal-human interfaces, herd immunity barriers, and evolutionary and mutational characteristics. High-priority viral infectious diseases with potential to become disease X in the future, are also evaluated on the basis of their transmission pathways, including airborne/ respiratory, vector-borne, and direct contact. Overall, viruses had much greater likelihood of becoming "pathogen X" than either bacteria or other microorganisms.

Respiratory viruses, particularly RNA viruses, have notably high potential to become pathogen X. Vector-borne viruses might also become pathogen X, and mosquito-borne viruses would be more likely than tick-borne viruses to do so. Many contagious viral infectious diseases lead to severe clinical outcomes but have relatively low likelihood of causing global pandemics. Coronaviruses in the *Coronaviridae* and influenza viruses in the *Orthomyxoviridae* were identified as top-priority pathogens X with potential to cause the next COVID pandemic.

Fuente: News Medical Life Sciences. Disponible en https://n9.cl/6sx58z

Leading science labs in Korea join world's largest vaccine testing network

Aug 5. Two leading scientific organisations based in Korea, the Korea Disease Control and Prevention Agency (KDCA) and International Vaccine Institute (IVI), are joining the world's largest network dedicated to the standardised testing of epidemic and pandemic vaccines.

- KDCA and IVI join global group of laboratories set up to standardise assessment of new vaccines.
- Expansion of network to Korea could help the country more quickly respond to future outbreaks.
- CEPI set up the centralised group of labs in 2020 to respond to the COVID-19 pandemic.
- KDCA and IVI already working with CEPI on pandemic preparedness and response efforts.

Set up by the Coalition for Epidemic Preparedness Innovations (CEPI), the network aims to accelerate the development of vaccines to respond more quickly to future outbreaks of viral threats in as little as 100 days.

This includes potentially deadly infections like coronaviruses, pandemic influenza, and a novel or as-yet-identified 'Disease X'.

KDCA and IVI are the first institutions headquartered in Korea to join the network now made up of twenty laboratories. They will work together and with scientific groups across Africa, the Americas, Asia, Australasia and Europe as a 'centralised laboratory', using the same tools and protocols to evaluate multiple vaccine candidates created from different developers as though they have been tested 'under one roof'. This can help overcome the current challenge of being unable to easily compare vaccine candidates as different measurements and techniques are used by different laboratories. Minimising variability in the vaccine data could help researchers and regulators based in Korea more rapidly select the best-performing vaccine candidates.

"When multiple vaccine candidates are undergoing testing, differences in how data is collected becomes an issue. As well as potential variations in markers of immunity, there can be distinctions in how and where samples are collected, transported and stored" explains Dr Kent Kester, Executive Director of Vaccine R&D at CEPI. "This impacts the quality and usefulness of the data produced. KDCA and IVI's new membership to our Centralised Laboratory Network will lessen these problems, to more reliably and quickly evaluate potentially life-saving vaccines under development."

Expanding CEPI's Centralised Laboratory Network's footprint to include sites in Korea could also help the region more quickly respond to an emerging local outbreak as time is not wasted shipping samples for testing to laboratories further afield.

"The inclusion of KDCA and IVI in CEPI's Centralised Laboratory Network will facilitate harmonized and expedited evaluation of vaccine candidates during epidemics and pandemics," says Dr. Manki Song, Deputy Director General of Science at IVI. "By joining this global network, KDCA and IVI can further increase their contributions to pandemic preparedness and global health security by enhancing our shared capabilities in clinical sample analysis and vaccine development."

"By joining CEPI's Centralised Laboratory Network together with IVI, KDCA expects to strengthen global partnerships in vaccine evaluation, enhancing preparedness for emerging infectious diseases and potential pandemic preparedness," says Dr. Seungkwan Lim, Commissioner of KDCA. "To strengthen global health security, we will continue to expand our R&D infrastructure for vaccine development, targeting CEPI priority pathogens and Disease X, while deepening global research collaboration."

As part of its broader policy priorities, the Korean government pledged during the June presidential election to expand joint research on infectious diseases, strengthen international cooperation in responding to public health crises, and enhance its infectious disease response systems.

Set up in 2020 in response to the COVID-19 pandemic, CEPI's Centralised Laboratory Network has made significant contributions to the development of several COVID-19 vaccines and vaccines being designed against other emerging infectious diseases. CEPI has provided up to US $57 million to run the network.

To date, CEPI has allocated approximately US$350 million allocated to Korean companies and institutions advancing research to prepare for future epidemic and pandemic threats. This includes existing partnerships with KDCA and IVI. Since joining CEPI in 2020, the South Korean government has contributed $51 million to support CEPI's global efforts.

Fuente: CEPI. Disponible en https://n9.cl/bb0ns

La variante "Frankenstein" de la COVID-19 llega a Sudamérica: ¿En qué países hay casos confirmados y cuáles son los síntomas?

7 ago. La variante "Frankenstein" (XFG) de la COVID-19 ha sido detectada en países de Sudamérica como Argentina y Brasil, generando alerta por su rápida capacidad de mutación.

¿Qué es la variante "Frankenstein" y cuáles son sus síntomas?



La variante "Frankenstein" es una cepa recombinante del SARS-CoV-2. Esto significa que es una combinación de dos variantes preexistentes, la LF.7 y la LP.8.1.2. El nombre proviene de su naturaleza altamente mutada, similar a la descripción de la variante Ómicron en el pasado.

Los síntomas asociados con esta variante son los mismos que los de otras cepas de COVID-19. Estos pueden variar en gravedad y generalmente incluyen:

- Fiebre.
- Tos.
- Dificultad para respirar.

Aunque la Organización Mundial de la Salud (OMS) ha clasificado a la XFG como una "variante bajo monitoreo", no hay evidencia que sugiera que causa una enfermedad más grave que otras variantes en circulación.

La variante XFG se ha detectado en varios países a nivel mundial. En América Latina, Brasil ha reportado un aumento significativo en la circulación de esta cepa. Específicamente, en Río de Janeiro, se identificaron 46 casos entre el 1 y el 8 de julio de 2025, lo que representó el 62% de los genomas analizados en ese periodo. También se han confirmado casos en otros estados brasileños como São Paulo, Ceará y Santa Catarina.

Por su parte, Argentina ha registrado tres casos de la variante XFG entre la semana epidemiológica 9 y 28 de 2025, según el Boletín Epidemiológico Nacional.

La OMS ha señalado un aumento general de la variante en varias regiones, incluyendo América Latina.

Fuente: TV Azteca Chiapas. Disponible en https://n9.cl/7b6tl

Enfermedad X: La OMS se prepara para próxima pandemia letal

7 ago. Mucho se ha escuchado sobre la "enfermedad x", pero muchos desconocen qué es y cómo la OMS se está preparando para una posible pandemia desde hace años.

El temor ha invadido las redes ante la posibilidad de una próxima pandemia, ya que mucho se ha escuchado sobre la "Enfermedad X", la cual ha incluido la Organización Mundial de la Salud (OMS) dentro de su lista de patógenos que deben investigar con urgencia, ya que podría ser letal y causar una grave epidemia internacional.

A pesar de su reciente popularización en redes, este término ya había adoptado por la OMS desde el 2017, fecha en que presentaron una lista de patógenos que podían provocar futuros brotes o pandemias, entre las cuales se encontraron "la enfermedad del virus del Ébola, la fiebre de Lassa, el síndrome respiratorio de

Oriente Medio (MERS), el síndrome respiratorio agudo severo (SARS), la fiebre del Valle del Rift, la COVID-19, el Zika y la "enfermedad X".

La "enfermedad X" no se trata de una enfermedad como tal, sino que es un término que adoptó la Organización Mundial de la Salud para referirse a un patógeno desconocido que podría causar una grave epidemia internacional. De esta forma, se busca realizar investigaciones avanzadas que sirvan para estar preparados para futuras enfermedades no conocidas, intentando así tener una acción rápida en futuras pandemias.

"Es esencial centrarse en los patógenos y familias de virus prioritarios para que puedan ser investigados y desarrollar las contramedidas necesarias a fin de dar una respuesta rápida y eficaz a las epidemias y pandemias", comentó Michael Ryan, directivo ejecutivo del Programa de Emergencias Sanitarias de la OMS.

La pandemia por COVID-19, además de los estragos, dejó un serie de aprendizajes en la comunidad científica sobre cómo actuar ante futuras epidemias internacionales. No obstante, debido a que la COVID-19 ya había estado siendo estudiada con anticipación dentro de la lista de patógenos prioritarios, fue posible "desarrollar vacunas seguras y eficaces en tiempo récord", por lo que este modelo seguirá siendo implementado.

De esta forma, cuando la "enfermedad X" se llegara a presentar, ya se contarán con avances y estudios que permitirán una pronta acción de las autoridades para garantizar la sanidad a los ciudadanos.

Fuente: TV Azteca Chiapas. Disponible en https://n9.cl/1h06q

Why long-term follow-up should start early in vaccine trials

Aug 8. In 1974, the World Health Organisation (WHO), at the request of its members, launched the Expanded Program on Immunisation (EPI). The aim was to make life-saving vaccines available to all globally. A study published in Lancet to mark the 50th anniversary of the EPI showed the impact of the initiative on public health. The study's authors found that the program averted 154 million deaths.1 The EPI program is estimated to have been directly responsible for a 40% reduction in infant mortality during the same period. According to the study, as many as 146 million deaths were averted in children under five years old, including an estimated 101 million in infants under one year old.

Recent outbreaks of familiar vaccine-preventable illnesses such as measles (in the US and abroad3) and pertussis (in the EU4 and especially the Czech Republic5) have reignited debates about vaccines. Vaccination programs can be cost-effective and life-saving public health tools. A crucial factor in any vaccine program is the ability to demonstrate the vaccine's efficacy and safety. Demonstrating safety and efficacy ensures that the vaccine is effective for its intended use, and that the benefits outweigh the potential risks, safeguarding patient well-being. Vaccine programs only succeed when the public feel confident in the safety of the vaccines in question. Similarly, vaccine trials only succeed when participants are willing to join them. Trial participants put their health in the hands of vaccine developers for the greater good of humanity. In doing so, they need to be confident that potential trial-related risks are mitigated and managed by the vaccine trial team. While long-term follow up (LTFU) was always a critical element of vaccine trials, there has been a recent push from regulators to follow up for longer periods. This means sponsors need to be prepared to gather data that demonstrates vaccine safety and efficacy over a more extended term.

This data can be used to increase trust with physicians and patients and to demonstrate vaccines' effectiveness and safety.

How COVID-19 changed vaccine trials

Before the COVID-19 pandemic, vaccine trials were a relatively niche area of clinical research. Typically, trials took between 5 and 10 years to conduct efficacy and safety studies. The urgency of the COVID-19 pandemic led to an unprecedented acceleration of vaccine development timelines. At the same time, regulators fast-tracked the regulatory review and approval process for vaccines. ICON provided clinical trial services to support one of the largest and most expeditious randomised clinical trials ever conducted. Our team helped accelerate the sponsor's mission to develop the world's first safe and effective investigational vaccine for COVID-19 vaccine to be approved. This partnership redefined industry expectations in terms of trial management and speed, while never compromising safety, quality and integrity. However, the speed with which vaccines became available may have unintentionally contributed to public fears about vaccine safety. Addressing these fears requires both effective communication and long-term data. While communication is largely in the hands of physicians and public health officials, sponsors have a significant role to play in gathering the necessary long-term data.

Demonstrating long-term safety starts in the early phases

When it comes to demonstrating long-term safety, vaccine developers should start with the end in mind. Planning for long-term follow up (LTFU) when designing study protocols will ensure the right data is captured both during and after a vaccine trial. Today sponsors can draw from a wide array of real world data (RWD) to understand the long-term impact of their vaccine or treatment. Clinical trial tokenisation (CTT) enables sponsors to follow patients for years after the trial ends by substituting Personal Identifiable Information (PII) with a unique token or deidentifier. This token is then used as a reference point so that real world healthcare data can be analysed to understand trends in disease, indication and post-exposure safety/effectiveness patterns without compromising patient privacy. Patient data can be captured discreetly allowing sponsors to track large volumes of real world patient data for cohorts of study participants. This provides real world evidence (RWE) of vaccine efficacy and interactions with other illnesses or drugs. However, to leverage CTT, sponsors must ensure that participants consent to being followed for a specified period of time once the trial is over.

When designing a study sponsors should consider what the minimum follow up period will be. While this may be dictated by the regulatory requirements, it can be worth considering a longer follow up period as well as the possibility of extension studies. Sponsors must also decide whether to deploy passive or active surveillance of participants and what data points to capture. Special attention may be necessary to account for population-specific groups such as older people, pregnant women or immunocompromised individuals as well as those with comorbidities. Sponsors will need to demonstrate to regulators that they have received informed consent and that the data is secured to protect patient privacy.

The future of vaccine trials

Having begun this article with a look back at the half-century of vaccination through the WHO EPI, it seems apt to close with a look to the future. As sponsors and supporters of vaccine trials we have a responsibility to conduct long-term follow up that demonstrate the continued safety of vaccines for years to come. By incorporating long-term follow up, RWD, and RWE strategies in clinical trials from as early as possible,

sponsors will help ensure the success of their vaccine programs. In doing so they can support individuals to confidently make informed decisions about vaccination.

This National Immunisation Awareness Month we thank both past and future vaccine trial participants for contributing to the development of safe and effective vaccines which save lives.

Fuente: ICON. Disponible en https://n9.cl/tqyzn

GSK's Phase 3b Study on Meningococcal Vaccine: A Potential Game Changer?

Aug 8. GlaxoSmithKline (GSK) is conducting a Phase 3b study titled A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response And Safety of The Meningococcal Group B Vaccine Rmenb+Omv Nz When Administered to Healthy Participants Aged 10 To 20 Years Old, Who Were Primed During the First 2 Years Of Life. The study aims to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ, in adolescents and young adults who were initially vaccinated as infants. This research is significant as it seeks to confirm whether a booster dose enhances immunity in previously vaccinated individuals compared to those who have never received the vaccine.

The intervention being tested is the rMenB+OMV NZ vaccine, also known as Bexsero. It is a biological intervention designed to boost immunity against meningococcal group B infections in participants who were vaccinated as infants.

This interventional study is randomized with a parallel assignment model and is open-label, meaning no masking is involved. The primary purpose is prevention, focusing on comparing immune responses between previously vaccinated (primed) participants and those who are vaccine-naive.

The study began on July 7, 2025, with the latest update on August 6, 2025. These dates are crucial as they mark the study's progress and timeline for completion, which is yet to be determined.

The outcome of this study could significantly impact GSK's stock performance and investor sentiment, as successful results may enhance the marketability of the Bexsero vaccine. In the competitive landscape of vaccine development, positive findings could position GSK favorably against other pharmaceutical companies working on similar vaccines.

The study is currently ongoing, with further details available on the ClinicalTrials portal.

Fuente: THE GLOBE AND MAIL. Disponible en https://n9.cl/8cszp

Vacuna contra el VPH protegerá frente al 90 % de los casos de cáncer de cuello uterino

10 ago. El Perú da un paso decisivo en la lucha contra el cáncer de cuello uterino. El Ministerio de Salud (Minsa) incorporó la vacuna nonavalente contra el Virus del Papiloma Humano (VPH) al Esquema Nacional de Vacunación, una dosis capaz de prevenir 9 variantes del virus responsable del 90 % de los casos de cáncer de cuello uterino y otros tumores asociados.

"El Minsa incorporó dicha dosis al Esquema Nacional de Vacunación. Será gratuita para menores de hasta 18 años."

La medida se oficializó a través de la Resolución Ministerial N° 440-2025/MINSA, publicada el pasado 18 de julio.

"La decisión permitirá que niñas, niños y adolescentes hasta los 18 años reciban la vacuna de forma gratuita en colegios, centros de salud y campañas comunitarias", indicó la directora de la asociación de pacientes Esperantra, Karla Ruiz De Castilla.

Según dijo, la decisión del Minsa marca un avance fundamental para reducir la desigualdad en prevención oncológica. "Garantizar que la vacuna llegue a quienes más la necesitan es clave para salvar vidas", recordó.

Con la incorporación de esta vacuna, De Castilla precisó que el país refuerza su estrategia de prevención primaria contra el cáncer de cuello uterino, avanzando hacia una cobertura más equitativa y efectiva para las poblaciones más vulnerables.

UN PASO CLAVE FRENTE A LA PRINCIPAL CAUSA DE MUERTE ONCOLÓGICA EN MUJERES

El cáncer de cuello uterino sigue siendo la primera causa de muerte por cáncer en mujeres peruanas, superando al cáncer de mama. De acuerdo con el informe "Reducir la brecha de equidad: atención oncológica para la mujer en Perú", de Economist Impact, en el año 2022 se registraron 2,545 fallecimientos por este tipo de cáncer, en comparación con 1,951 por cáncer de mama.

El estudio en mención advierte que la enfermedad afecta con mayor frecuencia a mujeres jóvenes, de bajos ingresos y residentes en zonas rurales o comunidades indígenas, donde la vacunación enfrenta mayores dificultades de acceso.

Gracias a su inclusión en el Fondo Rotatorio de la Organización Panamericana de la Salud (OPS), De Castilla resaltó que el Perú podrá adquirir la vacuna nonavalente a menor costo y con disponibilidad garantizada, ya que todas las dosis cuentan con certificación de calidad de la OMS.

Fuente: Gestión Perú. Disponible en https://n9.cl/9xztj

Global Virus Network reaffirms support for mRNA vaccines and collaborative vaccine research

Aug 11. The Global Virus Network (GVN), a coalition of leading human and animal virologists from 80+ Centers of Excellence and Affiliates in more than 40 countries dedicated to advancing pandemic preparedness, is unequivocally committed to the continued development and deployment of mRNA vaccines and the global scientific collaboration that makes such innovation possible.

Vaccination remains one of public health's greatest achievements, preventing an estimated 4.4 million deaths globally each year. Building on this foundation, mRNA vaccine platforms have emerged as one of the most significant biomedical innovations of the 21st century, fundamentally reshaping our ability to respond rapidly and effectively to emerging viral threats. The real-world impact of mRNA vaccines has been striking. Between 2020 and 2024, COVID-19 vaccines are estimated to have prevented approximately 7.5 million deaths globally. In the United States alone, over 298 million mRNA vaccine doses were administered within the first

six months of rollout, with fewer than 1% of recipients experiencing significant adverse reactions or complications. Furthermore, clinical data showed that between March 2021 and January 2022, mRNA vaccines reduced the death rate by about 90%, and were 94% effective against severe disease during the Omicron wave.

Unlike traditional vaccines, which use weakened or inactivated viruses or parts of the pathogen to stimulate immunity, mRNA vaccines deliver synthetic genetic instructions that teach cells to produce a harmless viral protein. This approach primes the immune system without exposing individuals to the actual pathogen, offering a safe and adaptable platform with broad potential. Although propelled into the global spotlight by COVID-19, mRNA technology has been under development for decades, with early applications targeting rabies, influenza, and Zika, and more recently, showing promise in cancer immunotherapy.

"mRNA vaccine technology has fundamentally changed our ability to respond quickly and precisely to emerging viral threats," said Johan Neyts, PhD, Director of the GVN Center of Excellence at KU Leuven in Belgium, and a global leader in antiviral drug and vaccine development. "Various members of the GVN are working across continents to accelerate innovation in mRNA-based vaccines, not only for coronaviruses but also for dengue, Zika, Lassa fever, and other high-consequence pathogens."

The GVN emphasizes that scientific transparency, public health engagement, and a global commitment to research must remain at the heart of mRNA vaccine deployment strategies. "Global acceptance of vaccines, especially new platforms like mRNA, depends not only on scientific rigor but also on building and sustaining trust within communities," said Heidi Larson, PhD, Founding Director of the Vaccine Confidence Project and an internationally recognized expert in vaccine confidence and risk communication. " The GVN serves a critical function in this effort by convening trusted scientific voices around the world and advancing transparent, culturally informed engagement that helps bridge the gap between innovation and public confidence."

Around the world, governments and research institutions are advancing mRNA development and infrastructure as part of their pandemic preparedness and public health strategies. From South Africa to South Korea, Brazil to Belgium, GVN Centers are playing pivotal roles in these efforts.

“South Africa is leading a transformative moment in global health by building sustainable mRNA vaccine research and manufacturing ecosystems,” said Quarraisha Abdool Karim, PhD, Co-Director of the GVN Center of Excellence at CAPRISA in South Africa and an internationally esteemed epidemiologist advancing health equity and scientific capacity across Africa. “By harnessing mRNA innovation locally, we’re not only responding to today’s needs but also empowering future generations of African scientists.”

The GVN stands committed to advocating for a globally coordinated approach to the development and deployment of mRNA vaccines that includes:

- Expanding mRNA research and manufacturing capacity in low- and middle-income countries to close gaps in access and build regional resilience.
- Supporting next-generation mRNA innovation, including thermostable and self-amplifying formulations, to improve global distribution and longevity.
- Combating vaccine misinformation through collaborative initiatives with educators, journalists, and community leaders to ensure scientifically accurate, culturally sensitive messaging.

As a science-driven organization, the GVN is dedicated to advancing pandemic preparedness by fostering the exchange of knowledge, building global training capacity, accelerating translational research, and supporting effective and equitable responses to viral threats. mRNA vaccines are not just a product of biomedical ingenuity; they are a testament to what global collaboration can achieve when rooted in evidence and transparency.

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is a worldwide coalition comprising 80+ Virology Centers of Excellence and Affiliates across 40+ countries, whose mission is to facilitate pandemic preparedness against viral pathogens and diseases that threaten public health globally. GVN advances knowledge of viruses through (i) data-driven research and solutions, (ii) fostering the next generation of virology leaders, and (iii) enhancing global resources for readiness and response to emerging viral threats. GVN provides the essential expertise required to discover and diagnose viruses that threaten public health, understand how such viruses spread illnesses, and facilitate the development of diagnostics, therapies, and treatments to combat them. GVN coordinates and collaborates with local, national, and international scientific institutions and government agencies to provide real-time virus informatics, surveillance, and response resources and strategies. GVN's pandemic preparedness mission is achieved by focusing on Education & Training, Qualitative & Quantitative Research, and Global Health Strategies & Solutions. The GVN is a non-profit organization. For more information, please visit www.gvn.org

Fuente: EurekAlert. Disponible en https://n9.cl/8rw2y

Pfizer introduces 20-valent Pneumococcal Conjugate Vaccine (PCV20) for adults in India

Aug 11. Pfizer has announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer's vaccine marks a significant advancement in protection against pneumococcal disease in adults.

image credit- shutterstock

Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease. It enables timely and proactive protection for all adults, including those living with chronic conditions. PCV20 will be available as a single shot vaccine and those vaccinated with PCV20 may not need a second dose.

Meenakshi Nevatia, Managing Director, Pfizer Ltd., India, said, "We are excited to launch PCV20, our 20-valent pneumococcal conjugate vaccine, in India. We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country."

Adults over 50 years of age, as well as individuals with comorbidities such as asthma, COPD (Chronic Obstructive Pulmonary Disease), chronic kidney disease, and diabetes, face a higher risk of developing pneumococcal infections, which can result in complications, hospitalisation, and even death.

Timely immunisation is critical to reducing the risk of severe illness, hospitalisation, and mortality caused by pneumococcal disease. Vaccination with PCVs are considered one of the most effective public health tools for reducing the burden of pneumococcal disease.

The introduction of PCV20 in India strengthens Pfizer's longstanding commitment to preventive health and builds on 25 years of leadership in pneumococcal vaccine innovation.

Fuente: BioSpectrum India. Disponible en https://n9.cl/yi95y

SK bioscience takes on Pfizer, MSD with late-stage pneumococcal vaccine

Aug 13. SK bioscience has entered the final stage of clinical trials for its pneumococcal vaccine and is accelerating preparations for commercialization. The company is expanding its production facilities in partnership with Sanofi and has also entered the Chinese market, one of the largest in Asia.

Although the company posted an operating loss of 31.2 billion won ($22.5 million) in the second quarter of this year based on separate financial statements, continuing its trend of losses, it is maintaining its aggressive R&D investment policy. Notably, SK bioscience has invested 33.7 billion won to expand its vaccine portfolio, with more than half of its total R&D expenses dedicated to commercializing its vaccines.

Among the vaccines currently under development, the product closest to commercialization is GBP410, a pneumococcal vaccine for children. Since signing a joint development agreement with Sanofi in 2014, the company has been conducting global phase 3 clinical trials and is on the verge of commercialization.

GBP410 has demonstrated equivalent immunogenicity and safety to existing approved vaccines through multinational phase 2 clinical trials, and phase 3 trials are underway in about 7,700 children and adolescents worldwide.

Upon launch, it is expected to compete with Pfizer's Prevenar 20 (20-valent vaccine) and MSD's Vaxneuvance (15-valent vaccine), and is being developed to cover 20 or more serotypes.

Production capacity is also being expanded in line with commercialization. SK bioscience has expanded its vaccine production facility at L House in Andong, North Gyeongsang Province, securing approximately 4,200 square meters of new space. The facility is expected to obtain certification from the U.S. FDA for current good manufacturing practices (cGMP) in mid-2026.

The company is also moving forward with its entry into the Chinese market. Clinical trials in China are mandatory for local sales, and SK bioscience recently received approval from the Center for Drug Evaluation (CDE) under the China's National Medical Products Administration (NMPA) for its phase 1 and 3 clinical trial applications (CTAs) for GBP410. The goal is to quickly complete phase 1 in China and then proceed to phase 3.

The company plans to actively utilize its cooperation network with Sanofi to penetrate the Chinese market. Sanofi has experience in launching various vaccines and immunotherapeutics in China, including the respiratory syncytial virus (RSV) preventive antibody therapy "Beyfortus" (nirsevimab), and this know-how is expected to contribute to the commercialization of GBP410.

"GBP410 is scheduled to complete global phase 3 trials by 2027 and then initiate the regulatory approval process, with commercialization expected as early as 2028," an SK bioscience official said.

Fuente: Korea Biomedical Review. Disponible en https://n9.cl/m5ce9

Grupo IHP participa en el ensayo europeo de una nueva vacuna contra la meningitis en lactantes desde las seis semanas de vida

13 ago. Grupo IHP ha formado parte del ensayo clínico internacional MET58, cuyos resultados muestran avances significativos en la protección frente a la meningitis en bebés. La investigación, recientemente publicada en la revista Infectious Diseases and Therapy, ha analizado por primera vez la administración de la vacuna tetravalente MenACYW-TT (MenQuadfi®) desde las seis semanas de edad, frente a la indicación actual a partir de los 12 meses.

El estudio ha comparado esta vacuna con la ya comercializada MCV4-TT (Nimenrix), administrándolas junto a las vacunas habituales del calendario (hexavalente, neumococo y triple vírica). En total, han participado 1.660 bebés de entre seis semanas y 18 meses, repartidos en 33 centros de siete países europeos.

En representación del grupo pediátrico andaluz, el doctor Ignacio Salamanca, coordinador de la Unidad de Investigación de Grupo IHP, ha sido uno de los investigadores del ensayo. "Hasta ahora, la vacuna sólo estaba indicada a partir del año de vida, dejando desprotegidos a los menores de esa edad. Este estudio demuestra que se puede iniciar la vacunación desde los 42 días sin comprometer la respuesta inmunitaria ni la eficacia del resto de vacunas coadministradas", ha afirmado.

Los resultados son muy positivos: más del 95 % de los lactantes alcanzaron niveles de protección

adecuados tras la dosis de recuerdo. La vacuna mostró una eficacia igual o superior frente a los serotipos C, W e Y, y una respuesta suficiente frente al serogrupo A, sin interferencias con otras vacunas infantiles. Además, no se registraron efectos adversos relevantes, sólo reacciones leves como fiebre, irritabilidad o dolor en la zona de inyección.

"Este avance abre la posibilidad de contar con una nueva herramienta de prevención frente a la enfermedad meningocócica invasora en lactantes, el grupo de mayor riesgo, con tasas de incidencia cuatro veces superiores a las del resto de la población", ha subrayado el doctor Salamanca.

Fuente: Diario de Sevilla. Disponible en https://n9.cl/7deae

With scrapped mRNA funding, a vaccine maker finds a silver lining

Aug 14. When the HHS pulled $500 billion in funding from the development of mRNA vaccines earlier this month, Secretary Robert F. Kennedy Jr. said in a statement that the Make America Healthy Again agenda would enable a shift to "safer, broader vaccine platforms."

Experts, however, pointed to the unprecedented speed with which mRNA vaccines were developed and distributed in response to the COVID-19 pandemic that would not have been possible using traditional immunization methods. University of Minnesota infectious disease expert Mike Osterholm tweeted, "I haven't seen a more dangerous decision in public health in my 50 years in the business. "

Beyond implications for future pandemic preparedness, the funding pullback also revealed a dynamic within the pharma industry between existing and emerging technologies, particularly as it pertains to public health and government funding for vaccines.

The technology behind mRNA vaccines has been celebrated in scientific circles as a major step forward in immunization, allowing for a timely response to new viruses, but the industry hasn't put all of its eggs in that one basket. Older technologies like live-attenuated vaccines and viral vectors, for example, are still used in many kinds of shots, and companies that use these traditional methods could find that less funding for mRNA gives their own vaccines a boost — for now.

"In general for us, I see it as something that bodes positively," said David Dodd, CEO of GeoVax, a biotech that uses a viral vector platform called modified vaccinia ankara in the clinic for COVID and head and neck cancers, as well as preclinical programs in mpox, Ebola, Marburg, Zika and more. "For the last five years, we were at a point where if you're not doing mRNA, then you're out of date and no one was going to support you, and that was a little bit too dramatic because there's no one technology or platform that covers everything you need."

Still, the mRNA platform holds plenty of value and should play a role in any robust public health system, Dodd said. Nothing compares to the manufacturing speed and access mRNA provides. But the technology also has limitations, particularly because it targets a specific antigen when a broader, multi-antigen response could be more fully protective against a disease in the long run.

There are pros and cons for each type, and different vaccine technologies don't have to — and shouldn't — be mutually exclusive, Dodd said.

Fuente: PharmaVoice. Disponible en https://n9.cl/g5dqg

New Study to Assess Immunogenicity of Butantan-DV Vaccine in ARDs

Aug 15. A new study will evaluate the safety and immunogenicity of the live attenuated tetravalent Butantan-Dengue vaccine (Butantan-DV) in individuals with granulomatosis with polyangiitis (GPA)—a form of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)—among other autoimmune rheumatic diseases (ARDs).

The study, sponsored by the University of São Paulo General Hospital in Sãu Paolo, Brazil, will test the vaccine in patients aged 7 to 59 years as well as in healthy age- and sex-matched volunteers.

"The Butantan-DV vaccine is a single-dose, tetravalent, live-attenuated formulation derived from all four dengue serotypes. Phase 2-3 data in the general population have demonstrated an overall efficacy of ~80 % and an acceptable safety profile, with clear operational advantages over other licensed vaccines (broader age indication and single-dose schedule)," the researchers wrote. "However, its immunogenicity and safety have not been prospectively examined in ARD patients under low-grade or no immunosuppression—precisely the subgroup for whom live vaccines may be permissible but still pose theoretical risks."

The open-label, phase 3b prospective study expects to enroll 318 patients with an ARD and 159 age- and sex -matched controls, all of whom live in dengue-endemic areas of Brazil.

The participants will receive a single subcutaneous 0.5 mL Butantan-DV dose on day 1, with follow-up visits on days 7, 14, and 42. At these visits, they will have a clinical examination, laboratory testing, and a review of an adverse-event diary.

Long-term follow-up of the participants will continue to day 400 to monitor safety signals and to assess antibody persistence.

Two substudies, one on cellular immunity and another on viremia, will also be performed.

The primary outcome measure will be seroconversion rates in low-grade immunosuppressed patients with ARDS compared with healthy controls at day 42. Additional outcomes include common and serious adverse events, viremia kinetics, T-cell immunity, and durability of the antibody responses.

The study aims to inform dengue vaccine policy for individuals from 7 to 59 years old living with autoimmune rheumatic diseases in dengue endemic areas.

Fuente: Rare Disease Advisor. Disponible en https://n9.cl/qavw0

Ab&B Bio-Tech's RSV Vaccine Gains Approval in China and U.S.

Aug 17. Ab&B Bio-Tech CO., LTD. JS announced that its Investigational New Drug application for a self-developed Recombinant RSV vaccine (CHO cell) (Adjuvant) has been approved by both the China Center for Drug Evaluation and the U.S. Food and Drug Administration. This vaccine, targeting the highly contagious Respiratory Syncytial Virus, shows promising preclinical results with higher expression levels, better thermal stability, and superior immunogenicity compared to existing vaccines. The approval marks a significant step forward for the company in addressing a major health concern, potentially enhancing its market position and offering a new preventive solution for RSV infections.

- Ab&B Bio-Tech's RSV vaccine IND approved in China and U.S.
- The vaccine shows superior preclinical results, enhancing market position.

More about Ab&B Bio-Tech CO., LTD. JS Class H

Ab&B Bio-Tech CO., LTD. JS is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods. The company aims to replace traditional and imported vaccines in China and expand its presence in international markets. Its product range includes the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate, among others.

Fuente: Tip Ranks. Disponible en https://n9.cl/2qlew

New mRNA treatment could protect us from all viruses

Aug 17. Columbia University researchers have created a new mRNA-based therapy that could help protect against all sorts of viruses.

Inspired by a rare genetic mutation that makes some people naturally virus-resistant, the team—led by immunologist Dusan Bogunovic—found a way to mimic this superpower in others.

How the treatment works

They designed a nasal drip using mRNA to temporarily boost 10 key antiviral genes in your body. Delivered with tiny lipid particles, this treatment kicked off just enough immune response to block viruses like flu, COVID-19, and Zika in lab animals—without causing harmful inflammation.

Potential game-changer in pandemic preparedness

If this works in humans, it could mean quick, broad protection against new viral outbreaks—even before vaccines are ready.

The researchers are still fine-tuning things for people, but this approach could seriously level up how we fight future pandemics.

Fuente: NewsBytes. Disponible en https://n9.cl/9m2gp

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2025/08/01"[Date - Publication] : "2025/08/17"[Date - Publication])) 871 records

Dengue Vaccines.

Boscardin SB.Curr Top Microbiol Immunol. 2025 Aug 13. doi: 10.1007/82_2025_320. Online ahead of print.PMID: 40794141

Tackling vaccine hesitancy and fatigue.

Jarvis S.Vet Rec. 2025 Aug 2;197(3):77. doi: 10.1002/vetr.5823.PMID: 40748146

Trained immunity in the lung.

Idiiatullina E, Parker D.Elife. 2025 Aug 1;14:e104918. doi: 10.7554/eLife.104918.PMID: 40748050

Hepatitis E vaccine landscape update 2025.

Kim SB, Agampodi S, Saluja T, Sahastrabuddhe S, Kim HS, Kim JH, Lynch JA.Expert Rev Vaccines. 2025 Dec;24(1):1-16. doi: 10.1080/14760584.2025.2543809. Epub 2025 Aug 6.PMID: 40757700

Clinical progress note: Pertussis.

Hanna S, Samies N.J Hosp Med. 2025 Aug;20(8):862-865. doi: 10.1002/jhm.70080. Epub 2025 May 19.PMID: 40387798

Olfactory disorder after COVID-19 vaccination.

Kawabata M, Mori E, Yanagi N, Tei M, Otori N.Rhinology. 2025 Aug 1;63(4):441-447. doi: 10.4193/Rhin23.499.PMID: 40305821

Cancer mRNA vaccines: clinical application progress and challenges.

Li H, Min L, Du H, Wei X, Tong A.Cancer Lett. 2025 Aug 10;625:217752. doi: 10.1016/j.canlet.2025.217752. Epub 2025 Apr 28.PMID: 40306545

Eliciting antitumor immunity via therapeutic cancer vaccines.

Peng K, Zhao X, Fu YX, Liang Y.Cell Mol Immunol. 2025 Aug;22(8):840-868. doi: 10.1038/s41423-025-01316-4. Epub 2025 Jul 9.PMID: 40629076

From dengue to chikungunya: Guangdong as a sentinel for arboviral threats in East Asia.

Feng Y, Chang F, Yang Y, Lu H.Biosci Trends. 2025 Aug 2. doi: 10.5582/bst.2025.01228. Online ahead of print.PMID: 40754456

Accelerating vaccine development: Plug-and-play platforms for emerging infectious diseases.

Yang K.Virus Res. 2025 Aug;358:199601. doi: 10.1016/j.virusres.2025.199601. Epub 2025 Jun 21.PMID: 40550258

Maternal RSVpreF Vaccine: A Novel Agent for Respiratory Syncytial Virus Prevention in Infants.

Fly JH, Stultz JS, Eiland LS.Ann Pharmacother. 2025 Aug;59(8):758-766. doi: 10.1177/10600280241302775. Epub 2024 Dec 30.PMID: 40576156

The role and implication of rotavirus VP8 in viral infection and vaccine development.

Soni S, Kennedy MA, Wang D, Li F.Virology. 2025 Aug;609:110563. doi: 10.1016/j.virol.2025.110563. Epub 2025 May 8.PMID: 40378555

Efficacy, public health impact and optimal use of the Takeda dengue vaccine.

Cracknell Daniels B, Ferguson NM, Dorigatti I.Nat Med. 2025 Aug;31(8):2663-2672. doi: 10.1038/s41591-025-03771-y. Epub 2025 Jun 25.PMID: 40563017

Oropharyngeal Cancer and the HPV Vaccine: Analysis of Social Media Content.

Matthews MR, Abdulbaki H, Ryan WR, Hackman TG, Farzal Z.Laryngoscope. 2025 Aug;135(8):2770-2776. doi: 10.1002/lary.32076. Epub 2025 Feb 17.PMID: 39960222

Challenges and opportunities in mRNA vaccine development against bacteria.

Aernout I, Verbeke R, Thery F, Willems P, Elia U, De Smedt SC, Rappuoli R, Peer D, Impens F, Lentacker I.Nat Microbiol. 2025 Aug;10(8):1816-1828. doi: 10.1038/s41564-025-02070-z. Epub 2025 Jul 29.PMID: 40730911

Strategies for combating FIPV infection: antiviral agents and vaccines.

Gao F, Wen G.Res Vet Sci. 2025 Aug;192:105709. doi: 10.1016/j.rvsc.2025.105709. Epub 2025 May 27.PMID: 40446698

Clustering vaccine hesitancy and social media use of nurses and nursing students: a cross-sectional study.

Comparcini D, Simonetti V, Totaro M, Governatori L, Pastore F, Di Lorenzo A, Tafuri S, Keisala J, Mikkonen K, Unsworth J, Tomietto M, Cicolini G.Appl Nurs Res. 2025 Aug;84:151976. doi: 10.1016/j.apnr.2025.151976. Epub 2025 Jun 13.PMID: 40744541

Chitosan-based nanomaterials: Pioneering a review in veterinary medicine applications.

Yang K, Zhu R, Bao H, Xu S, Gao Y, Xue Y, Wang J, Wang X, Pan Y, Hong L, Zhao K.Int J Biol Macromol. 2025 Aug;320(Pt 4):146011. doi: 10.1016/j.ijbiomac.2025.146011. Epub 2025 Jul 14.PMID: 40669647

Tolerogenic antigen-specific vaccine induces VISTA-enriched regulatory T cells and protects against arthritis in DRB104:01 mice.

Romero-Castillo L, Pandey RK, Xu B, Beusch CM, Oliveira-Coelho A, Zeqiraj K, Svensson C, Xu Z, Luo H, Sareila O, Sabatier P, Ge C, Cheng L, Urbonaviciute V, Krämer A, Lindgren C, Haag S, Viljanen J, Zubarev RA, Kihlberg J, Linusson A, Burkhardt H, Holmdahl R.Mol Ther. 2025 Aug 6;33(8):3528-3545. doi: 10.1016/j.ymthe.2025.04.034. Epub 2025 Apr 24.PMID: 40285352

Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial.

Wu S, Huang J, Wang B, Li J, Wu J, Zhang Z, Luo L, Zhang J, Huo N, Long J, Huang H, Chen Z, Zhang M, Zhao Z, Dan J, Song X, Mao H, Huo S, Yan H, Zhang Y, Wang X, Hou L.Nat Commun. 2025 Aug 7;16(1):7281. doi: 10.1038/s41467-025-62698-7.PMID: 40775215

Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity.

Hashimoto S, Hirai T, Ueda K, Kakihara M, Tokunoh N, Ono C, Matsuura Y, Takayama K, Yoshioka Y.Mucosal Immunol. 2025 Aug;18(4):793-809. doi: 10.1016/j.mucimm.2025.03.006. Epub 2025 Apr 1.PMID: 40180151

Vaccine misinformation among Arabic-speakers in Australia and the audience and appetite for a game-based intervention.

Vasiliadis S, Cook J, Nissan K, Cook W, Hopkins K, Lepage C, Thomson A, Danchin M, Kaufman J.Vaccine. 2025 Aug 9;62:127599. doi: 10.1016/j.vaccine.2025.127599. Online ahead of print.PMID: 40784110

Association between vaccine uptake and SARS-CoV-2 infection among staff at a jail and prison in the USA.

Bailey A, Kang AW, Stagoff-Belfort C, Martin RA.Int J Prison Health (2024). 2025 Aug 12. doi: 10.1108/IJOPH-10-2024-0058. Online ahead of print.PMID: 40787786

Vaccine hesitancy and its relationship with adverse childhood and protective and compensatory experiences: A cross-sectional study.

Ohyama K, Isumi A, Doi S, Okada S.Medicine (Baltimore). 2025 Aug 1;104(31):e43614. doi: 10.1097/MD.0000000000043614.PMID: 40760520

Modulation of oral vaccine efficacy by the gut microbiota.

Hou Y, Li J, Wu Y.NPJ Vaccines. 2025 Aug 1;10(1):179. doi: 10.1038/s41541-025-01240-8.PMID: 40750603

Chitosan and mannose-modified dual-functional mRNA-LNP vaccines for robust systemic and mucosal immune responses.

Yi J, Lu Y, Liu N, Wang Z, Zhang H, Xing H, Li M, Jin L, Zheng A.J Control Release. 2025 Aug 10;384:113891. doi: 10.1016/j.jconrel.2025.113891. Epub 2025 May 27.PMID: 40441491

A Systematic Review and Meta-Analysis of Health-State Utility Values for Infectious Diseases With Pandemic Potential and Associated Vaccine Adverse Reactions.

Kitano T, Salmon DA, Dudley MZ, Saldanha IJ, Thompson DA, Engineer L.Value Health. 2025 Aug;28(8):1280-1287. doi: 10.1016/j.jval.2025.02.007. Epub 2025 Mar 4.PMID: 40049326

Advancing mRNA vaccines: A comprehensive review of design, delivery, and efficacy in infectious diseases.

Lu Y, Qian C, Huang Y, Ren T, Xie W, Xia N, Li S.Int J Biol Macromol. 2025 Aug;319(Pt 3):145501. doi: 10.1016/j.ijbiomac.2025.145501. Epub 2025 Jun 24.PMID: 40571008

Strong Herd Effects of Human Papillomavirus Vaccination.

Chesson HW, Markowitz LE.J Infect Dis. 2025 Aug 14;232(2):e189-e192. doi: 10.1093/infdis/jiaf121.PMID: 40042854

A jab is not a vaccine; it's a 'shot'.

Demjén Z, Elena Semino, Gleave R.Public Health. 2025 Aug;245:105815. doi: 10.1016/j.puhe.2025.105815. Epub 2025 Jun 9.PMID: 40494211

Immunization Coverage and Barriers among Hajj and Umrah Pilgrims: Insights into Vaccine Uptake and Compliance.

Bulkhi AA, Almoallim HM, Obaid MS, Hariri NH, Alqashqri HS, Alghamdi IA, Alkhotani AMA, Siddiqui MI, Adly HM, Garout MA, Elfaki EA, Saleh SAK, Bakhsh NM, Alhazmi RSHH, Alhazmi AS, Al-Tawfiq JA, Alamri FA, Khan AA.J Epidemiol Glob Health. 2025 Aug 7;15(1):104. doi: 10.1007/s44197-025-00447-1.PMID: 40773127

Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy.

Aguilar G, Tapia-Calle G, Robinson C, Baron B, Lowson D, Maximos B, Rezelj VV, de Groot AM, Bet N, van Paassen V, Le Gars M, Struyf F, Ruiz-Guiñazú J.Hum Vaccin Immunother. 2025 Dec;21(1):2538340. doi: 10.1080/21645515.2025.2538340. Epub 2025 Aug 13.PMID: 40808283

Advances and Strategies in Enhancing mRNA Cancer Vaccines.

Zhang M, Chen S, Hu H, Ong Y, Ni Q.Adv Mater. 2025 Aug 7:e09880. doi: 10.1002/adma.202509880. Online ahead of print.PMID: 40772339

Current and emerging Mpox vaccine strategies: A comprehensive review.

Ortiz-Prado E, Kyriakidis NC, López-Cortés A, Vasconez-Gonzalez J, Suarez I, Pazmiño-Almeida J, Barriga-Collantes M, Cadena MP, Reascos-Arteaga M, Acosta-Muñoz E, Acosta-Muñoz MC, Villarreal K, Izquierdo-Condoy JS.Vaccine. 2025 Aug 9;62:127598. doi: 10.1016/j.vaccine.2025.127598. Online ahead of print.PMID: 40784109

Cancer vaccines: Discovery, development, and challenges for clinical translation.

Zhang Z, Yao S, Wang Y, Luo K, Amiji M, Anderson KC.Biomaterials. 2025 Aug 7;325:123615. doi: 10.1016/j.biomaterials.2025.123615. Online ahead of print.PMID: 40795707

Drivers of human papillomavirus vaccine uptake in migrant populations and interventions to improve coverage: a systematic review and meta-analysis.

Iwami M, Bouaddi O, Razai MS, Mansour R, Morais B, Ali NM, Crawshaw AF, Bojang S, Seedat F, Deal A, Webb S, Carter J, Aspray N, Clemente NS, Arroyo-Laguna J, Krishna S, Augustin Y, Staines HM, Hargreaves S.Lancet Public Health. 2025 Aug;10(8):e693-e711. doi: 10.1016/S2468-2667(25)00148-3.PMID: 40738554

Impact of vaccines on antimicrobial resistance.

Dougan G, Hugo-Webb E.J Med Microbiol. 2025 Aug;74(8). doi: 10.1099/jmm.0.002050.PMID: 40810654

Immune Aspects of Clostridioides difficile Infection and Vaccine Development.

Glover RC, Peritore-Galve FC, Lacy B, Zackular JP.Infect Dis Clin North Am. 2025 Aug 12:S0891-5520(25)00071-6. doi: 10.1016/j.idc.2025.07.008. Online ahead of print.PMID: 40803973

Respiratory mucosal vaccines: Applications, delivery strategies and design considerations.

Shi T, Ye Y, Fan Z, Yang Q, Ma Y, Zhu J.Biomed Pharmacother. 2025 Aug;189:118326. doi: 10.1016/j.biopha.2025.118326. Epub 2025 Jul 8.PMID: 40633204

Effectiveness of the live zoster vaccine in patients with type 2 diabetes: a nationwide emulated target trial.

Kim TH, Lee K, Lee S, Oh J, Park J, Jo H, Son Y, Kim S, Rhee SY, Smith L, Cho H, Jung J, Yeo SG, Lee H, Yon DK.Clin Microbiol Infect. 2025 Aug;31(8):1363-1370. doi: 10.1016/j.cmi.2025.05.003. Epub 2025 May 9.PMID: 40349966

Novel Klebsiella pneumoniae and Pseudomonas aeruginosa MAPS vaccine combining O polysaccharides and pathogen-specific proteins.

Amin MN, Sinclair JE, Curtis B, Sycheva L, Fox H, Choi M-J, Shridhar S, Kolasny J, Nkeze J, Apolinario E, Hyun S, Hegerle N, Sen S, Permala Booth J, Leney M, Molrine D, Saia G, Pasetti M, Broering T, Michon F, Malley R, Siber GR, Tennant SM, Ambrosino D, Simon R, Cross A.mBio. 2025 Aug 13;16(8):e0080725. doi: 10.1128/mbio.00807-25. Epub 2025 Jun 26.PMID: 40569061

Decolonizing global health: Africa's pursuit of pharmaceutical sovereignty.

Mulumba M, Oga J, Koomson N, Kara TA, Cynthia AN, Forman L.BMC Health Serv Res. 2025 Aug 1;25(1):1015. doi: 10.1186/s12913-025-13211-9.PMID: 40751192

Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure.

Ganaie FA, Nahm MH.Hum Vaccin Immunother. 2025 Dec;21(1):2545032. doi: 10.1080/21645515.2025.2545032. Epub 2025 Aug 13.PMID: 40804314

COVID-19 vaccine booster uptake and effectiveness among persons with systemic autoimmune and rheumatic diseases.

Ziemba YC, Elkin EP, Kazemian E, Wilson BM, Siddiqui H, Schleicher CB, Hsiao CA, Zidar DA, Kushi LH, Figueiredo JC, Skarbinski J, Crawford JM.J Rheumatol. 2025 Aug 1:jrheum.2025-0535. doi: 10.3899/jrheum.2025-0535. Online ahead of print.PMID: 40750311

Sociodemographic and Occupational Factors Associated With COVID-19 Vaccine and Influenza Vaccine Uptake Among Healthcare Workers, in Albania, 2022-2023: A Multicenter Study.

Xhaferi A, Bino S, Daja R, Vasili A, Sulo J, Mebonia N, Ndreu E, Nika M, Jani N, Dabaj E, Sustarova N, Moçi A, Toçi D, Fico A, Tomini E, Robinson S, Jorgensen P, Katz MA.Clin Infect Dis. 2025 Aug 1;81(1):30-40. doi: 10.1093/cid/ciaf202.PMID: 40459287

Pregnancy reduces COVID-19 vaccine immunity against novel variants.

Parish MA, Sachithanandham J, Gutierrez L, Park HS, Yin A, Roznik K, Creisher P, Lee JS, St Clair LA, Werner A, Pilgrim-Grayson C, Berhane L, Golding H, Shea P, Fenstermacher K, Rothman R, Burd I, Sheffield

J, Cox AL, Pekosz A, Klein SL.NPJ Vaccines. 2025 Aug 13;10(1):191. doi: 10.1038/s41541-025-01236-4.PMID: 40804265

Chicken IL-17 as a potent adjuvant enhances IBDV VP2 DNA vaccine immunogenicity and protective efficacy.

Zhang J, Li W, Huo S, Xin X, Wang L.Poult Sci. 2025 Aug;104(8):105247. doi: 10.1016/j.psj.2025.105247. Epub 2025 May 1.PMID: 40347786

Efficacy and Safety of Tetanus-Toxoid Conjugate Typhoid Vaccine (Vi-TT) in Children and Adolescents: A Systematic Review and Meta-Analysis.

Gyawali R, Poudyal N, Docherty A.Asia Pac J Public Health. 2025 Aug 11:10105395251362546. doi: 10.1177/10105395251362546. Online ahead of print.PMID: 40788116

Clinical progress note: Varicella Zoster.

Zhang S, Hersh AL, Jones TW.J Hosp Med. 2025 Aug 13. doi: 10.1002/jhm.70126. Online ahead of print.PMID: 40801156

Cell lines and primary cultures uses for vaccine development for bacterial pathogens of fish: a systematic review.

Salinas-Parra N, Torrealba D, Ahumada A, Figueroa C, Gallardo-Matus J.Fish Shellfish Immunol. 2025 Aug 5;166:110625. doi: 10.1016/j.fsi.2025.110625. Online ahead of print.PMID: 40769272

Innovative adjuvant strategies for next-generation pertussis vaccines.

Yu G, Yang W, Ma Y, Zhang N, Tang D, Jin Y, Shi L, Wang M, Liu D, Xue C, Sun B.Hum Vaccin Immunother. 2025 Dec;21(1):2545636. doi: 10.1080/21645515.2025.2545636. Epub 2025 Aug 13.PMID: 40801273

Combining Intramuscular and Intranasal Immunization With the MF59-Adjuvanted Respiratory Syncytial Virus Pre-Fusion Protein Subunit Vaccine Induces Potent Humoral and Cellular Immune Responses in Mice.

Shi J, Lei H, Zhang Y, Ye C, Huang X, Lu Y, Liu Y, Liu J, Ao D, Zhou Y, Li J, Lu G, Song X, Wei X.MedComm (2020). 2025 Jul 15;6(8):e70301. doi: 10.1002/mco2.70301. eCollection 2025 Aug.PMID: 40672433

Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2024.

Pingali C, Yankey D, Elam-Evans LD, Trahan A, Markowitz LE, DeSisto CL, Hughes M, Valier MR, Stokley S, Singleton JA.MMWR Morb Mortal Wkly Rep. 2025 Aug 14;74(30):466-472. doi: 10.15585/mmwr.mm7430a1.PMID: 40811113

Intranasal measles virus- and mumps virus-based SARS-CoV-2 vaccine candidates prevent SARS-CoV-2 infection and transmission.

Hsu CC, Chamblee M, Ye C, Shamseldin MM, Yoo SJ, Li P, Zhang Y, Liu Y, Hall JM, Xu J, Miao H, Thongpan I, K C M, Liang X, Yount JS, Peeples ME, Boyaka PN, Dubey P, Martinez-Sobrido L, Liu SL, Li J.Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2506821122. doi: 10.1073/pnas.2506821122. Epub 2025 Aug 6.PMID: 40768351

Melanoma update: is a cure now in sight?

Liaqat S, Khattak MA.Intern Med J. 2025 Aug;55(8):1242-1250. doi: 10.1111/imj.70085. Epub 2025 Jun 19.PMID: 40536073

Respiratory syncytial virus prevention in immunocompromised hosts: gaps and opportunities.

Murray A, Chu HY.Curr Opin Infect Dis. 2025 Aug 1;38(4):300-304. doi: 10.1097/QCO.0000000000001124. Epub 2025 Jun 5.PMID: 40471043

Misinformation Is Eroding the Foundation of Public Health.

Lewis BP.J Am Pharm Assoc (2003). 2025 Aug 1:102492. doi: 10.1016/j.japh.2025.102492. Online ahead of print.PMID: 40754257

Parasite and host immune factors that impact the development of a mucosal vaccine for Cryptosporidium.

Merolle M, Striepen B, Hunter CA.Mucosal Immunol. 2025 Aug;18(4):782-792. doi: 10.1016/j.mucimm.2025.05.002. Epub 2025 May 14.PMID: 40379259

Vaccination Against Meningococcal Disease in Children-A European Perspective.

Næss LM, Watle SV.Acta Paediatr. 2025 Aug 7. doi: 10.1111/apa.70224. Online ahead of print.PMID: 40772470

Determinants of HPV Vaccine Uptake in Women in the United States: A Scoping Review of Socioecological Influences.

Kyei GK, Kyei EF, Ansong R.Policy Polit Nurs Pract. 2025 Aug 17:15271544251364251. doi: 10.1177/15271544251364251. Online ahead of print.PMID: 40820338

Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence.

Fouda GG, Singh A, Nelson A, Janes H, Martin T, Levy O, Wu D, Zou F, Jean-Philippe P, De Paris K, Van Rompay KKA, Permar SR.Curr HIV Res. 2025 Aug 8. doi: 10.2174/011570162X366522250721113420. Online ahead of print.PMID: 40798950

Vaccine hesitancy in an allergy and immunology clinic in an underserved community.

Wu AG, Drum W, Silverberg N, Wathan K, Bao H, Lam G, Chan DV, Lee-Wong MF.J Allergy Clin Immunol Glob. 2025 Apr 17;4(3):100475. doi: 10.1016/j.jacig.2025.100475. eCollection 2025 Aug.PMID: 40607311

Transforming drug and vaccine delivery for equitable access in global health.

Yang X, Zhang L, Staykov K, Wu Z, Jaklenec A.Biochem Biophys Res Commun. 2025 Aug 5;779:152415. doi: 10.1016/j.bbrc.2025.152415. Online ahead of print.PMID: 40773922

Pregnant women's perceptions of RSVpreF vaccine and Nirsevimab for infant RSV prevention.

Nuzhath T, Khobragade N, Regan AK, Pinkney JA, Wise L, Callaghan T.Vaccine. 2025 Aug 8;62:127590. doi: 10.1016/j.vaccine.2025.127590. Online ahead of print.PMID: 40782461

Global research hotspots and trends of the vaccines: Based on ESI hot papers.

He M, Shi R, Cao H, Wang Y, Zhu Y, Wang X, Liang L, Xia X.Hum Vaccin Immunother. 2025 Dec;21(1):2546195. doi: 10.1080/21645515.2025.2546195. Epub 2025 Aug 13.PMID: 40799115

High-dose versus standard-dose influenza vaccine for immunocompromised patients: A systematic review and meta-analysis of randomised clinical trials.

Rivera-Izquierdo M, Verdejo-Iáñez A, Morales-Portillo A, González-Alcaide M, Láinez-Ramos-Bossini AJ, Martínez-Ruiz V, Fernández-Martínez NF, Martín-delosReyes LM, Jiménez-Mejías E, Guerrero-Fernández de Alba I, Valero-Ubierna MDC, Lardelli-Claret P, Schoenenberger-Arnaiz JA, Jiménez-Moleón JJ.J Infect. 2025 Aug;91(2):106538. doi: 10.1016/j.jinf.2025.106538. Epub 2025 Jun 23.PMID: 40562238

Attitudes Towards the HPV Vaccine Among Oropharyngeal Cancer Patients in a Post-COVID World.

Mnajjed L, Fassina G, Li H, Patel RJ.Laryngoscope Investig Otolaryngol. 2025 Jul 16;10(4):e70201. doi: 10.1002/lio2.70201. eCollection 2025 Aug.PMID: 40677963

Understanding vaccine recommendation behaviours among healthcare workers in Senegal: A cross-sectional analysis.

Cortaredona S, Verger P, Constance J, Diallo A, Ba EH, Maradan G, Sokhna C, Peretti-Watel P.Trop Med Int Health. 2025 Aug;30(8):853-864. doi: 10.1111/tmi.70002. Epub 2025 Jun 29.PMID: 40582960

East Coast fever mRNA vaccines - sweetening the promise.

Nene V.Trends Parasitol. 2025 Aug;41(8):620-627. doi: 10.1016/j.pt.2025.06.008. Epub 2025 Jul 10.PMID: 40645885

Author Correction: Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection.

Shen J, Li J, Shen Q, Hou J, Zhang C, Bai H, Ai X, Su Y, Wang Z, Zhang Y, Xu B, Hao J, Wang P, Zhang Q, Ye AY, Li Z, Feng T, Li L, Qi F, Wang Q, Sun Y, Liu C, Xi X, Yan L, Hong H, Chen Y, Xie X, Xie J, Liu X, Du R, Plebani R, Zhang L, Zhou D, Church G, Si L.Nat Microbiol. 2025 Aug;10(8):2093. doi: 10.1038/s41564-025-02053-0.PMID: 40506515

Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults.

Prosser LA, Wallace M, Rose AM, Mercon K, Janusz CB, Gebremariam A, Hutton DW, Leidner AJ, Zhou F, Ortega-Sanchez IR, Moulia D, Link-Gelles R, Saydah S, Shah M, Pike J.JAMA Netw Open. 2025 Aug 1;8(8):e2523688. doi: 10.1001/jamanetworkopen.2025.23688.PMID: 40773198

VaxPulse: Active Global Vaccine Infodemic Risk Assessment.

Dimaguila GL, Javed M, Munakabayo J, Khademi S, Clothier H, Hickman J, Buttery J.Stud Health Technol Inform. 2025 Aug 7;329:1185-1189. doi: 10.3233/SHTI251026.PMID: 40776044

Sterilized protective immunity induced by DAM and DAM^{+} in mouse models for both VACV and MPXV.

Gao Z, Zheng T, Wu J, Ding H, Lu J, Si J, Xu Y, Liu H, Yu G, Ma R, Qi J, Zhao Y, Ran J, Wang Q, Ma X, Liu Z, Wang H, Gao GF.Sci Bull (Beijing). 2025 Aug 15;70(15):2514-2524. doi: 10.1016/j.scib.2025.05.013. Epub 2025 May 14.PMID: 40484742

Awareness and acceptability of herpes zoster vaccination in people living with HIV.

Motet C, Libois A, Martin C, Dauby N.Prev Med Rep. 2025 Jun 16;56:103143. doi: 10.1016/j.pmedr.2025.103143. eCollection 2025 Aug.PMID: 40606641

Respiratory syncytial virus vaccine effectiveness.

Wagner J.Lancet. 2025 Aug 9;406(10503):599. doi: 10.1016/S0140-6736(25)01229-2.PMID: 40783284

Expanding human papillomavirus vaccine options.

Vorsters A, Amponsah-Dacosta E.Lancet Infect Dis. 2025 Aug;25(8):829-830. doi: 10.1016/S1473-3099(25)00144-6. Epub 2025 Mar 19.PMID: 40120598

Estimating community-wide indirect effects of influenza vaccination: triangulation using mathematical models and bias analysis.

Arinaminpathy N, Reed C, Biggerstaff M, Nguyen AT, Athni TS, Arnold BF, Hubbard A, Reingold A, Benjamin-Chung J.Am J Epidemiol. 2025 Aug 5;194(8):2412-2422. doi: 10.1093/aje/kwae365.PMID: 39290087

Impact of Covid-19 Pandemic on Knowledge and Attitude of Nursing Students Regarding Vaccination and Vaccine Hesitancy in China: A Cross-Sectional Study.

Li L, Zhang C, Han B, Wang H, Li X, Qiao C.Health Sci Rep. 2025 Jul 30;8(8):e71078. doi: 10.1002/hsr2.71078. eCollection 2025 Aug.PMID: 40740286

Preparation and immunogenicity studies of NvIBDV VP2-ferritin nanoparticles.

Gao S, Zhou X, Li X, Luo L, Yang K, Huang Y, Bao Y, Wu X, Guo Y, Li J, Shao Y, Wang L, Liu Z, Sun M, Liang L.BMC Vet Res. 2025 Aug 6;21(1):506. doi: 10.1186/s12917-025-04914-6.PMID: 40764574

Lyophilized SARS-CoV-2 self-amplifying RNA vaccines for microneedle array patch delivery.

Driskill MM, Coates IA, Hurst PJ, Rajesh NU, Dulay MT, Waymouth RM, Akahata W, Matsuda K, Smith JF, Jacobson GB, Perry JL, Tian S, DeSimone JM.J Control Release. 2025 Aug 10;384:113944. doi: 10.1016/j.jconrel.2025.113944. Epub 2025 Jun 9.PMID: 40499765

Democracy, Trust, and Political Orientation: Disentangling Mechanisms Shaping Individuals' Vaccine Attitudes.

Antonini M, Singh R, Melegaro A, Torbica A, Ward JK, Berardi C, Attwell K, Kellner A, Feiring E, Hagen TP, Genie M, Murauskienė L, McGregor N, Sequeira AR, Yang D, Paolucci F.J Health Polit Policy Law. 2025 Aug 11:12166725. doi: 10.1215/03616878-12166725. Online ahead of print.PMID: 40785020

Effect of a multicomponent HPV intervention on self-reported HPV vaccine uptake and intention among French adolescents and parents: results from the national, cluster-randomised PrevHPV trial.

Dussault J, Gagneux-Brunon A, Le Duc-Banaszuk AS, Bruel S, Michel M, Gauchet A, Oudin Doglioni D, Sicsic J, Raude J, Barret AS, Thilly N, Mueller JE; PrevHPV Group.BMJ Public Health. 2025 Aug 3;3(2):e001007. doi: 10.1136/bmjph-2024-001007. eCollection 2025.PMID: 40761362

Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.

Agbenyega T, Schuind AE, Adjei S, Antony K, Aponte JJ, Buabeng PBY, Clemens JD, Hossain L, Kemp TJ, Mercer LD, Pinto LA, Qadri F, Sukraw K, Bhat N, Zaman K.Lancet Infect Dis. 2025 Aug;25(8):861-872. doi: 10.1016/S1473-3099(25)00031-3. Epub 2025 Mar 19.PMID: 40120597

Willingness to Pay for the COVID-19 Vaccine and Its Correlates in Bangladesh: Cross-Sectional Study.

Hossain MB, Alam MZ, Islam MS, Sultan S, Faysal MM, Rima S, Hossain MA, Mamun AA, Mamun AA.JMIRx Med. 2025 Aug 15;6:e69827. doi: 10.2196/69827.PMID: 40815785

Long-term immunogenicity and boostability of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in adults receiving immunosuppressive therapy and adults living with HIV - 3-year follow-up of a prospective cohort study.

Schnyder JL, Haggenburg S, Garcia Garrido HM, Reiners A, Meek B, Grobusch MP, Goorhuis A.Clin Infect Dis. 2025 Aug 6:ciaf438. doi: 10.1093/cid/ciaf438. Online ahead of print.PMID: 40794691

Effect of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients.

Bea S, Ahn HY, Woo J, Shin JY, Cho SW.J Clin Endocrinol Metab. 2025 Aug 7;110(9):e3109-e3116. doi: 10.1210/clinem/dgae858.PMID: 39657695

Rotavirus Vaccine Effectiveness Stratified By National-Level Characteristics: An Introduction to the 24-Country MNSSTER-V Project, 2007-2023.

Burnett E, Umana J, Anwari P, Mujuru HA, Groome MJ, Van Trang N, Iniguez V, Gheorghita S, Sahakyan G, Nazurdinov A, Michael F, Mandomando I, Desormeaux AM, Eraliev U, Enweronu-Laryea C, Nalunkuma C, Bonkoungou I, Muhsen K, Luhata Lungayo C, Omore R, Goldfarb DM, Robinson AL, McCracken J, Uwimana J, N'Zue K, Rey-Benito G, Weldegebriel G, Mwenda JM, Parashar UD, Tate JE.J Infect Dis. 2025 Aug 14;232(2):308-315. doi: 10.1093/infdis/jiae597.PMID: 39607893

The roles of tissue-resident memory T cells (TRMs) in diseases and vaccine development: A comprehensive review.

Wei H, Wang Y, Jiang S, Zhang X, Zhang J.Vaccine. 2025 Aug 10;62:127605. doi: 10.1016/j.vaccine.2025.127605. Online ahead of print.PMID: 40789264

Superior immune responses from thermostable, single-administration rabies vaccines prepared using atomic layer deposition.

Randolph T, Coleman H, Rauch AM, Hubert H, Witeof AE, Walker KD, Funke HH, Garcea RL.J Pharm Sci. 2025 Aug 5;114(9):103936. doi: 10.1016/j.xphs.2025.103936. Online ahead of print.PMID: 40759319

Prioritizing countries for TB vaccine readiness research using a global stakeholder-centric approach.

Gill MM, Limaye R, Pelzer PT, Frick M, Kerkhoff AD.PLOS Glob Public Health. 2025 Aug 1;5(8):e0004668. doi: 10.1371/journal.pgph.0004668. eCollection 2025.PMID: 40749042

Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study.

Mahathumnuchok T, Koosakulchai V, Sangsupawanich P, Intapiboon P, Rachatawiriyakul P, Sangiemchoey A, Kaewpiboon K, Yuenyongviwat A.Trop Dis Travel Med Vaccines. 2025 Aug 14;11(1):30. doi: 10.1186/s40794-025-00266-z.PMID: 40814071

Improved Resolution of Influenza Vaccination Responses With High-Throughput Live Virus Microneutralisation.

Adams L, Stevenson-Leggett P, Lee JL, Bazire J, Dowgier G, Hobbs A, Roustan C, Borg A, Carr C, Innocentin S, Webb LMC, Smith C, Bawumia P, Lewis N, O'Reilly N, Kjaer S, Linterman MA, Harvey R, Wu MY, Carr EJ.Influenza Other Respir Viruses. 2025 Aug;19(8):e70140. doi: 10.1111/irv.70140.PMID: 40812785

Whole recombinant yeast-based vaccines: concept, importance, issues, and future scope.

Kumar R, Srivastava V, Ahmad A, Mandal SM, Baindara P.Crit Rev Biotechnol. 2025 Aug 4:1-16. doi: 10.1080/07388551.2025.2536808. Online ahead of print.PMID: 40759560

Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older.

Komiya K, Hirano Y, Kamei K, Yoshida A, Morii J, Kobayashi R, Sato R.Infect Dis Ther. 2025 Aug;14(8):1755-1773. doi: 10.1007/s40121-025-01177-4. Epub 2025 Jul 6.PMID: 40618285

Healthcare workers' attitudes toward influenza vaccine prescriptions in China.

Cao Y, Wang Q, Zhao J, Zhang Y, Huo R, Li Q, Yang W, Yi H, Feng L.Glob Health Res Policy. 2025 Aug 4;10(1):34. doi: 10.1186/s41256-025-00430-0.PMID: 40760695

A qualitative study on barriers and facilitators of COVID-19 vaccination during pregnancy among pregnant women in Malaysia.

Mohamed Pauzi MH, Abdul Kadir A, Muhamad R, Mat Yudin Z.PLoS One. 2025 Aug 8;20(8):e0329895. doi: 10.1371/journal.pone.0329895. eCollection 2025.PMID: 40779546

Human T Cell Responses to Flavivirus Vaccines.

Wullimann D, Ljunggren HG.Eur J Immunol. 2025 Aug;55(8):e70027. doi: 10.1002/eji.70027.PMID: 40820807

Adenovirus Nanoparticles Displaying RBD Induce a Protective Immune Response Against BA.5 in Mice.

Mo C, Wang Z, Liu D, Yang X, Zhang Q, Ye L, Yuan S, Deng S, Lai Z, Huang D, Yang Y, Xu D, Yuan J, Zhu Y, Liu H, Zhou C, Liao X, Li X, Liu W, Zhou R, Tian X.Int J Nanomedicine. 2025 Aug 6;20:9771-9785. doi: 10.2147/IJN.S511173. eCollection 2025.PMID: 40791772

One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial.

Kuriyama K, Murakami K, Sugiura K, Sakui S, Schuring RP, Mori M.Vaccine. 2025 Aug 2;62:127562. doi: 10.1016/j.vaccine.2025.127562. Online ahead of print.PMID: 40753673

Commentary: Sex Differences in the COVID-19 Vaccine Uptake in the United States.

Moghadami M, Karimi SM.Am J Health Promot. 2025 Aug 4:8901171251362791. doi: 10.1177/08901171251362791. Online ahead of print.PMID: 40758766

Children's socio-moral reasoning about vaccine-like behaviors.

Probst S, Warneken F.J Health Psychol. 2025 Aug;30(9):2250-2263. doi: 10.1177/13591053251314684. Epub 2025 Feb 5.PMID: 39910950

Immunostimulatory effects of multiple short-hairpin RNAs enhance foot-and-mouth disease vaccine-induced humoral immunity.

Kim A, Hwang JH, Lee G, Park JH, Lee MJ, Kim SM.Antiviral Res. 2025 Aug;240:106202. doi: 10.1016/j.antiviral.2025.106202. Epub 2025 May 27.PMID: 40441607

Structural basis of broad protection against influenza virus by human antibodies targeting the neuraminidase active site via a recurring motif in CDR H3.

Jo G, Yamayoshi S, Ma KM, Swanson O, Torres JL, Ferguson JA, Fernández-Quintero ML, Huang J, Copps J, Rodriguez AJ, Steichen JM, Kawaoka Y, Han J, Ward AB.Nat Commun. 2025 Aug 1;16(1):7067. doi: 10.1038/s41467-025-62174-2.PMID: 40750588

Papillomavirus vaccine: a revolution in the fight against cervical cancer in the Democratic Republic of Congo.

Tague C, Yokolo H, Makeda D, Ekouo J, Kihanduka E, Akilimali A.Ann Med Surg (Lond). 2025 Jun 25;87(8):4701-4703. doi: 10.1097/MS9.0000000000003492. eCollection 2025 Aug.PMID: 40787539

In Silico Identification of Antigenic Peptides and multi-epitope Vaccine Design against Trichomonas Vaginalis.

Ikram E, Yavas C, Akcali N, Batur LK, Eslamkhah S, Koseoglu AE, Aslan ES.Acta Parasitol. 2025 Aug 8;70(4):174. doi: 10.1007/s11686-025-01111-1.PMID: 40779085

Co-design as a participatory approach for enhancing HPV health literacy among youths: a program evaluation.

Dennehy J, Rauh L, Nahar K.Ann Med. 2025 Dec;57(1):2535519. doi: 10.1080/07853890.2025.2535519. Epub 2025 Aug 4.PMID: 40757412

Can an AI Chatbot Employ Psychological Counseling Techniques to Motivate Individuals to Receive Vaccinations?

Li Y, Li M, Lu W, He M.Stud Health Technol Inform. 2025 Aug 7;329:1958-1959. doi: 10.3233/SHTI251298.PMID: 40776315

An Investigation of MMR-Related Mumps Cluster Following Immunization Among Practical Nursing Students, Bangkok, Thailand, 2024.

Lertsakulbunlue S, Srithammavong D, Tepsittha K, Kanjanasombut H, Poonyakanok V, Luvira V, Pisutsan P, Charoenwisedsil R, Leowattana P, Watakulsin P, Suphanchaimat R, Lukebua A, Dangsagul W, Kwanchum K, Rattanathumsakul T, Doungngern P.J Trop Med. 2025 Aug 1;2025:9974081. doi: 10.1155/jotm/9974081. eCollection 2025.PMID: 40787098

Vaccination protects animal and human health and reduces the economic burden of preventable cases: rabies in vaccinated dogs and cats (2002-2022).

Nathan M, Boutelle C, Ross Y, Wallace RM, Bonaparte S.J Am Vet Med Assoc. 2025 Aug 1:1-10. doi: 10.2460/javma.25.01.0036. Online ahead of print.PMID: 40752523

Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia.

Kättström M, Uggla B, Virta C, Melin M, Ekström N, Magnuson A, Andersson PO, Hammarlund Y, Lockmer S, Nilsson I, Roth D, Svensson M, Tolf T, Kimby E, Norén T, Athlin S.Haematologica. 2025 Aug 1;110(8):1774-1785. doi: 10.3324/haematol.2024.286942. Epub 2025 Mar 6.PMID: 40045895

A single-dose intranasal immunization with a novel bat influenza A virus-vectored MERS vaccine provides effective protection against lethal MERS-CoV challenge.

Shi L, Roy S, Lang Y, Wen Y, Mitchell WJ, Yang W, Wang L, Zhang J, Liu H, Driver JP, Peiris M, Ma W.mBio. 2025 Aug 13;16(8):e0110725. doi: 10.1128/mbio.01107-25. Epub 2025 Jun 30.PMID: 40586550

Development and reproductive safety of AdCLD-CoV19, an adenoviral vector-based COVID-19 vaccine, in female Sprague-Dawley rats and their offspring.

Park SJ, Kim S, Kim S, Shin KS, Kang CY, Hong EJ, Im WJ, Jeong JS, Yu WJ, Ko KC, Kim YB.Toxicol Appl Pharmacol. 2025 Oct;503:117503. doi: 10.1016/j.taap.2025.117503. Epub 2025 Aug 6.PMID: 40780534

The United Kingdom meningococcal vaccine (4CMenB) programme against gonorrhoea: A review of the evidence and knowledge gaps.

Ladhani SN, Mandal S, Mohammed H, Saunders J, Andrews N, Ramsay ME, Fifer H.J Infect. 2025 Aug 7;91(3):106582. doi: 10.1016/j.jinf.2025.106582. Online ahead of print.PMID: 40782890

COVID-19 vaccine attitudes, beliefs, intentions and behaviors among pregnant women within the context of dynamic national policy recommendations in Brazil, Ghana, Kenya, and Pakistan.

Schue JL, Miller ES, Fesshaye B, Singh P, Souza RT, Badzi CD, Amoah EM, Jessani S, Asim M, Gichere I, Costa ML, Cecatti JG, Torpey K, Saleem S, Temmerman M, Gottlieb SL, Limaye RJ.Vaccine. 2025 Aug 6:127595. doi: 10.1016/j.vaccine.2025.127595. Online ahead of print.PMID: 40774917

Community willingness to participate in a Nipah vaccine trial in Bangladesh.

Nahar N, Parveen S, Gurley ES, Ghosh PK, Jabeen I, Haidar MR, Jahan F, Munim MS, Chanda KF, Ali MW, Akhtar Z, Shirin T, Banu S, Chowdhury AI, Alam A, Dawes BE, Fusco J, Monath TP, Heppner G, Luby SP.Vaccine. 2025 Aug 9;62:127578. doi: 10.1016/j.vaccine.2025.127578. Online ahead of print.PMID: 40784108

Coxiella burnetii: Emerging threats, molecular insights, and advances in diagnosis and control measures.

Mohammadi MR, Moradkasani S, Latifian M, Esmaeili S.J Microbiol Methods. 2025 Aug 5:107213. doi: 10.1016/j.mimet.2025.107213. Online ahead of print.PMID: 40774611

Protective efficacy and immune response to adjuvanted Pseudomonas putida ghost vaccine in Nile tilapia.

Abd-Elrasoul O, Soliman H, Marzouk Fouad A.Fish Shellfish Immunol. 2025 Aug 8;166:110648. doi: 10.1016/j.fsi.2025.110648. Online ahead of print.PMID: 40784511

Recent Developments of RNA Vaccines and Therapeutics: Reagents, Formulations, and Characterization.

Tomeh MA, Smith RK, Watkinson A.Mol Pharm. 2025 Aug 11. doi: 10.1021/acs.molpharmaceut.5c00670. Online ahead of print.PMID: 40788115

An Overview of Vaccine Development Strategies for Columnaris-Causing Bacteria in Cultured Fish.

Harrison CE, LaFrentz BR, Shoemaker CA, Lange MD, Liles MR, Mohammed HH, Beck BH, Churchman EM, Peatman E, Bruce TJ.J Fish Dis. 2025 Aug;48(8):e14155. doi: 10.1111/jfd.14155. Epub 2025 May 30.PMID: 40448373

Community readiness and acceptance for the implementation of the malaria vaccine among caretakers of at-risk children in sub-Saharan Africa: a systematic review and meta-analysis.

Kigongo E, Puleh SS, Kabunga A, Akech SI, Ocen F, Opollo MS, Ebong M.Malar J. 2025 Aug 12;24(1):259. doi: 10.1186/s12936-025-05384-9.PMID: 40797258

Willingness to pay and preference for HPV vaccine among parents in China: A study based on a multi-center cross-sectional survey.

Luo W, Wang D, Qin R, Xu G, Zhou L.Hum Vaccin Immunother. 2025 Dec;21(1):2531651. doi: 10.1080/21645515.2025.2531651. Epub 2025 Aug 7.PMID: 40773223

Adjuvanted recombinant zoster vaccine is effective against herpes zoster ophthalmicus, and is associated with lower risk of acute myocardial infarction and stroke in adults aged 50 years.

Rayens E, Sy LS, Qian L, Wu J, Ackerson BK, Luo Y, Zheng C, Cheng Y, Vega Daily LI, Song J, Takhar HS, Ku JH, Cohen RA, Yun H, Oraichi D, Seifert H, Tseng HF.Clin Infect Dis. 2025 Aug 9:ciaf440. doi: 10.1093/cid/ciaf440. Online ahead of print.PMID: 40795767

Immunoinformatics study of CD40 ligand-targeting vaccine constructs: a novel immunotherapeutic approach.

Sadeghi SA, Mohamadi M, Bamehr H, Heidarnejad F, Bolhassani A.Osong Public Health Res Perspect. 2025 Aug 11. doi: 10.24171/j.phrp.2025.0077. Online ahead of print.PMID: 40785381

SARS-CoV-2 vaccines elicit differential Fc effector functions.

Manamela NP, Motsoeneng BM, Spencer H, Hermanus T, Mzindle N, Ayres F, Makhado Z, Serage R, Gray GG, Bekker LG, Madhi SA, Moore PL, Richardson SI.iScience. 2025 Jul 9;28(8):113084. doi: 10.1016/j.isci.2025.113084. eCollection 2025 Aug 15.PMID: 40740485

Immunogenic mutanome of breast cancer: Advances, challenges and future directions in neoantigen-based immunotherapy.

Alkayyal AA, Saeedi NH, Moawadh MS.Adv Clin Exp Med. 2025 Aug 1. doi: 10.17219/acem/205014. Online ahead of print.PMID: 40748773

A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naive Japanese adults 65 years of age.

Kishino H, Inoue S, Matsuoka O, Yagi M, Igarashi R, Oshima N, Sawata M, Platt HL.Vaccine. 2025 Aug 4;62:127456. doi: 10.1016/j.vaccine.2025.127456. Online ahead of print.PMID: 40763490

BNT162b2 XBB.1.5-Adapted Single Dose Vaccine Uptake and Effectiveness in Children Aged 5-17 Years in California and Louisiana.

Andersen KM, McColgan MD, Mateus JS, Yu T, Zhou A, Puzniak L, Lopez SMC.J Pediatr. 2025 Aug 14:114778. doi: 10.1016/j.jpeds.2025.114778. Online ahead of print.PMID: 40818804

Development of multiplexed flow based assay for simultaneous identification and estimation of meningococcal capsular polysaccharide serogroups A, C, W, Y and X for conjugate vaccine manufacturing.

Patni S, Verma R, Desarda M, Naikwade S, Deorukhakar H, Dhere R, Mallya A.J Immunol Methods. 2025 Aug;542:113895. doi: 10.1016/j.jim.2025.113895. Epub 2025 Jun 8.PMID: 40494493

A candidate multi-epitopes vaccine against encephalomyocarditis virus confers protection in mice.

Li H, Cheng R, Dong P, Chen Y, Mo R, Yue J, Li D, Yang Y, Ali A, Li X, Feng R.Vet Microbiol. 2025 Aug;307:110621. doi: 10.1016/j.vetmic.2025.110621. Epub 2025 Jun 26.PMID: 40592123

The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trial.

Saso A, Kanteh E, Jeffries D, Okoye M, Mohammed N, Kumado M, Roetynck S, Jobe H, Faal A, Roberts E, Gageldonk P, Buisman AM, Fröberg J, Cavell B, Lesne E, Barkoff AM, He Q, Tanha K, Bibi S, Kelly D, Diavatopoulos D, Kampmann B; Gambian Pertussis Study Team; members of the PERISCOPE consortium.Lancet Infect Dis. 2025 Aug;25(8):909-924. doi: 10.1016/S1473-3099(25)00072-6. Epub 2025 Mar 25.PMID: 40154521

Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among adults aged 50 years and older in Germany.

Waize M, Marijic P, Marijam A, Gkalapi F, Turriani E, Jakobs F, Jaidhauser I, Münch D, Pedron S, Zarkadoulas E.Expert Rev Vaccines. 2025 Dec;24(1):782-796. doi: 10.1080/14760584.2025.2539887. Epub 2025 Aug 5.PMID: 40718894

An intranasal quadruple variant vaccine approach using SARS-CoV-2 and influenza A: Delta, Omicron, H1N1and H3N2.

Singh R, Gulani M, Vijayanand S, Arte T, Adediran E, Pasupuleti D, Patel P, Ferguson A, Uddin M, Zughaier SM, D'souza MJ.Int J Pharm. 2025 Aug 6;683:126043. doi: 10.1016/j.ijpharm.2025.126043. Online ahead of print.PMID: 40759221

Vaccination in dermatology 2025: Update considering current recommendations of the German Standing Committee on Vaccination.

Stoevesandt J, Schmalzing M, Mohme S, Goebeler M.J Dtsch Dermatol Ges. 2025 Aug;23(8):925-930. doi: 10.1111/ddg.15785. Epub 2025 Jun 11.PMID: 40495641

Exploring Blockchain Technology to Improve Vaccine Access in Low-Resource Countries.

Babu A, Dacso M, He Y, Amith M.Stud Health Technol Inform. 2025 Aug 7;329:2090-2091. doi: 10.3233/SHTI251364.PMID: 40776381

Immunogenicity of monovalent and multivalent subunit vaccines against SARS-CoV-2 variants in mice with divergent vaccination history.

Wang R, Lyu Y, Chen M, Sun L, Zhou S, Cui Y, Ma J, Kong D, Lu J, Li X, Xie L.Microbiol Spectr. 2025 Aug 5;13(8):e0290724. doi: 10.1128/spectrum.02907-24. Epub 2025 Jul 17.PMID: 40673708

Pandemic transition: A review of social media text mining for pandemic transition in the post-vaccination era.

Bakhshaei K, Rezaei Z, Ahmadi M, Banad YM.Artif Intell Med. 2025 Aug 14;169:103242. doi: 10.1016/j.artmed.2025.103242. Online ahead of print.PMID: 40819607

Development of an epitope-based vaccine from mycoplasma genitalium adhesion protein: addressing antibiotic resistance through immune-informatics.

Rehman HM, Bilal M, Muhammad Shoaib, Latif T, Syed R, Khalid F, Khan MN, Khan SA, Ahmed N, Tahir S, Bashir H.Toxicol Res (Camb). 2025 Jul 27;14(4):tfaf102. doi: 10.1093/toxres/tfaf102. eCollection 2025 Aug.PMID: 40726761

Challenges associated with pertussis detection, monitoring, and vaccination in adults.

Regan AK.Expert Rev Anti Infect Ther. 2025 Aug;23(8):639-650. doi: 10.1080/14787210.2025.2516556. Epub 2025 Jul 9.PMID: 40591517

Exploring off-label vaccine use: a survey of the global national immunization technical advisory group network.

Roberts C, Top KA, Henaff L, Tunis M, Singh A, van Holten J, Ruta S, Desai S.Vaccine. 2025 Aug 12;62:127581. doi: 10.1016/j.vaccine.2025.127581. Online ahead of print.PMID: 40803145

Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden.

Malinga J, Braunack-Mayer L, Masserey T, Cavelan A, Chandramohan D, Dicko A, Ouédraogo JB, Kelly SL, Le Rutte EA, Nekkab N, Penny MA.PLOS Glob Public Health. 2025 Aug 4;5(8):e0004549. doi: 10.1371/journal.pgph.0004549. eCollection 2025.PMID: 40758687

The impact of egg adaptation and immune imprinting on influenza vaccine effectiveness.

Ashraf M, Stein AN, Youhanna J, Rockman S, McMahon M, McGovern I, Rajaram S, Miller MS.Vaccine. 2025 Aug 13;62:127393. doi: 10.1016/j.vaccine.2025.127393. Online ahead of print.PMID: 40812022

Trust, A Key to Counter Vaccine Hesitancy.

Abdelkader S, Jefferson AA.J Infect Dis. 2025 Aug 14;232(2):274-277. doi: 10.1093/infdis/jiaf239.PMID: 40338052

SARS-CoV-2: lessons in virus mutation prediction and pandemic preparedness.

Tang W, Kim J, Lee RT, Maurer-Stroh S, Renia L, Tay MZ.Curr Opin Immunol. 2025 Aug;95:102560. doi: 10.1016/j.coi.2025.102560. Epub 2025 May 15.PMID: 40378522

PRRSV vector vaccine based on VEEV-VSVG recombinant replicon elicits efficient immune responses in piglets.

Rong Z, Jiao M, Tian L, Wang X, Zhang M, Zhang C, Liu S, Wei L, Chen H, Li X, Qian P.Vaccine. 2025 Aug 1;62:127572. doi: 10.1016/j.vaccine.2025.127572. Online ahead of print.PMID: 40752247

Construction and protective evaluation of a recombinant attenuated Salmonella vaccine delivering Mycoplasma synoviae antigens.

Zhang G, Han L, Zhao Y, Li Z, Li YA, Li Q, Wang S, Shi H.Virulence. 2025 Dec;16(1):2545554. doi: 10.1080/21505594.2025.2545554. Epub 2025 Aug 11.PMID: 40778425

Adverse drug reactions following SARS-CoV-2 vaccination of 3805 healthcare workers cause substantial sick-leave and are correlated to vaccine regimen, age, sex and serological response.

Lidström AK, Albinsson B, Sund F, Lindbäck J, van Hunsel F, Fall T, Westman G.Vaccine. 2025 Aug 6;62:127553. doi: 10.1016/j.vaccine.2025.127553. Online ahead of print.PMID: 40773962

From adhesion to invasion: the multifaceted roles of *Mycobacterium tuberculosis* lipoproteins.

Li M, Zhang Q, Wang Y, Xie J, Liang T, Liu Z, Xiang X, Zhou Q, Gong Z.J Drug Target. 2025 Aug;33(7):1088-1097. doi: 10.1080/1061186X.2025.2472208. Epub 2025 Mar 3.PMID: 39993287

Improving Human Papillomavirus (HPV) Vaccine Uptake in Canada: A Call for Equity and Inclusivity.

Doucette N, Steenbeek A.Community Health Equity Res Policy. 2025 Aug 14:2752535X251368427. doi: 10.1177/2752535X251368427. Online ahead of print.PMID: 40808520

The PB subunit vaccine evokes immune response against fox encephalitis.

Xu J, Zhang B, Wang B, Ye Z, Yin B, Zhu Y.Virology. 2025 Aug;609:110561. doi: 10.1016/j.virol.2025.110561. Epub 2025 Apr 30.PMID: 40373715

Obese individuals exhibit distinct temporal gene expression dynamics in response to influenza vaccination.

Hockman M, Matthews J, Carlock MA, Ross TM, Gresham D, Ghedin E.Microbiol Spectr. 2025 Aug 5;13(8):e0335424. doi: 10.1128/spectrum.03354-24. Epub 2025 Jun 23.PMID: 40548708

Motivational Interviewing for Vaccine Uptake in Latinx Adults (MI Vacuna): Study protocol for a pragmatic multiple-period cluster-randomized crossover trial.

Scrivano RM, van de Water BJ, Rueras N, Alfonso J, McManama O'Brien KH, Soto X, Caumeran VJS, Campos BM, Mancusi M, Diehl B, Southwick E, Moreno E, Bora C, Armbruster S, Abuelezam NN, Calvo R, Haneuse S, Davison KK.Contemp Clin Trials. 2025 Aug;155:107987. doi: 10.1016/j.cct.2025.107987. Epub 2025 Jun 14.PMID: 40523466

Retraction notice to "Effect of vaccine education intervention on vaccine uptake and vaccine knowledge among older adults: A systematic review with meta-analysis" [Vaccine 56 (2025) 127182].

Chan YT, Chair SY, Gao RT, Ng MH, Lee VWY.Vaccine. 2025 Aug 6:127570. doi: 10.1016/j.vaccine.2025.127570. Online ahead of print.PMID: 40774916

Biomimetic Apatite Nanoparticles and Microcrystalline Tyrosine as Biocompatible Vaccine Adjuvants: Performance in a Bluetongue Virus Sheep Model.

Pérez E, Sebastián V, Rodríguez-Largo A, de Miguel R, Gómez Á, Kramer MF, Graessel A, Parra-Torrejón B, Delgado-López JM, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J, de Blas I, Reina R, Pérez M, Luján L.ACS Appl Mater Interfaces. 2025 Aug 13;17(32):45538-45554. doi: 10.1021/acsami.5c10402. Epub 2025 Jul 8.PMID: 40626498

The influence of SARS-CoV-2 vaccination on in vitro fertilization outcomes.

Heusler AA, Weintraub A, Stein D, Melamed-Yekel Y, Kalfon S, Pasternak Y, Kulak D.Hum Vaccin Immunother. 2025 Dec;21(1):2541495. doi: 10.1080/21645515.2025.2541495. Epub 2025 Aug 3.PMID: 40754982

A multivalent mRNA vaccine elicits robust immune responses and confers protection in a murine model of monkeypox virus infection.

Li Y, Cheng L, Jiang L, Li Z, Rao J, Wu T, Zhang F, Xie B, He Y, Wang L, Zhang Z, Chen S.Nat Commun. 2025 Aug 9;16(1):7373. doi: 10.1038/s41467-025-61699-w.PMID: 40783493

Real-world effectiveness of recombinant herpes Zoster vaccine: a retrospective, cohort study in Japan.

Ohfuji S, Toyama N, Kondo K, Muto H, Fukushima W.BMC Infect Dis. 2025 Aug 5;25(1):985. doi: 10.1186/s12879-025-11369-5.PMID: 40764905

A Video-Based Intervention to Assess COVID-19 and Influenza Vaccine Acceptability in a Pediatric Emergency Department.

Ebbing B, Fullerton L, Putnam S, Kundurti N, Dehority W.Pediatr Emerg Care. 2025 Aug 12. doi: 10.1097/PEC.0000000000003466. Online ahead of print.PMID: 40790526

Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged 50 years with a history of herpes zoster: A phase 3, randomized controlled trial.

Jegede B, Zhou Y, Hawksworth H, Hui DSC, Montenegro Guerra N, Põder A, Ramon JM, Välimaa H, Villanueva-Quintero GD, Mwakingwe-Omari A; Z-062 study group.J Infect. 2025 Aug 6;91(3):106573. doi: 10.1016/j.jinf.2025.106573. Online ahead of print.PMID: 40780591

Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign.

Nicola S, Badiu I, Rashidy N, Saracco E, Montabone E, Lo Sardo L, Boem M, Marmora V, Corradi F, Ricotti A, Borrelli R, Rolla G, Negrini S, Brussino L.World Allergy Organ J. 2025 Jul 28;18(8):101095. doi: 10.1016/j.waojou.2025.101095. eCollection 2025 Aug.PMID: 40761579

Policy recommendations for healthcare authorities, organizations and professionals on vaccine hesitancy in Europe: From evidence to practice.

Correia T, Hilário AP, Guerreiro C, Mendonça J, Morais R, Augusto FR, Beja A.Health Policy. 2025 Aug;158:105361. doi: 10.1016/j.healthpol.2025.105361. Epub 2025 May 29.PMID: 40446640

A monkeypox nanovaccine candidate based on three protein antigens and silica nanoparticles.

Wei Z, Zhao X, Yu W, Shen L, Yang Y, Qi J, Hu T.Int J Biol Macromol. 2025 Aug;319(Pt 2):145471. doi: 10.1016/j.ijbiomac.2025.145471. Epub 2025 Jun 23.PMID: 40562151

[Immunosuppression in Cancer: Strategies for Infection Prevention].

Schwicht C, von Bergwelt-Baildon M, Spiekermann K.Dtsch Med Wochenschr. 2025 Aug;150(17):1013-1018. doi: 10.1055/a-2414-8494. Epub 2025 Aug 7.PMID: 40774301

Engaging rural and non-Hispanic Black persons in conversations about the COVID-19 vaccine: a process evaluation of a natural helper intervention.

McGee RE, Barrett DA, Bednarczyk RA, Grant-Whitlock M, Kegler MC, Jacob Arriola KR.Vaccine. 2025 Aug 8;60 Suppl 1:127587. doi: 10.1016/j.vaccine.2025.127587. Online ahead of print.PMID: 40784327

Immunization errors of COVID-19 vaccines in Minas Gerais.

Ferreira WV, Andrade TIX, Barbosa TCP, Santos RCD, Oliveira SH, Guimarães VC, Guimarães EAA, Oliveira VC.Rev Bras Enferm. 2025 Aug 8;78(3):e20230525. doi: 10.1590/0034-7167-2023-0525. eCollection 2025.PMID: 40802435

Influence of structural modifications in synthetic vectors of lipid adjuvants on mRNA vaccine delivery.

Chilumula S, Hanchate P, Patri SV, Marepally S.Biomater Sci. 2025 Aug 12. doi: 10.1039/d5bm00839e. Online ahead of print.PMID: 40792498

Membrane Expression Enhances Folding, Multimeric Structure Formation, and Immunogenicity of Viral Capsid Proteins.

Cui J, Yuan F, Qin J, Jeon JH, Yun DS, Wang T, Xu R, Cao H, Tungate AA, Netherton CL, Chen J.ACS Infect Dis. 2025 Aug 8;11(8):2104-2115. doi: 10.1021/acsinfecdis.5c00067. Epub 2025 Jul 9.PMID: 40632771

Serotyping, molecular typing, and vaccine protein screening for Riemerella anatipestifer: Overcoming challenges in prevention and treatment.

Li Y, Huang Z, Zhu X, Liu C, Cao S, Li Y.Vet Microbiol. 2025 Aug 8;309:110663. doi: 10.1016/j.vetmic.2025.110663. Online ahead of print.PMID: 40818300

Evaluation of a bivalent vaccine composed of iron scavenger receptors PMI1426 and PMI1945 against Proteus mirabilis.

Mohammadzadeh R, Habibi M, Asadi Karam MR.Future Microbiol. 2025 Aug;20(11):723-733. doi: 10.1080/17460913.2025.2525711. Epub 2025 Jul 2.PMID: 40600645

Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies.

Gallo M, Lasagna A, Renzelli V, Morviducci L, Cortellini A, Monami M, Marino G, Gori S, Verzé M, Ragni A, Tuveri E, Sciacca L, D'Oronzo S, Giuffrida D, Natalicchio A, Giorgino F, Marrano N, Zatelli MC, Montagnani M, Felicetti F, Mazzilli R, Fogli S, Franchina T, Argentiero A, Candido R, Perrone F, Aimaretti G, Avogaro A, Silvestris N, Faggiano A.J Endocrinol Invest. 2025 Aug;48(8):1717-1738. doi: 10.1007/s40618-025-02586-5. Epub 2025 Apr 23.PMID: 40266540

Oral immunization with a DNA vaccine encoding capsid protein and IFN-gamma provokes efficient and long-term immunity against nervous necrosis virus.

Peng H, Zhang C, Shang C, Wei C, Wu Y, Cao Z, Li P, Zhou Y, Sun Y.Fish Shellfish Immunol. 2025 Aug 6;166:110641. doi: 10.1016/j.fsi.2025.110641. Online ahead of print.PMID: 40774548

Effect of CARD (Comfort-Ask-Relax-Distract) on acceptance of school-based vaccinations: A controlled before and after study.

Taddio A, Mulvey K, Gudzak V, Bucci LM, Logeman C, McMurtry CM, Trotz-Williams L, MacDonald NE.Hum Vaccin Immunother. 2025 Dec;21(1):2516180. doi: 10.1080/21645515.2025.2516180. Epub 2025 Aug 6.PMID: 40768553

A lyophilized anti-rabies mRNA-LNP vaccine induces early and robust immune responses from a single-dose subcutaneous administration.

Wang Y, Yu T, Zhang S, Li N, Zhao J, Mi L, Cai Y, Yao N, Hu R, Miao F.Vet Microbiol. 2025 Aug;307:110612. doi: 10.1016/j.vetmic.2025.110612. Epub 2025 Jun 27.PMID: 40609501

Experiences and perceptions about vaccines and reporting of adverse events following immunisation: a qualitative study among mothers in Northern Ghana.

Ansah NA, Weibel D, Chatio ST, Oladokun ST, Duah E, Ansah P, Oduro A, Sturkenboom M.BMJ Public Health. 2025 Aug 10;3(2):e001761. doi: 10.1136/bmjph-2024-001761. eCollection 2025.PMID: 40791271

Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells.

Zhou J, Liu Y, Xu W, Bhatta R, Han J, Baskaran D, Devmal S, Leal C, Wang H.Acta Biomater. 2025 Aug 6:S1742-7061(25)00588-4. doi: 10.1016/j.actbio.2025.08.005. Online ahead of print.PMID: 40774368

Using the CARD system for university-based pop-up vaccination clinics: A two-stage hybrid effectiveness-implementation study.

Gudzak V, Logeman C, Crown N, Ilersich ANT, Folinas M, McMurtry CM, Bucci LM, Shea C, Shah V, Boon H, Katz J, Dolovich L, Taddio A.Hum Vaccin Immunother. 2025 Dec;21(1):2509484. doi: 10.1080/21645515.2025.2509484. Epub 2025 Aug 7.PMID: 40773168

A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease.

Sevilla-Ortega C, Angelina A, Martín-Cruz L, Pérez-Diego M, Maldonado A, Lavín B, Marcos-Ramiro B, Pérez de Llano L, Gayá A, Real FX, Conejero L, Subiza JL, Palomares O.Nat Commun. 2025 Aug 3;16(1):7129. doi: 10.1038/s41467-025-62632-x.PMID: 40753200

Enterovirus A71 priorities, challenges, and future opportunities in humoral immunity and vaccine development.

Bifani AM, Tee HK, Antanasijevic A, Clément S, Tapparel C.NPJ Vaccines. 2025 Aug 15;10(1):194. doi: 10.1038/s41541-025-01184-z.PMID: 40817335

Using black knowledges to recognise and address barriers to COVID-19 vaccination in Malawi.

Odenigbo C, Mkandawire P, Wesche S, Crighton E.BMC Public Health. 2025 Aug 6;25(1):2661. doi: 10.1186/s12889-025-23747-4.PMID: 40770749

Trust typologies and HPV awareness in the U.S.: a latent class analysis.

Stimpson JP, Tamirisa K, Morenz AM, Adhikari EH, Rodriguez Francis JK.Vaccine. 2025 Aug 12;62:127606. doi: 10.1016/j.vaccine.2025.127606. Online ahead of print.PMID: 40803146

Factors influencing COVID-19 vaccine uptake among vulnerable communities in Texas: Perceptions of 2-1-1 helpline callers.

Savas LS, Cuccaro P, Zhang K, Hernandez R, Haffey ME, Reininger B, Mendiola A, Dominguez O, Sifuentes M, Bauer C, Fernandez ME.Vaccine. 2025 Aug 4;60 Suppl 1:127554. doi: 10.1016/j.vaccine.2025.127554. Online ahead of print.PMID: 40763395

Measles and MMR: Do I need another vaccine?

Bowie K.BMJ. 2025 Aug 4;390:r1632. doi: 10.1136/bmj.r1632.PMID: 40759452

Mental health issues, coping mechanisms, and COVID-19 vaccine acceptance among chronically ill patients in tertiary health facilities in Central Region, Ghana.

Ninnoni JPK, Commey IT, Harmah EB, Amoadu M.Discov Ment Health. 2025 Aug 9;5(1):119. doi: 10.1007/s44192-025-00241-2.PMID: 40783631

An efficient bivalent vaccine against duck Tembusu and duck plague viruses based on ribosomal skipping of DHAV-1 2A1 and abundant expression of DPV protein.

Wu L, Deng X, Wang M, Cheng A.Poult Sci. 2025 Aug;104(8):105317. doi: 10.1016/j.psj.2025.105317. Epub 2025 May 17.PMID: 40424885

When Reassurance Falls Short: Rethinking Vaccine Risk Communication.

Kieber-Emmons T.Monoclon Antib Immunodiagn Immunother. 2025 Aug;44(4):69-70. doi: 10.1177/21679436251366315. Epub 2025 Aug 6.PMID: 40763119

COVID-19 vaccine safety studies- the need for a third group for extended monitoring.

Kaur U, Chakrabarti SS.Expert Opin Drug Saf. 2025 Aug 3:1-7. doi: 10.1080/14740338.2025.2542249. Online ahead of print.PMID: 40737552

Supporting Vaccine Programs.

Hawkins J.Am J Nurs. 2025 Aug 1;125(8):21. doi: 10.1097/AJN.0000000000000113a. Epub 2025 Jul 24.PMID: 40702618

CARD (Comfort Ask Relax Distract) and community pharmacy vaccinations: Evaluation of effectiveness outcomes from a cluster randomized trial.

Taddio A, Morrison J, Logeman C, Gudzak V, Bucci LM, McMurtry CM, Yang M, Folinas M, Moineddin R, MacDonald NE.Hum Vaccin Immunother. 2025 Dec;21(1):2488064. doi: 10.1080/21645515.2025.2488064. Epub 2025 Aug 6.PMID: 40768541

Quantitative Measurement of Individual and Contextual Determinants of COVID-19 Vaccination in General Population Samples: A Scoping Review.

Moran C, Seidel S, Abolhosseini S, Coroiu A, Sohail R, Gamboa J, Valdarchi AB, Hernandez L, Campbell TS.Int J Behav Med. 2025 Aug;32(4):619-633. doi: 10.1007/s12529-024-10337-8. Epub 2024 Dec 18.PMID: 39695051

Populations Addressed in Vaccines Approved via the European Medicines Agency.

Gräf DD, Westphal L, Kimmelman J, Hallgreen CE.Clin Pharmacol Ther. 2025 Aug;118(2):459-469. doi: 10.1002/cpt.3694. Epub 2025 May 5.PMID: 40325802

Natural peptidoglycan nanoparticles enable rapid antigen purification and potent delivery of plant-derived vaccines.

Song SJ, Diao HP, Zhang SS, Kang S, Liu C, Kim S, Yun J, Meng HX, Moon H, Kim WY, Kim KH, Yang MJ, Kim KS, Guo YF, Hwang I.Plant Commun. 2025 Aug 11;6(8):101418. doi: 10.1016/j.xplc.2025.101418. Epub 2025 Jun 16.PMID: 40528346

Protective Effects of Recombinant Zoster Vaccine and Antiviral Therapy Against Cardiovascular Disease Following Herpes Zoster Infection.

Xu X, Ray I, Tang E, Arnold BF, Acharya NR.J Infect Dis. 2025 Aug 14;232(2):465-473. doi: 10.1093/infdis/jiaf105.PMID: 40036845

Comparison of the efficacy of Mycoplasma gallisepticum vaccine programmes in chickens.

Ferguson-Noel N, Dos Santos M, Ehsan M, Oluwayinka EB.Avian Pathol. 2025 Aug;54(4):385-397. doi: 10.1080/03079457.2024.2443508. Epub 2025 May 27.PMID: 39679453

Understanding factors influencing the implementation and uptake of less-established adult vaccination programmes: A meta-ethnography of COVID-19 vaccination in Nigeria.

Ojumu A, Ibrahim SA, Seale AC, Fayehun O, Gill P.Glob Public Health. 2025 Dec;20(1):2544183. doi: 10.1080/17441692.2025.2544183. Epub 2025 Aug 12.PMID: 40799014

Recommendation for Human Papillomavirus Vaccine after Abnormal Pap Smear in Unvaccinated Active Duty Women.

Stout CE, Poiani LTH, Mcglynn A, Enujioke CDRSC.Mil Med. 2025 Aug 13:usaf404. doi: 10.1093/milmed/usaf404. Online ahead of print.PMID: 40802575

New insights into an old vaccine: potency and breadth of neutralizing antibodies elicited by the yellow fever vaccine 17D are boosted by heterologous Orthoflavivirus infection.

Coulter FJ, Estrada AE, Micheletti CA, Luo S, Osman SR, Nix CD, Hu S, Naleway AL, Messer WB.medRxiv [Preprint]. 2025 Aug 1:2025.07.31.25332277. doi: 10.1101/2025.07.31.25332277.PMID: 40766119

Progress towards a Group B streptococcal vaccine - where are we now?

Thorn N, Karampatsas K, Le Doare K, Heath PT.Vaccine. 2025 Aug 6;62:127575. doi: 10.1016/j.vaccine.2025.127575. Online ahead of print.PMID: 40773961

Severe Immune Thrombocytopenia and Myositis After 23-Valent Pneumococcal Vaccine.

Gampala A, Minnaganti D, Weidemann D.J Pediatr Health Care. 2025 Aug 12:S0891-5245(25)00195-6. doi: 10.1016/j.pedhc.2025.07.003. Online ahead of print.PMID: 40801863

Persistent immunological repercussions of late antiretroviral initiation in children living with HIV.

Thomé B, Pacola DP, Negra MD, Durigon GS, Marques HHS, Costa PR, Miraglia JL, Vieira VA, Jacintho LC, Itto LYU, Avelino-Silva VI, Abrams E, Kallás EG.AIDS. 2025 Aug 8. doi: 10.1097/QAD.0000000000004311. Online ahead of print.PMID: 40779493

Mast Cells: Key Players in Host Defence Against Infection.

Li NS, Yeh YW, Li L, Xiang Z.Scand J Immunol. 2025 Aug;102(2):e70046. doi: 10.1111/sji.70046.PMID: 40790788

A systematic review of the efficacy of cancer vaccines in advanced breast cancer.

Charalampopoulou A, Filippatos C, Malandrakis P, Zagouri F, Gavriatopoulou M, Ntanasis-Stathopoulos I.Breast Cancer. 2025 Aug 5. doi: 10.1007/s12282-025-01751-1. Online ahead of print.PMID: 40762664

Structure-based design of a multi-epitope vaccine candidate against marburg virus using immunoinformatics and dynamics simulations.

Saadh MJ, Muhammad FA, Albadr RJ, Ballal S, Singh A, Devi A, Joshi KK, Saidkhodjaeva S, Taher WM, Alwan M, Jawad MJ, Al-Nuaimi AMA.J Mol Graph Model. 2025 Aug 5;141:109130. doi: 10.1016/j.jmgm.2025.109130. Online ahead of print.PMID: 40782386

Assessing the structural boundaries of broadly reactive antibody interactions with diverse H3 influenza hemagglutinin proteins.

Dzimianski JV, Nagashima KA, Cruz JM, Sautto GA, O'Rourke SM, Serrão VHB, Ross TM, Mousa JJ, DuBois RM.J Virol. 2025 Aug 14:e0045325. doi: 10.1128/jvi.00453-25. Online ahead of print.PMID: 40810533

Characterization of pneumococcal conjugates in vaccine process development by multi-detection hydrodynamic chromatography.

Jia X, Deng JZ, Winters MA, Paulines MJ, Tong W, Cannon E, Biba M, Zhuang P.J Pharm Biomed Anal. 2025 Aug 15;261:116826. doi: 10.1016/j.jpba.2025.116826. Epub 2025 Mar 20.PMID: 40121703

Polish Mothers and Cervical Cancer Prophylaxis: What Do They Know and What Attitude Do They Have Toward Human Papillomavirus Vaccination?

Matusiak K, Bumbuliene Z.J Pediatr Adolesc Gynecol. 2025 Aug;38(4):467-473. doi: 10.1016/j.jpag.2025.04.002. Epub 2025 Apr 13.PMID: 40228695

Mobilizing COVID-19 Vaccination Partnerships for Newcomer Refugees and Immigrants in the Calgary, Canada Area, 2021-2022.

Aghajafari F, Wall L, Weightman AM, Ness A, Lake D, Anupindi K, Moorthi G, Kuk B, Santana M, Coakley A.J Immigr Minor Health. 2025 Aug;27(4):539-549. doi: 10.1007/s10903-025-01687-w. Epub 2025 May 2.PMID: 40312594

Optimizing delivery in a multivalent subunit influenza vaccine using mixed polymeric microparticle degradation rates.

Pena ES, Ontiveros-Padilla L, Lukesh NR, Williamson GL, Murphy CT, Hendy DA, Roque JA 3rd, Carlock MA, Ross TM, Ainslie KM, Bachelder EM.J Control Release. 2025 Aug 10;384:113936. doi: 10.1016/j.jconrel.2025.113936. Epub 2025 Jun 6.PMID: 40482923

Baculovirus-mediated production and purification of ferritin nanoparticles for rift valley fever vaccine development.

Rodrigues MQ, Tambaclal A, Kloss B, Alves PM, Roldão A.J Biol Eng. 2025 Aug 14;19(1):75. doi: 10.1186/s13036-025-00550-8.PMID: 40813690

Deletion of the 59-67 amino acid region in nonstructural protein 1 attenuates the pathogenesis of porcine epidemic diarrhea virus and enhances host interferon responses.

Li W, Zhang M, Li K, Zhou P, Suolang S, Zhou H, He Q, Luo R.Int J Biol Macromol. 2025 Aug;320(Pt 1):145762. doi: 10.1016/j.ijbiomac.2025.145762. Epub 2025 Jul 3.PMID: 40617424

Description of Multicopy Recombinant Hepatitis B Surface Antigen: From Expression to Immune Analysis.

Bakangil Ö, Karaaslan E, Hasanoğlu Sayın S, Keskin S, Doymaz MZ.Mol Biotechnol. 2025 Aug 8. doi: 10.1007/s12033-025-01492-8. Online ahead of print.PMID: 40781577

Understanding Vaccine Disparities in the Bronx, New York, Through a Mixed Methods Analysis of Community and Provider Perspectives.

Bell BI, Hill S, Olivera J, Fong V, Schumacher M, Friedman-DeLuca M, Cheng T, Jain C, Niderberg T, Sinclair T, Gutnick DN, Oki OA, Stephenson-Hunter C.AJPM Focus. 2025 May 23;4(4):100373. doi: 10.1016/j.focus.2025.100373. eCollection 2025 Aug.PMID: 40678819

Mucoadhesive chitosan-based nano vaccine as promising immersion vaccine against Edwardsiella tarda challenge in Nile tilapia (Oreochromis niloticus).

Nandhakumar, Ramachandran I, Elumalai P.Vet Immunol Immunopathol. 2025 Aug;286:110976. doi: 10.1016/j.vetimm.2025.110976. Epub 2025 Jul 11.PMID: 40663881

Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform-specific priming and immune imprinting.

Kalkeri R, Zhu M, Cloney-Clark S, Parekh A, Gorinson D, Cai Z, Cai MR, Mahato S, Chau G, Babu TM, Wald A, Ramanathan P, Aurelia LC, Selva KJ, Marchese AM, Fries L, Dunkle LM, Chung AW, Plested JS.J Infect. 2025 Aug;91(2):106543. doi: 10.1016/j.jinf.2025.106543. Epub 2025 Jun 26.PMID: 40581329

Pre-post data from a cogenerational health outreach program within federally qualified health centers: experiences in the encore intergenerational vaccine corps and assessments of different generations and public issues.

Halvorsen CJ, Lopez B, Collier KM, Medved C, Emerman J.Data Brief. 2025 Jun 16;61:111783. doi: 10.1016/j.dib.2025.111783. eCollection 2025 Aug.PMID: 40612481

Immunologic profiling of the infant immune response to whole-cell and acellular pertussis vaccines.

Creech CB, Leguia M, Goll JB, Howard LM, Vila-Sanjurjo A, Yoder S, Juarez D, Garcia-Glaessner A, Gelber CE, Jimenez-Truque N, Cherikh S, Gil AI, Crowe JE, Cotos RC, Edwards KM, Lanata CF.NPJ Vaccines. 2025 Aug 11;10(1):189. doi: 10.1038/s41541-025-01170-5.PMID: 40790123

Computational design of inhibitory peptides and an mRNA-Based multi-epitope vaccine targeting the MIC3 protein of Eimeriatenella.

Fattahi R, Shivaee A, Bahraminia M, Omidi N, Kalani BS.Exp Parasitol. 2025 Aug;275:108986. doi: 10.1016/j.exppara.2025.108986. Epub 2025 Jul 11.PMID: 40653079

Polygenic prediction of cellular immune responses to mumps vaccine.

Coombes BJ, Ovsyannikova IG, Schaid DJ, Warner ND, Poland GA, Kennedy RB.Genes Immun. 2025 Aug;26(4):413-417. doi: 10.1038/s41435-025-00335-5. Epub 2025 Jun 10.PMID: 40494895

Cryo-EM led analysis of open and closed conformations of Chagas vaccine candidate TcPOP.

Batra S, Olmo F, Ragan TJ, Kaplan M, Calvaresi V, Frank AM, Lancey C, Assadipapari M, Ying C, Struwe WB, Hesketh EL, Kelly JM, Barfod L, Campeotto I.Nat Commun. 2025 Aug 5;16(1):7164. doi: 10.1038/s41467-025-62068-3.PMID: 40764299

Estimating the Waning Effectiveness of COVID-19 Vaccines From Population-Level Surveillance Data in Hong Kong.

Chen H, Huang X, Wang C, Cowling BJ, Tsang TK.J Infect Dis. 2025 Aug 14;232(2):e341-e345. doi: 10.1093/infdis/jiaf207.PMID: 40247690

Collateral damage from violent incidents: human costs of polio immunization.

Badizadegan K, Thompson KM.Bull World Health Organ. 2025 Aug 1;103(8):484-492. doi: 10.2471/BLT.25.293307. Epub 2025 Jun 10.PMID: 40766732

Enterotoxigenic Escherichia coli Vaccine Candidate MecVax With Protein Antigens Prepared From Animal-Free Media Is Equally Immunogenic and Protective Against Adhesins CFA/I, CS1-CS6 and Toxins LT and STa.

Upadhyay I, Edao B, Zhang W.Microbiol Immunol. 2025 Aug 16. doi: 10.1111/1348-0421.70008. Online ahead of print.PMID: 40818101

The effect of outcome choice on vaccine dose allocation: a modelling study.

Burch E, Christensen H, Brooks-Pollock E.J Theor Biol. 2025 Aug 7;610:112156. doi: 10.1016/j.jtbi.2025.112156. Epub 2025 May 27.PMID: 40441375

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study.

Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, Al Thani AA, Al-Kanaani Z, Al-Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul-Rahim HF, Nasrallah GK, Al-Kuwari MG, Butt AA, Al-Romaihi HE, Al-Thani MH, Al-Khal A, Bertollini R, Abu-Raddad LJ.BMC Infect Dis. 2025 Aug 17;25(1):1028. doi: 10.1186/s12879-025-11410-7.PMID: 40820125

Analysis of HPV vaccination and influencing factors among 9-14-year-old girls in underdeveloped areas of northwestern China: A cross-sectional survey report on guardians.

Chen Y, Jiang N, Jiao Y, Chen J, Cao A, An J, Dang Y.Vaccine. 2025 Aug 6;62:127568. doi: 10.1016/j.vaccine.2025.127568. Online ahead of print.PMID: 40780093

DNA vaccine targeting betacoronavirus spike protein blocks neuroinvasion and neuroinflammation in swine via dual antiviral-immunomodulatory action.

Yu H, Shi J, Fu G, Cao Z, Qiu R, Zhao T, Zhang J, Lan Y, Guan J, Zhao K, Gao F, He W, Li Z.NPJ Vaccines. 2025 Aug 7;10(1):187. doi: 10.1038/s41541-025-01247-1.PMID: 40774966

Influenza virus-like particles presenting *Toxoplasma gondii* dense granule protein 7 protect mice from lethal ME49 challenge.

Mao J, Kang HJ, Heo SI, Quan FS.Nanomedicine (Lond). 2025 Aug 13:1-12. doi: 10.1080/17435889.2025.2546769. Online ahead of print.PMID: 40799047

In silico screening of epitopes as potential vaccine candidates against pathogenic Acinetobacter baumannii.

Islam MM, Han K, Bang YJ, Lee JC, Shin WS, Oh MH.Genes Genomics. 2025 Aug;47(8):899-909. doi: 10.1007/s13258-025-01656-5. Epub 2025 Jun 26.PMID: 40569346

Helminth infections affect host immune responses to viral infections and vaccines.

Diego JG, Desai P, Yeung ST, Damani-Yokota P, Khanna KM, Diamond MS, Schotsaert M.FEMS Microbiol Rev. 2025 Aug 11:fuaf036. doi: 10.1093/femsre/fuaf036. Online ahead of print.PMID: 40796112

A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity.

Hamid FA, Le NN, Song D, Amin H, Hicks L, Bird S, Siram K, Hoppe B, Demeler B, Evans JT, Burkhart DJ, Pravetoni M.J Control Release. 2025 Aug 10;384:113901. doi: 10.1016/j.jconrel.2025.113901. Epub 2025 May 27.PMID: 40441493

Recombinant canine distemper virus expressing virus-like particle VP2 protein of mink enteritis virus protects minks against lethal challenges of both viruses.

Jiang Y, Sun Y, Zhai B, Chen T, Li Y, Ren L, Ma Y, Han K, Wang J, Bi Z, Hu B, Zhao J.Vet Microbiol. 2025 Aug;307:110625. doi: 10.1016/j.vetmic.2025.110625. Epub 2025 Jun 26.PMID: 40609500

Eighteen-Year Longitudinal Study of Uncomplicated and Complex Acute Otitis Media During the Pneumococcal Conjugate Vaccine Era, 2006-2023.

Fuji N, Salamone FN, Kaur R, Bajorski P, Gonzalez E, Wang L, Ali M, Miller A, Grant LR, Arguedas A, Pichichero ME.J Infect Dis. 2025 Aug 14;232(2):417-429. doi: 10.1093/infdis/jiaf154.PMID: 40112171

Tertiary amine N-oxide zwitterionic lipids facilitate muscle-selective mRNA vaccine delivery for enhancing cDC1-mediated antitumor efficacy.

Yang H, Gao Z, Zhou Y, Ge X, Pan X, Li J, Zhang Z, Jin X, Liu G, He Z, Liu H, Liu Z, Liu L, Chen Y.J Control Release. 2025 Aug 10;384:113892. doi: 10.1016/j.jconrel.2025.113892. Epub 2025 May 26.PMID: 40436347

Efficacy of a PP2A vaccine for Angiostrongylus costaricensis against rat lungworm disease caused by Angiostrongylus cantonensis in wild-caught rats (Rattus rattus) in Hawaii.

Jarvi SI, Osuna A, Pitt WC, Farias M, Shiels L, Howe K, Jacquier S, Shiels AB, Sugihara R, Phan J, Samblas MG, Friedman DE, Severino M, Amano K, Allison M, Luiz B, Holtquist Z.Vaccine. 2025 Aug 6;62:127532. doi: 10.1016/j.vaccine.2025.127532. Online ahead of print.PMID: 40773963

Responding to Emerging Epidemics: Insights From Stakeholders on Mpox Vaccine Rollout in Philadelphia.

Richterman A, O'brien C, Ghadimi F, Sumners E, Ford A, Houston N, Tate S, Aitcheson N, Nkwihoreze H, Jemmott JB, Momplaisir F.Open Forum Infect Dis. 2025 Jul 16;12(8):ofaf417. doi: 10.1093/ofid/ofaf417. eCollection 2025 Aug.PMID: 40756649

Immunoinformatics analysis of the proteins MPT83 and MPT51 to design a possible chimeric vaccine against Mycobacterium tuberculosis.

Loureiro RTO, Andrade SJT, do Carmo EJ, Higa AM, de Lima Procópio RE.Braz J Microbiol. 2025 Aug 6. doi: 10.1007/s42770-025-01755-1. Online ahead of print.PMID: 40768028

Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01(E-4) in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial.

Dagnew AF, Han LL, Naidoo K, Fairlie L, Innes JC, Middelkoop K, Tameris M, Wilkinson RJ, Ananworanich J, Bower D, Schlehuber L, Frahm N, Cinar A, Dunne M, Schmidt AC.Lancet HIV. 2025 Aug;12(8):e546-e555. doi: 10.1016/S2352-3018(25)00124-9. Epub 2025 Jul 1.PMID: 40614747

Inequalities in HPV vaccine offer among Italian regions: Analysis of regional prevention plans.

Torrisi M, Casigliani V, Mammolenti E, Porretta A, Rizzo C, Tavoschi L.Hum Vaccin Immunother. 2025 Dec;21(1):2546196. doi: 10.1080/21645515.2025.2546196. Epub 2025 Aug 15.PMID: 40814897

Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes.

Gristick HB, Hartweger H, Nishimura Y, Gavor E, Nagashima K, Koranda NS, Gnanapragasam PNP, Kakutani LM, Segovia LN, Donau OK, Keeffe JR, West AP Jr, Martin MA, Nussenzweig MC, Bjorkman PJ.J Exp Med. 2025 Oct 6;222(10):e20250693. doi: 10.1084/jem.20250693. Epub 2025 Aug 12.PMID: 40794027

Pandemic paradox: How the COVID-19 crisis transformed vaccine hesitancy into a two-edged sword.

Ortiz-Prado E, Suárez-Sangucho IA, Vasconez-Gonzalez J, Santillan-Roldán PA, Villavicencio-Gomezjurado M, Salazar-Santoliva C, Tello-De-la-Torre A, Izquierdo-Condoy JS.Hum Vaccin Immunother. 2025 Dec;21(1):2543167. doi: 10.1080/21645515.2025.2543167. Epub 2025 Aug 12.PMID: 40791124

Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine.

Kee SA, Olivera A, Chatman L, Khalid MB, Li MJ, Chu E, Zektser E, Laky K, Frischmeyer-Guerrerio PA.J Allergy Clin Immunol Glob. 2025 May 13;4(3):100495. doi: 10.1016/j.jacig.2025.100495. eCollection 2025 Aug.PMID: 40497015

Effectiveness of COVID-19 vaccines against post COVID-19 condition/long COVID: systematic review and meta-analysis.

Peine C, Stoliaroff-Pepin A, Reinacher U, Heldt K, Sarganas G, Piechotta V, Mikolajewska A, Pilic A, Barkowski N, Bleve D, Giebeler MH, Poser S, Searle L, Kißner E, Nitsche L, Bayram F, Siemens W, Ziegler A, Meerpohl JJ, Sandmann F, Wichmann O, Harder T.Clin Microbiol Infect. 2025 Aug 1:S1198-743X(25)00367-2. doi: 10.1016/j.cmi.2025.07.026. Online ahead of print.PMID: 40754067

Enhancing Vaccine Safety Surveillance: Extracting Vaccine Mentions from Emergency Department Triage Notes Using Fine-Tuned Large Language Models.

Khademi S, Black J, Palmer C, Javed M, Clothier H, Buttery J, Dimaguila GL.Stud Health Technol Inform. 2025 Aug 7;329:1170-1174. doi: 10.3233/SHTI251023.PMID: 40776041

Accelerating the approval of mpox vaccines based on lessons learnt from COVID-19 vaccines through the lens of regulatory science.

Li S, Yu X, Yao Y, Yao T, Xu M.BMJ Glob Health. 2025 Aug 14;10(8):e018517. doi: 10.1136/bmjgh-2024-018517.PMID: 40813101

Broadly active intranasal influenza vaccine with a nanocomplex particulate adjuvant targeting mast cells and toll-like receptor 9.

Ontiveros-Padilla L, Hendy DA, Pena ES, Williamson GL, Murphy CT, Lukesh NR, Ashcraft KA, Abraham MA, Landon CD, Staats HF, Abraham SN, Carlock M, Ross TM, Petrovsky N, Heise MT, Bachelder EM, Ainslie KM.J Control Release. 2025 Aug 10;384:113855. doi: 10.1016/j.jconrel.2025.113855. Epub 2025 May 18.PMID: 40393528

Manuscript title: Cytokines Associated With Moderate and Severe Adverse Events During a Sporozoite Malaria Vaccine Trial with Controlled Human Malaria Infection.

Jatt LP, Gillespie KM, Van P, Hoffman SL, Jackson LA, Murphy SC, Heath JR, Kublin JG.J Infect Dis. 2025 Aug 14:jiaf435. doi: 10.1093/infdis/jiaf435. Online ahead of print.PMID: 40811667

Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025.

Hills SL, Sutter RA, Miller ER, Asturias EJ, Chen LH, Bell BP, McNeil MM, Rakickas J, Wharton M, Meyer S, Staples JE.Euro Surveill. 2025 Aug;30(32). doi: 10.2807/1560-7917.ES.2025.30.32.2500543.PMID: 40814789

Causal Effects of Life-Course Adiposity and Metabolic Mediators on the Immune Response to COVID-19 Vaccination.

Liang P, Li C, Li Y, Xiong J, Mi J, Xiao P.J Med Virol. 2025 Aug;97(8):e70540. doi: 10.1002/jmv.70540.PMID: 40751707

Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies.

Shah D, Shah V, Shah K, Shah PJ, Alsadhan M, Haslam A, Prasad V, Qazilbash MH, Chakraborty R, Mohyuddin GR.EClinicalMedicine. 2025 Jul 22;86:103378. doi: 10.1016/j.eclinm.2025.103378. eCollection 2025 Aug.PMID: 40735344

Safety and efficacy of a novel glycoengineered recombinant vaccine candidate against Haemonchus contortus in sheep.

Sajovitz-Grohmann F, Adduci I, Werling D, Wiedermann S, Wortha LN, Prole B, Zlöbl J, Elster J, Tichy A, Joachim A, Wittek T, Hinney B, Yan S, Lichtmannsperger K.NPJ Vaccines. 2025 Aug 11;10(1):190. doi: 10.1038/s41541-025-01249-z.PMID: 40790301

Understanding and improving vaccine efficacy in older adults.

Hofer SJ, Rapp S, Klenerman P, Simon AK.Nat Aging. 2025 Aug;5(8):1455-1470. doi: 10.1038/s43587-025-00939-6. Epub 2025 Aug 14.PMID: 40813812

Assessing the relative vaccine effectiveness of a fourth COVID-19 dose on hospitalization in Malaysia amidst evolving omicron variants: An emulated target trial.

Jayaraj VJ, Husin M, Tok PSK, Ismail MZH, Omar MA, Rampal S, Sivasampu S.Vaccine. 2025 Aug 7;62:127569. doi: 10.1016/j.vaccine.2025.127569. Online ahead of print.PMID: 40780091

An Analysis of Dental Hygienists' Practices and Perceptions Toward HPV Vaccination.

Griner SB, Farris AN, Kline N, Neelamegam M, Cotter JC, Nhpang RS, Dickinson C, Thompson EL.J Cancer Educ. 2025 Aug 14. doi: 10.1007/s13187-025-02702-2. Online ahead of print.PMID: 40813745

VaxPulse: Monitoring of Online Public Concerns to Enhance Post-Licensure Vaccine Surveillance.

Javed M, Khademi S, Hickman J, Buttery J, Clothier H, Dimaguila GL.Stud Health Technol Inform. 2025 Aug 7;329:728-732. doi: 10.3233/SHTI250936.PMID: 40775954

Development of microfluidic ELISA for measuring humoral responses to clostridial antigens in vaccinated cattle.

Park JY, Woolums A, Wills R, Vann R, Seo KS.J Immunol Methods. 2025 Aug;542:113900. doi: 10.1016/j.jim.2025.113900. Epub 2025 Jun 23.PMID: 40562351

Effects of a Theory- and Evidence-Based, Motivational Interviewing-Oriented Artificial Intelligence Digital Assistant on Vaccine Attitudes: A Randomized Controlled Trial.

Li Y, Li M, Yorke J, Bressington D, Chung J, Xie YJ, Yang L, He M, Sun TC, Leung AYM.J Med Internet Res. 2025 Aug 8;27:e72637. doi: 10.2196/72637.PMID: 40779743

In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy.

de Omena Neta GC, da Silva Junior JWB, Rocha RML, da Silva Fernandes Duarte AK, Gomes ESB, Zanchi FB, de Sales Marques C, de Carvalho Fraga CA.Cell Biochem Biophys. 2025 Aug 13. doi: 10.1007/s12013-025-01830-2. Online ahead of print.PMID: 40804146

Dengue vaccine rollout in India: lessons for Pakistan's public health preparedness.

Sah S, Ahsan A, Tariq R, Yadav T.Ann Med Surg (Lond). 2025 Jul 16;87(8):5360-5362. doi: 10.1097/MS9.0000000000003585. eCollection 2025 Aug.PMID: 40787504

Comparison of adverse reactions to COVID-19 XBB.1.5 and influenza vaccination in the 2023-24 Japanese influenza season.

Kawai N, Ikematsu H, Bando T, Lee WJ, Matsuura S, Tetsunari M, Echizen M, Kawashima T.J Infect Chemother. 2025 Aug;31(8):102728. doi: 10.1016/j.jiac.2025.102728. Epub 2025 May 31.PMID: 40456446

Blood Borders: State laws, vaccine misinformation, and the threat to the United States blood supply.

Jacobs JW, Chooljian DM, Raza S, Stephens LD, Schlafer TD, Cohn CS, Tobian AAR, Bloch EM, Booth GS.Transfusion. 2025 Aug;65(8):1534-1542. doi: 10.1111/trf.18312. Epub 2025 Jun 16.PMID: 40521642

Factors influencing healthcare worker symptomatic respiratory infection and vaccine uptake during the post-COVID-19 pandemic period.

Townsend L, Domegan L, Wang W, Quirke S; PRECISE Steering Group; Bergin C, Fleming C.Antimicrob Steward Healthc Epidemiol. 2025 Aug 13;5(1):e183. doi: 10.1017/ash.2025.10094. eCollection 2025.PMID: 40808898

Unadjusted Analysis of a Population-Based Study of Measles, Mumps, and Rubella Vaccination and Autism.

Jablonowski K, Hooker B.Integr Med (Encinitas). 2025 Aug;24(4):10-12.PMID: 40703412

Pneumococcal vaccination at 65 years and vaccination coverage in at-risk adults: A retrospective population-based study in France.

Wyplosz B, Grenier B, Roche N, Roubille F, Loubet P, Sultan A, Fougère B, Fernandes J, Duhot D, Moulin B, Raguideau F, Blanc E, Goussiaume G.PLoS One. 2025 Aug 11;20(8):e0329703. doi: 10.1371/journal.pone.0329703. eCollection 2025.PMID: 40788911

A self-amplifying mRNA vaccine expressing PRV gD induces robust immunity against virulent mutants.

Ling T, Xin Z, Huan-Huan L, Ya-Ting Z, Ya-Mei L, Rong-Li G, Damiani AM, Sai-Sai C, Chuan-Jian Z, Rui D, Shu-Yu M, Jia-Li Y, Qian-Qian Z, Ruo-Nan T, Osterrieder N, Shu-Hua X, Ji-Chun W.NPJ Vaccines. 2025 Aug 14;10(1):193. doi: 10.1038/s41541-025-01251-5.PMID: 40813770

Comparative evaluation of serological assays for detecting antibodies against structural proteins elicited by foot-and-mouth disease virus vaccines of serotypes O, A, Asia 1 and SAT 2.

Scian R, Mejías MP, Caldevilla C, Cardillo S, Malirat V, Bergmann IE.Vet Immunol Immunopathol. 2025 Aug;286:110978. doi: 10.1016/j.vetimm.2025.110978. Epub 2025 Jul 23.PMID: 40714574

Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports.

Su Y, Huang Y, Wei J, Wang X, Zhou Y, Wu X, Fu H.Hum Vaccin Immunother. 2025 Dec;21(1):2539590. doi: 10.1080/21645515.2025.2539590. Epub 2025 Aug 1.PMID: 40746171

An O-Specific Polysaccharide Shigella flexneri 3a Conjugate Vaccine is Immunogenic and Protective against Virulent Keratoconjunctival Challenge in Guinea Pigs.

Janardhanan J, Wagh C, Yang J, Charles RC, Pansuriya RK, Chowdhury F, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET.Am J Trop Med Hyg. 2025 Aug 5:tpmd250269. doi: 10.4269/ajtmh.25-0269. Online ahead of print.PMID: 40763727

Perceptions of influenza and SARS-CoV-2 vaccination among health care personnel in Thailand, 2024.

Prasert K, Praphasiri P, Ditsungnoen D, Srichaijaroonpong S, Ungcharoen R, Kerdsin A, Nakphook S, Davis WW, Pittayawonganon C, Bazant ES, Moen AC, Patel JC, Carlton JG, Montgomery MP.PLoS One. 2025 Aug 14;20(8):e0329473. doi: 10.1371/journal.pone.0329473. eCollection 2025.PMID: 40811717

Epitope mapping of vaccine antigens Tc24 and TSA1 with antibodies from Trypanosoma cruzi infected patients.

Dumonteil E, Herrera C.Res Sq [Preprint]. 2025 Aug 7:rs.3.rs-7216993. doi: 10.21203/rs.3.rs-7216993/v1.PMID: 40799730

Unveiling Prospective Therapeutic Potential of Conserved Hypothetical Plasmodium falciparum Proteins by Using Integrated Proteo Genomic Annotation and In-Silico Therapeutic Discovery Approach.

Panda M, Srivastava V, Singh S, Prusty D.Protein J. 2025 Aug;44(4):437-463. doi: 10.1007/s10930-025-10265-w. Epub 2025 Apr 11.PMID: 40216665

A crisis of credibility: the global cost of US vaccine misinformation.

Larson HJ, Piatek SJ.Lancet. 2025 Aug 16;406(10504):668-670. doi: 10.1016/S0140-6736(25)01495-3. Epub 2025 Jul 30.PMID: 40752500

Establishing a Multicenter Active Adverse Events Following Immunization Sentinel Surveillance Network Across 22 Tertiary Care Hospitals in India: Protocol for a Prospective Observational Study.

Sharan A, Das MK, Pm A, Poluru R, Kashyap NK, Burri C, Bonhoeffer J, Aneja S, Polpakara D, Arora NK; MAASS Study Group.JMIR Res Protoc. 2025 Aug 8;14:e64050. doi: 10.2196/64050.PMID: 40779307

Role of the clinical pharmacist in managing rabies post-exposure prophylaxis in an elderly cancer patient: A case report from a tertiary care hospital.

Waheeda Rahman M, Ghafur A, Rakkesh N, A P.J Oncol Pharm Pract. 2025 Aug 8:10781552251365911. doi: 10.1177/10781552251365911. Online ahead of print.PMID: 40776724

Promotion of COVID-19 vaccination for youth and families in Worcester, Massachusetts: a Diffusion of Innovations approach.

Borg A, Goulding M, Minkah P, Perrone D, Castiel M, Rosal MC, Lemon SC, Ryan GW.Vaccine. 2025 Aug 7;60 Suppl 1:127586. doi: 10.1016/j.vaccine.2025.127586. Online ahead of print.PMID: 40780078

FDA Review of Novavax's COVID-19 Vaccine-Regulatory Integrity and Deviations From Standard Practice.

Zettler PJ, Cha S, Despres S, Lurie P.JAMA. 2025 Aug 12;334(6):479-480. doi: 10.1001/jama.2025.9898.PMID: 40489310

The dismantling of the U.S. vaccine regulatory framework.

Yamey G, Beyrer C.Vaccine. 2025 Aug 12;62:127557. doi: 10.1016/j.vaccine.2025.127557. Online ahead of print.PMID: 40803141

Variation in Severity of Symptoms Associated With Two Snow Mountain Virus Inocula.

Qu H, Rouphael N, Mulligan M, Wang Y, Sablon O, Moe CL, Liu P.J Med Virol. 2025 Aug;97(8):e70546. doi: 10.1002/jmv.70546.PMID: 40767536

An African swine fever virus-specific antibody reactome reveals antigens as potential candidates for vaccine development.

Guo S, Ru Y, Zhang H, Xue J, Liu H, Men D, Cui Z, Shen C, Tian H, Ma C, Gong J, Xu J, Wang D, Gong R, Zhang X, Rong H, Wang Y-Y, Liu C, Dai Z, Tao S, Deng J, Zheng H, Li F, Zhang X-E.J Virol. 2025 Aug 14:e0047825. doi: 10.1128/jvi.00478-25. Online ahead of print.PMID: 40810547

A novel multi-epitope-based peptide recombinant influenza A vaccine prototype utilizing neuraminidase and hemagglutinin surface proteins: From in silico to preliminary study.

Mirzaee M, Hosseini SM, Farahmand B, Fotouhi F, Bahramali G.Comput Biol Chem. 2025 Aug;117:108411. doi: 10.1016/j.compbiolchem.2025.108411. Epub 2025 Feb 28.PMID: 40058305

Pathogenic mechanisms and molecular features of a novel UL2 gene-deficient duck enteritis virus endemic to China.

Yin D, Gao Y, Xu M, Wang J, Song X, Li Z, Peng J, Kang M, Wei B, Yu C, Qian Y, Jung YS, Hu F, Lv J, Qin Z, Li Y.Virulence. 2025 Aug 13:2547325. doi: 10.1080/21505594.2025.2547325. Online ahead of print.PMID: 40801158

An adjuvant database for preclinical evaluation of vaccines and immunotherapeutics.

Natsume-Kitatani Y, Kobiyama K, Igarashi Y, Aoshi T, Nakatsu N, Tripathi LP, Ito J, Nyström-Persson J, Kosugi Y, Allendes Osorio RS, Nagao C, Temizoz B, Kuroda E, Standley DM, Kiyono H, Nakanishi K, Uematsu S, Hamaguchi I, Yasutomi Y, Kunisawa J, Yamasaki S, Coban C, Yamada H, Mizuguchi K, Ishii KJ.Cell Chem Biol. 2025 Aug 7:S2451-9456(25)00228-4. doi: 10.1016/j.chembiol.2025.07.005. Online ahead of print.PMID: 40795871

Case report of vaccine-induced anaphylactic reaction reclassified after vaccine challenge.

Aman M, Abou Turk CA, Carlson JC.J Allergy Clin Immunol Glob. 2025 Apr 22;4(3):100484. doi: 10.1016/j.jacig.2025.100484. eCollection 2025 Aug.PMID: 40476089

Impact of Coronavirus Disease-2019 on Influenza and Tdap Vaccination Rates in Pregnant Patients.

Njagu R, Freedy K, Brucker A, Feng K, Lunn S, Greene M, Swamy GK, Dotters-Katz S.Am J Perinatol. 2025 Aug;42(11):1485-1490. doi: 10.1055/a-2510-3783. Epub 2025 Feb 7.PMID: 39919807

The combination of inactivated and subunit vaccines enhances protective efficacy against Mycoplasma synoviae.

Yi C, Xu Q, Han Y, Deng M, Li G, Li C, Sun X, Zhong M, Jin M, Kang C.Poult Sci. 2025 Aug;104(8):105248. doi: 10.1016/j.psj.2025.105248. Epub 2025 May 10.PMID: 40393263

An in-silico-designed multiepitope vaccine candidate can efficiently protect mice against pathogenic species of Shigella.

Vansofla AN, Hajizade A, Nazarian S, Tarverdizadeh Y, Shahmaleki A.J Immunol Methods. 2025 Aug;542:113905. doi: 10.1016/j.jim.2025.113905. Epub 2025 Jul 16.PMID: 40681015

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial.

Martinon-Torres F, Virta MM, Koski S, de la Cueva IS, Szymanski HT, Bosis S, Drăgănescu AC, Silfverdal SA, Zambrano B, Dhingra MS, B'Chir S, Syrkina O, Lyabis O, Vasquez GA, Rehm C; MET58 Study Group.Infect Dis Ther. 2025 Aug;14(8):1843-1865. doi: 10.1007/s40121-025-01190-7. Epub 2025 Jul 15.PMID: 40665158

Young Men's Communication Needs for the Human Papillomavirus (HPV) Vaccine: A Cross-Cultural, Qualitative Analysis in Scotland, Spain, and the USA.

Brunton CG, Carnegie E, Pow J, Todorova I, Petrova D, Garcia-Retamero R, Whittaker A.Int J Behav Med. 2025 Aug 7. doi: 10.1007/s12529-025-10387-6. Online ahead of print.PMID: 40775576

DNA vaccination combined with immune checkpoint inhibition eradicates tumors, inducing life-long immunity against breast cancer in mice.

Domínguez-Romero AN, Esquivel-García CA, Martínez-Cortés F, Martínez-Zarco BA, Odales J, Abraham-Ruiz S, Maruri J, Villegas-Ruiz V, Gevorkian G, Manoutcharian K.Mol Immunol. 2025 Aug;184:51-63. doi: 10.1016/j.molimm.2025.06.003. Epub 2025 Jun 7.PMID: 40483788

Effectiveness of COVID-19 vaccination among dialysis and kidney transplant patients compared to matched controls - a nationwide cohort study.

Helanne H, Kortela E, Helve J, Järvinen A, Forsblom E, Rimhanen-Finne R, Karonen T, Ollgren J, Helanterä I, Finne P.Clin Microbiol Infect. 2025 Aug 6:S1198-743X(25)00370-2. doi: 10.1016/j.cmi.2025.07.029. Online ahead of print.PMID: 40780554

Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.

Wang Y, Sun D, Laney V, Wang H, Wang LL, Lu ZR.Adv Drug Deliv Rev. 2025 Aug 14:115675. doi: 10.1016/j.addr.2025.115675. Online ahead of print.PMID: 40818568

Single self-cleaving mRNA vaccine expressing multiple viral structural proteins elicits robust immune responses and protects nursing piglets against PDCoV infection.

Yu R, Bai Y, Zhang L, Zhou P, Zhang Z, Yang J, Lu Y, Wang D, Peng Y, Li D, He J, Wang Y, Zhang Q, Yuan L, Guo H, Pan L, Liu X.J Virol. 2025 Aug 6:e0084925. doi: 10.1128/jvi.00849-25. Online ahead of print.PMID: 40767477

Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.

Moro PL, Getahun A, Romanson B, Marquez P, Tepper NK, Olson CK, Jones JM, Nair N, Broder KR.Vaccine. 2025 Aug 1;62:127497. doi: 10.1016/j.vaccine.2025.127497. Online ahead of print.PMID: 40752249

Parental and step-parental attitudes toward childhood vaccination in Kaduna State of Nigeria: a health belief model approach.

Sahabi MM, Majdabadi ZA, Negarandeh R, Poortaghi S.BMC Public Health. 2025 Aug 6;25(1):2664. doi: 10.1186/s12889-025-23949-w.PMID: 40770709

The importance of parental human papillomavirus vaccine series initiation for reducing sex disparities in human papillomavirus vaccine series initiation among children in the United States.

Pollard E, Holt HK, Vu M, Tsai MH.Prev Med Rep. 2025 Jul 5;56:103160. doi: 10.1016/j.pmedr.2025.103160. eCollection 2025 Aug.PMID: 40687064

Population preventable fraction of total multiple sclerosis risk associated with non-specific effects of vaccinations against hepatitis B virus and influenza A and B viruses in a middle eastern country.

Akhtar S, Muzaini HE, Al-Hashel JY, Alroughani R.Neurol Sci. 2025 Aug;46(8):3775-3782. doi: 10.1007/s10072-025-08187-7. Epub 2025 Apr 22.PMID: 40261520

COVID-19 vaccine hesitancy among European older adults: the role of living alone, social isolation and loneliness.

Taeldeman V, Paredis M, Braekman E, Verhaegen KA, Bracke P, Delaruelle K.Prev Med. 2025 Aug;197:108325. doi: 10.1016/j.ypmed.2025.108325. Epub 2025 May 28.PMID: 40447114

A Phase IV, open-label, single-arm, multicentric clinical trial for evaluation of Human Papillomavirus 9vHPV vaccine immunogenicity in Men Who Have Sex with Men living with HIV: GeSIDA Study 10017.

Ron R, Díaz-García C, Sendagorta E, Cabello-Úbeda A, Moreno E, Crespillo-Andújar C, Feltes-Ochoa R, Carrillo-Acosta I, Navarro-Soler R, Esteban H, Górgolas M, Moreno S, Pérez-Molina JA, Serrano-Villar S.Clin Infect Dis. 2025 Aug 6:ciaf435. doi: 10.1093/cid/ciaf435. Online ahead of print.PMID: 40794702

A multivalent peptide vaccine against malaria, targeting Plasmodium CSP and mosquito AgTRIO.

Chuang YM, Ledizet M, Mattessich M, Fikrig E.J Infect Dis. 2025 Aug 13:jiaf432. doi: 10.1093/infdis/jiaf432. Online ahead of print.PMID: 40804022

Gonorrhoea vaccine rollout aims to save NHS millions and combat soaring cases.

O'Dowd A.BMJ. 2025 Aug 4;390:r1636. doi: 10.1136/bmj.r1636.PMID: 40759448

Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.

Keeley AJ, Camara FE, Armitage EP, de Crombrugghe G, Sillah J, Fofana ML, Rollinson V, Senghore E, Jammeh M, Whitcombe AL, Bittaye A, Ceesay H, Ceesay I, Samateh B, Manneh M, Carducci M, Rovetini L, Boero E, Massai L, Sanyang LC, Camara O, Cessay EE, Iturriza M, Moriel DG, Kucharski A, Smeesters PR, Botteaux A, Jagne YJ, Moreland NJ, Clarke E, Kampmann B, Marks M, Rossi O, Salje H, Turner CE, de Silva TI.Nat Med. 2025 Aug 8. doi: 10.1038/s41591-025-03868-4. Online ahead of print.PMID: 40781379

Influenza vaccination uptake of health care workers in a tertiary hospital: Findings from qualitative research in Mysuru, India.

van Wijlick JM, Sahana KS, Mahesh PA, Jayaraj BS, Rajagopal GM, Pell C.Glob Public Health. 2025 Dec;20(1):2541228. doi: 10.1080/17441692.2025.2541228. Epub 2025 Aug 6.PMID: 40770596

Evaluation of an Online Training Course in Motivational Interviewing for Occupational Health Clinicians to Address Vaccine Hesitancy.

Saif NT, Elghannam M, Diaz L, Hodorowicz MT, Doyle ML, Baumer S, Girmay T, Edwards LA, Gucer PW, Cloeren M.J Occup Environ Med. 2025 Aug 1;67(8):e525-e535. doi: 10.1097/JOM.0000000000003405. Epub 2025 Mar 27.PMID: 40165505

How Rwanda mounted a research response with an investigational vaccine just ten days into a Marburg outbreak.

Nsanzimana S, Bigirimana N, Hatchett R, Bailey S, Butera N, Butera Y, Cramer JP, Finan A, Forkin CM, Hacker AM, Hassan S, Leamy V, Mutabazi V, Nyombayire J, Remera E, Rwagasore E, Tedeschi E, Warfield KL, Lurie N.NPJ Vaccines. 2025 Aug 1;10(1):178. doi: 10.1038/s41541-025-01224-8.PMID: 40750585

Effects of Buzzy® and ShotBlocker® on Pain and Anxiety During Immunization in Children: A Randomized Controlled Trial.

Sari D, Onder HE, Taskiran N, Yardimci F, Tas SK.Pain Manag Nurs. 2025 Aug;26(4):e325-e331. doi: 10.1016/j.pmn.2024.12.023. Epub 2025 Jan 25.PMID: 39864997

Differential innate immune activation by four different CpG-ODNs in porcine and murine cells: Implications for vaccine design.

Vedelago G, Palacios LM, Castell SD, Marin C, Ruiz Moreno FN, Felici ME, Dho ND, Allemandi DA, Palma SD, Morón G, Bessone FA, Alustiza FE, Crespo MI, Maletto BA.Res Vet Sci. 2025 Aug;191:105692. doi: 10.1016/j.rvsc.2025.105692. Epub 2025 May 12.PMID: 40381581

Therapeutic Cancer Vaccines in Colorectal Cancer: Platforms, Mechanisms, and Combinations.

Gallio C, Esposito L, Passardi A.Cancers (Basel). 2025 Aug 6;17(15):2582. doi: 10.3390/cancers17152582.PMID: 40805277

Foot-and-mouth disease virus O/ME-SA/SA-2018: A new emerging threat posed by viruses circulating in Asia?

Edwards N, Shaw AE, Di Nardo A, Sowood A, Hicks HM, Wadsworth J, Parekh K, Mccarron A, Kumarawadu PL, Eltahir YM, Mohamed MS, Dahal LR, Pandey KR, Poudel N, Taylor E, Horton DL, Mioulet V, Ludi A, Knowles NJ, King DP, Lasecka-Dykes L.Infect Genet Evol. 2025 Aug;132:105771. doi: 10.1016/j.meegid.2025.105771. Epub 2025 May 24.PMID: 40419097

SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey.

Enyereibe NW, Ilori E, Steinhardt L, Stafford K, Dan-Nwafor C, Ochu CL, Ibrahim D, Alagi M, Ibrahim BS, Iwara IE, Mba N, Ibrahim Z, Ahmed RA, Botson I, Ogbonna SU, Igumbor E, Abubakar J, Ahmed N, Nwiyi GO, Ihemeje CE, Okoi C, John D, Ashikeni M, Muhammad BL, Iriemenam NC, Okunoye O, Greby SM, Bassey O, Okoye M, Blanco N, Mitchell A, Ipadeola O, Antonza GS, Mpamugo A, Makava F, Charurat M, Adebajo S, Swaminathan M, Ifedayo A, Ihekweazu C.Sci Rep. 2025 Aug 10;15(1):29272. doi: 10.1038/s41598-025-14253-z.PMID: 40784905

Development and External Validation of the FluScoreVax Risk Score for Influenza That Incorporates Vaccine Status.

Ebell MH, Chen Y, Luo F, Shen Y, Coenen S, Little P, Barrett B, Merenstein D, Ieven M.J Am Board Fam Med. 2025 Aug 11. doi: 10.3122/jabfm.2024.240366R1. Online ahead of print.PMID: 40789620

Immunogenicity of differentially glycosylated Marburg virus glycoproteins expressed in mammalian and insect cells.

Li J, Wang S, Cui Y, Song L, Song Z, Huang P, Chi X, Fang T, Dong Y, Li R, Fan P, Wang Y, Bi L, Li J, Zhang G, Yu C.Virol J. 2025 Aug 11;22(1):275. doi: 10.1186/s12985-025-02884-7.PMID: 40790492

Identification of candidate vaccine antigens using 2-D gel electrophoresis and immunoproteomics for cross protection against Glaesserella parasuis.

Hau SJ, Eberle KC, Nally JE, Nielsen DW, Lippolis JD, Brockmeier SL.Vet Microbiol. 2025 Aug;307:110594. doi: 10.1016/j.vetmic.2025.110594. Epub 2025 Jun 9.PMID: 40516376

Maternal antibody transfer efficiency: The impact of M. bovis-BoHV-1 combined vaccine.

Zhang S, Liu G, Guo A, Chen Y.Virology. 2025 Aug 12;611:110656. doi: 10.1016/j.virol.2025.110656. Online ahead of print.PMID: 40819481

Corrigendum to "Engineering a novel multi-epitope mRNA vaccine against major bacterial meningitis pathogens: E. coli K1, group B Streptococcus, Listeria monocytogenes, Neisseria meningitidis, and Streptococcus pneumoniae" [Int. J. Biol. Macromol. volume 317, part 1, June 2025, 144311].

Fattahi N, Khoshnood S, Omidi N, Kalani BS.Int J Biol Macromol. 2025 Aug 8:146692. doi: 10.1016/j.ijbiomac.2025.146692. Online ahead of print.PMID: 40780979

Human papillomavirus vaccination by country of birth and sex among adolescents receiving care in community-based clinics.

Lucas JA, Marino M, Guzman CEV, Lyon-Scott K, Ramirez AG, Mertes G, Larson Z, Datta R, Bensken WP, Heintzman J.Acad Pediatr. 2025 Aug 15:103126. doi: 10.1016/j.acap.2025.103126. Online ahead of print.PMID: 40819804

Evolving trends in HPV vaccination coverage among women aged 9-45 in Chengdu, China: insights from 2017 to 2023.

Li J, Zhao D, Zi T, Huang R, Zhao F, Li L, Zheng J, Wang L.Vaccine. 2025 Aug 7;62:127579. doi: 10.1016/j.vaccine.2025.127579. Online ahead of print.PMID: 40780092

Naringenin as a phytogenic adjuvant systematically enhances the protective efficacy of H9N2 inactivated vaccine through coordinated innate-adaptive immune priming in chickens.

Jiao L, Song Z, Zhou Y, Zhu T, Yu R, Wang Z, Qiu Y, Miao J, Zhang S, Liu Z, Wang D.Poult Sci. 2025 Aug;104(8):105257. doi: 10.1016/j.psj.2025.105257. Epub 2025 May 2.PMID: 40344923

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.

Janani L, Munro APS, Wright A, Aley PK, Babbage G, Baxter D, Bawa T, Bibi S, Bula M, Cathie K, Chatterjee K, Cosgrove C, Enever Y, Galiza E, Goodman AL, Green CA, Harris M, Hicks A, Jones CE, Kanji N, van der

Klaauw AA, Libri V, Llewelyn MJ, Mansfield R, McGregor AC, Minassian AM, Moore P, Mujadidi YF, Belhadef HT, Holliday K, Osanlou O, Osanlou R, Pacurar M, Palfreeman A, Regan K, Saich S, Saralaya D, Sharma S, Sheridan R, Stokes M, Thomson EC, Todd S, Twelves C, Wright D, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Nguyen-Van-Tam JS, Cornelius V, Lambe T, Heath PT, Liu X, Faust SN; COV-BOOST study group.J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576. Online ahead of print.PMID: 40782888

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses.

Authié P, Souque P, Moncoq F, Noirat A, Blanc C, Ciret S, Bourgine M, Hardy D, Guinet F, Majlessi L, Charneau P, Nemirov K.Vaccine. 2025 Aug 1;62:127563. doi: 10.1016/j.vaccine.2025.127563. Online ahead of print.PMID: 40753671

A Nanomodulator Enhances Radiotherapy-Induced In Situ Cancer Vaccine by Promoting Antigen-Presenting of Tumor-Associated Macrophage.

Zhao X, Li M, Li J, Han Y, Gong Y, Zhang Z, Shi J, Jin CY, Liu J, Si P.Adv Sci (Weinh). 2025 Aug 5:e02876. doi: 10.1002/advs.202502876. Online ahead of print.PMID: 40761180

Association of COVID-19 Vaccination Status With Hospitalization and Illness Severity Among Pregnant Women: A Nationwide Population-Based Study in South Korea.

Jeon B, Koo H, Yun J, Park S, Choi HK, Han E.Health Secur. 2025 Aug 7. doi: 10.1089/hs.2024.0141. Online ahead of print.PMID: 40773377

A step closer to a vaccine for Nipah virus.

Mills G.Vet Rec. 2025 Aug 2;197(3):88. doi: 10.1002/vetr.5833.PMID: 40748160

I'm gonna make him a vaccine he can't refuse.

Piñeiro Pérez R.An Pediatr (Engl Ed). 2025 Aug 9:503858. doi: 10.1016/j.anpede.2025.503858. Online ahead of print.PMID: 40784834

Distribution of serotypes and antibiotic resistance profiles of Streptococcus pneumoniae in hospitalized adult patients: aretrospective multicenter surveillance in China (2018-2019).

Zhao C, Zhang F, Wang Z, Yang S, Chen H, Wang H.BMC Infect Dis. 2025 Aug 5;25(1):980. doi: 10.1186/s12879-025-11377-5.PMID: 40764912

Community Resilience to COVID-19 Among Under-Resourced Black, Indigenous and Latinx Populations: A Mixed-Methods Study.

Cacari Stone L, Rishel Brakey H, Sanchez-Youngman S, Boursaw B, Pandhi N, Hearp L, Tsosie N, McGill C, Villalobos S, Canchola A, Werito V, Keetso E, Parker T.Health Educ Behav. 2025 Aug;52(1_suppl):53S-65S. doi: 10.1177/10901981251347155. Epub 2025 Jul 23.PMID: 40698533

Correction: Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications.

Leong KY, Tham SK, Poh CL.Virol J. 2025 Aug 9;22(1):272. doi: 10.1186/s12985-025-02880-x.PMID: 40781629

Functional characterization of the Clostridium perfringens quadruple point mutant epsilon toxin.

Hemanth RA, Namrutha MR, Bindu S, Prajapati A, Yogisharadhya R, Karabasanavar N, Mohanty NN, Chanda MM, Shivachandra SB.Biologicals. 2025 Aug 9;91:101851. doi: 10.1016/j.biologicals.2025.101851. Online ahead of print.PMID: 40784141

HER1 (EGFR) and/or HER2 Inclusion Potentiates the Antitumor Effect Elicited by a HER3-Specific Monovalent Vaccine.

Bermudez-Abreut E, Bergado-Báez G, Fundora-Barrios T, Arencibia-Perezleo J, Lopez Medinilla A, Chao L, Sanchez Ramirez B.Mol Cancer Ther. 2025 Aug 1;24(8):1226-1239. doi: 10.1158/1535-7163.MCT-24-0973.PMID: 40237095

Addressing vaccination coverage among pediatric solid organ transplant candidates and recipients in the post-COVID-19 pandemic period of increased vaccine hesitancy.

Thomas SJ, Feldman A, Hayde N, Nailescu C, Navin MC, Ross LF, Wightman A, Appel JM, Ardura MI, Chen JK, Daly KP, Fisher R, Goldberg A, Kelly B, Larson HJ, Michaels MG, Twombley K, George RP, Bobrowski A; American Society of Transplant, Pediatric Community of Practice.Am J Transplant. 2025 Aug 12:S1600-6135(25)02916-8. doi: 10.1016/j.ajt.2025.08.007. Online ahead of print.PMID: 40812615

Immune Response to COVID-19 Vaccination in Children With Cancer.

Body A, Lal L, Downie P, Anazodo A, O'Brien T, Padhye B, Fuentes-Bolanos N, Srihari S, Stephanie Ahern E, Haber M, Smith C, Lineburg K, Turville S, Naing Z, Rawlinson W, Buttery J, Raina MacIntyre C, Milch V, Segelov E.Pediatrics. 2025 Aug 8:e2024070209. doi: 10.1542/peds.2024-070209. Online ahead of print.PMID: 40774663

The Impact of the Coronavirus Disease 2019 Pandemic on Parental Childhood Vaccine Attitudes in the United States.

Higgins DM, Bryan MA, O'Leary ST, Opel DJ.Acad Pediatr. 2025 Aug;25(6):102829. doi: 10.1016/j.acap.2025.102829. Epub 2025 Apr 7.PMID: 40204184

Tiantan vaccinia virus-based vaccine with promising safety provides sustained protection against mpox in non-human primates.

Zhu L, Pan S, Huang B, Zhang J, Yang Z, Cong Z, Ma J, Qiu S, Liu Y, Zhang J, Li N, Lu J, Chen T, Hou Y, Zhang D, Wei Q, Li D, Tan W, Zhang Y, Xue J.Nat Commun. 2025 Aug 5;16(1):7183. doi: 10.1038/s41467-025-62594-0.PMID: 40764511

Vaccine therapy for rheumatoid arthritis: A step forward.

Nikhat S, Huttenlocher D, Khosravi-Maharlooei M.Mol Ther. 2025 Aug 6;33(8):3470-3472. doi: 10.1016/j.ymthe.2025.07.026. Epub 2025 Jul 28.PMID: 40730179

Capturing the Dynamic Nature of Choice: Qualitative Perspectives on Contraceptive Acceptability from Cameroon and Kenya.

Deignan C, Odiachi A, Kisaakye P, Woks NIE, Amongin D, Spindler E, Ayuk Agbor JA, Bukuluki P, Bagabo A, Awor E, Short Fabic M, McLarnon C, Lundgren R, Pryor S, Larson E, Fotso JC, Mohamadou H, Saleta L, McDougal L.Stud Fam Plann. 2025 Aug 3. doi: 10.1111/sifp.70030. Online ahead of print.PMID: 40753587

General practitioner consultation for postmenopausal bleeding after COVID-19 vaccination-a self-controlled cohort study.

Jajou R, van Puijenbroek EP, Veldkamp R, Overbeek JA, van Hunsel FPAM, Kant AC.Br J Clin Pharmacol. 2025 Aug;91(8):2352-2362. doi: 10.1002/bcp.70045. Epub 2025 Mar 18.PMID: 40099868

Protective efficacy of Interferon-γ and β-glucan adjuvanted formalin killed vaccines in Nile tilapia against Edwardsiella tarda infection.

Guha R, Lakshmi S, Wang T, Wangkahart E, Elumalai P.Dev Comp Immunol. 2025 Aug;169:105404. doi: 10.1016/j.dci.2025.105404. Epub 2025 Jun 17.PMID: 40553751

Equity in protection: bridging global data gaps for an EBV vaccine-a systematic review and meta-analysis.

Muckian MD, Shi T, Qarkaxhija V, Kapoor S, Morgan T, Stagg HR.BMJ Glob Health. 2025 Aug 14;10(8):e015534. doi: 10.1136/bmjgh-2024-015534.PMID: 40813096

Real-world effectiveness of the adjuvanted recombinant zoster vaccine in 50-year-old adults with autoimmune diseases.

Constenla D, Lonnet G, Aris E, Ramsanjay RK, Servotte N, Mwakingwe-Omari A, Alsdurf H, Yun H.J Infect Dis. 2025 Aug 11:jiaf395. doi: 10.1093/infdis/jiaf395. Online ahead of print.PMID: 40795879

Why Should Clinicians Care About Infectious Disease Existential Hazards?

Ball RT Jr.AMA J Ethics. 2025 Aug 1;27(8):E593-600. doi: 10.1001/amajethics.2025.593.PMID: 40748278

Respiratory syncytial virus vaccine effectiveness - Authors' reply.

Payne AB, Mitchell PK, Watts JA, Link-Gelles R.Lancet. 2025 Aug 9;406(10503):599-600. doi: 10.1016/S0140-6736(25)01227-9.PMID: 40783283

Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults.

Samandari T, Achola M, Hutter JN, Mboya G, Otieno W, Kee JJ, Huang Y, Aponte JJ, Ockenhouse CF, Lee CK, Polakowski L, Yacovone M, Tapley A, Dadabhai S, Mkhize NN, Kaldine H, Bhebhe S, Moore PL, Hural J, Garrett N, Kublin JG.J Infect Dis. 2025 Aug 2:jiaf398. doi: 10.1093/infdis/jiaf398. Online ahead of print.PMID: 40751436

Evaluation of Immune Responses to Tdap Booster During Pregnancy in Women Who Received Whole Cell or Acellular Pertussis Vaccines During Childhood.

Hall JM, Caution KJ, Holt KJA, Gupta YA, Guo M, Mir UQ, Skoff TH, Hariri S, Pan X, Worly B, Dubey P.Emerg Microbes Infect. 2025 Aug 14:2547732. doi: 10.1080/22221751.2025.2547732. Online ahead of print.PMID: 40811865

From decentralization to re-centralization: lessons learned from Vietnam's rapid reversal in the financing of the Expanded Program on Immunization.

Nguyen KP, Ong TD, Zhang X, Do TM, Do TQT, Tang S.Lancet Reg Health West Pac. 2025 Aug 4;61:101648. doi: 10.1016/j.lanwpc.2025.101648. eCollection 2025 Aug.PMID: 40799773

Refining uncertainty about the TAK-003 dengue vaccine with a multi-level model of clinical efficacy trial data.

Alkuzweny M, España G, Perkins TA.medRxiv [Preprint]. 2025 Aug 1:2025.07.31.25332513. doi: 10.1101/2025.07.31.25332513.PMID: 40766139

You can't nudge into vaccination: Comparing the effects of nudge types and Covid-19 vaccination attitudes on vaccine willingness.

Barbosa S, Sánchez-Mora J, Corredor JA.J Health Psychol. 2025 Aug;30(9):2368-2384. doi: 10.1177/13591053241264932. Epub 2024 Jul 27.PMID: 39066555

Selective knockout of key CMV receptors in fetal cells blocks direct and endocytic pathways of entry in the guinea pig.

Qin Y, Choi KY, El-Hamdi N, McGregor A.bioRxiv [Preprint]. 2025 Aug 5:2025.08.05.668711. doi: 10.1101/2025.08.05.668711.PMID: 40799542

Glyceraldehyde-3-phosphate dehydrogenase facilitates Mycoplasma synoviae colonisation in the lower respiratory system.

Zare S, Marenda MS, Arachchige SNK, Shil P, Shahid MA, Kordafshari S, Rodrigo CH, Kawarizadeh A, O'Rourke D, Noormohammadi AH.Vet Microbiol. 2025 Aug 11;309:110675. doi: 10.1016/j.vetmic.2025.110675. Online ahead of print.PMID: 40803170

COVID-19 vaccination around the time of conception and risk of placenta-mediated adverse pregnancy outcomes.

Regan AK, Bruce L, Lavin Venegas C, Török E, Platt RW, Gravel CA, Alton GD, Dimanlig-Cruz S, Shah PS, Barrett J, Walker MC, El-Chaâr D, Wilson K, Sprague AE, Buchan SA, Kwong JC, Wilson SE, Håberg SE, Okun N, Dhinsa T, Dunn S, Fell DB.Acta Obstet Gynecol Scand. 2025 Aug 1. doi: 10.1111/aogs.70025. Online ahead of print.PMID: 40747952

Validation of TypeSeq2, a Next-Generation-Based Sequencing Assay for the Detection of 46 Human Papillomavirus Genotypes, at the US National Cancer Institute and Costa Rica Laboratories.

Sierra MS, Coto C, Porras C, Herrero R, Ugalde D, Sauer AN, Mora D, Montes CP, Schussler J, Hoffman AC, Hicks B, Ruggieri D, Cortes B, Hildesheim A, Kreimer AR, Wentzensen N, Dagnall C, Liu D.J Infect Dis. 2025 Aug 12:jiaf369. doi: 10.1093/infdis/jiaf369. Online ahead of print.PMID: 40796225

Live-attenuated Toxoplasma gondii PruΔpp2a-c mutant elicits protective immunity against toxoplasmosis in mice and cats.

Xie SC, Lv YH, Wang M, Zheng XN, Wang JL, Fu BQ, Zhu XQ.Int J Parasitol. 2025 Aug 7:S0020-7519(25)00136-5. doi: 10.1016/j.ijpara.2025.08.002. Online ahead of print.PMID: 40783178

Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).

Luvira V, Lawpoolsri S, Phumratanaprapin W, Jongkaewwattana A, Nanthapisal S, Muangnoicharoen S, Kamolratanakul S, Sabmee Y, Duangdee C, Narakorn P, Surichan S, Mercer LD, Raghunandan R, Polyak CS, Wirachwong P, Flores J, Pitisuttithum P.Vaccine. 2025 Aug 10;62:127601. doi: 10.1016/j.vaccine.2025.127601. Online ahead of print.PMID: 40789265

Vaccination Coverage Against Coronavirus Disease 2019 in People Living on Quilombos in Brazil and Its Association With the Human Development Index and the Quality of the Health System.

Costa PT, Mello LS, Marques LFA, Dos Santos VS, Marson FAL.J Med Virol. 2025 Aug;97(8):e70533. doi: 10.1002/jmv.70533.PMID: 40762247

COVID-19 Vaccination Coverage and Associated Factors Among Underserved Communities in South Carolina: Results from a Cross-Sectional Study.

Kanyangarara M, Vora S, Seck F, Dhankhode N, Mundagowa PT.J Racial Ethn Health Disparities. 2025 Aug 14. doi: 10.1007/s40615-025-02601-8. Online ahead of print.PMID: 40810893

Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study.

Choi WS, Lee J, Ottaviano C, Samson S, Peng L, Shin S, Choe S, Kim WJ.Vaccine. 2025 Aug 1;62:127521. doi: 10.1016/j.vaccine.2025.127521. Online ahead of print.PMID: 40752250

Effectiveness of influenza vaccination against infection in UK healthcare workers during winter 2023-24: the SIREN cohort study.

McGeoch LJ, Foulkes S, Whitaker H, Munro K, Khawam J, Sparkes D, Charlett A, Brown CS, Atti A, Islam J, Hopkins S, Andrews N, Hall VJ.J Infect. 2025 Aug 13:106585. doi: 10.1016/j.jinf.2025.106585. Online ahead of print.PMID: 40816721

Evaluation of Chinese Yam Polysaccharide-Aluminum Hydroxide Nanoparticle Combination Adjuvant for Porcine Circovirus Type 2 Vaccine and Underlying Mechanisms.

Zhao Q, Zhang Z, Song B, Zhang J, Li Y, Li Z, Chen H, Xu P, Zhu Y, Yang R, Zhao X, Shi W, Gu P.Mol Pharm. 2025 Aug 4;22(8):5062-5074. doi: 10.1021/acs.molpharmaceut.5c00716. Epub 2025 Jul 7.PMID: 40623244

Superior protective efficacy of genotype IVa-based single-cycle viral hemorrhagic septicemia virus (VHSV) vaccine compared to formalin-killed VHSV vaccine against VHSV genotype Ia in rainbow trout (Oncorhynchus mykiss).

Lee KM, Kim SY, Kim KH.Fish Shellfish Immunol. 2025 Aug;163:110409. doi: 10.1016/j.fsi.2025.110409. Epub 2025 May 11.PMID: 40360043

Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.

Strother C, Bouffard N, Smolynets O, Graham NR, Elko EA, Sabundayo B, Durbin AP, Whitehead SS, Taatjes DJ, Kirkpatrick BD, Greene L, Pierce KK, Diehl SA.J Invest Dermatol. 2025 Aug;145(8):2021-2033.e3. doi: 10.1016/j.jid.2024.11.015. Epub 2024 Dec 27.PMID: 39733933

Immunogenicity assessment of Hepatitis A-VP1 and Hepatitis B surface antigen (HBsAg) fusion protein: a novel bivalent vaccine candidate.

Hannan M, Jabalameli L, Aghasadeghi MR, Harzandi N, Sadat SM.Iran J Microbiol. 2025 Aug;17(4):636-643. doi: 10.18502/ijm.v17i4.19257.PMID: 40785716

Erysipelothrix rhusiopathiae occurrence, epidemiology and vaccine reactions in cetaceans: a thirty-year retrospective based on two global surveys.

Lacave G, Cox E.Dis Aquat Organ. 2025 Aug 14;163:63-78. doi: 10.3354/dao03862.PMID: 40810335

RSV vaccination uptake among adults aged 60 years and older in the United States during the 2023-2025 vaccination seasons.

La EM, McGuiness CB, Singer D, Yasuda M, Chen CC.Hum Vaccin Immunother. 2025 Dec;21(1):2535755. doi: 10.1080/21645515.2025.2535755. Epub 2025 Aug 5.PMID: 40763207

In vitro characterization of the E. ruminantium pLAMP multi-epitope DNA poly (lactic-co-glycolic acid) nanoparticle vaccine in sheep peripheral blood mononuclear cells.

Nesane M, Pretorius A, van Wyngaardt W, Tshilwane SI, Faber FE, Steyn H, Lemmer Y, van Kleef M, Thema N.Vet Immunol Immunopathol. 2025 Aug;286:110977. doi: 10.1016/j.vetimm.2025.110977. Epub 2025 Jul 22.PMID: 40712337

Profile of Selected MicroRNAs as Markers of Sex-Specific Anti-S/RBD Response to COVID-19 mRNA Vaccine in Health Care Workers.

Anticoli S, Dorrucci M, Iessi E, Zaffina S, Carsetti R, Vonesch N, Tomao P, Ruggieri A.Int J Mol Sci. 2025 Aug 7;26(15):7636. doi: 10.3390/ijms26157636.PMID: 40806764

Booster effect of the fourth dose of the SARS-CoV-2 mRNA vaccine in kidney transplant recipients.

Hayashi A, Kawabe M, Yamamoto I, Ohki Y, Kobayashi A, Urabe F, Miki J, Yamada H, Matsuo N, Tanno Y, Horino T, Ohkido I, Kimura T, Yamamoto H, Yokoo T.Clin Exp Nephrol. 2025 Aug;29(8):1053-1062. doi: 10.1007/s10157-025-02651-6. Epub 2025 Mar 11.PMID: 40067572

High levels of endogenous Omega-3 Fatty Acids promote dendritic-cell antigen presentation and improve dendritic cell-based cancer vaccine efficacy in mice.

Tiwary S, Hsu KS, Goldfarbmuren KC, Xia Z, Berzofsky JA.Cancer Immunol Res. 2025 Aug 4. doi: 10.1158/2326-6066.CIR-24-0927. Online ahead of print.PMID: 40758122

Vaccine sceptics appointed to advise Italian government on immunisation.

Paterlini M.BMJ. 2025 Aug 11;390:r1710. doi: 10.1136/bmj.r1710.PMID: 40789608

Assessing barriers and facilitators of attitudes toward seasonal influenza vaccination among pregnant women using the Health Belief Model.

Huang F, Zhu J, Qiu J, Li J, Liao Y, Li Z, Huang Z, Guo X, Sun X.Hum Vaccin Immunother. 2025 Dec;21(1):2523091. doi: 10.1080/21645515.2025.2523091. Epub 2025 Aug 12.PMID: 40797352

Unveiling the responsible antigen in vaccine-induced immune thrombotic thrombocytopenia.

Uzoigwe CE.Br J Haematol. 2025 Aug 5. doi: 10.1111/bjh.70084. Online ahead of print.PMID: 40762348

The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody.

Rawi R, Morano NC, Cheung CS, Du H, Gorman J, Prabhakaran M, Becker JE, Bylund T, Charaf S, Chen X, Lee M, Harris DR, Olia AS, Ou L, Wang L, Wang S, Zhang B, Kanekiyo M, McDermott AB, Zhou T, Shapiro L, Kwong PD.Structure. 2025 Aug 6:S0969-2126(25)00264-3. doi: 10.1016/j.str.2025.07.015. Online ahead of print.PMID: 40816277

Detection method for identifying duck hepatitis A virus 3 virulent and attenuated strains based on RPA CRISPR single-base recognition system.

Chen L, Zhang Q, Sun W, Mauk MG, Li Q.Poult Sci. 2025 Aug;104(8):105241. doi: 10.1016/j.psj.2025.105241. Epub 2025 May 1.PMID: 40398301

Temporal transcriptome analysis of head kidney revealed protective cellular immunity in flounder (Paralichthys olivaceus) immunized with inactivated Edwardsiella piscicida.

Wu X, Xing J, Tang X, Sheng X, Chi H, Zhan W.Vaccine. 2025 Aug 12;62:127613. doi: 10.1016/j.vaccine.2025.127613. Online ahead of print.PMID: 40803142

Effects of a mild inflammatory challenge on cytokines and sickness behavior: A randomized controlled trial using the influenza vaccine.

Jolink TA, Feldman MJ, Antenucci NM, Cardenas MN, West TN, Nakamura ZM, Muscatell KA.Brain Behav Immun. 2025 Aug;128:429-439. doi: 10.1016/j.bbi.2025.04.018. Epub 2025 Apr 14.PMID: 40239903

Strengthening vaccine capacity building on the African continent.

[No authors listed]Nat Commun. 2025 Aug 13;16(1):7525. doi: 10.1038/s41467-025-62839-y.PMID: 40804064

Elevated alanine transaminase in liver transplant recipients after BNT162b2 vaccination: a cohort study.

Bergmann JS, Hamm SR, Bering L, Pedersen CR, Bock A, Heidari SL, Villadsen GE, Fialla AD, Willemoe GL, Holland-Fischer P, Nielsen SD.NPJ Vaccines. 2025 Aug 2;10(1):181. doi: 10.1038/s41541-025-01233-7.PMID: 40753181

Preclinical evaluation of a live avian metapneumovirus subtype B vaccine strain with cross-protective efficacy in chickens.

Kim SJ, Kim HJ, Noh YH, Won HK, Hong SM, Yoon IJ, Choi KS.Poult Sci. 2025 Aug;104(8):105283. doi: 10.1016/j.psj.2025.105283. Epub 2025 May 10.PMID: 40398299

In silico analysis of VEGFR2 and c-MET in consideration with immunologic facts: Implications for mRNA vaccine design against breast cancer.

Ghayoumian M, Shamsi F, Madanchi H, Ranjbar MM, Jalalirad R, Sarrami Forooshani R, Mahdavi M.Int Immunopharmacol. 2025 Aug 9;164:115315. doi: 10.1016/j.intimp.2025.115315. Online ahead of print.PMID: 40784276

The Effects of Motivational Interviewing on Promoting Human Papillomavirus Vaccination Initiation and Completion Among South Asian Mother/Daughter Dyads: A Pilot Randomised Controlled Trial.

Chan DNS, Choi KC, Lee PPK, So WKW.Int J Behav Med. 2025 Aug;32(4):574-585. doi: 10.1007/s12529-025-10349-y. Epub 2025 Jan 17.PMID: 39825031

Oral cholera vaccine uptake, acceptance and confidence among residents of a high-risk township in Zambia: key insights for future vaccination programs.

Miti E, Mukosha M, Mwaba J, Mulavu M, Meyer JC, Mudenda S, Godman B, Mwila C, Hamachila A, Kalungia AC.Int Health. 2025 Aug 12:ihaf087. doi: 10.1093/inthealth/ihaf087. Online ahead of print.PMID: 40796201

Corrigendum to "Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children" [Vaccine 61 (2025) 127245].

Costello LM, Kerns EK, McCulloh RJ, Roberts JR, Blatt DB, Tanski SE, Smith TR, Dehority W, Huntwork MP, Alamarat Z, Delaney MD, Hockett CW, McKee RS, Miller JM, Chang D, Ounpraseuth S, Newcomer SR.Vaccine. 2025 Aug 13;62:127584. doi: 10.1016/j.vaccine.2025.127584. Online ahead of print.PMID: 40812023

Nanoadjuvant-Mediated EV-Derived Artificial APC to Trigger Protective Immunity Against Virus Infection.

Pan X, Lv Y, Zheng Z, Li C, Hu L, Lin J, Tang R, Wang X.Small. 2025 Aug 13:e01291. doi: 10.1002/smll.202501291. Online ahead of print.PMID: 40801246

Latent Profiles in Herpes Zoster Vaccine Hesitancy among Middle-Aged and Elderly Adults: A Cross-Sectional Study in Shanghai, China.

Wang X, Shang S, Zhang E, Zou T, Li Y, Huang Z, Fang Q.Am J Infect Control. 2025 Aug 12:S0196-6553(25)00503-6. doi: 10.1016/j.ajic.2025.08.004. Online ahead of print.PMID: 40812550

Elicitation of neutralizing antibodies and IgG4 subclass switching following booster vaccination with ancestral COVID-19 mRNA vaccines does not reduce breakthrough infections.

Berber E, Jarrett EE, Hanley HB, Uno N, Ross TM.Hum Vaccin Immunother. 2025 Dec;21(1):2547517. doi: 10.1080/21645515.2025.2547517. Epub 2025 Aug 14.PMID: 40812315

Effects of booster vaccination on post-treatment oxygen deterioration in hospitalized mild-to-moderate COVID-19 Japanese patients with comorbidities during the Omicron wave.

Hayai S, Fukumitsu K, Suzuki A, Fukihara J, Katano T, Yonezawa T, Ogisu T, Tanaka H, Inoue T, Kako H, Maeda Y, Ishii M, Niimi A, Imaizumi K, Yamaguchi E.J Infect Chemother. 2025 Aug;31(8):102764. doi: 10.1016/j.jiac.2025.102764. Epub 2025 Jun 26.PMID: 40581258

The role of the S1 gene in glandular stomach pathogenesis and tropism of infectious bronchitis virus H120 strain in poultry.

Dai Z, Teng Y, Song J, Xiao Z, Zhang J, Feng K, Shao G, Zhang X, Xie Q.Microbiol Spectr. 2025 Aug 12:e0000825. doi: 10.1128/spectrum.00008-25. Online ahead of print.PMID: 40792512

Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA.

Mayer SE, Kluberg SA, Spence O, Oraichi D, Seifert H, Ali O, Yun H, Simon AL, Ko JS, Hugh C, Her M, Shattuck K, Jamal-Allial A, Djibo DA, Daniels K, Ma Q, McMahill-Walraven CN, Ogilvie RP, Palmsten K, Selvan M, Ziyadeh N, Ogdie A, George MD.RMD Open. 2025 Aug 7;11(3):e005839. doi: 10.1136/rmdopen-2025-005839.PMID: 40780731

Pediatric Invasive Pneumococcal Disease Spectrum Before Third-Generation Pneumococcal Conjugate Vaccine Implementation.

Levy C, Estivaux A, Varon E, Béchet S, Ouldali N, Hau I, Cohen R.J Pediatric Infect Dis Soc. 2025 Aug 7;14(7):piaf056. doi: 10.1093/jpids/piaf056.PMID: 40492721

Coverage rates and reasons for pneumococcal vaccination among adults with chronic medical conditions and the elderly in Japan: a web-based, cross-sectional study.

Kim Y, Taniguchi H, Okuyama K, Kawakami K.BMJ Open. 2025 Aug 8;15(8):e098133. doi: 10.1136/bmjopen-2024-098133.PMID: 40780725

Clonal expansion and diversification of germinal center and memory B cell responses to booster immunization in primates.

Deimel LP, Nishimura Y, Silva Santos GS, Baharani VA, Hernandez B, Oliveira TY, MacLean AJ, Canis M, Shawraz S, Gazumyan A, Hartweger H, Bieniasz PD, Hatziioannou T, Martin MA, Nussenzweig MC.Cell Rep. 2025 Aug 12;44(8):116142. doi: 10.1016/j.celrep.2025.116142. Online ahead of print.PMID: 40802507

Comparison table: Pneumococcal vaccine recommendations for adults 50 years old.

[No authors listed]Med Lett Drugs Ther. 2025 Aug 4;67(1734):e1. doi: 10.58347/tml.2025.1734g.PMID: 40729443

Comparison table: Pneumococcal vaccine recommendations for adults 19-49 years old.

[No authors listed]Med Lett Drugs Ther. 2025 Aug 4;67(1734):e1. doi: 10.58347/tml.2025.1734f.PMID: 40729442

Closing the pertussis immunity gap: vaccine equity saves infant lives.

Muloiwa R, Forsyth KD.Lancet Infect Dis. 2025 Aug;25(8):835-836. doi: 10.1016/S1473-3099(25)00109-4. Epub 2025 Mar 25.PMID: 40154520

Evaluation of Simultaneous Production Strategies for Adenoviral Vector-Based SARS-CoV-2 Multivalent Vaccines via an Expanded Allele-specific Competitive Blocker PCR Quantification Method.

Chang S, Park H, Shin J, Park S, Park B, Kang CY.Anal Chem. 2025 Aug 5;97(30):16219-16226. doi: 10.1021/acs.analchem.5c01281. Epub 2025 Jul 25.PMID: 40710045

The Meningitis Vaccine Appears to Protect Against Gonorrhea-Scientists May Now Know Why.

Anderer S.JAMA. 2025 Aug 5;334(5):377-378. doi: 10.1001/jama.2025.10102.PMID: 40601590

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).

Belij-Rammerstorfer S, Sheehan E, Li G, Bibi S, Wright D, Voysey M, Bissett C, Barman N, Camara S, Yong AA, Costa Clemens SA, Harris M, Flaxman A, Barrett J, Hussain K, Lipunga G, Shaw RH, Smith H, Cheruiyot S, Gitonga JN, Mugo D, Karanja HK, Warimwe GM, Hamaluba MM, Weckx LY, Pollard AJ, Lambe T.EBioMedicine. 2025 Aug;118:105847. doi: 10.1016/j.ebiom.2025.105847. Epub 2025 Jul 16.PMID: 40675005

Nudging towards COVID-19 and influenza vaccination in children with medically at-risk conditions.

Wang B, Andraweera P, Danchin M, Blyth CC, Vlaev I, Ong JJ, Dodd J, Couper J, Sullivan TR, Cuthbert AR, Rak A, Herewane K, Paparo L, Karnon J, Spurrier N, Cusack M, Mordaunt D, Simatos D, Dekker G, Carlson S, Tuckerman J, Wood N, Whop L, Marshall HS.J Public Health (Oxf). 2025 Aug 6:fdaf097. doi: 10.1093/pubmed/fdaf097. Online ahead of print.PMID: 40794921

Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China.

Gao L, Zhang X, Mo X, Sun Y, Yao T, Li Y, Li J, Yang F, Yuan C, Nie X, Wang F, Feng Y, Yang J, Liang X, Wang S.Vaccine. 2025 Aug 11;62:127596. doi: 10.1016/j.vaccine.2025.127596. Online ahead of print.PMID: 40795702

JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States.

Duffy J, Yih WK, Walton K, DeSilva MB, Glanz JM, Hambidge SJ, Jackson LA, Klein NP, Lewin BJ, Naleway AL, Sundaram ME, Maro JC, Weintraub E.Infection. 2025 Aug;53(4):1321-1328. doi: 10.1007/s15010-024-02428-1. Epub 2024 Nov 20.PMID: 39565485

Facilitators and barriers to implementation of HPV vaccination in Tanzania: a mixed-methods study exploring perspectives from national, subnational, and community stakeholders, 2018-2023.

Carlton JG, Pamba D, Ryan N, Olomi W, Ntinginya NE, Tinuga F, Maganga L, William W, Lwilla A, Kapesa E, Mwakisisile J, Magesa D, Mbunda A, Grund JM, McCormick LJ, Hyde T, Casey R.Vaccine. 2025 Aug 1;62:127560. doi: 10.1016/j.vaccine.2025.127560. Online ahead of print.PMID: 40752248

Surveillance of Tick-Borne Encephalitis Virus-Comparison of Vaccination- and Infection-Induced Seroprevalences in Lower Bavaria, Germany.

Girl P, Schindler A, Martin S, Dobler G, Borde JP.J Med Virol. 2025 Aug;97(8):e70514. doi: 10.1002/jmv.70514.PMID: 40704580

Immunoevasion strategies for African swine fever virus: Modulation of antigen presentation pathways.

Lv P, Wang Z, Chen H, Chen Y, Liao H, Wei K, Lv S, Cui M.Virulence. 2025 Dec;16(1):2541711. doi: 10.1080/21505594.2025.2541711. Epub 2025 Aug 15.PMID: 40817451

State-Level Public Awareness of HPV, HPV Vaccine, and Association With Cancer.

Garg A, Damgacioglu H, Graboyes EM, Seal S, Deshmukh AA, Sonawane K.JAMA Oncol. 2025 Aug 14:e252638. doi: 10.1001/jamaoncol.2025.2638. Online ahead of print.PMID: 40810950

Public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in six Latin American countries.

Han R, Gomez JA, Bellei N, Cintra O, de Veras BMG, van Oorschot D, Guzman-Holst A.Expert Rev Vaccines. 2025 Dec;24(1):750-758. doi: 10.1080/14760584.2025.2539892. Epub 2025 Aug 13.PMID: 40718959

Sociodemographic Predictors of Human Papillomavirus Vaccine Uptake Among Young Adults in the United States: A Cross-sectional Analysis and Implications for Cancer Prevention in Nursing Practice.

Kyei GK, Kyei EF, Oppong AF, Ansong R.Cancer Nurs. 2025 Aug 11. doi: 10.1097/NCC.0000000000001538. Online ahead of print.PMID: 40802568

Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort.

Killander Möller I, Hedberg P, Wagner P, Sparén P, Gisslén M, Nauclér P, Aleman S, Bergman P, Carlander C; CLHIP study group.Vaccine. 2025 Aug 8;62:127580. doi: 10.1016/j.vaccine.2025.127580. Online ahead of print.PMID: 40782463

The influence of audience's regulatory focus on the persuasive effect of different pro-vaccine messages.

Xia D, Su Y, Song M, Zhu T, Zhao N, Sun H.PLoS One. 2025 Aug 6;20(8):e0328638. doi: 10.1371/journal.pone.0328638. eCollection 2025.PMID: 40768418

US medical groups sue to reverse overhaul of vaccine recommendations.

Furlow B.Lancet Child Adolesc Health. 2025 Aug 4:S2352-4642(25)00240-8. doi: 10.1016/S2352-4642(25)00240-8. Online ahead of print.PMID: 40774268

Robert F Kennedy Jr pulls funding for mRNA vaccine research.

Tanne JH.BMJ. 2025 Aug 6;390:r1664. doi: 10.1136/bmj.r1664.PMID: 40769520

CD40 agonistic-monovalent streptavidin fusion antibody for targeted neoantigen peptide delivery and potent cancer vaccination.

Jung D, Cai X, Wan Z, Lee N, Ramseier NT, Hu Y, Lim SO, Lee SS.bioRxiv [Preprint]. 2025 Aug 2:2025.07.30.663779. doi: 10.1101/2025.07.30.663779.PMID: 40766694

Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study.

Kim Y, Han K, Kim JH.Ophthalmic Epidemiol. 2025 Aug;32(4):403-411. doi: 10.1080/09286586.2024.2399345. Epub 2024 Sep 17.PMID: 39288331

Cost-Effectiveness of the 2023-2024 COVID-19 Booster Vaccine-Reducing Barriers to Access.

Koiso S, Hyle EP.JAMA Netw Open. 2025 Aug 1;8(8):e2523695. doi: 10.1001/jamanetworkopen.2025.23695.PMID: 40773203

Immune cell transcriptional profiles from pre-vaccination peripheral blood predict immune response to preventative MUC1 cancer vaccine.

Yuan DY, McKeague ML, Raghu VK, Schoen RE, Finn OJ, Benos PV.Eur J Cancer. 2025 Aug 5;228:115685. doi: 10.1016/j.ejca.2025.115685. Online ahead of print.PMID: 40815873

Lumazine Synthase Nanoparticles as a Versatile Platform for Multivalent Antigen Presentation and Cross-Protective Coronavirus Vaccines.

Joseph J, Modenkattil Sethumadhavan K, Ahlawat P, Prakash M, Kandpal G, Raj G, Srivastava H, Charulekha P, K Dev A, Radhakrishnan A, Singh V, Yadav R, Chandramohanan P, Varghese R, Rizvi ZA, Awasthi A, Raj VS.ACS Nano. 2025 Aug 12;19(31):28295-28314. doi: 10.1021/acsnano.5c06081. Epub 2025 Jul 31.PMID: 40745975

Mass Spectrometry-Based Analysis of Surface Proteins in *Staphylococcus aureus* Clinical Strains: Identification of Promising k-mer Targets for Diagnostics.

Svetlicic E, Alarcon LA, Karlsson R, Jers C, Mijakovic I.J Proteome Res. 2025 Aug 7. doi: 10.1021/acs.jproteome.5c00321. Online ahead of print.PMID: 40772958

Implementing a co-design approach to facilitate a COVID-19 vaccination rapid response.

Baur C, Saperstein SL, Griffis RL, Vazquez C, Barnes L, Fish JN.Vaccine. 2025 Aug 13;62:127585. doi: 10.1016/j.vaccine.2025.127585. Online ahead of print.PMID: 40812021

Association between autologous formalin-fixed tumor vaccine (AFTV) therapy, molecular pathological markers, and survival outcomes in glioblastoma.

Koriyama S, Muragaki Y, Nitta M, Maruyama T, Saito T, Tsuzuki S, Kobayashi T, Ro B, Komori T, Masui K, Kawamata T.Brain Tumor Pathol. 2025 Aug 7. doi: 10.1007/s10014-025-00507-1. Online ahead of print.PMID: 40773050

Safety and efficacy of an inactivated tetravalent water-in-oil emulsion Escherichia coli vaccine against the E. coli peritonitis syndrome.

Landman WJM, van Eck JHH, Schellekens M, Feberwee A.Avian Pathol. 2025 Aug;54(4):427-437. doi: 10.1080/03079457.2024.2448510. Epub 2025 Jan 17.PMID: 39743962

Breed-specific humoral immune responses to lumpy skin disease vaccination and its associated factors in cattle.

Bok EY, Jung M, Kim UH, Lee HG, Do YJ, Son YB, Choi Y, Ha S.Vet Immunol Immunopathol. 2025 Aug 6;287:110983. doi: 10.1016/j.vetimm.2025.110983. Online ahead of print.PMID: 40795755

An in silico vaccinomics strategy to develop multiepitope vaccine using essential hypothetical protein as a target against Brevundimonas subvibrioides: A combined subtractive proteomics and immunoinformatics approach.

Paul I, Roy A, Sarkar T, Dutta S, Ray S.Microb Pathog. 2025 Aug;205:107651. doi: 10.1016/j.micpath.2025.107651. Epub 2025 May 5.PMID: 40334722

Public health impact of adjuvanted RSVPreF3 vaccine in older adults: a modeling study in nine countries in Middle East and North Africa.

Zimovetz E, Assiri AM, Al Dallal S, van Oorschot D, Guzman-Holst A, Gomez JA, Han R.Expert Rev Vaccines. 2025 Dec;24(1):759-768. doi: 10.1080/14760584.2025.2539886. Epub 2025 Aug 11.PMID: 40717657

Recombinant TgDDX3X DEAD-box Protein Confers Partial Protection in Murine Models of Acute and Chronic Toxoplasmosis.

Wang S, Wang J, Fan Y, Zhang H, Wu J, Ying T, Ma H, Wang Q, Wang L, Wang Y, Tian X, Mei X, Zhang Z, Yang Z.Acta Trop. 2025 Aug 11:107780. doi: 10.1016/j.actatropica.2025.107780. Online ahead of print.PMID: 40803623

Influence of eHealth literacy on acceptance of healthcare services with risks in China: chain-mediating effect of general risk propensity and self-efficacy.

Chen J, Chen X, Tang Z, Lei L, Zhan Y, Liu S, Zhou H, Wan J, Chen Z, Wu Y, Luo Z.Public Health. 2025 Aug 14;247:105891. doi: 10.1016/j.puhe.2025.105891. Online ahead of print.PMID: 40816112

Comment on "newborn screening programs promote vaccine acceptance among parents in Turkey".

Daungsupawong H, Wiwanitkit V.Postgrad Med. 2025 Aug;137(6):447. doi: 10.1080/00325481.2025.2517536. Epub 2025 Jun 11.PMID: 40474581

Retraction Note: Novel adjuvant nano-vaccine induced immune response against Acinetobacter baumannii.

Piri-Gharaghie T, Doosti A, Mirzaei SA.AMB Express. 2025 Aug 1;15(1):113. doi: 10.1186/s13568-025-01923-4.PMID: 40748412

Molecular epidemiology of human papillomavirus genotypes among HIV-negative women and women living with HIV with cervical cancer in two regions in Nigeria.

Nyam CJ, Musa J, Joyce BT, Kim K, Wang J, Green SJ, Gursel DB, Abdulkareem F, Akanmu AS, Silas OA, Imade GE, Anorlu R, Ogunsola F, Sagay AS, Murphy RL, Hou L, Mehta SD.Int J STD AIDS. 2025 Aug 17:9564624251362592. doi: 10.1177/09564624251362592. Online ahead of print.PMID: 40820278

Glycoengineering of nematode antigens using insect cells: a promising approach for producing bioactive vaccine antigens of the barber's pole worm Haemonchus contortus.

Adduci I, Sajovitz-Grohmann F, Wortha LN, Dutkiewicz Z, Weidinger H, Joachim A, Wittek T, Werling D, Wilson IBH, Lichtmannsperger K, Yan S.Glycobiology. 2025 Aug 11;35(9):cwaf044. doi: 10.1093/glycob/cwaf044.PMID: 40757507

Mn^{2+}-loaded carboxymethyl chitosan nanoparticle as a multifunctional adjuvant to efficiently enhance the performance of inactivated pseudorabies virus vaccines.

Xie N, Zhang J, Cui Y, Yang B, Guo A, Wu Y, Sun W, Scherman D, Liu Y.Int J Biol Macromol. 2025 Aug;320(Pt 4):145648. doi: 10.1016/j.ijbiomac.2025.145648. Epub 2025 Jun 30.PMID: 40602573

Evaluating the MS-HLJ strain as a novel inactivated vaccine candidate: Long-term immune protection against Mycoplasma synoviae in poultry.

Yang P, Li Y, Zhou N, Zhou H, Li J, Jiang Y, Cui W, Ding G, Tang L, Wang X, Li Y.Microb Pathog. 2025 Aug;205:107640. doi: 10.1016/j.micpath.2025.107640. Epub 2025 Apr 28.PMID: 40306592

Evolution of Aluminium Sensitisation in a French Paediatric Population.

Miranda L, Oriane LL, Nour N, Pierre S, Christine L, Brigitte M.Contact Dermatitis. 2025 Aug;93(2):171-173. doi: 10.1111/cod.14782. Epub 2025 Apr 1.PMID: 40169184

Completion of Multidose COVID-19 Vaccination Among Adolescents and Adults in Urban Informal Settlements in Nairobi, Kenya.

Ng'oda M, Izudi J, Otieno C, Mwanga D, Sanya RE, Ziraba A.Am J Trop Med Hyg. 2025 Jun 10;113(2):338-343. doi: 10.4269/ajtmh.24-0737. Print 2025 Aug 6.PMID: 40494313

Generalized linear modeling of flow cytometry data to analyze immune responses in tuberculosis vaccine research.

Maldonado P, Dutt TS, Hitpas A, Podell B, Anderson GB, Henao-Tamayo M.NPJ Syst Biol Appl. 2025 Aug 10;11(1):90. doi: 10.1038/s41540-025-00572-4.PMID: 40783500

Reference intervals for functional lymphocyte proliferation studies using ^{3}H thymidine uptake in adults.

Ameratunga R, Lim D, Longhurst H, Mehrtens J, Leung E, Lehnert K, Steele R, Woon ST.J Immunol Methods. 2025 Aug;542:113884. doi: 10.1016/j.jim.2025.113884. Epub 2025 May 27.PMID: 40441410

Digital Media Coverage of Respiratory Syncytial Virus-Related News in India: Mixed Methods Content Analysis of Disease Burden and Intervention.

Hora R, Ray A, Kumari A, Mehra R, Kaur A, F Quadri S, Ray B, Singh Koshal S, Kumar Singh S, Sultana A, Deb Roy A.JMIR Form Res. 2025 Aug 5;9:e70322. doi: 10.2196/70322.PMID: 40764064

Stabilization of H5 highly pathogenic avian influenza hemagglutinin improves vaccine-elicited neutralizing antibody responses.

Dosey A, Dadonaite B, Gillespie RA, Leaf EM, Vukovich MJ, McGowan J, Grey E, Muramatsu H, Jun RHJ, Pardi N, Kanekiyo M, Bloom JD, King NP.bioRxiv [Preprint]. 2025 Aug 2:2025.07.30.667762. doi: 10.1101/2025.07.30.667762.PMID: 40766360

Clonotype-enriched somatic hypermutations drive affinity maturation of a public human antibody targeting an occluded sarbecovirus epitope.

Rao VN, Sapse IA, Cohn H, Yoo DK, Tong P, Clark JJ, Bozarth B, Chen Y, Srivastava K, Singh G, Krammer F, Simon V, Wesemann DR, Bajic G, Coelho CH.Cell Rep. 2025 Aug 6:116122. doi: 10.1016/j.celrep.2025.116122. Online ahead of print.PMID: 40803328

Preparing for Future Pandemics: Vaccine Effectiveness Against SARS-CoV-2 Variant in a High-Risk Hospital Environment-A Case Study From Vietnam.

Nguyen HT, Duong LH, Pham TQ, Dao TH, Nguyen KT, Nguyen HT, Ngu ND, Tran DN, Le KT, Trinh TS, Doorn HRV, Vogt F, Nguyen KC.Asia Pac J Public Health. 2025 Aug 9:10105395251360136. doi: 10.1177/10105395251360136. Online ahead of print.PMID: 40782037

Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023-December 2024.

Li J, Zhang Z, Wang M.Prev Med Rep. 2025 Jun 26;56:103150. doi: 10.1016/j.pmedr.2025.103150. eCollection 2025 Aug.PMID: 40678810

Vaccine refusal in cancer patients at the French hospital: a normative re-analysis through a 'neopotterian theory of global bioethics'.

Stoeklé HC, Sekkate S, Bennouna J, Beuzeboc P, Hervé C.Monash Bioeth Rev. 2025 Aug 13. doi: 10.1007/s40592-025-00263-0. Online ahead of print.PMID: 40802037

Molecular characterization and genetic diversity of mumps virus genotype G in Pakistan during the 2023 outbreaks.

Fatima H, Salman M, Jamal Z, Hakim R, Umair M, Qazi J.Infect Genet Evol. 2025 Aug;132:105766. doi: 10.1016/j.meegid.2025.105766. Epub 2025 May 18.PMID: 40393578

COVID-19 Vaccine Uptake and Socioeconomic Position in China in 2021.

Xu J, Gong F, Zhang M.Asia Pac J Public Health. 2025 Aug 15:10105395251363724. doi: 10.1177/10105395251363724. Online ahead of print.PMID: 40814728

COVID-19 vaccine type controls stromal reprogramming in draining lymph nodes.

Fair-Mäkelä R, Thorén P, Näsiaho J, Sundqvist P, Piiroinen I, Kähäri L, Julkunen I, Ivaska J, Hub E, Rot A, Ghimire B, Alanko J, Salmi M.Sci Immunol. 2025 Aug 15;10(110):eadr6787. doi: 10.1126/sciimmunol.adr6787. Epub 2025 Aug 15.PMID: 40815672

Mumps Seroprevalence in Vellore, South India: A Community-Based Cross-Sectional Study.

Madhavan R, Varghese T, Eswaran A, Gandhi V, Saravanan P, Raj L, Raju R, Xavier JVL, Joseph JS, Premkumar PS, Rose W, John J.Am J Trop Med Hyg. 2025 Aug 12:tpmd250069. doi: 10.4269/ajtmh.25-0069. Online ahead of print.PMID: 40795852

Early Adolescent Immunization Schedule Preferences: U.S. National Online Survey of Parents of Children Aged 9-10 Years.

Zimet G, Lim E, Matsunaga M, Liebermann E, Kornides M, Fontenot HB.J Adolesc Health. 2025 Aug;77(2S):S14-S17. doi: 10.1016/j.jadohealth.2025.05.003.PMID: 40716907

Recombinant pseudorabies virus expressing the consensus VP2 protein of porcine parvovirus 1 (PPV1) protects pigs against pseudorabies virus and PPV1.

Tian X, Wang H, Song H, Wei Z, Zhu X, Liu G, Sun M, Huang X, Chen M, Tang Y, Wang H, Yang Y, An T.Vet Res. 2025 Aug 5;56(1):162. doi: 10.1186/s13567-025-01592-y.PMID: 40765053

Fusion with CTB enhances the immunogenicity and protective efficacy of MIC2 subunit vaccine against Eimeria tenella.

Wei H, Chen S, Liu C, Huang H, Su X, Bai Y, Liang L, Ding J, Tang X, Luo H, Yao B, Wang Y, Zhang H.Poult Sci. 2025 Aug;104(8):105296. doi: 10.1016/j.psj.2025.105296. Epub 2025 May 15.PMID: 40449102

Bridging the vaccine gap: overcoming barriers for special healthcare needs children in China.

Liu Y, Dang Y, Wang L, Huang Y.Lancet Reg Health West Pac. 2025 Jul 29;61:101644. doi: 10.1016/j.lanwpc.2025.101644. eCollection 2025 Aug.PMID: 40777838

Pregnant and breastfeeding women concerns during a group B Streptococcus phase ll clinical trial: A qualitative study in Kampala, Uganda.

Ssali A, Nalubega P, Namugumya R, Kyohere M, Le Doare K, Seeley J.Vaccine. 2025 Aug 8;62:127592. doi: 10.1016/j.vaccine.2025.127592. Online ahead of print.PMID: 40782462

Contraindications to Immunization of Solid Organ Transplant Patients With Varicella Vaccine-Reply.

Feldman AG, Danziger-Isakov LA.JAMA Pediatr. 2025 Aug 1;179(8):922-923. doi: 10.1001/jamapediatrics.2025.1310.PMID: 40455424

Risk of Immune Thrombocytopenic Purpura Recurrence Following Second Measles-Containing Vaccine Dose.

Zerbo O, Modaressi S, Fireman B, Ross P, Goddard K, Nelson J, Glanz J, Irving SA, Lewin B, DeSilva M, Hambidge SJ, Sundaram ME, Klein NP.Pediatrics. 2025 Aug 1;156(2):e2025070931. doi: 10.1542/peds.2025-070931.PMID: 40701566

Normative influence in a time of distrust and polarization: how perceived social norms predict COVID-19 vaccination intentions among Black Americans.

Lin T, Wang Y, Thier K, Nan X.J Behav Med. 2025 Aug;48(4):644-658. doi: 10.1007/s10865-025-00578-7. Epub 2025 Jun 9.PMID: 40489008

Multidimensional challenges in Brazil's decision-making process of vaccines adoption: The case of childhood pneumococcal conjugate vaccines.

Sartori AMC, de Soárez PC, Novaes HMD, Victer TVDF, Araujo ACM, do Carmo GMI, Wada MY, Fernandes EG.J Infect Public Health. 2025 Aug;18(8):102812. doi: 10.1016/j.jiph.2025.102812. Epub 2025 May 15.PMID: 40378685

Clinical progress note: Tetanus.

Donaghy F, Karunakaran S.J Hosp Med. 2025 Aug 16. doi: 10.1002/jhm.70160. Online ahead of print.PMID: 40818092

Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: Report from a meeting of the World Health Organization.

Varma A, Andrews NJ, Carazo S, Walter K, Kissling E, Skowronski DM, Feikin DR.Vaccine. 2025 Aug 13;62:127567. doi: 10.1016/j.vaccine.2025.127567. Online ahead of print.PMID: 40812018

A commentary on "COVID-19 vaccine hesitancy among parents of children with systemic lupus erythematosus".

Daungsupawong H, Wiwanitkit V.Clin Exp Pediatr. 2025 Aug;68(8):624-625. doi: 10.3345/cep.2025.00304. Epub 2025 Apr 16.PMID: 40241597

Development of a blocking ELISA to evaluate the neutralizing antibody level against canine distemper virus and identification of novel spatial conformation epitopes.

Wang Z, He K, Ye G, Jiang S, Mu L, Cai C, Zeng Y, Zhang A, Li L, Han L.Int J Biol Macromol. 2025 Aug;319(Pt 3):145622. doi: 10.1016/j.ijbiomac.2025.145622. Epub 2025 Jun 27.PMID: 40582658

Tolerance of Inactivated SARS-CoV-2 Vaccine for People Living with HIV: A Real-World Evidence Analysis from a Retrospective Cohort Study.

He Q, Zhou T, Feng Y, Li Y, Ni Z, Zhang N, Chen J, Ni M, Zhao S, Wang K.J Epidemiol Glob Health. 2025 Aug 14;15(1):106. doi: 10.1007/s44197-025-00452-4.PMID: 40810755

Effects of Passive Information Dissemination on Human Papillomavirus Vaccination Attitudes and Knowledge Among Pharmacy Visitors: A Cluster Randomized Controlled Trial.

Wakui N, Kawakubo S, Harayama M, Kageyama I, Kobayashi Y, Kodama K, Asakawa M, Ogino T, Kikuchi M, Kato H.J Am Pharm Assoc (2003). 2025 Aug 7:102901. doi: 10.1016/j.japh.2025.102901. Online ahead of print.PMID: 40782983

Development of an African horse sickness VP6 DIVA diagnostic ELISA.

Tinarwo M, Dennis SJ, Hitzeroth II, Meyers AE, Rybicki EP, Mbewana S.Virol J. 2025 Aug 12;22(1):276. doi: 10.1186/s12985-025-02898-1.PMID: 40796889

Investigating how homeopaths and chiropractors navigate patient requests for vaccination information in Ontario, Canada: a qualitative study.

Okusanya IG, Dubé E, Filice E, Malo B, Bettinger J, Driedger M, Graham J, Greyson D, Kawchuk G, MacDonald N, MacDonald S, Meyer SB.Arch Public Health. 2025 Aug 15;83(1):210. doi: 10.1186/s13690-025-01689-y.PMID: 40817225

Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV vaccine.

Grinyo-Escuer A, Reddy S, Chenine AL, Whitbeck JC, Jacobsen S, Sheetz A, Doolan K, Norden DM, Frey N, Holtsberg FW, Aman MJ, Fink K, Diamond MS, Schieffelin JS, Crowe JE Jr, Davidson E, Doranz BJ.Cell Rep. 2025 Aug 1;44(8):116098. doi: 10.1016/j.celrep.2025.116098. Online ahead of print.PMID: 40753572

Prevalence of human adenovirus in children with acute gastroenteritis in the New Vaccine Surveillance Network (NVSN) from 2016 to 2019.

Kinzler AJ, Wikswo ME, Balasubramani GK, D'Agostino HEA, Sax T, Dauer K, Weinberg GA, Szilyagi P, Sahni LC, Boom JA, Schuster JE, Selvarajan R, Harrison CJ, Staat MA, Payne DC, Halasa NB, Klein EJ, Englund JA, Martin JM, Hickey R, Michaels MG, Williams JV.J Clin Virol. 2025 Aug;179:105822. doi: 10.1016/j.jcv.2025.105822. Epub 2025 Jun 6.PMID: 40499355

Beneath the rhetoric of global justice: Reinforcement of global hegemonic governmentality by South Korea's Global Vaccine Hub Project.

Gim J, Park J, Kim S.Global Health. 2025 Aug 9;21(1):44. doi: 10.1186/s12992-025-01134-3.PMID: 40783710

Comparison of clinical characteristics of hospitalized pediatric patients with respiratory syncytial virus infections before and during/after the coronavirus disease 2019 pandemic in Japan -importance of universal prevention using maternal vaccination and nirsevimab.

Karahashi Y, Yamanaka T, Aizawa Y, Habuka R, Tsukano S, Saitoh A.J Infect Chemother. 2025 Aug 6;31(9):102779. doi: 10.1016/j.jiac.2025.102779. Online ahead of print.PMID: 40774505

Prevalence of HPV, cytological abnormalities, and impact of the HPV vaccine in Mexico: a Nationwide Study of 596,944 women.

García-Gil A, Luna-Ruiz-Esparza MA, Moreno-Camacho JL, Calva-Espinosa DY, González-Mena LE, Hernández-Lezama LF, Kuri-Morales P, Balcázar-Rodríguez JC, Campos-Romero A, Alcántar-Fernández J.Lancet Reg Health Am. 2025 Jun 25;48:101156. doi: 10.1016/j.lana.2025.101156. eCollection 2025 Aug.PMID: 40657432

Effectiveness of CONFIVAC, an intervention to enhance paediatric nurses and paediatricians skills to promote vaccination: A mixed-methods cluster randomized trial.

Roel E, Henderson E, Valmayor S, Porthé V, Asensio A, Ramírez-Morros A, Bruna X, Pasarín MI, Rius C, Díez E; CONFIVAC Research Group.Vaccine. 2025 Aug 15;62:127603. doi: 10.1016/j.vaccine.2025.127603. Online ahead of print.PMID: 40818260

Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden.

Nurminen ML, Lindemo P, Sundström A, Zethelius B, Larsson M, Attelind S, Pihlström N, Ljung R, Arthurson V.Clin Drug Investig. 2025 Aug 12. doi: 10.1007/s40261-025-01466-3. Online ahead of print.PMID: 40796716

Vaccination in adults at-increased risk of herpes zoster in Canada: insights from a multidisciplinary panel consensus.

Ghesquière W, Tessier D, Brown V, Guenther L, Haaland D, Igoe J, MacDonald KS, Whiskin C.Expert Rev Vaccines. 2025 Dec;24(1):769-781. doi: 10.1080/14760584.2025.2539884. Epub 2025 Aug 5.PMID: 40717622

Design and nonviral delivery of live attenuated vaccine to prevent chronic hepatitis C virus-like infection.

Trivedi S, Dravid P, Passchier TC, Murthy S, Kasudhan KS, Reguraman N, Kellar J, Chandra R, Cassady C, Burbelo PD, Grakoui A, Sharma H, Simmonds P, Kapoor A.Nat Commun. 2025 Aug 15;16(1):7629. doi: 10.1038/s41467-025-62813-8.PMID: 40817105

COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.

Jeong NY, Cho S, Lim E, Lee JR, Song JY, Park JS, Choi NK.Vaccine. 2025 Aug 14;63:127619. doi: 10.1016/j.vaccine.2025.127619. Online ahead of print.PMID: 40818314

Enhanced Cycling Performance of Li-Rich Oxide Cathode via a Vaccine Effect.

Yao K, Wang Y, Xie X, Li M, Zhang A, Zhang X, Li G, Li L.Angew Chem Int Ed Engl. 2025 Aug 4;64(32):e202500183. doi: 10.1002/anie.202500183. Epub 2025 Jun 16.PMID: 40468978

Epstein-Barr virus (EBV) infection and its sequelae in the immunocompetent host.

Meirhaeghe MR, Balfour HH Jr.J Clin Virol. 2025 Aug 8;180:105854. doi: 10.1016/j.jcv.2025.105854. Online ahead of print.PMID: 40816194

Unilateral uveitis following adjuvanted Varicella-Zoster subunit vaccine in a patient with previously resolved Varicella Zoster acute retinal necrosis.

Trinco A, Zicarelli F, Romano F, Oldani M, Riva A, Invernizzi A.J Ophthalmic Inflamm Infect. 2025 Aug 2;15(1):58. doi: 10.1186/s12348-025-00508-3.PMID: 40751852

Vaccine-Educated T cells and a CD123 Bispecific T-Cell Engager for Treatment of Acute Myeloid Leukemia.

Liegel J, Stroopinsky D, Cheloni G, Karagkouni D, Nahas M, Ma Y, Torres D, Saldarriaga I, Wang S, Arruda de Amaral A, Ploumakis A, Clohessy SG, Abirached J, Bisharat L, Fraenkel PG, Yildirim O, Bonnevaux H, Guerif S, Rallis K, Chedid G, Kufe D, Vlachos IS, Avigan DE, Rosenblatt J.Blood Adv. 2025 Aug 14:bloodadvances.2024015449. doi: 10.1182/bloodadvances.2024015449. Online ahead of print.PMID: 40811786

Playing CARD (Comfort Ask Relax Distract): Upping our game on the quality of vaccine delivery.

MacDonald NE, Bucci LM, Taddio A.Hum Vaccin Immunother. 2025 Dec;21(1):2526226. doi: 10.1080/21645515.2025.2526226. Epub 2025 Aug 6.PMID: 40768513

Authors' reply: a commentary on "COVID-19 vaccine hesitancy among parents of children with systemic lupus erythematosus".

Sausukpaiboon K, Penboon N, Rianthavorn P.Clin Exp Pediatr. 2025 Aug;68(8):626-627. doi: 10.3345/cep.2025.01200. Epub 2025 Jul 18.PMID: 40685245

Evaluation of recent pre-booster studies on hepatitis B vaccine effectiveness across WHO regions with HBV prevalence above 1% in the general population up to 60 years of age: a systematic review.

Zadeh Mehrizi T, Eshrati B, Ebrahimi Shahmabadi H.Arch Virol. 2025 Aug 15;170(9):193. doi: 10.1007/s00705-025-06382-7.PMID: 40817198

The community pharmacists' opinion regarding pharmacist as immunizers for expanding their role and service in Thailand.

Sae-Lim O, Miranshahid A, Daewha S, Siriwat S, Ditsarapong C.Prim Health Care Res Dev. 2025 Aug 15;26:e73. doi: 10.1017/S1463423625100376.PMID: 40815089

Traveling children: Current situation and compliance with hepatitis A vaccination recommendations.

Varoqui C, Thollot F.Arch Pediatr. 2025 Aug 14:363-367. doi: 10.1016/j.arcped.2025.05.002. Online ahead of print.PMID: 40816924

Adsorption of antigen to polymeric nanoparticles enhances cytotoxic T-cell responses and anti-tumor immunity by targeting conventional type 1 dendritic cells.

Huete-Carrasco J, Zhu J, Van den Eynde BJ, Mayer CT, Sparwasser T, Ward RW, Lavelle EC.Immunol Cell Biol. 2025 Aug 4. doi: 10.1111/imcb.70049. Online ahead of print.PMID: 40760824

Comparison of seroconversion rates after hepatitis B vaccination in patients with advanced chronic kidney disease and those receiving maintenance hemodialysis.

Fujikura T, Isobe S, Oikawa S, Ishigaki S, Katahashi N, Iwakura T, Ohashi N, Kato A, Yasuda H.Clin Exp Nephrol. 2025 Aug;29(8):1045-1052. doi: 10.1007/s10157-025-02648-1. Epub 2025 Mar 4.PMID: 40035977

Structural insights into VRC01-class bnAb precursors with diverse light chains elicited in the IAVI G001 human vaccine trial.

Lin X, Cottrell CA, Kalyuzhniy O, Tingle R, Kubitz M, Lu D, Yuan M, Schief WR, Wilson IA.Proc Natl Acad Sci U S A. 2025 Aug 19;122(33):e2510163122. doi: 10.1073/pnas.2510163122. Epub 2025 Aug 11.PMID: 40789024

Protection of Nile tilapia against Aeromonas hydrophila using a cobalt oxide nanoparticle vaccine containing inactivated whole cell bacteria.

Lakshmi S, Smith D, Mai T, Elumalai P, Thompson KD.Dev Comp Immunol. 2025 Aug;169:105409. doi: 10.1016/j.dci.2025.105409. Epub 2025 Jul 1.PMID: 40609713

A reply to the letter: comment on "newborn screening programs promote vaccine acceptance among parents in Turkey".

Erdal İ, Kahraman AB, Yıldız Y, Yalçin SS.Postgrad Med. 2025 Aug;137(6):448-449. doi: 10.1080/00325481.2025.2517532. Epub 2025 Jun 11.PMID: 40476484

Nsp2 replicase-mediated viral uncoating in porcine alveolar macrophages contributes to the attenuation of PRRSV-2 live attenuated vaccine.

Bai Y-Z, Xu H, Liu Y-G, Sun Y, Xu S-J, Wang M-X, Wang Q, Tian Z-J, Leng C-L, Wang G, An T-Q, Cai X-H, Zhang H-L, Tang Y-D.J Virol. 2025 Aug 4:e0063625. doi: 10.1128/jvi.00636-25. Online ahead of print.PMID: 40757848

A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population.

Fiévez S, Ta A, Bellier L, Blanc E, El Khoury JY, Beillat M, Sabra A, Sivignon M, Ilic A, Perdrizet J.Infect Dis Ther. 2025 Aug 15. doi: 10.1007/s40121-025-01209-z. Online ahead of print.PMID: 40815494

Functional and epitope specific monoclonal antibody discovery directly from immune sera using cryo-EM.

Ferguson JA, Raghavan SSR, Alzua GP, Bhavsar D, Huang J, Rodriguez AJ, Torres JL, Bottermann M, Han J, Krammer F, Batista FD, Ward AB.Sci Adv. 2025 Aug 15;11(33):eadv8257. doi: 10.1126/sciadv.adv8257. Epub 2025 Aug 15.PMID: 40815640

Use of presumptive recommendations and other strategies to encourage HPV vaccine uptake: Results from a national survey of primary care health professionals.

Ilyasova AA, Queen TL, Gilkey M, Fogel BN, Odebunmi OO, Yanguela J, Bamogo A, Patel Y, Laurie E, Ozawa S, Wheeler SB, Spees LP.PLoS One. 2025 Aug 4;20(8):e0327872. doi: 10.1371/journal.pone.0327872. eCollection 2025.PMID: 40758686

Corrigendum to 'Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants' [AJOG Global Reports Volume 4, Issue 4, November 2024, 100395].

Hsiao A, Yee A, Izikson R, Fireman B, Hansen J, Lewis N, Gandhi-Banga S, Selmani A, Talanova O, Kabler H, Inamdar A, Klein NP.AJOG Glob Rep. 2025 Jun 17;5(3):100536. doi: 10.1016/j.xagr.2025.100536. eCollection 2025 Aug.PMID: 40678107

Maternal Respiratory Syncytial Virus (RSV) Vaccination: Current Status and Comparison to Monoclonal Antibodies (mAbs) for RSV Prevention in Infants and Children.

Ali A, Shamim L, Ibrahim A, Humayun MA, Khan MH, Akbar A, Jindal S, Ahmed S, Shrestha J, Nveed MA.J Mother Child. 2025 Aug 16;29(1):93-100. doi: 10.34763/jmotherandchild.20252901.d-25-00012. eCollection 2025 Feb 1.PMID: 40818150

Design and initial findings of a natural history study of anal HPV and associated lesions among young adult women in Costa Rica.

Haas CB, Ocampo R, Liu D, Zúñiga M, Guillen D, Clarke MA, Carvajal LJ, Hildesheim A, Schussler J, Sierra M, Darragh TM, Palefsky JM, Porras C; Costa Rica HPV Vaccine Trial (CVT) Group; Kreimer AR, Herrero R.Int J Cancer. 2025 Aug 15. doi: 10.1002/ijc.70082. Online ahead of print.PMID: 40815549

Draft genome and antibiotic resistance profile of a multidrug-resistant *K. pneumoniae*-ST152 strain KA017_S253 from a neonatal blood culture in Ghana.

Tetteh FKM, Egyir B, Boateng W, Owusu-Nyantakyi C, Danso JK, Haq K, Sampane-Donkor E, Duedu KO.Microbiol Resour Announc. 2025 Aug 11:e0058825. doi: 10.1128/mra.00588-25. Online ahead of print.PMID: 40788146

Effect of COVID-19 vaccination appointment letters on uptake by sociodemographic characteristics: a regression discontinuity analysis in Sweden, December 2020 to September 2021.

Varotsis G, Hammar U, Bonander C, Lundmark P, Kennedy B, Gomez MF, Martinell M, Dyar OJ, Sarkadi A, Kristiansson R, Svaleryd H, Fall T.Eur J Public Health. 2025 Aug 1;35(4):795-802. doi: 10.1093/eurpub/ckaf097.PMID: 40581614

Descriptive Epidemiology of the 2022-2023 Cholera Outbreak in Lebanon and Lessons Learned in the Context of a Humanitarian Emergency Situation.

Abiad F, Abubakar A, Hilal N, Ghalayini W, Ghosn N, Feghali R, Jouni A, Baakliny M, Assi M, Sinno S, Rady A, Chughtai AA.Open Forum Infect Dis. 2025 Jul 18;12(8):ofaf428. doi: 10.1093/ofid/ofaf428. eCollection 2025 Aug.PMID: 40799794

Third-person effects of HPV vaccination news: Exploring the relationships among media exposure, presumed media influence, and Chinese female college students' behavioral intentions.

Liang W, Chen H.Hum Vaccin Immunother. 2025 Dec;21(1):2546739. doi: 10.1080/21645515.2025.2546739. Epub 2025 Aug 14.PMID: 40814216

Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults 50 years of age: a randomised, active-controlled, non-inferiority trial.

Jin PF, Quan YR, Xiu SX, Jiang XM, Pan HX, Shen Y, Wang XW, Kong J, Wang WJ, Cao X, Xu KW, Yang M, Yang K, Wan WY, Wang KQ, Chen L, Yao AH, Xue YP, Wan N, Xu M, Tao SY, Peng L, Yan FR, Li CG, Li JX.Nat Commun. 2025 Aug 15;16(1):7590. doi: 10.1038/s41467-025-62800-z.PMID: 40817094

A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines.

Destexhe E.NPJ Vaccines. 2025 Aug 13;10(1):192. doi: 10.1038/s41541-025-01245-3.PMID: 40804241

Correction for Kim et al., "Self-assembling Gn head ferritin nanoparticle vaccine provides full protection from lethal challenge of Dabie bandavirus in aged ferrets".

Kim D, Kim E, Kim S, Chung Y, Lai C-J, Cha I, Cho S-D, Choi Y, Dai X, Kim S, Kang S, Kwak M-J, Liu Z, Choi Y, Park S-H, Choi YK, Jung JU.mBio. 2025 Aug 13;16(8):e0143025. doi: 10.1128/mbio.01430-25. Epub 2025 Jun 27.PMID: 40576351

[Distribution of the COVID-19 vaccine: experience in EcuadorOperacionalizacao da vacinacao contra a COVID-19: experiencia no Equador].

Ruales J, Garzón X, Aldaz C, Vásconez N, Jácome F, Cevallos J, Pinos J, Pérez-Tasigchana F, Díaz A, Whittembury A.Rev Panam Salud Publica. 2025 Aug 8;49:e89. doi: 10.26633/RPSP.2025.89. eCollection 2025.PMID: 40786649

Anti-microbiota vaccine induces lysine-mediated modulation of tick immunity affecting Borrelia colonization.

Mateos-Hernandez L, Denis-Abuin L, Wu-Chuang A, Maitre A, Roháčková H, Rego ROM, Piloto-Sardiñas E, Valdes J, Porcelli S, Heckmann A, Moutailler S, Lucas-Torres C, Moos M, Opekar S, Kratou M, Obregon D,

Cabezas-Cruz A.FEMS Microbiol Ecol. 2025 Aug 14:fiaf082. doi: 10.1093/femsec/fiaf082. Online ahead of print.PMID: 40810454

Corrigendum to "Social processes, practical issues, and COVID-19 vaccination among hesitant adults" [Vaccine 41(35) (2023) 5150-5158].

Willis DE, Reece S, Gurel-Headley M, Selig JP, Li J, Zimmerman S, Cornett LE, McElfish PA.Vaccine. 2025 Aug 12;62:127583. doi: 10.1016/j.vaccine.2025.127583. Online ahead of print.PMID: 40803143

Survey to understand the impacts of vaccine availability.

Howard S.Vet Rec. 2025 Aug 2;197(3):110. doi: 10.1002/vetr.5850.PMID: 40748133

How can healthcare professionals address vaccine hesitancy in practice?

Chemais M, MacDonald N, Dubé E, Søborg B, Cevik M, Harboe ZB, Velikov P; ESCMID Vaccines Study Group (EVASG).Clin Microbiol Infect. 2025 Aug 13:S1198-743X(25)00393-3. doi: 10.1016/j.cmi.2025.08.002. Online ahead of print.PMID: 40816467 No abstract available.

Chitosan-coated PLGA nanoparticles as a delivery system for infectious bursal disease viral antigen in chickens.

Kumar V, Panickan S, Kumar A, Ramakrishnan S, Saxena S, Shrivastava S, Dandapat S.Avian Pathol. 2025 Aug 15:1-39. doi: 10.1080/03079457.2025.2547584. Online ahead of print.PMID: 40814829

Corrigendum to "B subunit of the type 2 Shiga toxin e variant (Stx2e) bundled by a five-stranded alpha-helical coiled coil protects piglets from porcine edema disease" [Vaccine 61 (2025) 127140].

Arakawa T, Uefuji H, Tamaki Y, Oogai S, Arakawa H.Vaccine. 2025 Aug 13;62:127582. doi: 10.1016/j.vaccine.2025.127582. Online ahead of print.PMID: 40812019

Screening of immunogenic antigens from scuticociliate in Takifugu rubripes, and the development and evaluation of subunit vaccines.

Wang X, Wang S, Ni X, Zhao G, Sun Q, Zhang Z, Pan M, Li R.Fish Shellfish Immunol. 2025 Aug;163:110385. doi: 10.1016/j.fsi.2025.110385. Epub 2025 Apr 30.PMID: 40315937

Recombinant Bacillus subtilis Displaying DHAV-1 VP1 Protein as a Dual-Function Probiotic: Evaluation of Immunological Efficacy, Growth Performance, Antioxidant Capacity, and Intestinal Health in Cherry Valley Ducks.

Chen B, Tang Y, Huang L, Wang Z, Li J, Zhang M, Yang Y, Zhang D, Jing B, Zeng Y, Ni X, Yang J, Pan K.Probiotics Antimicrob Proteins. 2025 Aug 15. doi: 10.1007/s12602-025-10720-1. Online ahead of print.PMID: 40815365

Chikungunya's global rebound and Asia's growing vulnerability: Implications for integrated vector control and pandemic preparedness.

Ni J, Li Z, Hu X, Zhou H, Gong Z.Biosci Trends. 2025 Aug 8. doi: 10.5582/bst.2025.01239. Online ahead of print.PMID: 40790814

Trends in pediatric vaccination coverage in Italy from 2000 to 2023.

Villani L, Causio FA, Savoia C, Pastorino R, Ricciardi W, Boccia S, de Waure C.Eur J Public Health. 2025 Aug 1;35(4):781-787. doi: 10.1093/eurpub/ckaf107.PMID: 40628384

Emerging neuroinfectious diseases: public health implications.

Kim CY, Holroyd KB, Thakur KT.Curr Opin Neurol. 2025 Aug 1;38(4):436-442. doi: 10.1097/WCO.0000000000001401. Epub 2025 Jun 11.PMID: 40501312

Toxoplasma cyst wall CST9 elicits an acute-associated humoral response in humans and mice and protects against chronic infection in immunized mice.

Saldarriaga Cartagena AM, Rivera EM, Sánchez-López EF, Formigo PM, Legarralde A, Ganuza A, Alonso AM, Clemente M, Angel SO.Microb Pathog. 2025 Aug;205:107638. doi: 10.1016/j.micpath.2025.107638. Epub 2025 Apr 25.PMID: 40287105

Purpura Fulminans Caused by Streptococcus pneumoniae Serotype 23A in a Young Post-Splenectomy Man: A Case Report.

Hamasaki A, Yumoto T, Fukushima S, Hagiya H, Chang B, Akeda Y, Hongo T, Tsukahara K, Naito H, Nakao A.J Infect Chemother. 2025 Aug 12:102791. doi: 10.1016/j.jiac.2025.102791. Online ahead of print.PMID: 40812724

Pediatric tuberculosis and BCG vaccine in Japan.

Horikoshi Y, Toizumi M.Vaccine. 2025 Aug 7;62:127564. doi: 10.1016/j.vaccine.2025.127564. Online ahead of print.PMID: 40780094

RNA modification is the mark and strategy for host-microbe interactions.

Tian Y, Wang X.Cell Mol Life Sci. 2025 Aug 8;82(1):306. doi: 10.1007/s00018-025-05842-2.PMID: 40779243

Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial.

Mercer LD, Seña AC, Colgate ER, Crothers JW, Wright PF, Al-Ibrahim M, Tritama E, Vincent A, Mainou BA, Zhang Y, Konopka-Anstadt J, Bandyopadhyay AS, Fix A, Konz JO, Gast C.Lancet Infect Dis. 2025 Aug 13:S1473-3099(25)00285-3. doi: 10.1016/S1473-3099(25)00285-3. Online ahead of print.PMID: 40818478

Modulating Immunogenicity and Reactogenicity in mRNA-Lipid Nanoparticle Vaccines through Lipid Component Optimization.

Kawaguchi Y, Kimura M, Karaki T, Tanaka H, Ono C, Ishida T, Matsuura Y, Hirai T, Akita H, Shimizu T, Yoshioka Y.ACS Nano. 2025 Aug 5;19(30):27977-28001. doi: 10.1021/acsnano.5c10648. Epub 2025 Jul 23.PMID: 40700637

Distal airway epithelial progenitors mediate TGF-β release to drive lung $CD8^+$ T_{RM} induction following mucosal BCG vaccination.

Blake JA, Seifert J, Miranda-Hernandez S, Ruscher R, Giacomin PR, Doolan DL, Kupz A.Mucosal Immunol. 2025 Aug;18(4):973-988. doi: 10.1016/j.mucimm.2025.05.007. Epub 2025 May 30.PMID: 40451435

Decoding virulence and resistance in Klebsiella pneumoniae: Pharmacological insights, immunological dynamics, and in silico therapeutic strategies.

Alishvandi A, Barancheshemeh M, Firuzpour F, Aram C, Kamali MJ, Keikha M.Microb Pathog. 2025 Aug;205:107691. doi: 10.1016/j.micpath.2025.107691. Epub 2025 May 10.PMID: 40355055

Atypical Influenza A(H3N2) Activity Patterns in Germany, 2021-2023, and Characterization of Newly Emerged Virus Clades.

Duwe S, Oh DY, Wedde M, Börnigen D, Ignatius R, Kleist MV, Reiche J, Biere B, Wolff T, Dürrwald R.J Med Virol. 2025 Aug;97(8):e70530. doi: 10.1002/jmv.70530.PMID: 40772603

The promise of mRNA vaccines in cancer treatment: Technology, innovations, applications, and future directions.

Tang W, Wu Q, Liang A, Shi J, Chen J, Zhu X, Mao L.Crit Rev Oncol Hematol. 2025 Aug;212:104772. doi: 10.1016/j.critrevonc.2025.104772. Epub 2025 May 22.PMID: 40412579

Feasibility and Acceptability of Pay-it-forward in Increasing Uptake of HPV Vaccination among 15- to 18-Year-Old Girls in China: Pilot RCT Results.

Li Y, Qin C, Li KT, He Y, Qiu S, Wu D, Li J.Cancer Prev Res (Phila). 2025 Aug 1;18(8):485-492. doi: 10.1158/1940-6207.CAPR-24-0549.PMID: 40296640

Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.

Diya O, Gayed J, Lowry FS, Ma H, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Cutler M, Belanger T, Cooper D, Xu X, Mogg R, Türeci Ö, Şahin U, Swanson KA, Modjarrad K, Anderson AS, Gurtman A, Kitchin N.Infect Dis Ther. 2025 Aug;14(8):1973-1987. doi: 10.1007/s40121-025-01185-4. Epub 2025 Jul 1.PMID: 40591130

A Reassessment of Serious Adverse Events After Human Papillomavirus Vaccination in the Nagoya Survey in Japan by Using Incidentality Analysis.

Suzumura Y.Cureus. 2025 Aug 5;17(8):e89441. doi: 10.7759/cureus.89441. eCollection 2025 Aug.PMID: 40766093

Increase in serogroup W invasive meningococcal disease in England associated with pilgrimage to Saudi Arabia, January 2024 to June 2025.

Campbell H, Lucidarme J, Clark SA, Heymer EJ, Ribeiro S, Bai X, Ahmad S, Ramsay ME, Borrow R, Ladhani SN.Euro Surveill. 2025 Aug;30(31):2500509. doi: 10.2807/1560-7917.ES.2025.30.31.2500509.PMID: 40776896

Unveiling the Immunostimulatory Potential of the HSPA1A Mini-Chaperones Compared to the HSPA1A and HSP27 Chaperones: In Silico and In Vitro Insights for Vaccine Development.

Heidarnejad F, Ekhlasi F, Moradi Pordanjani P, Nemati F, Bolhassani A.Protein J. 2025 Aug 14. doi: 10.1007/s10930-025-10285-6. Online ahead of print.PMID: 40813535

Active surveillance for influenza A virus in swine reveals within-farm reassortment and cocirculation of distinct subtypes and genetic clades.

Thomas MN, Janzen GM, Markin A, Sharma A, Hewitt K, Li G, Baker AL, Gauger PC, Anderson TK.Vet Microbiol. 2025 Aug 11;309:110681. doi: 10.1016/j.vetmic.2025.110681. Online ahead of print.PMID: 40818301

Burden of Respiratory Syncytial Virus infection in older adults hospitalised in England during 2023/24.

Symes R, Keddie SH, Walker J, McKeever T, Ahmad S, Arnold D, Evans CM, Pelosi E, Rahman N, Sapey E, Zambon M, Watson C, Bernal JL, Lim WS; HARISS network collaborators.J Infect. 2025 Aug 6:106570. doi: 10.1016/j.jinf.2025.106570. Online ahead of print.PMID: 40780588

Top 10 drugs most frequently associated with adverse events of myocarditis and pericarditis.

Cho J, Jo H, Park J, Oh J, Kim H, Kim S, Lee H, Jo Y, Jeong J, Lee S, Woo HG, Smith L, López Sánchez GF, Rhee SY, Yang JM, Yon DK.Sci Rep. 2025 Aug 7;15(1):28849. doi: 10.1038/s41598-025-13234-6.PMID: 40770014

Imagine your immune system is a sports team: Language expectancies in the use of physician analogies and jargon.

Yan J, Wilson SR, Liao D.Patient Educ Couns. 2025 Aug;137:108810. doi: 10.1016/j.pec.2025.108810. Epub 2025 May 13.PMID: 40403642

Venous Thrombosis Associated with Different Types of SARS-CoV-2 Vaccines in the Netherlands-Results of the TERA Case-Control Study.

van Dijk WJ, Kant AC, van Hylckama Vlieg A, Rosendaal FR.Thromb Haemost. 2025 Aug 8. doi: 10.1055/a-2665-2400. Online ahead of print.PMID: 40780270

Effects of test-and-treat versus preexposure prophylaxis on elimination of HIV transmission: analysis of 24 HIV prevention trials.

Garratt A, Muraleetharan A, Fairhead C, Hill A.AIDS. 2025 Aug 1;39(10):1470-1475. doi: 10.1097/QAD.0000000000004232. Epub 2025 May 2.PMID: 40327671

An adolescent presenting with IgA nephropathy and persistent decreased kidney function after COVID-19 vaccination during follow-up for asymptomatic hematuria: a clinicopathological study.

Morisawa K, Takahashi T, Matsuoka K, Hashiguchi A, Yamanaka M, Hamada R, Honda M.CEN Case Rep. 2025 Aug;14(4):635-640. doi: 10.1007/s13730-025-00989-0. Epub 2025 Apr 13.PMID: 40221577

Successful treatment of MPO-ANCA positive crescentic IgA nephropathy/IgA vasculitis with nephritis potentially triggered by a COVID-19 vaccine in a young adult female using corticosteroids, rituximab, and avacopan.

Kaseda K, Terakawa R, Matsui R, Yasukawa M, Asakawa S, Arai S, Yamazaki O, Tamura Y, Ohashi R, Shibata S, Fujigaki Y.CEN Case Rep. 2025 Aug;14(4):626-632. doi: 10.1007/s13730-025-00991-6. Epub 2025 Apr 9.PMID: 40202709

Characterization of immunopathological changes in the feather pulp of CVI988-vaccinated pullets challenged with a very virulent plus Marek's disease virus strain.

Bonorino FC, Garcia Marin JF, Fares A, Khaled N, Emmanuel D, Kulkarni RR, Gimeno I.Avian Pathol. 2025 Aug;54(4):521-529. doi: 10.1080/03079457.2025.2472838. Epub 2025 Mar 13.PMID: 40017374

Immune Control of AIDS Progression by an Adenovirus-Based Therapeutic Vaccination in Acute Simian Immunodeficiency Virus-Infected Macaques.

He Y, Wu C, Feng F, Liu Z, Zhang X, Yang Q, Chen Z, Shi M, Wen Z, Liu Y, Hu F, Li L, Sun C, Chen L, Li P.MedComm (2020). 2025 Aug 1;6(8):e70309. doi: 10.1002/mco2.70309. eCollection 2025 Aug.PMID: 40757099

Development of an enteric pathogen multiplex immunoassay to measure antibody responses in blood and saliva for integrated serology applications.

Avolio LN, Pisanic N, Kruczynski KL, Moss WJ, Talaat KR, Kaminski RW, Clarkson KA, Elwood S, Mosha R, Houpt ER, Mduma ER, Platts-Mills JA, Heaney CD.J Immunol Methods. 2025 Aug;542:113898. doi: 10.1016/j.jim.2025.113898. Epub 2025 Jun 20.PMID: 40545133

Quaternized chitosan-coated PLGA nanoparticles co-deliver resveratrol and all-trans retinoic acid to enhance humoral immunity, cellular immunity and gastrointestinal mucosal immunity.

Yang D, Wang N, Cao L, Liu H, Cheng H, Ma H, Li L, Zou Y, Zhao X, Zhou X, Song X, Zhang D, Li M, Jia R, Yin Z.Colloids Surf B Biointerfaces. 2025 Aug 5;256(Pt 1):114994. doi: 10.1016/j.colsurfb.2025.114994. Online ahead of print.PMID: 40774228

A cost-benefit analysis of using wastewater monitoring to guide typhoid vaccine campaigns.

Keshaviah A, Akram AA, Rizmie D, Raxter I, Hasan R, Rahman Z, Suchana AJ, Jahan F, Rahman A, Rahman M, Rahman M, Diamond MB, D'Agostino AL.Trop Dis Travel Med Vaccines. 2025 Aug 4;11(1):24. doi: 10.1186/s40794-025-00260-5.PMID: 40754580

Self-assembled ferritin tuberculosis nanovaccines targeting ESAT-6 and CFP-10 elicit potent immunogenicity in mice.

Guo F, Dong S, Song Y, Qian Y, Jiang H, Zhang W, Li B, Qian Z, Wang X, Xu G, Wang H, Xu T.Int J Biol Macromol. 2025 Aug;320(Pt 4):146101. doi: 10.1016/j.ijbiomac.2025.146101. Epub 2025 Jul 17.PMID: 40683500

Analysis of three cases of disseminated BCG infection in infants after BCG vaccination in Beijing, China.

Li L, Xu J, Cai J, Wang M, Wang F, Yang L, Bai Y, Jia B, Li S.Hum Vaccin Immunother. 2025 Dec;21(1):2537482. doi: 10.1080/21645515.2025.2537482. Epub 2025 Aug 14.PMID: 40811145

Pathogenicity and virulence of Cryptococcus neoformans from an environmental perspective.

Casadevall A.Virulence. 2025 Dec;16(1):2547090. doi: 10.1080/21505594.2025.2547090. Epub 2025 Aug 14.PMID: 40810603

Immunogenicity and safety of a 2 + 1 DTPa priming schedule in Australian infants and the impact of maternally derived antibodies on pertussis antibody responses up to four years of age.

McAlister SM, Dierig A, van den Biggelaar AHJ, Thornton R, Cooper MN, McIntyre P, Richmond PC, Wood N.J Pediatric Infect Dis Soc. 2025 Aug 7:piaf067. doi: 10.1093/jpids/piaf067. Online ahead of print.PMID: 40795273

Tick and host microbiotas: immunomodulators in tick-borne diseases?

Boulanger N.Trends Parasitol. 2025 Aug 7:S1471-4922(25)00198-9. doi: 10.1016/j.pt.2025.07.009. Online ahead of print.PMID: 40780971

Complementary Strategy of Maternal Immunization with RSVpreF Vaccine and Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Among Italian Infants: A Cost-Effectiveness Assessment.

Polistena B, Midulla F, Sotgiu G, d'Angela D, Di Virgilio R, Spandonaro F.Infect Dis Ther. 2025 Aug;14(8):1883-1897. doi: 10.1007/s40121-025-01193-4. Epub 2025 Jul 18.PMID: 40679786

Barriers to COVID-19 vaccinations and moral struggle among nurses in a Chinese community: A critical medical anthropology analysis.

Siu JY.Vaccine. 2025 Aug 6;62:127574. doi: 10.1016/j.vaccine.2025.127574. Online ahead of print.PMID: 40773964

Post COVID 19 resurgence of diphtheria in Kano, Nigeria: analysis of 18,320 cases.

Abbas MA, Yusuf AL, Murtala HA, Abdullahi AA, Murtala AM, Torrelles JB, Aliyu MH, Salihu HM.EBioMedicine. 2025 Aug;118:105877. doi: 10.1016/j.ebiom.2025.105877. Epub 2025 Jul 25.PMID: 40714729

Comparative evaluation of indirect-ELISAs based on native antigens of Clostridium chauvoei for the detection of blackleg-specific antibodies in cattle.

Amitkumar M, Prajapati A, Bindu S, Sairam S, Shirisha A, Namrutha MR, Hemanth RA, Yogisharadhya R, Chanda MM, Shivachandra SB.Anaerobe. 2025 Aug;94:102975. doi: 10.1016/j.anaerobe.2025.102975. Epub 2025 May 30.PMID: 40451457

HIV-1 gp160 in nanodiscs: Unravelling structures and guiding vaccine design.

Elbaz NM, Nasr ML.Curr Opin Struct Biol. 2025 Aug 4;94:103122. doi: 10.1016/j.sbi.2025.103122. Online ahead of print.PMID: 40763538

A researcher's guide to studying sex differences in immune aging.

Baker C, Kim M, Benayoun BA.Trends Mol Med. 2025 Aug;31(8):702-717. doi: 10.1016/j.molmed.2025.01.005. Epub 2025 Jan 29.PMID: 39884873

Efficacy of a non-recombinant NADC34-like PRRSV-2 vaccine candidate against a recombinant NADC34-like PRRSV-2 isolate.

Qiu M, Li S, Cui M, Yang S, Zhu X, Meng Y, Lin Y, Lin H, Sun Z, Wang Y, Sen Jiang, Zheng W, Zhu J, Chen N.Vet Microbiol. 2025 Aug 11;309:110676. doi: 10.1016/j.vetmic.2025.110676. Online ahead of print.PMID: 40812026

Humoral response dynamics following inactivated SARS-CoV-2 vaccination and their association with subsequent infection and symptoms in individuals with and without prior SARS-CoV-2 infection: evidence from Sichuan Province, China.

Yu Y, Jia M, Zhong J, Feng L, Jiang X, Li Y, Huang Q, Chen Y, Wang X, Yue Y, Guo L, Liang X, Ren L, Yang W.Microbiol Spectr. 2025 Aug 11:e0219124. doi: 10.1128/spectrum.02191-24. Online ahead of print.PMID: 40788170

Impact of specific productivity and operation mode upon the biophysical properties of HIV-1 Gag-based virus-like particles.

Pérez-Rubio P, Lorenzo Romero E, Casas J, Díaz-Maneh A, Gòdia F, Cervera L, Lavado-García J.Appl Microbiol Biotechnol. 2025 Aug 8;109(1):179. doi: 10.1007/s00253-025-13560-9.PMID: 40781574

Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations.

Chancharoenthana W, Traitanon O, Leelahavanichkul A, Ronco C.Ren Fail. 2025 Dec;47(1):2541873. doi: 10.1080/0886022X.2025.2541873. Epub 2025 Aug 7.PMID: 40775743

Regulation of CD45 isoforms during human effector and memory CD8 T cell differentiation: Implications for T cell nomenclature.

McGuire DJ, Akondy RS, Yang S, Edupuganti S, Nagar S, Michael G, De Rosa SC, Newell EW, Farber DL, Kissick HT, McElrath MJ, Ahmed R.Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2322982122. doi: 10.1073/pnas.2322982122. Epub 2025 Aug 5.PMID: 40763029

Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System.

Sankar C, Evans S, Meyer JC, Gunter HM, Sekiti V, McCarthy K.Drug Saf. 2025 Aug;48(8):909-922. doi: 10.1007/s40264-025-01547-4. Epub 2025 Apr 16.PMID: 40238055

Measles Seroprevalence in Infants Under 9 Months of Age in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.

Ong DS, von Mollendorf C, Mulholland K, Do LAH.J Infect Dis. 2025 Aug 14;232(2):316-326. doi: 10.1093/infdis/jiaf177.PMID: 40179253

Effectiveness of the Human Papillomavirus Vaccine in Extended Age Groups: A Real-World Analysis Based on the Korean HPV Cohort Study.

Song H, Lee S, Choi S, Hur SY.Cancers (Basel). 2025 Aug 3;17(15):2561. doi: 10.3390/cancers17152561.PMID: 40805256

Characteristics of four natural poliovirus type 1 variants with six-nucleotide deletion (2,783-2,788 nt) in the VP1 region.

Lin J, Zhou L, Zhu C, Wei J, Lv B, Si Y, Zhu S, Ji T, Wang D, Yang Q, Xiao J, Yang L, Xiao K, Shao K, Zhang Y, Yan D.Microbiol Spectr. 2025 Aug 8:e0133425. doi: 10.1128/spectrum.01334-25. Online ahead of print.PMID: 40778757

COVID-19 Vaccine Adverse Events by Country Income Level: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Pimenta PDC, de Aquino Lima TC, Geraldine VGS, Tourinho FS, do Nascimento MC, Novaes RD, Dias LMRP.Am J Health Promot. 2025 Aug 5:8901171251365229. doi: 10.1177/08901171251365229. Online ahead of print.PMID: 40764277

Systematic review and meta-analysis of respiratory viral triggers for acute myocardial infarction and stroke.

Nguyen TQ, Vlasenko D, Shetty AN, Zhao E, Reid CM, Clothier HJ, Buttery JP.Cardiovasc Res. 2025 Aug 14;121(9):1330-1344. doi: 10.1093/cvr/cvaf092.PMID: 40570137

Enhanced hepatitis B virus-specific immunity by combining neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B virus infection.

Beretta M, Vesin B, Wei Y, Planchais C, Rosenbaum P, Ait-Goughoulte M, Pelletier N, Hardy D, Mouquet H, Bourgine M.Hepatology. 2025 Aug 1;82(2):470-486. doi: 10.1097/HEP.0000000000001179. Epub 2024 Dec 9.PMID: 39652775

A Host Cell Vector Model for Analyzing Viral Protective Antigens and Host Immunity.

Ahn SM, Song JH, Son SE, Kim HW, Kim G, Hong SM, Choi KS, Kwon HJ.Int J Mol Sci. 2025 Aug 2;26(15):7492. doi: 10.3390/ijms26157492.PMID: 40806621

Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy.

Winthrop KL, Klaff J, Penn SK, Liu Y, García C, Mysler E, Wells AF, Bu X, Fish I, Chen M, Cunningham AL.RMD Open. 2025 Aug 12;11(3):e005521. doi: 10.1136/rmdopen-2025-005521.PMID: 40803820

Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection.

Ponce LJ, Wang Y, Singh A, Chua HK, Chen M, Hor PX, Loh CY, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lin RJH, Lim C, Teo J, Goh YS, Ejima K; on behalf of the NCID Study Group; on behalf of the COVID-19 Cohort Study Group.J Med Virol. 2025 Aug;97(8):e70521. doi: 10.1002/jmv.70521.PMID: 40767533

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Pneumonia Hospitalization Among Medicare Beneficiaries Aged 65 in Long-Term Care.

Zielinski L, Andrejko K, Shang N, Park S, Derado G, Lindaas A, Zhang Y, Lufkin B, Chillarige Y, Kobayashi M.J Infect Dis. 2025 Aug 2:jiaf405. doi: 10.1093/infdis/jiaf405. Online ahead of print.PMID: 40751424

Lichen Planus Following COVID-19 Infection and Vaccination. Matched Case-Control Study.

Arduino PG, Kubanov A, Vlasova A, Martynov A, Petti S.Australas J Dermatol. 2025 Aug;66(5):289-295. doi: 10.1111/ajd.14522. Epub 2025 May 5.PMID: 40323017

Evaluation of the knowledge and attitudes of pregnant women undergoing preoperative assessment in the anesthesia clinic regarding Monkeypox virus disease in Turkey.

Bulut OK, Karataş SŞ, Öner SF.BMC Pregnancy Childbirth. 2025 Aug 14;25(1):853. doi: 10.1186/s12884-025-08001-4.PMID: 40813651

Topological Learning Prediction of Virus-like Particle Stoichiometry and Stability.

Liu X, Huang X, Wei GW.ArXiv [Preprint]. 2025 Aug 4:arXiv:2507.21417v2.PMID: 40766891

Global Burden of Human Metapneumovirus: Bridging Gaps in Prevention, Diagnostics and Treatment.

Adepoju VA, Adnani QES, Jamil S, Mohammadnezhad M, Abdulrahim A.Public Health Chall. 2025 Aug 1;4(3):e70094. doi: 10.1002/puh2.70094. eCollection 2025 Sep.PMID: 40756454

Balancing public health and individual autonomy: a study of China's vaccination policy.

Wang J, Zhai X.J Med Ethics. 2025 Aug 11:jme-2025-110762. doi: 10.1136/jme-2025-110762. Online ahead of print.PMID: 40789746

A case of ulcerative colitis in a patient undergoing surgery due to exacerbation resulting in toxic megacolon after SARS-CoV-2 vaccination.

Ogihara R, Matsuura M, Ishida T, Morikubo H, Mitsui T, Saito D, Miyoshi J, Shibahara J, Sunami E, Hisamatsu T.Clin J Gastroenterol. 2025 Aug;18(4):557-562. doi: 10.1007/s12328-025-02136-9. Epub 2025 Apr 28.PMID: 40295434

Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates.

Chiaro J, Peltonen K, Õunap K, Bailey A, Feola S, Wojciechowski S, Es-Haghi M, Azkargorta M, Elortza F, Russo S, Sallinen H, Anttila M, Gurvich O, Cerullo V, Kekarainen T.NPJ Vaccines. 2025 Aug 16;10(1):195. doi: 10.1038/s41541-025-01234-6.PMID: 40819132

R.I.S.E. ID: Adaptations to the Current Political Climate for the Infectious Diseases Frontline.

Bearman G, Nori P.Open Forum Infect Dis. 2025 Jul 25;12(8):ofaf443. doi: 10.1093/ofid/ofaf443. eCollection 2025 Aug.PMID: 40799779

Symptoms of long COVID in children and adolescents: a scoping review.

Gusmão ACS, Scaléa ACR, Uehara SCDSA.Rev Esc Enferm USP. 2025 Aug 4;59:e20240435. doi: 10.1590/1980-220X-REEUSP-2024-0435en. eCollection 2025.PMID: 40762988

Multifocal paraneoplastic encephalitis associated with anti-GABA-B and anti-Hu antibodies manifesting with status epilepticus and epilepsia partialis continua: Expanding the clinical-radiological spectrum.

Viola V, Asioli GM, Ferri L, Rossi S, Andrini E, Pierucci E, Lamberti G, Sambati L, Rinaldi R, Bisulli F, Spinardi L, Guarino M.J Neuroimmunol. 2025 Aug 15;405:578634. doi: 10.1016/j.jneuroim.2025.578634. Epub 2025 May 4.PMID: 40344695

Aged garlic extract major constituent S-1-propenyl-l-cysteine inhibits proinflammatory mRNA expression in bronchial epithelial IB3-1 cells exposed to the BNT162b2 vaccine.

Papi C, Gasparello J, Marzaro G, Macone A, Zurlo M, Di Padua F, Fino P, Agostinelli E, Gambari R, Finotti A.Exp Ther Med. 2025 Jun 10;30(2):153. doi: 10.3892/etm.2025.12903. eCollection 2025 Aug.PMID: 40529387

Antibiotic effects on the gut microbiome across diverse geographies.

Jaya LE, Brito IL.Trends Microbiol. 2025 Aug 5:S0966-842X(25)00215-X. doi: 10.1016/j.tim.2025.07.003. Online ahead of print.PMID: 40769834

Serotype 3 associated invasive pneumococcal disease in children: analysis of 15 years of Australian national surveillance data.

Homaira N, Khan JR, Jaffé A.Thorax. 2025 Aug 15;80(9):662-664. doi: 10.1136/thorax-2025-223125.PMID: 40360260

Prior immunological memory to pertussis toxin affects the avidity development of anti-PT IgG antibodies after acellular pertussis booster vaccination.

Knuutila A, Ahvenainen N, Barkoff AM, Mertsola J, van Gageldonk P, Buisman A, Pinto MV, Kelly D, He Q.Emerg Microbes Infect. 2025 Aug 13:2547720. doi: 10.1080/22221751.2025.2547720. Online ahead of print.PMID: 40803045

De novo generation of viruses in animals: from infection models to vaccine development.

Cochin M, Driouich J-S, Luciani L, Nougairède A.mSphere. 2025 Aug 11:e0074224. doi: 10.1128/msphere.00742-24. Online ahead of print.PMID: 40788033

Host-intrinsic and host-extrinsic factors modulate immunity to Mtb infection, reinfection, and noncanonical vaccination routes.

Bromley JD, Simonson AW, Shalek AK, Flynn JL.Cell Rep Med. 2025 Aug 5:102286. doi: 10.1016/j.xcrm.2025.102286. Online ahead of print.PMID: 40780201

Effect of disialoganglioside GD3 on the subgel, gel and fluid phases of cationic DODAB vesicles.

Ejarque JB, Couto ACF, Matos T, Duarte EL, Lamy MT, Rozenfeld JHK.Biophys Chem. 2025 Aug 4;326:107503. doi: 10.1016/j.bpc.2025.107503. Online ahead of print.PMID: 40763433

Utility of mobile applications in the management of hepatitis B: A systematic review.

Romero-Vico J, Vargas-Accarino E, Palom A, Fabrellas N, Buti M.Gastroenterol Hepatol. 2025 Aug-Sep;48(7):502395. doi: 10.1016/j.gastrohep.2025.502395. Epub 2025 Feb 19.PMID: 39983899

Glycosylation orchestrates virulence and pathogenicity of periodontal keystone pathogens.

Zhao D, Wu Q, Li Z, Liu Y, Yi S, Zhou X, Peng X.Crit Rev Microbiol. 2025 Aug 1:1-15. doi: 10.1080/1040841X.2025.2530482. Online ahead of print.PMID: 40748205

Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department.

Silva-Afonso RF, Platas-Abenza G, Guerrero-Soler M, Gallardo-Rodríguez P, Gil-Sánchez F, Pérez-Paz G, Cartagena-Llopis L, Fuster-Pérez M, Sánchez-Valero M, Esclapez-Martínez A, Solís-Aniorte N, Fernández-Martínez Y, Ronda-Pérez E, Escribano-Cañadas I, Rodríguez-Díaz JC, Merino De Lucas E, Chico-Sánchez P, Sánchez-Payá J, Gras-Valentí P.Enferm Infecc Microbiol Clin (Engl Ed). 2025 Aug-Sep;43(7):435-443. doi: 10.1016/j.eimce.2025.03.017. Epub 2025 Jun 3.PMID: 40467410

Symbolic show of strength: a predictor of risk perception and belief in misinformation.

Stein R, Rutchick AM, Sin AY, Jarrin Rueda LF.J Soc Psychol. 2025 Aug 2:1-27. doi: 10.1080/00224545.2025.2541206. Online ahead of print.PMID: 40751578

Mini review: SHEN26, a novel oral antiviral drug for COVID-19 treatment.

Zheng P, Li G, Chen Y, Li S, Yang S, Guo D, Zhou Q, Zhang X.Bioorg Med Chem Lett. 2025 Aug 15;124:130243. doi: 10.1016/j.bmcl.2025.130243. Epub 2025 Apr 16.PMID: 40250816

Clinical and immunological insights into SARS-CoV-2 reinfection: a propensity score-matched cohort study.

Zhao C, Liu L, Ge Z, Wang J, Wang R, Jiang Z, Tian D, Chen Z.BMC Infect Dis. 2025 Aug 1;25(1):970. doi: 10.1186/s12879-025-11398-0.PMID: 40751140

Analysis of *Streptococcus dysgalactiae* subspecies *equisimilis* gene transcripts during experimental primate necrotizing myositis.

Eraso JM, Olsen RJ, Long SW, Faili A, Kayal S, Musser JM.mBio. 2025 Aug 13;16(8):e0134925. doi: 10.1128/mbio.01349-25. Epub 2025 Jul 22.PMID: 40693777

Is equitable priority vaccination of vulnerable people feasible in a real-world context? The case of Belgium.

Vermeiren E, Scheerens C, Stouten V, Crombez J, De Maeseneer J, van Loenhout JAF.Eur J Public Health. 2025 Aug 1;35(4):774-780. doi: 10.1093/eurpub/ckaf075.PMID: 40493534

Acute transverse myelitis and associate vaccine complication in SARS-CoV-2 patients: a retrospective cohort analysis in real-world database.

Lu JY, Yang SF, Tzeng SL, Lee YT, Wang YH, Yeh CB.Virol J. 2025 Aug 12;22(1):277. doi: 10.1186/s12985-025-02905-5.PMID: 40796844

Serum vitamin D and the risk of SARS-CoV-2 and seasonal influenza infection during the twindemic period.

Ito A, Yamamoto S, Islam Z, Tan T, Oshiro Y, Inamura N, Nemoto T, Konishi M, Horii K, Mizoue T, Sugiura W, Ohmagari N.Clin Nutr ESPEN. 2025 Aug;68:263-266. doi: 10.1016/j.clnesp.2025.05.007. Epub 2025 May 6.PMID: 40339959

Bacterial type IV secretion system induces specific and nonspecific protective immunity.

Castanheira FVS, Pereira MSF, Ataide MA, Mascarenhas DPA, Guerra RO, Quirino GFS, Almeida F, Zamboni DS.mBio. 2025 Aug 13;16(8):e0044825. doi: 10.1128/mbio.00448-25. Epub 2025 Jun 25.PMID: 40558085

Sociodemographic Inequalities in COVID-19 Booster Dose Vaccination Coverage: a Retrospective Study of 196 Provinces in Peru.

Intimayta-Escalante C, Tapia-Sequeiros G, Rojas-Bolivar D.J Racial Ethn Health Disparities. 2025 Aug;12(4):2399-2408. doi: 10.1007/s40615-024-02060-7. Epub 2024 Jun 24.PMID: 38914811

Emergence of a piliated and multidrug-resistant *Streptococcus pneumoniae* serotype 35B-ST156 clone in Japan.

Miyazaki H, Nakano S, Shibuya R, Chang B, Miyazaki Y, Matsumoto T, Akeda Y.Microbiol Spectr. 2025 Aug 5:e0063225. doi: 10.1128/spectrum.00632-25. Online ahead of print.PMID: 40762490

New Onset of Hair Loss Disorders During the Coronavirus Disease 2019 Pandemic: A Korean Nationwide Population-Based Study.

Cho Y, Lim JW, Yoon YN, Kim CY, Lee YW, Choe YB, Yu DA.Ann Dermatol. 2025 Aug;37(4):250-258. doi: 10.5021/ad.25.007.PMID: 40736525

Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.

Herate C, Ferrier-Rembert A, Relouzat F, Gallouët AS, Pascal Q, Letscher H, Cavarelli M, Dereuddre-Bosquet N, Gros W, Delache B, Langlois S, Timera H, Jarjaval F, Bossevot L, Ludot C, Brua C, Lechemia M, Ferraris O, Silvestre N, Le Grand R, Tournier JN.Nat Commun. 2025 Aug 7;16(1):7306. doi: 10.1038/s41467-025-62681-2.PMID: 40775237

Bi(OTf)$_3$-promoted direct activation of formidable per-O-acetylated L-rhamnose Donor: Stereoselective access to α-L-rhamnopyranosides.

Yadav A, Kumar N, Kashyap S.Carbohydr Res. 2025 Aug;554:109527. doi: 10.1016/j.carres.2025.109527. Epub 2025 May 17.PMID: 40424804

Medical vs Nonmedical Immunization Exemptions for Child Care and School Attendance: Policy Statement.

Hackell JM, Brothers K, Bode S, Costello LM, Kafer LM, O'Leary ST; Committee on Practice and Ambulatory Medicine; Committee on Infectious Diseases; Committee on State Government Affairs; Council on School Health.Pediatrics. 2025 Aug 1;156(2):e2025072714. doi: 10.1542/peds.2025-072714.PMID: 40716772

Development of therapeutic cancer vaccines based on cancer immunity cycle.

Zhang J, Zheng Y, Xu L, Gao J, Ou Z, Zhu M, Wang W.Front Med. 2025 Aug;19(4):553-599. doi: 10.1007/s11684-025-1134-6. Epub 2025 Jul 14.PMID: 40653561

Amino acid changes in two viral proteins drive attenuation of the yellow fever 17D vaccine.

Zhang J, Chavez EC, Winkler M, Liu J, Carver S, Lin AE, Biswas A, Tamura T, Tseng A, Wang D, Benhamou A, O' Connell AK, Matsuo M, Norton JE, Kenney D, Adamson B, Kleiner RE, Burwitz B, Crossland NA, Douam F, Ploss A.Nat Microbiol. 2025 Aug;10(8):1902-1917. doi: 10.1038/s41564-025-02047-y. Epub 2025 Jul 8.PMID: 40629111

A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.

Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J, Bobisse S, Chiffelle J, Gehert T, Müller M, Pak H, Krämer AI, Altimiras ER, Racle J, Taillandier-Coindard M, Muehlethaler K, Auger A, Saugy D, Murgues B, Benyagoub A, Gfeller D, Laniti DD, Kandalaft L, Rodrigo BN, Bouchaab H, Tissot S, Coukos G, Harari A, Bassani-Sternberg M.Nat Biotechnol. 2025 Aug;43(8):1360-1372. doi: 10.1038/s41587-024-02420-y. Epub 2024 Oct 11.PMID: 39394480

Application of Cord Blood-Derived Exosomes in Tumor Prevention and Treatment.

Huang C, Li Y, Zhang B, Tang Y, Huang Y, Wei W.Clin Med Insights Oncol. 2025 Aug 10;19:11795549251365360. doi: 10.1177/11795549251365360. eCollection 2025.PMID: 40799502

Ewe litter size and lamb birth weight: Effects on lamb health, performance, and carcass traits.

Van Donkersgoed J.Can Vet J. 2025 Aug 1;66(8):911-914. eCollection 2025 Aug.PMID: 40786727

Long-Acting In Situ Cancer Vaccines by Oncolytic STING-Activating Microgels.

Tan H, Guo J, Wang Y, Chen W, Zhong Z, Deng C.Small. 2025 Aug 5:e03561. doi: 10.1002/smll.202503561. Online ahead of print.PMID: 40761011

Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity.

Daman AW, Antonelli AC, Redelman-Sidi G, Paddock L, Khayat S, Ketavarapu M, Cheong JG, Jurado LF, Benjamin A, Jiang S, Ahimovic D, Lawless VR, Bale MJ, Loutochin O, McPherson VA, Divangahi M, Niec RE, Pe'er D, Pietzak E, Josefowicz SZ, Glickman MS.Cancer Cell. 2025 Aug 11;43(8):1442-1459.e10. doi: 10.1016/j.ccell.2025.05.002. Epub 2025 May 29.PMID: 40446799

[Comparative Analysis of Free HPV Vaccination Programs Across Countries with Different Income Levels Worldwide: From Implementation to Evaluation].

Zhu YW, Chen YP, Liang YX, Wang SY.Zhonghua Yu Fang Yi Xue Za Zhi. 2025 Aug 11;59:167-175. doi: 10.3760/cma.j.cn112150-20250508-00403. Online ahead of print.PMID: 40796287

Phage Therapy: A Targeted Solution for Brucellosis.

Lashtoo Aghaee B, Alikhani MY, Kazemi S, Ahmadyousefi M, van Leeuwen WB, Nasaj M.Vector Borne Zoonotic Dis. 2025 Aug 11. doi: 10.1177/15303667251367519. Online ahead of print.PMID: 40788720

Advancements in Artificial Cell Preparation and Biomedical Applications.

Liu J, Pan Y, Liu Z, Qi Y, Huang Y.Macromol Biosci. 2025 Aug;25(8):e2500052. doi: 10.1002/mabi.202500052. Epub 2025 Mar 25.PMID: 40129352

Research progress on the bioactivity of platycodin D from Platycodon grandifloras.

Song Y, Lv X, Ding C, Liu X, Han Y, Chen S, Li M, Zhao T.Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9673-9701. doi: 10.1007/s00210-025-03875-9. Epub 2025 Mar 11.PMID: 40064661

Post-exposure prophylaxis regimen of rabies monoclonal antibody and vaccine in category 3 potential exposure patients: a phase 4, open-label, randomised, active-controlled trial.

Kulkarni PS, Potey AV, Kapse D, Bhamare C, Gawande A, Munshi R, Pawar S, Gogtay NJ, Agarwal A, Tambe M, Thakre S, Samuel CJ, Khan SMS, S RH, Rana D, Singh N, Kamath V, Bhalla HL, Poonawalla CS, Mani RS, Gunale B; RAB-04 study group.Lancet. 2025 Aug 9;406(10503):627-635. doi: 10.1016/S0140-6736(25)00735-4.PMID: 40783290

Mapping of human monoclonal antibody responses to XBB.1.5 COVID-19 monovalent vaccines: a B cell analysis.

Fantin RF, Clark JJ, Cohn H, Jaiswal D, Bozarth B, Rao V, Civljak A, Lobo I, Nardulli JR, Srivastava K, Yong JS, Andreata-Santos R, Bushfield K, Lee ES, Singh G; PVI Study Group; Kleinstein SH, Krammer F, Simon V, Bajic G, Coelho CH.Lancet Microbe. 2025 Aug;6(8):101103. doi: 10.1016/j.lanmic.2025.101103. Epub 2025 May 30.PMID: 40456237

Gold Nanoparticle-mRNA Conjugates Encapsulated in Lipid Nanoparticles for Coordinated Codelivery of Multiple mRNAs.

Hwang D, Park SA, Kim JH, Lee SY, Lee J, Kim HS, Kim KA, Lee SH, Oh TJ, Lee J, An S.ACS Omega. 2025 Jul 25;10(30):32998-33007. doi: 10.1021/acsomega.5c02145. eCollection 2025 Aug 5.PMID: 40787400

Anti-CV2/CRMP5 autoantibodies as drivers of sensory neuron excitability and pain in rats.

Martin L, Stratton HJ, Salih LY, Dumaire N, Gomez K, Do LD, Loya-Lopez S, Tang C, Calderon-Rivera A, Ran D, Nunna V, Bellampalli SS, François-Moutal L, Luo S, Porreca F, Ibrahim M, Rogemond V, Honnorat J, Khanna R, Moutal A.Nat Commun. 2025 Aug 7;16(1):7311. doi: 10.1038/s41467-025-62380-y.PMID: 40775229

Characterizing and engineering post-translational modifications with high-throughput cell-free expression.

Wong DA, Shaver ZM, Cabezas MD, Daniel-Ivad M, Warfel KF, Prasanna DV, Sobol SE, Fernandez R, Tobias F, Filip SK, Hulbert SW, Faull P, Nicol R, DeLisa MP, Balskus EP, Karim AS, Jewett MC.Nat Commun. 2025 Aug 5;16(1):7215. doi: 10.1038/s41467-025-60526-6.PMID: 40764296

Current Epidemiological Trends and Public Health Challenges of Hepatitis A Virus Infection in Thailand.

Poovorawan Y, Kanokudom S, Inma P, Nilyanimit P, Wanlapakorn N.Am J Trop Med Hyg. 2025 Aug 5:tpmd250083. doi: 10.4269/ajtmh.25-0083. Online ahead of print.PMID: 40763728

Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.

Xie N, Shen G, Huang C, Zhu H.Chin Med J (Engl). 2025 Aug 4. doi: 10.1097/CM9.0000000000003708. Online ahead of print.PMID: 40757404

Measles Outbreak Investigation in Chandigarh in 2023: A Case Series.

Mahajan V, Singh MP, Sharma A, Kanta P, Gupta S, Guglani V.Indian Pediatr. 2025 Aug;62(8):593-598. doi: 10.1007/s13312-025-00112-7. Epub 2025 Jun 10.PMID: 40493112

Comparison between Western Reserve strain and Tiantan strain of oncolytic vaccinia virus vector expressing exogenous gene Aphracilistes vastus lectin.

Zhang H, Pang W, Zhou J, Ye T, Chen K, Zhou Y, Li G.Biochem Biophys Res Commun. 2025 Aug 15;775:152155. doi: 10.1016/j.bbrc.2025.152155. Epub 2025 Jun 3.PMID: 40482588

Psychological Distance to Science: Psychometric Evaluation of the Swedish PSYDISC-Scale and as a Predictor of Science Skepticism.

Jansson B, Halmedal C, Salomonsson T.Scand J Psychol. 2025 Aug;66(4):510-522. doi: 10.1111/sjop.13104. Epub 2025 Mar 3.PMID: 40033865

From prototype to outbreak: conserved pathogenesis of Oropouche virus in a novel murine pregnancy model highlights its public health implications.

Gunter KB, Bowen JM, Clarke AT, McFarlane M, Omoga DCA, Pozuelos S, Rogers LM, Aronoff DM, Vornhagen J, Brennan B, Tilston NL.bioRxiv [Preprint]. 2025 Aug 2:2025.08.02.668287. doi: 10.1101/2025.08.02.668287.PMID: 40766593

T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.

Cimen Bozkus C, Brown M, Velazquez L, Thomas M, Wilson EA, O'Donnell T, Kaminska A, Ruchnewitz D, Geertz D, Bykov Y, Kodysh J, Oguntuyo KY, Roudko V, Hoyos D, Srivastava KD, Kleiner G, Alshammary H, Karekar N, McClain C, Gopal R, Nie K, Del Valle D, Delbeau-Zagelbaum D, Rodriguez D, Setal J; Mount Sinai COVID-19 Biobank Team; Carroll E, Wiesendanger M, Gulko PS, Charney A, Merad M, Kim-Schulze S, Lee B, Wajnberg A, Simon V, Greenbaum BD, Chowell D, Vabret N, Luksza M, Bhardwaj N.iScience. 2025 Jul 2;28(8):113044. doi: 10.1016/j.isci.2025.113044. eCollection 2025 Aug 15.PMID: 40746995

Construction of an ASFV proteome library via multiple optimization strategies for high-throughput analysis.

Guo S, Ouyang L, Zhang H, Li M, Zhou W, Liang A, Wang L, Gong R, Wang D, Liu C, Dai Z, Tao S, Deng J, Zhang G, Zhang XE, Li F.Acta Biochim Biophys Sin (Shanghai). 2025 Aug 1. doi: 10.3724/abbs.2025125. Online ahead of print.PMID: 40746182

Morphology- and adhesion-dual biomimetic nanovaccine boosts antigen cross-presentation through subcellular transport regulation.

Wang Z, Zhou H, Su Q, Qiu Q, Deng W, Zhang M, Xu Z, Li J, Xiao J, Duan X.Sci Adv. 2025 Aug;11(31):eadx6732. doi: 10.1126/sciadv.adx6732. Epub 2025 Jul 30.PMID: 40737412

PD-1 is requisite for skin T_{RM} cell formation and specification by TGFβ.

Devi KSP, Wang E, Jaiswal A, Konieczny P, Kim TG, Nirschl CJ, Verma A, Liu Y, Milczanowski J, Christo SN, Gandolfo LC, Haitz K, Vardam TD, Wu P, King SL, Tse SW, Pradhan K, Jiang X, Tian T, Fuhlbrigge RC, Schmults CD, Clark RA, Kupper TS, Freeman GJ, Mackay LK, Naik S, Newell EW, Elemento O, Suarez-Farinas M, Anandasabapathy N.Nat Immunol. 2025 Aug;26(8):1339-1351. doi: 10.1038/s41590-025-02228-1. Epub 2025 Jul 29.PMID: 40730902

Calls with suicidality and psychological distress to a national helpline during the COVID-19 pandemic.

Daniels S, Yeshayahu H, Zalsman G, Yihia S, Sarel-Mahlev E, Benatov J.J Psychiatr Res. 2025 Aug;188:57-63. doi: 10.1016/j.jpsychires.2025.05.054. Epub 2025 May 23.PMID: 40435791

Embracing cancer immunotherapy with manganese particles.

Moosavi Zenooz A, Eterafi M, Azarmi Giglou S, Safarzadeh E.Cell Oncol (Dordr). 2025 Aug;48(4):899-920. doi: 10.1007/s13402-025-01070-9. Epub 2025 May 21.PMID: 40397376

Media Representation of Scientists in Jornal Nacional: Reaffirmation of Stereotypes During the First Year of the COVID-19 Pandemic.

Massarani L, Oliveira T, Medeiros A, Tavares C, Soares C, Magalhães E, Gagliardi J, Maia L, Ramalho M, Carneiro M.Health Commun. 2025 Aug;40(9):1732-1743. doi: 10.1080/10410236.2024.2420143. Epub 2024 Oct 28.PMID: 39466111

Affinity-purified sHBsAg-based virus-like particles as a platform for foreign mRNA binding.

Gackowska K, Krejmer-Rabalska M, Drazkowska K, Jemielity J, Krol E, Szewczyk B.Virology. 2025 Aug 11;611:110651. doi: 10.1016/j.virol.2025.110651. Online ahead of print.PMID: 40815903

[Brief history of laboratory-based epidemiological surveillance in the Mexican Institute for Social Security].

Santacruz-Tinoco CE, Alvarado-Yaah JE, Anguiano-Hernández YM, Martínez-Miguel B, Cabrera-Gaytán DA, Chávez-Navarro L.Rev Med Inst Mex Seguro Soc. 2025 Aug 14;63(5):e6698. doi: 10.5281/zenodo.16748267.PMID: 40815556

Prediction of vaccination coverage levels in populations with increasing levels of heterogeneity.

Bai F.J Biol Dyn. 2025 Dec;19(1):2545188. doi: 10.1080/17513758.2025.2545188. Epub 2025 Aug 12.PMID: 40796191

Vaccination with Acinetobacter baumannii adhesin Abp2D provides protection against catheter-associated urinary tract infection.

Timm MR, Tamadonfar KO, Nye TM, Villicaña JB, Pinkner JS, Dodson KW, Ellebedy AH, Hultgren SJ.Nat Commun. 2025 Aug 9;16(1):7341. doi: 10.1038/s41467-025-62402-9.PMID: 40783485

Engineered Nanobody Chimeras Recruits Anti-HBV Antibodies for Target Cancer Immunotherapy.

Zhang Z, Li Y, Wang Z, Hong H, Wu Z.J Med Chem. 2025 Aug 5. doi: 10.1021/acs.jmedchem.5c00666. Online ahead of print.PMID: 40763296

Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome.

Gào X, Zhao C, Yang J, Yang Z, Feng J, Zhan S, Fan D, Liu Z.NPJ Vaccines. 2025 Aug 2;10(1):182. doi: 10.1038/s41541-025-01239-1.PMID: 40753095

Extracellular vesicle-mediated delivery of circp53 suppresses the progression of multiple cancers by activating the CypD/TRAP/HSP90 pathway.

Yu X, Ding P, Guo M, Tang X, Wang Z, Zhang Y, Zhou L, Lv X, Shi H, Huang H, Mao J, Gu Z, Gu C, Yang Y.Exp Mol Med. 2025 Aug 1. doi: 10.1038/s12276-025-01506-0. Online ahead of print.PMID: 40744997

Scalable Cell-Free Production of Active T7 RNA Polymerase.

Rezvani RN, Aw R, Chan W, Satish K, Chen H, Lavy A, Rimal S, Patel DA, Rao G, Swartz JR, DeLisa MP, Kvam E, Karim AS, Krüger A, Kightlinger W, Jewett MC.Biotechnol Bioeng. 2025 Aug;122(8):2241-2250. doi: 10.1002/bit.28993. Epub 2025 Apr 29.PMID: 40296704

In Vivo Evolution of Monoclonal Antibody CR3022 to Achieve Cross-Neutralization of SARS-CoV-2 and Implications for Vaccine Strategies Against SARS-Related Viruses.

Fu Y, Feng Z, Erickson SA, Halfmann PJ, Li L, Chervin JC, Troxell CA, Sun J, Yasuhara A, Changrob S, Huang M, Zheng NY, Yuan M, Kawaoka Y, Wilson IA, Wilson P.bioRxiv [Preprint]. 2025 Aug 6:2025.08.05.666673. doi: 10.1101/2025.08.05.666673.PMID: 40799602

Novel Swelling-Lytic Cell Death Triggered by Cargo-Free Ionizable Lipid Nanoparticles.

Wu J, Zhao Z, Wu H, Lin S, Huang L, Chen G, Yang Y, Wang H, Yan H, Shi Y, Zhu L, Hu G, Zheng L, Ouyang S.Adv Sci (Weinh). 2025 Aug 7:e09208. doi: 10.1002/advs.202509208. Online ahead of print.PMID: 40776529

Carrier-Free Nanoadjuvant-Loaded Bilayer Microneedles for Programmed and Individualized Cancer Chemo-Immunotherapy.

Huang C, Wang H, Yang X, Wang H, Li W, Zhang L, Zhu D.Nano Lett. 2025 Aug 13;25(32):12223-12232. doi: 10.1021/acs.nanolett.5c02670. Epub 2025 Aug 1.PMID: 40747820

Self-Assembling Aromatic Peptide Amphiphile Fibers for Multivalent Display of Enzymatically Linked Antigenic Proteins.

Wakabayashi R, Syahid Fathullah GD, Higuchi A, Cui H, Minamihata K, Kamiya N, Goto M.ACS Appl Mater Interfaces. 2025 Aug 6;17(31):44240-44248. doi: 10.1021/acsami.5c10222. Epub 2025 Jul 23.PMID: 40696880

Influenza vaccination in patients with heart failure compared to usual practice: A model-based cost-effectiveness analysis.

Liu R, Patel A, Liu H, Du X, Di Tanna GL, Jan S, Atkins ER.Vaccine. 2025 Aug 2;62:127566. doi: 10.1016/j.vaccine.2025.127566. Online ahead of print.PMID: 40753672

Development of a mouse model for *Klebsiella pneumoniae*-associated neonatal sepsis.

Miller JC, Choi M, Zhao Z, Mushrush EM, Legesse TB, Cross AS, Baliban SM, Tennant SM.Microbiol Spectr. 2025 Aug 1:e0069725. doi: 10.1128/spectrum.00697-25. Online ahead of print.PMID: 40748073

A randomized, placebo-controlled phase III trial of an autologous, formalin-fixed tumor vaccine for newly diagnosed glioblastoma: trial protocol.

Muragaki Y, Ishikawa E, Tamura M, Kawamata T, Gosho M, Hashimoto K, Komori T, Yokoo H, Matsutani M, Maebayashi K, Tanaka T, Yamaguchi S, Kanamori M, Yamamoto T, Hanihara M, Arakawa Y, Sasayama T, Abe T, Nakamura H, Mukasa A, Uzuka T, Nakajo K, Ohno T.Jpn J Clin Oncol. 2025 Aug 3;55(8):975-981. doi: 10.1093/jjco/hyaf078.PMID: 40377260

Racial and Ethnic Disparities in Preventive and Chronic Disease Care in Medicare Advantage vs. Traditional Medicare.

Tipirneni R, Stefanescu AR, Ruggiero DA, Hames AG, Ayanian JZ, Roberts ET.J Gen Intern Med. 2025 Aug 11. doi: 10.1007/s11606-025-09793-z. Online ahead of print.PMID: 40790002

Global burden of vaccine-associated Raynaud's phenomenon, 1968-2024: A comprehensive analysis of the pharmacovigilance database.

Jeong J, Kim H, Jo H, Park J, Cho J, Lee H, Cho H, Rahmati M, Woo HG, Yon DK.Eur J Clin Pharmacol. 2025 Aug;81(8):1197-1206. doi: 10.1007/s00228-025-03854-2. Epub 2025 Jun 6.PMID: 40478262

Germinal center immune dynamics: challenges for effective vaccination in the elderly.

Brenna C, Petrovas C.Immunotherapy. 2025 Aug 14:1-12. doi: 10.1080/1750743X.2025.2546279. Online ahead of print.PMID: 40808495

Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to frailty score: A post-hoc analysis of the DANFLU-1 randomized trial.

Espersen C, Johansen ND, Modin D, Janstrup KH, Nealon J, Samson S, Loiacono MM, Harris RC, Andrew MK, Larsen CS, Jensen AMR, Landler NE, Claggett BL, Solomon SD, Landray MJ, Gislason GH, Køber L, Jensen JUS, Sivapalan P, Biering-Sørensen T.J Infect Dis. 2025 Aug 13:jiaf420. doi: 10.1093/infdis/jiaf420. Online ahead of print.PMID: 40796377

Association of SARS-CoV-2 vaccination status with risk of influenza-like illness and loss of workdays in healthcare workers.

Dörr T, Lacy J, Ballouz T, Cusini A, Grässli F, Haile S, Kocan E, Möller JC, Puhan MA, Schlegel M, von Kietzell M, Rütti M, Stocker R, Vuichard Gysin D, Kahlert CR, Kuster SP, Kohler P; SURPRISE+ Study Group.Commun Med (Lond). 2025 Aug 9;5(1):347. doi: 10.1038/s43856-025-01046-8.PMID: 40783603

Perception of COVID-19 vaccines in rheumatology patients.

Romero-Bogado L, Steiner M, Andreu-Vázquez C, Thuissard-Vasallo IJ, Cobo-Ibáñez T, de la Cámara-Fernández I, Esteban-Vázquez A, Paredes-Romero MB, Richi-Alberti P, Trives-Folguera L, Vergara-Dangond C, Castañeda E, Acosta-Alfaro AV, Cueva-Nájera G, Sánchez-Díaz R, Puerto-Muñoz E, Muñoz-Fernández S.Medicine (Baltimore). 2025 Aug 1;104(31):e43618. doi: 10.1097/MD.0000000000043618.PMID: 40760579

Machine learning model for prediction of coronavirus disease 2019 within 6 months after three doses of BNT162b2 in Hong Kong.

Tan JT, Zhang R, Chan KH, Qin J, Hung IFN, Cheung KS.Hong Kong Med J. 2025 Aug;31(4):296-304. doi: 10.12809/hkmj2411879. Epub 2025 Jun 23.PMID: 40545950

Optimization of Production Conditions for Extracellular Vesicles from Lacticaseibacillus Paracasei LH23 Using Response Surface Methodology: Enhancement of Yield and Exploration of Stability, Safety, and Anti-inflammatory Capacity.

Zhang X, Yin S, Quan X, Han Y, Song H, Sun C, Hao L, Li J, Qi W, Wang N.Probiotics Antimicrob Proteins. 2025 Aug 15. doi: 10.1007/s12602-025-10666-4. Online ahead of print.PMID: 40815362

Drivers of Crimean-Congo Hemorrhagic Fever in Natural Host and Effects of Control Measures, Bulgaria.

Limon G, Tchakarova SR, Ludi A, Alexandrov T, Christova I, Petkova P, Maze E, Thomas K, Baker N, England M, Browning C, Wilsden G, Belij-Rammerstorfer S, Lambe T, Jolles A, Carroll M, Hewson R, Gubbins S, Charleston B, Lyons NA.Emerg Infect Dis. 2025 Aug 5;31(9). doi: 10.3201/eid3109.241952. Online ahead of print.PMID: 40764710

Genetics and humoral responses of the immune system to Aspergillus fumigatus.

Sanya DRA, Jayachandran K, Onésime D.Mol Immunol. 2025 Aug;184:164-198. doi: 10.1016/j.molimm.2025.06.007. Epub 2025 Jul 3.PMID: 40609370

Acquisition of quaternary trimer interaction as a key step in the lineage maturation of a broad and potent HIV-1 neutralizing antibody.

Liu Q, Parsons RJ, Wiehe K, Edwards RJ, Saunders KO, Zhang P, Miao H, Tilahun K, Jones J, Chen Y, Hora B, Williams WB, Easterhoff D, Huang X, Janowska K, Mansouri K, Haynes BF, Acharya P, Lusso P.Structure. 2025 Aug 7;33(8):1325-1336.e5. doi: 10.1016/j.str.2025.04.020. Epub 2025 May 23.PMID: 40412376

Streptococcus suis serotypes 2, 1/2, 1, and 14 isolated from the brain of pigs dead with neurological symptoms or sudden death in Italian farms.

Faccini S, Gintoli L, D'Incau M, Cursio E, Rosignoli C.Res Vet Sci. 2025 Aug;191:105683. doi: 10.1016/j.rvsc.2025.105683. Epub 2025 May 9.PMID: 40367724

Optimization of Bipolar Microsecond Electric Pulses for DNA Vaccine Delivery.

Williamson RH, DeWitt MR, Elhanafi D, Zaharoff DA, Sano MB.IEEE Trans Biomed Eng. 2025 Aug;72(8):2580-2590. doi: 10.1109/TBME.2025.3547311.PMID: 40036516

Assessing the evidence for effective biosafety risk management in *Coxiella burnetii* research.

Blacksell SD, Le KK, Gleeson LJ, Stenos J, Graves SR, Day NPJ.One Health. 2025 Aug 5;21:101159. doi: 10.1016/j.onehlt.2025.101159. eCollection 2025 Dec.PMID: 40808750

Intranasal Delivery of HPV Therapeutic Vaccines for Enhanced Mucosal Immunization and Anti-Tumor Immunity.

Xu Y, Yan X, Zhang F, Li Q, Wei T, Xiao Z, Chai Y, Wang C, Liu Z.ACS Nano. 2025 Aug 12. doi: 10.1021/acsnano.5c05354. Online ahead of print.PMID: 40794451

The Application of iPSCs in Tumour Immunotherapy.

Chen P, Gao J, Feng J, Tao H, Yu Y, Li Y, Liu J, Lu S, Wang W.Expert Rev Mol Med. 2025 Aug 11;27:e26. doi: 10.1017/erm.2025.10006.PMID: 40787691

Mannose receptor targeted PLGA nanoparticles ofEucommia ulmoidespolysaccharide through the MAPK and NF-κB pathway to enhance the immune activity of BMDCs.

Hu X, Meng J, Liao Y, Yang Y, Wang Y, Song Z, Liu Z, Feng H.Colloids Surf B Biointerfaces. 2025 Aug 5;256(Pt 1):115002. doi: 10.1016/j.colsurfb.2025.115002. Online ahead of print.PMID: 40784105

Predicting antigenic peptides using a multi-level pooling-based transformer model with enhanced Kolaskar & Tongaonkar's algorithm for feature selection.

S A, R I M, M JK.Comput Biol Chem. 2025 Aug 5;120(Pt 1):108615. doi: 10.1016/j.compbiolchem.2025.108615. Online ahead of print.PMID: 40779806

EgG1Y162 protein from Echinococcus granulosus modulates the immune functions of mouse splenic lymphocytes and regulates Th9 cells.

Chen X, Zhao H, Tuohetali A, Aizezi M, Song Y, Zhang X, Zhu J, Zhou T, Chen G, Lin R, Aimulajiang K.Int J Biol Macromol. 2025 Aug 11;322(Pt 1):146515. doi: 10.1016/j.ijbiomac.2025.146515. Online ahead of print.PMID: 40769342

Long-term COVID-19 symptoms and post-vaccination reactions among prolonged COVID-19 patients in the Kurdistan region of Iraq.

Kakamen A, Hamarash II.Data Brief. 2025 Jun 17;61:111785. doi: 10.1016/j.dib.2025.111785. eCollection 2025 Aug.PMID: 40677267

Rapid Emergence and Evolution of SARS-CoV-2 Intrahost Variants among COVID-19 Patients with Prolonged Infections, Singapore.

Su YCF, Zeller MA, Cronin P, Zhang R, Zhuang Y, Ma J, Wong FY, Ng GGK, O'Toole Á, Rambaut A, Low JG, Smith GJD.Emerg Infect Dis. 2025 Aug;31(8):1537-1549. doi: 10.3201/eid3108.241419. Epub 2025 Jul 1.PMID: 40592354

Current insights into polymeric micelles for nasal drug delivery.

Sipos B, Rajab F, Katona G, Csóka I.Expert Opin Drug Deliv. 2025 Aug;22(8):1137-1154. doi: 10.1080/17425247.2025.2511962. Epub 2025 May 30.PMID: 40420578

Mode of antiviral action of the galactose-specific lectin, AJLec, on the Junin virus propagation.

Urata S, Lee M, Tsuruta T, Igarashi R, Takeda K, Unno H.Antiviral Res. 2025 Aug;240:106189. doi: 10.1016/j.antiviral.2025.106189. Epub 2025 May 15.PMID: 40381661

Impact of delaying PCV20 implementation in France's pediatric national immunization program: A population-based Markov model.

Perdrizet J, Blanc E, El Khoury JY, Beillat M, Sabra A, Ilic A, Fiévez S.Infect Dis Now. 2025 Aug;55(5):105084. doi: 10.1016/j.idnow.2025.105084. Epub 2025 May 12.PMID: 40348336

Severe influenza A viral pneumonia in a hemodialysis patient: successful treatment with steroid pulse therapy.

Ito H, Ito S, Hirose T, Kimura T, Mori T, Ito S.CEN Case Rep. 2025 Aug;14(4):542-546. doi: 10.1007/s13730-024-00951-6. Epub 2024 Dec 11.PMID: 39658702

Trained immunity in farm animals.

Báez-Magaña M, Alva-Murillo N, Ochoa-Zarzosa A, López-Meza JE.Vet Res. 2025 Aug 8;56(1):166. doi: 10.1186/s13567-025-01594-w.PMID: 40781647

Pathogenic variants in chromatin-related genes: Linking immune dysregulation to neuroregression and acute neuropsychiatric disorders.

Dale RC, Mohammad S, Han VX, Nishida H, Goel H, Tangye SG, Hollway G, Tantsis E, Gill D, Patel S; Chromatin Immune-Brain Group.Dev Med Child Neurol. 2025 Aug;67(8):1095-1102. doi: 10.1111/dmcn.16276. Epub 2025 Feb 22.PMID: 39985218

Maximising adherent cell production via customisable and dissolvable bio-polymer microcarriers.

Cox TR, Lesmana D, O'Keeffe CJ, Lam A, Zou W, Lin Z, Lin X, Roberts TH, Lim KS, Oh SK, Radfar P, Ebrahimi Warkiani M, Ding L.Biomed Mater. 2025 Aug 7;20(5). doi: 10.1088/1748-605X/adf1cd.PMID: 40680777

Role of immunoglobulin M in Trachinotus ovatus defense against Cryptocaryon irritans infection.

Wu H, Tang S, Lu Y, Cen Y, Deng Y, Li Y, Dan X, Mo Z.Int J Biol Macromol. 2025 Aug;319(Pt 2):145556. doi: 10.1016/j.ijbiomac.2025.145556. Epub 2025 Jun 25.PMID: 40578639

Trends in vaccination coverage and equity in the Democratic Republic of the Congo from 2017 to 2023.

Lankiewicz E, Mpemba JKN, Dikassa PSL, Masiala VM, Maykondo BK, Hatton T, Nawaz S, Munar W, Arsenault C.Vaccine. 2025 Aug 15;62:127609. doi: 10.1016/j.vaccine.2025.127609. Online ahead of print.PMID: 40818261

Type 2 diabetes compromises SARS-CoV-2-specific immunological memory following ChAdOx1 nCoV-19 vaccination.

Bhat S, Basak P, Verma S, Siddiqui K, Dutta P, Das L, Singh H, Bhadada S, Sachdeva N.Vaccine. 2025 Aug 12;62:127604. doi: 10.1016/j.vaccine.2025.127604. Online ahead of print.PMID: 40803144

A versatile H5N1-VSV platform for safe influenza virus research applications.

Sownthirarajan B, Mason M, Loganathan G, Manivasagam S, Jangra RK, Tan GS, Perez DR, Manicassamy B.J Virol. 2025 Aug 8:e0097525. doi: 10.1128/jvi.00975-25. Online ahead of print.PMID: 40778766

How does the credibility of vaccine information compare across traditional search engines and AI-based conversational agents?

Dyda A, Stanceski K, Dakiniewich A, Pan A, Dunn AG.Public Health. 2025 Aug 1;247:105876. doi: 10.1016/j.puhe.2025.105876. Online ahead of print.PMID: 40752474

Biogenic gold nanoparticles synthesized using Streptomyces sp. M137-2 as potential vaccine adjuvant.

Ünlüer N, Gül-Mete A, Hameş EE.3 Biotech. 2025 Aug;15(8):244. doi: 10.1007/s13205-025-04389-0. Epub 2025 Jul 7.PMID: 40636945

Multivalent Co-assembly of LL37-CpG nanoparticles: Enhanced immune response through activating multiple cell internalization pathways.

Wei Y, Li W, Xu R, Xu C, Li X, Li N, Xu F, Yang K, Yuan B.Mater Today Bio. 2025 Jun 21;33:102011. doi: 10.1016/j.mtbio.2025.102011. eCollection 2025 Aug.PMID: 40621182

R9AP is a common receptor for EBV infection in epithelial cells and B cells.

Li Y, Zhang H, Sun C, Dong XD, Xie C, Liu YT, Lin RB, Kong XW, Hu ZL, Ma XY, Dai DL, Zhu QY, Li YC, Li Y, Liu SX, Yuan L, Zhou PH, Gao S, Tang YP, Yang JY, Han P, McGuire AT, Zhao B, Bei JX, Robertson E, Zeng YX, Zhong Q, Zeng MS.Nature. 2025 Aug;644(8075):205-213. doi: 10.1038/s41586-025-09166-w. Epub 2025 Jun 18.PMID: 40533557

Initiatives to increase childhood vaccination coverage: an international comparison.

Kroneman M, Fermin A, Rechel B, Allin S, Anell A, Behmane D, Bengough T, Blümel M, Bryndová L, Davidovics K, Belvis AG, Charalambous C, Economou C, Fadel S, Fronteira I, Gaál P, Grignon M, Kowalska-Bobko I, Lovrenčić IL, Mantwill S, Murauskienė L, Reinap M, Rohova M, Saunes IS, Theodorou M, Waitzberg R, Jong JD.Health Policy. 2025 Aug;158:105351. doi: 10.1016/j.healthpol.2025.105351. Epub 2025 May 19.PMID: 40449380

Establishment of a Lassa Fever Specimen Biobank in Nigeria.

Chi HF, Etafo J, Fonkeng F, Olufunke GB, Ireneh R, Abejegah C, Owhin S, Somiari S, Vessière A, Bausch DG, El Idrissi I, Fransman W, Kelly-Cirino C, Agogo E, Emperador DM, Adedosu NA.Am J Trop Med Hyg. 2025 May 27;113(2):382-386. doi: 10.4269/ajtmh.24-0527. Print 2025 Aug 6.PMID: 40425001

A Possible Case of Hypertensive Crisis With Aortic Dissection After an Anti-COVID-19 Vaccine.

Mohsenian L, Noroozi Z, Farahmand F.Angiology. 2025 Aug;76(7):699-703. doi: 10.1177/00033197241232619. Epub 2024 Feb 3.PMID: 38308612

Comparable immunogenicity of new modality biotherapeutics delivered subcutaneously or intravenously in non-human primates.

Koch V, Lechmann M, Bray-French K, Füth M, Husar E, Janssen N, Schneider A, Stubenrauch K, Hickling T, Kronenberg S.J Immunotoxicol. 2025 Dec;22(1):2537408. doi: 10.1080/1547691X.2025.2537408. Epub 2025 Aug 11.PMID: 40785401

Chimeric hepatitis B core virus-like particles displaying the receptor-binding domain of porcine deltacoronavirus elicit protective immunity in piglets.

Liu Y, Bi Z, Cai X, Han X, Yao L.Vet Microbiol. 2025 Aug 5;308:110659. doi: 10.1016/j.vetmic.2025.110659. Online ahead of print.PMID: 40780030

Practical Review on Aetio-Pathogenesis and Symptoms in Pigs Affected by Clinical and Subclinical Oedema Disease and the Use of Commercial Vaccines Under Field Conditions.

Hernandez-Garcia J, Ballarà Rodriguez I, Jordà Casadevall R, Bruguera S, Llopart D, Barba-Vidal E.Animals (Basel). 2025 Aug 4;15(15):2275. doi: 10.3390/ani15152275.PMID: 40805065

Cost assessment of a preventive vaccination program against highly pathogenic avian influenza in Austrian poultry farms.

Marschik T, Sawodny S, Kopacka I, Höflechner-Pöltl A, Revilla-Fernández S, Zimpernik I, Schmoll F, Käsbohrer A.Prev Vet Med. 2025 Aug 9;244:106655. doi: 10.1016/j.prevetmed.2025.106655. Online ahead of print.PMID: 40812036

ETEC biofilms are regulated by magnesium and lactate bioavailability.

Hollifield IE, Clement KL, Fernando KA, Blythe MD, Bitoun JP.Infect Immun. 2025 Aug 11:e0024325. doi: 10.1128/iai.00243-25. Online ahead of print.PMID: 40788160

An Italian Single-Center Genomic Surveillance Study: Two-Year Analysis of SARS-CoV-2 Spike Protein Mutations.

Cecchetto R, Tonon E, Palmisano A, Lagni A, Diani E, Lotti V, Mantoan M, Montesarchio L, Palladini F, Turri G, Gibellini D.Int J Mol Sci. 2025 Aug 5;26(15):7558. doi: 10.3390/ijms26157558.PMID: 40806685

T-cell immunity against influenza virus does not require Th1 or Th17 master regulator transcription factors.

Dhume K, Finn CM, Baffoe E, Kimball LA, Annamalai SN, Urdaneta-Páez V, Trivedi J, Azarian T, Strutt TM, McKinstry KK.Mucosal Immunol. 2025 Aug 15:S1933-0219(25)00088-1. doi: 10.1016/j.mucimm.2025.08.005. Online ahead of print.PMID: 40819821

Attitudes, beliefs, and knowledge about MMR vaccination among university students: Findings from a cross-sectional survey.

Schoenfisch C, Walz N, Wang T, East L.Aust N Z J Public Health. 2025 Aug 14;49(5):100263. doi: 10.1016/j.anzjph.2025.100263. Online ahead of print.PMID: 40816129

Zeolitic imidazolate frameworks enhanced transfection efficiency of mRNA loaded lipid nanoparticles.

Singh R, Bruce K, Heazlewood SY, White JF, de Vries M, Muir BW, Cao B, Mulet X, Layton D, Doherty CM.J Mater Chem B. 2025 Aug 14. doi: 10.1039/d4tb02101k. Online ahead of print.PMID: 40813562

An Activated Gasdermin Mimicking Polymer for Antitumor Immunity.

Li J, Mu Y, Chen Y, Zhang X, Wang Y, Wang J, Ying J, Yang H, Zhou X, Du Y, Xu C, Ding K, Shen Y, Liu X, Zhou T, Zhou Q.ACS Nano. 2025 Aug 14. doi: 10.1021/acsnano.5c12189. Online ahead of print.PMID: 40811768

Macrophage Response to Avirulent and Virulent Mycobacterium tuberculosis and Anti-TB Effects of Exosome Treatment.

Yang L, Lyu L, Li C, Zhang X, Ju Y, Zhang J, Liu J, Yue L, Ding N, Zhang X, Lu D, Yang T, Wang P, Wang J, Wang X, Xu S, Sheng Y, Jiang C, Wang J, Hu X, Bahetibieke T, Zhang Z, Chen F.Genomics Proteomics Bioinformatics. 2025 Aug 5:qzaf065. doi: 10.1093/gpbjnl/qzaf065. Online ahead of print.PMID: 40794594

Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development.

Huber F, Bassani-Sternberg M.Nat Rev Immunol. 2025 Aug 8. doi: 10.1038/s41577-025-01208-8. Online ahead of print.PMID: 40781552

Passive surveillance for Influenza A virus among swine, Brazil, 2009-2023.

Tochetto C, Gava D, Haach V, Schaefer R.Braz J Microbiol. 2025 Aug 6. doi: 10.1007/s42770-025-01749-z. Online ahead of print.PMID: 40768029

Antimalarial drug resistance and drug discovery: learning from the past to innovate the future.

Theodoridis L, Carvalho TG.Int J Parasitol Drugs Drug Resist. 2025 Aug;28:100602. doi: 10.1016/j.ijpddr.2025.100602. Epub 2025 Jul 8.PMID: 40680501

Emerging therapies for HBsAg seroclearance: spotlight on novel combination strategies.

Hui RW, Fung J, Seto WK, Yuen MF, Mak LY.Hepatol Int. 2025 Aug;19(4):704-719. doi: 10.1007/s12072-025-10828-0. Epub 2025 Jun 11.PMID: 40495020

An evaluation of Human Papillomavirus vaccination resources available to Aboriginal and Torres Strait Islander adolescents and parents and caregivers in Australia.

Butler TL, Morseu-Diop A, Brotherton JML, Peart L, Jayasekara I, Peart A, Ninomiya MM, Anderson K, Cunningham J, Garvey G, Jaure A, Whop LJ.Patient Educ Couns. 2025 Aug;137:108820. doi: 10.1016/j.pec.2025.108820. Epub 2025 May 5.PMID: 40367551

A novel ionizable lipid with comprehensive improvements in transfection potency, immune profile and safety of lipid nanoparticle.

Guo K, Bu L, Du J, Zhang W, Xia J, Tao M, Shao X, Liu L, Zhao W, Cai Y, Yang Y, Hou X, Lin A.J Control Release. 2025 Aug 14:114126. doi: 10.1016/j.jconrel.2025.114126. Online ahead of print.PMID: 40818720

BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.

Rahman MA, Goldfarbmuren KC, Sarkis S, Bissa M, Gutowska A, Schifanella L, Moles R, Doster MN, Andersen H, Jethmalani Y, Serebryannyy L, Cardozo T, Lewis MG, Franchini G.JCI Insight. 2025 Aug 8;10(15):e194633. doi: 10.1172/jci.insight.194633. eCollection 2025 Aug 8.PMID: 40779451

Identification and evaluation of cross-protection efficiency of the conserved antigens of Salmonella Enteritidis.

Zhao Y, Li G, Li Q, Shi H.Vaccine. 2025 Aug 14;62:127622. doi: 10.1016/j.vaccine.2025.127622. Online ahead of print.PMID: 40815961

From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults.

Lindsey KM, Farrell Z, Tutino R, Kowalski-Dobson T, Chu Z, Gherasim C, Cai S, Simjanovski G, Manthei D, Stoneman E, Krammer F, Valdez R, Gordon A.Vaccine. 2025 Aug 13;62:127593. doi: 10.1016/j.vaccine.2025.127593. Online ahead of print.PMID: 40812020

MicroRNAs in the abscopal effect: bridging radiotherapy and systemic anti-tumor immunity for enhanced cancer therapy.

Hosseinpour-Soleimani F, Tajbakhsh A, Salmasi Z, Pirsalehi MT, Irajie C.Clin Exp Metastasis. 2025 Aug 13;42(5):48. doi: 10.1007/s10585-025-10364-z.PMID: 40797149

Low intrinsic killing activity and no impact of its positivity on phase 3 pneumococcal vaccine adult studies.

Xu W, Antonello J, Nguyen J, Ma C, Cheng YW, Marullo K, Nolan K, Buchwald UK, Platt HL, Bonhomme M, LaFon DC, Burton RL, Nahm MH, Helmy R.J Infect Dis. 2025 Aug 11:jiaf427. doi: 10.1093/infdis/jiaf427. Online ahead of print.PMID: 40796175

Reconstructing the spread of measles in the 20th century: An epidemiological analysis of the period prior to the introduction of vaccination in Switzerland.

Friedauer C, Matthes KL, Lang P, Staub K.Am J Epidemiol. 2025 Aug 11:kwaf167. doi: 10.1093/aje/kwaf167. Online ahead of print.PMID: 40796137

Screening and Characterization of B-Cell Epitopes of Porcine Respiratory Coronavirus Receptor Binding Domain Using Monoclonal Antibodies.

Wang A, Wang J, Zhou J, Chen Y, Liu H, Liang C, Zhu X, Liu E, Wu S, Qi Y, Zhang G.Microbiol Immunol. 2025 Aug 3. doi: 10.1111/1348-0421.70002. Online ahead of print.PMID: 40753495

A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment.

Zhang Q, Miao Y, Chen Z, Liu Y, Chen L, Xiao Z, Shen H, Shen J, Pan F, Liu N, Lv X, Zhao H, Yu Q, Zheng Z, Chen Q, Yang Y.Adv Mater. 2025 Aug 2:e04987. doi: 10.1002/adma.202504987. Online ahead of print.PMID: 40751561

Analysing Adverse Event Databases: Principles, Challenges, and Examples.

Shahar E.J Eval Clin Pract. 2025 Aug;31(5):e70188. doi: 10.1111/jep.70188.PMID: 40618408

Using immunization registry data to explore initiation of HPV vaccination at ages 9 and 10.

Ryan GW, Kahl A, Janio E, Kintigh B, Callaghan D, Askelson NM.Hum Vaccin Immunother. 2025 Dec;21(1):2547432. doi: 10.1080/21645515.2025.2547432. Epub 2025 Aug 17.PMID: 40820295

Tat-specific antibodies associated with better HIV-associated motor function.

Hioe CE, Yengo CK, Liu X, Davis R, Enyindah-Asonye G, Klingler J, Tang AF, Bandres JC, Ganesan A, Lalani T, Yabes J, Agan BK, Liu X, Volsky DJ, Morgello S, Robinson-Papp J.Sci Rep. 2025 Aug 11;15(1):29353. doi: 10.1038/s41598-025-12624-0.PMID: 40790053

Transcriptome to reveal the immunological defenses in mandarin fish (Siniperca chuatsi) skin with LPS and poly (I:C) infection.

Shen Y, Gao J, Zhang M, Li Y, Aly RSS, Wang L, Yu M, Jiang H, Qiao Z, Chen X.Fish Shellfish Immunol. 2025 Aug 8;166:110652. doi: 10.1016/j.fsi.2025.110652. Online ahead of print.PMID: 40784512

Antiviral activity of the chemokine CXCL10 against West Nile virus.

Deroche L, Cavillon C, Garcia M, Larivière A, Marchal P, Chessa C, Damour A, Jousselin C, Bodet C, Lévêque N.Intervirology. 2025 Aug 8:1-20. doi: 10.1159/000547037. Online ahead of print.PMID: 40784352

Combined immunotherapy employing Wilms' tumor 1 peptide-pulsed dendritic cells and hormone or chemotherapeutic agents in patients with metastatic castration resistant prostate cancer.

Ogasawara M, Miyashita M, Yamagishi Y, Ota S.Ther Apher Dial. 2025 Aug;29(4):568-576. doi: 10.1111/1744-9987.70016. Epub 2025 Apr 13.PMID: 40223232

Classic versus innovative strategies for immuno-therapy in pancreatic cancer.

Formelli MG, Palloni A, Tavolari S, Deiana C, Andrini E, Di Marco M, Campana D, Lamberti G, Brandi G.Adv Drug Deliv Rev. 2025 Aug 7;225:115671. doi: 10.1016/j.addr.2025.115671. Online ahead of print.PMID: 40783052

A comparative analysis of the role of containment policies, vaccination strategies and virus variants in the COVID-19 pandemic across nine European countries.

Rancati S, Nicora G, Parimbelli E, Salemi M, Bellazzi R, Pala D.Sci Rep. 2025 Aug 8;15(1):29109. doi: 10.1038/s41598-025-10132-9.PMID: 40781086

Spectroscopic Characterization and Differentiation of SARS-CoV-2 Virus-like Particles.

Dodla A, Giergiel M, Mclean A, Kochan K, Earnest L, Edeling MA, McAuley JL, Godfrey DI, Purcell DFJ, Yap AHY, Montoya JC, Roberts JA, Collett S, Shukla S, Saxena S, Torresi J, Wood BR.Anal Chem. 2025 Aug 6. doi: 10.1021/acs.analchem.5c01859. Online ahead of print.PMID: 40767325

Incidence of pneumococcal and all-cause pneumonia in adults in Catalonia following the implementation of universal pneumococcal vaccination in children: 2015-2016 vs. 2017-2018.

Torras-Vives V, de Diego-Cabanes C, Satué-Gracia EM, Forcadell-Peris MJ, Ochoa-Gondar O, Vila-Córcoles Á.Enferm Infecc Microbiol Clin (Engl Ed). 2025 Aug-Sep;43(7):444-447. doi: 10.1016/j.eimce.2025.03.005. Epub 2025 Mar 28.PMID: 40157824

Structural Insights into Leishmania donovani Mevalonate Kinase and Its Interaction with Toll-Like Receptors During Early Infection.

Dikhit MR, Roy C, Kayet P, Basak S, Ganguly S, Das P.Acta Trop. 2025 Aug 7:107774. doi: 10.1016/j.actatropica.2025.107774. Online ahead of print.PMID: 40783067

Perspectives on prevention of type 1 diabetes and heterogeneities.

Stene LC.Diabetologia. 2025 Aug 6. doi: 10.1007/s00125-025-06512-5. Online ahead of print.PMID: 40768045

Priming VRC01-precursor B cells with non-envelope immunogens disfavors boosting with HIV-1 envelope.

Wilcox-King A, Wan YH, Scharffenberger SC, Chhan CB, Davis AR, Homad LJ, Seydoux E, MacPhee KJ, Siddaramaiah LK, Melo M, Dosenovic P, Irvine DJ, Hyrien O, Stamatatos L, McGuire AT.NPJ Vaccines. 2025 Aug 5;10(1):185. doi: 10.1038/s41541-025-01235-5.PMID: 40764319

Immunization of BALB/c mice with detoxified lipopolysaccharide and hydrolytic O-polysaccharide from Brucella melitensis either in combination with or conjugated to tetanus toxoid, enhances protective immune responses against the pathogen.

Khoramabadi N, Doust RH, Mobarez AM, Shapouri R.Comp Immunol Microbiol Infect Dis. 2025 Aug;121:102357. doi: 10.1016/j.cimid.2025.102357. Epub 2025 May 10.PMID: 40383101

Genomic analysis of Varicella zoster virus strains during an outbreak with atypical clinical presentations in Biswanath district of Assam, India.

Sarmah K, Sharma A, Sarma K, Alam ST, Dutta BS, Deka E, Laskar SA, Tishya NS, Lakshmi Priya MS, Baishya AC.Virus Genes. 2025 Aug;61(4):412-422. doi: 10.1007/s11262-025-02156-0. Epub 2025 Apr 12.PMID: 40220111

Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors.

Luo P, Liu J, Wang Z, Liao C, She L, Zou T, Chen J, Liu Z.Hum Vaccin Immunother. 2025 Dec;21(1):2539593. doi: 10.1080/21645515.2025.2539593. Epub 2025 Aug 13.PMID: 40808308

TGF-beta and IL-12 conversely orchestrate the formation of CD103(+) CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine.

Corgnac S, Damei I, Gentile C, Caidi A, Badel S, Phayanouvong M, Mami-Chouaib F.iScience. 2025 Jul 18;28(8):113147. doi: 10.1016/j.isci.2025.113147. eCollection 2025 Aug 15.PMID: 40799399

Rabies control via co-creation: A model for sustainable one health interventions.

Bor N, Njenga G, Slater A, Munywoki P, Chepyatich D, Owino D, Murungi MK, Muloi DM, Thomas LF.PLoS Negl Trop Dis. 2025 Aug 11;19(8):e0013350. doi: 10.1371/journal.pntd.0013350. Online ahead of print.PMID: 40788965

Epidemiology, clinical characteristics and genetic diversity of Nipah virus strains from Bangladesh: 2016 to 2023.

Satter SM, Rahman DI, Sultana S, Rahman MM, Aquib WR, Nazneen A, Farzin A, Chowdhury KIA, Sarkar T, Ema FA, Choudhury SS, Siddika A, Alam MR, Abdulla F, Ghosh PK, Qayum MO, Sarker MFR, Nasif MAO, Sen B, Chowdhury M, Hossain MS, Rahman M, Alam AN, Hossain ME, Shoemaker T, Spiropoulou C, Gurley ES, Luby SP, Klena JD, Banu S, Rahman MZ, Montgomery JM, Shirin T.Int J Infect Dis. 2025 Aug 7:108010. doi: 10.1016/j.ijid.2025.108010. Online ahead of print.PMID: 40783163

Navigating the Colorectal Cancer Maze: Unveiling Pathways To Diagnosis, Management, Pathophysiology and Prevention.

Al Kamzari KAM, Constantinou C.Curr Oncol Rep. 2025 Aug 9. doi: 10.1007/s11912-025-01707-w. Online ahead of print.PMID: 40781184

Mapping novel linear B-cell epitopes target Hepatitis C virus envelope proteins E1 and E2 by monoclonal antibodies for increasing the sensitive detection sites.

Tian Y, Liu H, Chen Y, Ma Z, Zhou J, Tao S, Sun F, Li J, Liu E, Zhu X, Zhang G, Wang A.Int J Biol Macromol. 2025 Sep;321(Pt 4):146659. doi: 10.1016/j.ijbiomac.2025.146659. Epub 2025 Aug 6.PMID: 40780329

Detection of antibodies against the African parasite Trypanosoma brucei using synthetic glycosylphosphatidylinositol oligosaccharide fragments.

Michel M, Stijlemans B, Michel D, Garg M, Geissner A, Seeberger PH, Silva DV.Glycoconj J. 2025 Aug;42(3-4):147-158. doi: 10.1007/s10719-025-10186-x. Epub 2025 Jun 24.PMID: 40553394

SARS-CoV2 vaccination during pregnancy - Vetting the impact on maternal health and long-term consequences for offspring brain function.

Gundacker A, Schaer R, Pollak A, Weber-Stadlbauer U, Pollak DD.Brain Behav Immun. 2025 Aug;128:549-557. doi: 10.1016/j.bbi.2025.04.029. Epub 2025 Apr 22.PMID: 40274002

DeepAssembly2: A Web Server for Protein Complex Structure Assembly Based on Domain-Domain Interactions.

Xia Y, Pu Y, Wang S, Zhuang J, Liu D, Hou M, Zhang G.J Mol Biol. 2025 Aug 1;437(15):169128. doi: 10.1016/j.jmb.2025.169128. Epub 2025 Apr 4.PMID: 40188941

[Expert consensus on the early prevention of human papillomavirus related non-cervical diseases (2025 edition)].

Cancer Prevention and Control Committee, Chinese Preventive Medicine Association; Vaccine and Immunization Branch, Chinese Preventive Medicine Association.Zhonghua Yi Xue Za Zhi. 2025 Aug 12;105(30):2536-2550. doi: 10.3760/cma.j.cn112137-20250519-01212.PMID: 40784787

Development and refinement of an online CARD (Comfort Ask Relax Distract) course for organizations and providers delivering vaccinations and other needle procedures.

Taddio A, Ilersich ANT, McMurtry CM, Constantin K, Bucci LM, Gudzak V, Logeman C, Crown N, Kohli M, Ledrew E, MacDonald NE, Card Knowledge Translation Team.Hum Vaccin Immunother. 2025 Dec;21(1):2491853. doi: 10.1080/21645515.2025.2491853. Epub 2025 Aug 6.PMID: 40768557

Lessons learned from upstream wastewater sampling in response to poliovirus in New York State.

Godinez A, Alazawi M, Neyra M, Hanson B, Neigel D, St George K, Lang D, Larsen DA.Sci Total Environ. 2025 Aug 8;997:180216. doi: 10.1016/j.scitotenv.2025.180216. Online ahead of print.PMID: 40782399

The burden of malaria in East Africa: prevalence, risk factors, and control strategies.

Bashir SG, Ahmed NI, Abdullahi YB, Abdi YH, Abdi MS, Musa MK.Malar J. 2025 Aug 8;24(1):255. doi: 10.1186/s12936-025-05492-6.PMID: 40781311

Cultural Influences: Female Students' Awareness and Perception Regarding Human Papillomavirus Vaccine.

Mohamed NA, Abdel-Aziz HR, Elsehrawy MG.SAGE Open Nurs. 2025 Aug 4;11:23779608251363840. doi: 10.1177/23779608251363840. eCollection 2025 Jan-Dec.PMID: 40771552

Phylodynamics of human metapneumovirus and evidence for a duplication-deletion model in G gene variant evolution.

Goya S, Nunley EB, Longley PC, Mathis JR, Varela CG, Kim DY, Nurik M, Naccache SN, Greninger AL.J Clin Virol. 2025 Aug 5;180:105848. doi: 10.1016/j.jcv.2025.105848. Online ahead of print.PMID: 40769077

First Report of Tenacibaculum dicentrarchi in Diseased Palm Ruff (Seriolella violacea, Guichenot 1848) From an Experimental Culture in Chile.

Avendaño-Herrera R, Araya-León H, Oliva M, Irgang R, Serrano E.J Fish Dis. 2025 Aug 6:e70039. doi: 10.1111/jfd.70039. Online ahead of print.PMID: 40767148

The dual threat: exploring the emergence of human metapneumovirus and SARS-CoV-2 coinfections in respiratory infections.

Goel F, Kumar D, Singh P, Rai SN.3 Biotech. 2025 Aug;15(8):235. doi: 10.1007/s13205-025-04384-5. Epub 2025 Jul 3.PMID: 40625421

Development of external morphological malformations induced by hyperthermia exposure during the blastula stage in an ex-ovo (shell-less) culture of Gallus gallus domesticus embryos.

Macias-Marin O, Guerrero-Barrera AL, Valdivia-Flores AG, Quezada-Tristan T, Ramirez-Castillo FY, Moreno-Flores AC, Galindo-Guerrero F, Avelar-Gonzalez FJ, Rodriguez-Padilla AD.Poult Sci. 2025 Aug;104(8):105341. doi: 10.1016/j.psj.2025.105341. Epub 2025 May 26.PMID: 40446690

The recombinant immunodominant regions 179-344 and 550-670 from SARS-COV2 spike protein can efficiently react with patients' sera.

Lotfian S, Soleimani A, Taromchi AH, Sabzehei F, Dinmohammadi H, Nedaei K.Microb Pathog. 2025 Aug;205:107604. doi: 10.1016/j.micpath.2025.107604. Epub 2025 Apr 24.PMID: 40287104

Navigating HPV Vaccination: a Qualitative Study on Chinese Women's Decision-Making Experiences.

Li D, Zhang W, Stinson J, Jibb L, Killackey T, Pope N, Wu F, Yuan C.J Cancer Educ. 2025 Aug;40(4):616-625. doi: 10.1007/s13187-024-02555-1. Epub 2025 Jan 20.PMID: 39831945

Prior appendectomy attenuates the immune protective efficacy of BCG vaccination against Mycobacterium tuberculosis infection.

Huang H, Xu W, Xiong S.Immunobiology. 2025 Aug 8;230(5):153106. doi: 10.1016/j.imbio.2025.153106. Online ahead of print.PMID: 40819502

Tracking wild-type measles virus in wastewater using multiplex RT-dPCR, A novel tool for measles surveillance.

Roman V, Jourdain F, Pele E, Brottet E, Guinard A, Mouly D, Medragh S, Cordevant C, Gassilloud B, Dina J.Water Res. 2025 Aug 9;287(Pt A):124379. doi: 10.1016/j.watres.2025.124379. Online ahead of print.PMID: 40819448

Evaluation of clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis.

Chen S, Sun Z, Li Y, Yang F, Wang P, Chen K, Wang J, Qiu M.EClinicalMedicine. 2025 Jul 24;86:103369. doi: 10.1016/j.eclinm.2025.103369. eCollection 2025 Aug.PMID: 40740294

Hepatitis A vaccination coverage in adults with chronic liver disease in primary care in England: a retrospective cohort study.

Meza-Torres B, Jamie G, Wimalaratna R, Williams R, Byford R, Forbes A, Elson W, Hinton W, Ordóñez-Mena JM, Pericleous M, Feher M, Whyte M, Joy M, de Lusignan S.Lancet Public Health. 2025 Aug;10(8):e647-e655. doi: 10.1016/S2468-2667(25)00139-2.PMID: 40738551

Bibliometric Insights into Human Metapneumovirus Interventions: Trends, Gaps, and Future Directions.

Gnanasekaran S, Murugan V, Venkataraman S, Rajendran V, Vinothini J, Vasudevan K.Disaster Med Public Health Prep. 2025 Aug 13;19:e238. doi: 10.1017/dmp.2025.10175.PMID: 40799012

Nasal and systemic immune responses correlate with viral shedding after influenza challenge in people with complex preexisting immunity.

Walters KA, Blatti CA 3rd, Zhu R, Banbury B, Giurgea LT, Bean R, Han E, Li Y, Scherler K, Sherry J, Formentini S, Zhou W, Cervantes-Medina A, Gouzoulis M, Rosas LA, Han A, Gatzke L, Bushell C, Sherry N, Taubenberger JK, Memoli MJ, Kash JC.Sci Transl Med. 2025 Aug 6;17(810):eadt1452. doi: 10.1126/scitranslmed.adt1452. Epub 2025 Aug 6.PMID: 40768601

Exploring the participant experience in controlled human infection model (CHIM) trials: A modified grounded theory study.

Mack AG, Halperin DM, Selig BM, Condran BR, Halperin SA.PLoS One. 2025 Aug 6;20(8):e0328378. doi: 10.1371/journal.pone.0328378. eCollection 2025.PMID: 40768397

Charge Detection Mass Spectrometry Reveals Norovirus GII.4 Virus-like Particles Failure to Complete.

Miller LM, Draper BE, Jarrold MF.J Am Soc Mass Spectrom. 2025 Aug 6;36(8):1696-1701. doi: 10.1021/jasms.5c00095. Epub 2025 Jul 15.PMID: 40663759

BCG Vaccination Reprograms the Function of M-MDSCs and Aggravates Necrotizing Enterocolitis in Neonates.

Chen Y, Li H, Zhang Y, Zhao F, Zhou J.Immunology. 2025 Aug;175(4):501-517. doi: 10.1111/imm.13946. Epub 2025 May 21.PMID: 40398926

Association of Inhaled Corticosteroid Use with COVID-19 Severity and Hospitalization in Patients With and Without Respiratory Disease.

Leibovitch M, Oberman B, Cohen J, Strahl T, Yosef N, Reichenberg Y, Shlomi D.J Aerosol Med Pulm Drug Deliv. 2025 Aug;38(4):192-201. doi: 10.1089/jamp.2025.0004. Epub 2025 Apr 18.PMID: 40250996

Preparation, and enzymatic activity analysis of an engineered capping enzyme.

Wang ZR, Li LT, Xiong FF, Zhao LB, Mao H, Zhu MY, Su SY, Guo ZY, He C.Enzyme Microb Technol. 2025 Aug;188:110640. doi: 10.1016/j.enzmictec.2025.110640. Epub 2025 Apr 1.PMID: 40188656

Serum-equivalency comparison, detection, and quantification of Group B *Streptococcus* anti-capsular polysaccharide antibodies from dried blood spots.

Bolcen S, Alston B, Patel PY, Li Y, Maniatis P, Giordano Schmidt D, Pavliakova D, Southwell JE, Tao Jia L, Gaylord M, Simon R, Silmon de Monerri NC, Rhodes J, Schrag S, Vishwanathan SA.Hum Vaccin Immunother. 2025 Dec;21(1):2544461. doi: 10.1080/21645515.2025.2544461. Epub 2025 Aug 14.PMID: 40812297

Genetic and antigenic characterization of classical and recombinant waterfowl parvoviruses circulating in Taiwan.

Hsu YC, Li KP, Chang PC, Shien JH, Hsu WL, Yen H, Hsu JP, Chen TT, Ou SC.Poult Sci. 2025 Aug 7;104(11):105654. doi: 10.1016/j.psj.2025.105654. Online ahead of print.PMID: 40819459

IL-2 and IFN-γ Secretion of Activated Jurkat T Cells *via* a Microdroplet-SERS based Single-Cell Immunoassay (Drop-SCIA).

Wang X, Wang J, Liang C, Xu S.Anal Chem. 2025 Aug 13. doi: 10.1021/acs.analchem.5c02142. Online ahead of print.PMID: 40804042

Mycobacterium tuberculosis curli pili facilitates pathogenicity by modulating central carbon metabolism.

Naidoo TJ, Ashokcoomar S, Truebody B, Mackenzie JS, Steyn AJC, Pillay M.Metabolomics. 2025 Aug 12;21(5):118. doi: 10.1007/s11306-025-02320-5.PMID: 40794122

Exposure to *Batrachochytrium dendrobatidis* metabolites altered ghost shrimp behavior and reduced mortality.

Parker-Athill EC, Muldro LC, Malinias AJ, McMahon TA.PeerJ. 2025 Aug 7;13:e19815. doi: 10.7717/peerj.19815. eCollection 2025.PMID: 40786113

Attitudes and behaviors toward vaccination among nursing students from Spain and Portugal: a cross-sectional study.

Pérez-Rivas FJ, Esteban-Gonzalo L, García-García D, Ajejas Bazán MJ, Roquette-Viana MC, Tholl AD, Marques-Vieira CMA.BMC Nurs. 2025 Aug 4;24(1):1012. doi: 10.1186/s12912-025-03627-3.PMID: 40760477

The waning of maternal measles antibodies: A multi-country maternal-infant seroprevalence study.

Tiley KS, Ten Hulscher-van Overbeek H, Basnet S, van Binnendijk R, Clarke E, Cose S, Dang DA, Hoang HTT, Holder B, Idoko OT, Kampmann B, Kibengo F, van der Klis F, Kazi AM, Leuridan E, Maertens K, Maldonado H, Nyantaro M, Omer S, Pasetti MF, Pollard AJ, Rots N, Sharma AK, Shrestha S, Tapia M, Wanlapakorn N, Voysey M.J Infect. 2025 Aug;91(2):106531. doi: 10.1016/j.jinf.2025.106531. Epub 2025 Jun 11.PMID: 40513621

Aging Compromises Terminal Differentiation Program of Cytotoxic Effector Lineage and Promotes Exhaustion in CD8⁺ T Cells Responding to Coronavirus Infection.

Zhu Z, Lou G, Luo Y, Yihunie K, Hoar J, Daniel JA, Evers BM, Yao C, Wu T.Aging Cell. 2025 Aug;24(8):e70109. doi: 10.1111/acel.70109. Epub 2025 May 21.PMID: 40396260

Visual recombinase aided amplification technology for detecting feline coronavirus.

Lu X, Cao Y, Zhang P, Chen X, Irwin DM, Shen Y.Vet J. 2025 Aug;312:106356. doi: 10.1016/j.tvjl.2025.106356. Epub 2025 Apr 12.PMID: 40228788

Stimulation of microglia in adolescence produces a long-lasting prophylactic effect on single prolonged stress-induced PTSD-like behavior in adult mice.

Song R, Ye M, Gao Z, Lu X, Liu L, Cao F, Yang R, Chen Z, Sun M, Li F, Hu W, Ren J, Zhu H, Feng Q, Huang C.Brain Behav Immun. 2025 Aug 15:106079. doi: 10.1016/j.bbi.2025.106079. Online ahead of print.PMID: 40819746

Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortium.

Hunter OF, McClymont E, Lau O, Bettinger JA, Castillo E, Crowcroft NS, Dubé È, Elwood C, Gantt S, Halperin SA, Langley JM, Money D, Naus M, Sauvé L, Top KA, van Schalkwyk J, Sadarangani M.Vaccine. 2025 Aug 11;62:127594. doi: 10.1016/j.vaccine.2025.127594. Online ahead of print.PMID: 40795701

Low-liver-accumulation lipid nanoparticles enhance the efficacy and safety of HPV therapeutic tumor vaccines.

Wang X, Tian Z, Wang M, Cai X, Yang S, Zeng J, Fang Y, Bai X, Wang P, Sun Y, Guo C, Liu T, Qian Q.J Transl Med. 2025 Aug 11;23(1):893. doi: 10.1186/s12967-025-06924-2.PMID: 40790751

A Clinical Investigation Into the Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Vaccination in Children With Acute Lymphoblastic Leukemia.

Wu Z, Jiang H, Zhou Y, Yang Y, Jiang H, Zhang F, Zhe L, Tang R, Xu J, Yan L, Lu S, Zhang T, Sun Q.J Med Virol. 2025 Aug;97(8):e70492. doi: 10.1002/jmv.70492.PMID: 40788085

Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season.

Verelst F, Singer D, Graham J, Grace M, La EM, Biundo E.Expert Rev Vaccines. 2025 Dec;24(1):797-806. doi: 10.1080/14760584.2025.2539893. Epub 2025 Aug 4.PMID: 40718987

Dendritic cell immunotherapy has its antitumor action improved by the LPS in the maturation process.

Lopes AMM, Vieira JF, da Silva SFM, Murta EFC, Michelin MA.Clin Transl Oncol. 2025 Aug;27(8):3501-3510. doi: 10.1007/s12094-025-03858-5. Epub 2025 Feb 20.PMID: 39979657

Dose and age-dependent effects of Eimeria spp. infection on cytokine and intestinal integrity gene expression in broiler chickens.

Lima PPABM, Paulino PG, da Silva NM, Galdino KCP, Rabello CA, Souza FG, Reis TL, Machado LDS, Souza FDR, Santos HA.Vet Parasitol. 2025 Aug;338:110550. doi: 10.1016/j.vetpar.2025.110550. Epub 2025 Jul 23.PMID: 40716185

A case of infectious endocarditis and vertebral discitis caused by Streptococcus pneumoniae serotype 23A.

Kawamura M, Ono D, Kawamura T, Mimura K, Ebata E, Chang B, Akeda Y, Yoshitake A, Mitsutake K, Oka H.J Infect Chemother. 2025 Aug;31(8):102749. doi: 10.1016/j.jiac.2025.102749. Epub 2025 Jun 7.PMID: 40490099

A perspective on the apparent pKa of ionizable lipids in mRNA-LNPs.

Simonsen JB, Larsson P.J Control Release. 2025 Aug 10;384:113879. doi: 10.1016/j.jconrel.2025.113879. Epub 2025 May 21.PMID: 40409373

Next-generation sequencing of Omicron SARS-CoV-2 variants in Hormozgan Province, Iran, and evaluation of the effects of mutations on RBD and ORF9b protein function.

Ahmadi K, Kavousipour S, Shahbazi B, Farzin F, Gharibi Z, Pishva MS, Pishahang A, Gouklani H.Infect Genet Evol. 2025 Aug 12;134:105812. doi: 10.1016/j.meegid.2025.105812. Online ahead of print.PMID: 40812543

Web-Based Video Intervention and Associated Factors for the Uptake of the Catch-Up Human Papillomavirus Vaccination in Japan: Randomized Controlled Trial.

Yoshioka T, Goto A, Mizushima T, Suzuki Y, Ueda Y, Yagi A, Sekine M, Kudo R, Garland SM, Kumarasamy S, Ismail-Pratt I, Reimer K, Miyagi E; Asia Pacific HPV Coalition.J Med Internet Res. 2025 Aug 15;27:e67778. doi: 10.2196/67778.PMID: 40815798

Diagnostic performance and kinetics of hepatitis E viral RNA and IgM antibody test positivity in a genotype 1 outbreak in South Sudan.

Koyuncu A, Nesbitt R, Alvarez C, Asilaza KV, Wamala J, Haile M, Gignoux E, Albela M, Gurley ES, Loro FB, Biem D, Rull M, Rumunu J, Ciglenecki I, Eckerle I, Azman AS.J Infect Dis. 2025 Aug 14:jiaf436. doi: 10.1093/infdis/jiaf436. Online ahead of print.PMID: 40811666

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, O'Reilly EM.Nat Med. 2025 Aug 11. doi: 10.1038/s41591-025-03876-4. Online ahead of print.PMID: 40790272

Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial.

Ma YT, Zuo J, Kirkham A, Curbishley S, Blahova M, Rowe AL, Bathurst C, Mehrzad H, Karkhanis S, Punia P, James MW, Stern N, Rao A, Hull D, Lowe F, Sylla P, Webster L, Hussain S, Yap C, Palmer D, Adams DH.Clin Cancer Res. 2025 Aug 14;31(16):3412-3423. doi: 10.1158/1078-0432.CCR-25-0142.PMID: 40499144

Barriers and facilitators associated with migrant parents' decisions regarding childhood vaccinations: A mixed methods systematic review.

Hurley F, Balanuta MS, Flanagan P.Vaccine. 2025 Aug 9;62:127588. doi: 10.1016/j.vaccine.2025.127588. Online ahead of print.PMID: 40784111

With Increasing Vaccination Reluctance, Does Rubella Immunity Predict Rubeola Immunity Well Enough?

Marohl R, McCormick K, Okut H, Keomany J, Wallace D, Grainger DA, Tatpati L.J Womens Health (Larchmt). 2025 Aug;34(8):973-978. doi: 10.1089/jwh.2024.0975. Epub 2025 Jun 11.PMID: 40495574

Chimeric antigen receptor-engineered (CAR)-T cell therapy for metastatic prostate cancer.

Tharian L, Verma S, Feinberg D, Parameswaran R, Gupta S.Cancer Lett. 2025 Aug 12;632:217986. doi: 10.1016/j.canlet.2025.217986. Online ahead of print.PMID: 40812718

Host innate immune antagonism and immune evasion strategies of porcine reproductive and respiratory syndrome virus.

He Z, Yan J, Liu M, Liao J, Li F, Guo C.Int J Biol Macromol. 2025 Aug 10:146756. doi: 10.1016/j.ijbiomac.2025.146756. Online ahead of print.PMID: 40796041

Towards Rabies Elimination in Pakistan: Barriers, Facilitators, and the Role of One Health.

Shaikh A, Habib SS, Saleem AF, Salahuddin N.J Epidemiol Glob Health. 2025 Aug 6;15(1):102. doi: 10.1007/s44197-025-00441-7.PMID: 40767988

Molecular characterization of lumpy skin disease virus in the cattle population of District Lower Chitral, Khyber Pakhtunkhwa, Pakistan.

Nizam AF, Maqsood I, Rahman HU, Awaz S, Shah IU, Ali MI, Khan B, Muhammad G, Azam A, Hidayat A.Antonie Van Leeuwenhoek. 2025 Aug 3;118(9):124. doi: 10.1007/s10482-025-02137-1.PMID: 40754559

The molecular adjuvant effect of the C-terminal peptide of complement C5a in a teleost fish.

Liu B, Liang JX, Ma ZY, Zhong YQ, Sun Y, Wang XY, Zhang DF, Zhang YA, Zhang XJ.Fish Shellfish Immunol. 2025 Aug;163:110415. doi: 10.1016/j.fsi.2025.110415. Epub 2025 May 13.PMID: 40373887

Vaccinating for My Family or for My Community? The Effect of Message Framing on Parental Intention to Vaccinate during the COVID Pandemic.

Wong CCY, Li LMW, Lee DKL, Lorez WP, Lo HYM.Int J Behav Med. 2025 Aug;32(4):586-596. doi: 10.1007/s12529-024-10313-2. Epub 2024 Aug 13.PMID: 39138781

Inducible genome-wide mutagenesis for improvement of pDNA production by E. coli.

Li Z, Sun G, Al'Abri I, Zhou Y, Crook N.Microb Cell Fact. 2025 Aug 13;24(1):183. doi: 10.1186/s12934-025-02821-x.PMID: 40796832

Real-time monitoring of attenuated cytomegalovirus using Raman spectroscopy allows non-destructive characterization during flow.

Athalye SM, Maruthamuthu MK, Esmaili E, Boodaghidizaji M, Sarathy N, Mayorga C, Raffaele J, Selvamani V, Smith JP, Matos T, Rustandi RR, Ardekani AM, Verma MS.Spectrochim Acta A Mol Biomol Spectrosc. 2025 Aug 7;345:126761. doi: 10.1016/j.saa.2025.126761. Online ahead of print.PMID: 40782423

Characterization of antigenically dominant regions in the hemagglutinin protein of B/victoria-lineage influenza B virus using monoclonal antibody escape mutants.

Matsuzaki Y, Sugawara K, Kadowaki Y, Kidoguchi Y, Shimotai Y, Mizuta K.Virus Res. 2025 Aug;358:199598. doi: 10.1016/j.virusres.2025.199598. Epub 2025 Jun 14.PMID: 40523503

Relapse and New-Onset of Autoimmune or Inflammatory Diseases Following Vaccination With SPIKEVAX: Pharmacovigilance Overview From the French Spontaneous Reported System.

Vettoretti L, Bouaskeur C, Magy-Bertrand N, Gautier S, Rabier MBV.Fundam Clin Pharmacol. 2025 Aug;39(4):e70027. doi: 10.1111/fcp.70027.PMID: 40452215

Genetic evolution of respiratory syncytial virus in pediatric acute respiratory infections: Insights from a non-epidemic season.

Gao X, Zou R, Zhou W, Zhao H, Lu C, Tian J, Hao J, Tang P, Wu K, Zhang Y, Yuan X, Yang C, Liu P.Infect Genet Evol. 2025 Aug;132:105775. doi: 10.1016/j.meegid.2025.105775. Epub 2025 May 28.PMID: 40446887

Effect of human survivin-2B-specific cytotoxic CD8+ T lymphocytes on CD44+/- HSC-2 and HSC-3 oral cancer cells.

Miyamoto S, Osaki A, Murai A, Hirohashi Y, Sasaki T, Ogi K, Tokura TA, Kanaseki T, Tsukahara T, Kina S, Torigoe T, Miyazaki A.Eur J Oral Sci. 2025 Aug;133(4):e70019. doi: 10.1111/eos.70019. Epub 2025 May 21.PMID: 40399621

Biomineralized engineered *Lactococcus lactis*-based in situ vaccination enhances antitumor immunity via sequential activation of chemo-immunotherapy.

Chen Z, Ke Y, Zhu J, Cen L, Rao W, Hong S, Wang Y, Shao J, Chu Y, Qian X, Liu B, Li R, Liu Q.J Immunother Cancer. 2025 Aug 17;13(8):e011799. doi: 10.1136/jitc-2025-011799.PMID: 40819921

Dose finding in early-phase human immunodeficiency virus type 1 prevention monoclonal antibody clinical trials.

Huang Y, Zhang B, Zhang L, Mayer BT, Martin T, Hahn W, Hyrien O, Gelderblom HC.Clin Trials. 2025 Aug;22(4):442-451. doi: 10.1177/17407745251347280. Epub 2025 Jul 5.PMID: 40616435

Population immunity enhances the evolution of SARS-CoV-2 in Beijing revealed by wastewater genomic surveillance.

Wang C, Chen W, Yu L, Wang X, Zhang L, Zhang X, Tang S, Han J, Gao W, Huang X, Zhang Y, An W, Yang M, Tian Z.Water Res. 2025 Aug 15;282:123649. doi: 10.1016/j.watres.2025.123649. Epub 2025 Apr 13.PMID: 40245799

Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: A systematic review and meta-analysis.

Ghajarzadeh M, Rastkar M, Mowry EM, Nourbakhsh B.Neurol Sci. 2025 Aug;46(8):3469-3476. doi: 10.1007/s10072-025-08098-7. Epub 2025 Apr 4.PMID: 40183837

Defining the host dependencies and the transcriptional landscape of RSV infection.

Sunshine S, Puschnik A, Retallack H, Laurie MT, Liu J, Peng D, Knopp K, Zinter MS, Ye CJ, DeRisi JL.mBio. 2025 Aug 15:e0101025. doi: 10.1128/mbio.01010-25. Online ahead of print.PMID: 40815167

Association between tick-bite history and safety of gelatin-containing vaccines: Analysis of a large database of the United States.

Chiu CY, Henao-Martínez AF, Agudelo Higuita NI.Ticks Tick Borne Dis. 2025 Aug 1;16(5):102532. doi: 10.1016/j.ttbdis.2025.102532. Online ahead of print.PMID: 40752174

The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence.

Desheva Y, Kudar P, Sergeeva M, Wong PF, Shvedova T, Bazhenova E, Krylova E, Kurpiaeva M, Romanovskaya-Romanko E, Krivitskaya V, Kudria K, Isakova-Sivak I, Stukova M.Int J Mol Sci. 2025 Aug 2;26(15):7476. doi: 10.3390/ijms26157476.PMID: 40806604

Systems biology-based assessment of immune responses to whole cell and acellular pertussis vaccines.

Leguia M, Vila-Sanjurjo A, Juarez D, Garcia-Glaessner A, Gil AI, Alvarez M, Cornejo R, Cherikh S, Gelber CE, Goll JB, Howard LM, Jimenez-Truque N, Edwards KM, Creech CB, Lanata CF.NPJ Vaccines. 2025 Aug 11;10(1):188. doi: 10.1038/s41541-025-01121-0.PMID: 40789865

Production of Envelope Protein-Based Virus-like Particles of DENV-2 in and Investigation of Their Binding Interactions with Gallic Acid Derivatives of Glucose as Potential Drug Candidates.

Sharma A, Nimesh S, Tapryal S.ACS Omega. 2025 Jul 21;10(30):33090-33107. doi: 10.1021/acsomega.5c02548. eCollection 2025 Aug 5.PMID: 40787407

Disseminated gonococcal infection developing two days after initial eculizumab administration in a patient with neuromyelitis optica spectrum disorder: A case report and literature review.

Nishida Y, Ono D, Kawamura M, Kawamura T, Mimura K, Fukaura H, Ebata E, Koyama S, Ebihara Y, Oka H.J Infect Chemother. 2025 Aug 6;31(9):102782. doi: 10.1016/j.jiac.2025.102782. Online ahead of print.PMID: 40780406

HPV vaccination and malignancy risks beyond cervical cancer: A retrospective global cohort study.

Seebauer C, Faluogy M, Sieg P, Olbrich H, Ludwig R.Pharmacol Res. 2025 Aug;218:107851. doi: 10.1016/j.phrs.2025.107851. Epub 2025 Jul 11.PMID: 40653128

An exploration of women's decision-making processes around accepting or declining vaccinations in pregnancy: A qualitative descriptive study.

Riada BN, Noonan M.Midwifery. 2025 Aug;147:104441. doi: 10.1016/j.midw.2025.104441. Epub 2025 May 2.PMID: 40359878

Respiratory syncytial virus infection in patients with haematological diseases: a retrospective multicentre study.

Herrmann S, Graefe S, Christopeit M, Sonnemann P, Hattenhauer T, Mispelbaum R, Monin MB, Orth HM, Flasshove C, Gruell H, Klein F, Klein U, Lehmann C, Naendrup JH, Stemler J, Salmanton-Garcia J, Markus T, Cornely OA, Mellinghoff SC.Infection. 2025 Aug;53(4):1341-1350. doi: 10.1007/s15010-024-02449-w. Epub 2024 Dec 17.PMID: 39688808

Serological differentiation between naturally acquired mpox and MVA-BN-vaccine induced antibody responses using ratios of MPXV and VACV antigen pairs in the MSD immunoassay.

Pettke A, Keszei M, Christ W, Mayola Danés N, Gredmark-Russ S, Söderholm S, Filén F, Storgärd E, Westergren V, Yman V, Aarum J, Klingström J, Johansen K, Ekström AM, Sondén K.Microbiol Spectr. 2025 Aug 8:e0018225. doi: 10.1128/spectrum.00182-25. Online ahead of print.PMID: 40778847

Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022.

Fletcher MA, Okasha O, Baay M, Syrochkina M, Hayford K.Eur J Clin Microbiol Infect Dis. 2025 Aug;44(8):1779-1796. doi: 10.1007/s10096-025-05114-8. Epub 2025 May 2.PMID: 40314731

Associations of health-related quality of life with beliefs about influenza vaccination in people with chronic diseases.

Arsenović S, Trajković G, Pekmezović T, Gazibara T.Res Social Adm Pharm. 2025 Aug;21(8):573-579. doi: 10.1016/j.sapharm.2025.03.061. Epub 2025 Mar 22.PMID: 40221288

Prevalence of Human Papillomavirus Genotypes in Unvaccinated 16- to 20-Year-Old Men in Quebec, Canada.

Wolfe C, Ionescu IG, Mayrand MH, Coutlée F, Sauvageau C.J Infect Dis. 2025 Aug 14;232(2):e203-e212. doi: 10.1093/infdis/jiaf094.PMID: 39982898

Exploring the Potential of miRNA-92a-3p as Lead for Sequence-Based Therapies for Malaria.

Prabhu SR, Paul S, Umakanth S, Hande M, Saadi AV, Gupta H, Satyamoorthy K.Acta Parasitol. 2025 Aug 11;70(4):179. doi: 10.1007/s11686-025-01117-9.PMID: 40788442

Determinants for not keeping up to date with COVID-19 vaccination in the 2023 vaccination round among medical risk groups, the Netherlands.

Osmënaj T, van Roon A, Labuschagne L, Pijpers J, Smagge B, de Melker H, van den Hof S, Hahné S.Vaccine. 2025 Aug 5;62:127561. doi: 10.1016/j.vaccine.2025.127561. Online ahead of print.PMID: 40768845

A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma.

Agarwal P, Guo M, Munjal K, Qi H, Parkinson R, Ferguson A, Mitchell C, Harrison J, Anders RA, Thompson ED, Wang H, De Jesus A, Zheng L, He J, Burkhart R, Narang A, George B, Jaffee EM, Yarchoan M, Laheru D, Osipov A.Clin Cancer Res. 2025 Aug 1;31(15):3205-3214. doi: 10.1158/1078-0432.CCR-24-3403.PMID: 40407726

Targeting Innate Immune Checkpoint TREX1 Is a Safe and Effective Immunotherapeutic Strategy in Cancer.

Xing C, Tu X, Huai W, Tang Z, Song K, Jeltema D, Knox K, Dobbs N, Yang K, Yan N.Cancer Res. 2025 Aug 1;85(15):2858-2875. doi: 10.1158/0008-5472.CAN-24-2747.PMID: 40327609

Primary versus systemic sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors.

Favoino E, Prete M, Liakouli V, Sisto A, Corrado A, Leone P, Lisco G, Vomero M, Biancalana E, Chiara E, Emmi G, Racanelli V, Marcoccia A, Grembiale RD, Cantatore FP, Navarini L, Ruscitti P, Ciccia F, Giacomelli R, Perosa F.Clin Exp Rheumatol. 2025 Aug;43(8):1380-1385. doi: 10.55563/clinexprheumatol/m7qpn3. Epub 2025 Apr 1.PMID: 40183325

HPV vaccination improves immune response in children with respiratory papillomatosis.

Prieto-Islas MA, Godoy-Dahbura E, Villalpando-Sánchez DC, Cortés-Benavides C, Hernández-Cuellar E, Castro-Eguiluz D, Alvarez-Neri H, Medina-Contreras O.Sci Rep. 2025 Aug 14;15(1):29885. doi: 10.1038/s41598-025-14787-2.PMID: 40813785

Evaluation of Nursing Students' Knowledge on Dental Injuries.

Akgül N, Yilmaz E, Akkurt O.Dent Traumatol. 2025 Aug;41(4):410-418. doi: 10.1111/edt.13046. Epub 2025 Feb 19.PMID: 39973004

Opportunities and Challenges for an Organizational Digital Public Health Strategy in a Provincial Public Health Program in Canada: Qualitative Description of Practitioner Perspectives.

Iyamu I, Haag D, Carson A, Wang I, King C, Roe I, Kerr K, Bartlett S, McKee G, Gilbert M.JMIR Public Health Surveill. 2025 Aug 12;11:e72588. doi: 10.2196/72588.PMID: 40795313

Preexisting Yellow Fever Virus and West Nile Virus Immunity and Pregnancy Outcomes in a Nigerian Cohort with Endemic Orthoflavivirus Exposure.

Kim TW, Herrera BB, Chaplin B, Naito-Keoho K, Ogwuche J, Sagay AS, Chang CA, Wang WK, Kanki PJ.Emerg Microbes Infect. 2025 Aug 12:2544720. doi: 10.1080/22221751.2025.2544720. Online ahead of print.PMID: 40793825

Expression of spike and hemagglutinin-esterase proteins is necessary to recover infectious recombinant bovine coronavirus.

Sugiura Y, Takahashi T, Ueno S, Amarbayasgalan S, Shimizu K, Ujike M, Suzuki T, Kamitani W.J Virol. 2025 Aug 11:e0102725. doi: 10.1128/jvi.01027-25. Online ahead of print.PMID: 40787988

A Comparative Analysis of Global Responses to Monkeypox Outbreaks: Lessons Learned and Future Directions - a Mini Narrative Review.

Anjum AF, Anjum MB, Rehman RU, Wei CR, Akilimali A, Humayun A.Ann Med Surg (Lond). 2025 Jul 16;87(8):5098-5105. doi: 10.1097/MS9.0000000000003577. eCollection 2025 Aug.PMID: 40787494

Visualization and tracking of tubule-derived, fluorescent-labeled NS1 as a marker of bluetongue virus in living cells.

Song Y, Liu X, Che Y, Wang J, Tian Z, Guan G, Roy P, Yin H, Du J.J Virol. 2025 Aug 7:e0089625. doi: 10.1128/jvi.00896-25. Online ahead of print.PMID: 40772685

Co-circulation of multiple serotypes of foot and mouth disease virus among susceptible multispecies animal population in India during 2021-2022.

Rout M, Tripathy JP, Giri P, Rautaray SS, Dahiya SS, Biswal JK, Subramaniam S, Mohapatra JK, Singh RP.Acta Trop. 2025 Aug;268:107709. doi: 10.1016/j.actatropica.2025.107709. Epub 2025 Jun 27.PMID: 40582608

Membrane vesicles from selected Clostridioides difficile strains induce epithelial-mesenchymal transition in colonic epithelial cells: insights from in vitro and in vivo studies.

Azimirad M, Noori M, Mazhari S, Keshavarz Azizi Raftar S, Ghorbaninejad M, Meyfour A, Mortazavi P, Zali MR, Di Bella S, Sun X, Baghaei K, Yadegar A.Microb Pathog. 2025 Aug 14;208:107988. doi: 10.1016/j.micpath.2025.107988. Online ahead of print.PMID: 40816603

Comparative analyses of COVID-19 in-hospital mortality in people living with HIV during SARS-CoV-2 pre-delta, delta, and omicron waves: data from the who global clinical platform.

Inzaule S, Silva R, Ford N, Thwin SS, Waasila J, Zumla A, Doherty M, Diaz J, Bertagnolio S.AIDS. 2025 Aug 14. doi: 10.1097/QAD.0000000000004323. Online ahead of print.PMID: 40811072

The Association of HPV Vaccination and Risk of Immune-Mediated Diseases.

Zhang Q, Chang R, Wei JC, Wang SI, Hung YM.QJM. 2025 Aug 7:hcaf154. doi: 10.1093/qjmed/hcaf154. Online ahead of print.PMID: 40795224

Bacillus Calmette-Guérin (BCG) in combination with PANVAC™ vs. BCG alone in adults with high-grade BCG-refractory non-muscle-invasive bladder cancer.

Ho M, Lazarovich A, Saoud R, Dahmen A, Tremblay S, Telfer S, Maruf M, Singer EA, Weiss RE, Jang TL, Elsamra SE, Merino M, Dolan R, Valera V, Rodriquez BW, Railkar R, Bellfield S, Stamatakis L, Shih J, Donahue RN, Navarro CP, Apolo AB, Gulley JL, Schlom J, Agarwal PK.Urol Oncol. 2025 Aug 7:S1078-1439(25)00222-4. doi: 10.1016/j.urolonc.2025.06.006. Online ahead of print.PMID: 40781051

Immunogenicity and safety of the accelerated 2-dose intradermal rabies pre exposure prophylaxis regimen in immunocompetent and immunocompromised pediatric populations: a comparative study.

Agarwal A, Singh C, Mathur SB, Manchanda V, Agarwal K, Mantan M, Khan AM.Infection. 2025 Aug 8. doi: 10.1007/s15010-025-02623-8. Online ahead of print.PMID: 40779007

Geroscience: A Translational Review.

Kritchevsky SB, Cummings SR.JAMA. 2025 Aug 7. doi: 10.1001/jama.2025.11289. Online ahead of print.PMID: 40773213

Natural language processing evaluation of trends in cervical cancer incidence in radiology reports: A ten-year survey.

López-Úbeda P, Martín-Noguerol T, Luna A.Radiography (Lond). 2025 Aug 4:103117. doi: 10.1016/j.radi.2025.103117. Online ahead of print.PMID: 40759620

Epidemiology and genotypic diversity of rhinovirus in school-age children with acute respiratory illnesses seeking medical care.

Banerjee D, Schuster JE, Midgley CM, Lee B, Moffatt M, Lively JY, Toepfer AP, Weinberg GA, Boom JA, Sahni LC, Avadhanula V, Piedra PA, Staat MA, Payne DC, Halasa N, Williams JV, Hickey RW, Michaels MG, Englund JA, Klein EJ, Sasidharan A, Rha B, Harrison CJ, Selvarangan R.J Clin Virol. 2025 Aug;179:105806. doi: 10.1016/j.jcv.2025.105806. Epub 2025 May 28.PMID: 40479933

Positive predictive value of cervical cancer screening results recommended for colposcopy by human papillomavirus vaccination status at 3 U.S. healthcare systems.

Pocobelli G, Lykken J, Haas JS, Tiro J, Doria-Rose VP, Hyun N, Silver MI, Kamineni A, Chubak J.Cancer Causes Control. 2025 Aug 6. doi: 10.1007/s10552-025-02039-7. Online ahead of print.PMID: 40768171

Cytokines, chemokines, and immune cells involved in oral immunity towards the dental cariogenic bacterium Streptococcus mutans: Therapeutic interventions and vaccination.

Kazerooni MT, Hemmati S.Biomed Pharmacother. 2025 Aug 1;190:118394. doi: 10.1016/j.biopha.2025.118394. Online ahead of print.PMID: 40752424

A Framework for Evaluating the Use of Surveillance Systems for Short-Term Influenza Forecasting.

Maroufi N, Barnard LT, Huang QS, Dobbie G, Aminisani N, Albrecht S, Nghiem N, Baker MG.Influenza Other Respir Viruses. 2025 Aug;19(8):e70144. doi: 10.1111/irv.70144.PMID: 40730485

Chronic Conditions and Adherence to COVID-19 Preventive Measures in Pitt County, North Carolina.

Grantham LB, Kipp AM, Lea CS, Simeonsson KL.AJPM Focus. 2025 Apr 30;4(4):100359. doi: 10.1016/j.focus.2025.100359. eCollection 2025 Aug.PMID: 40654527

The effect of sleep and shift work on the primary immune response to messenger RNA-based COVID-19 vaccination.

Brouwers TMJ, Çobanoğlu ÜG, Geers D, Rietdijk WJR, Gommers L, Bogers S, Lammers GJ, van der Horst GTJ, Chaves I, GeurtsvanKessel CH, Koch BCP, de Vries RD, van Baarle D, van der Kuy HM, Lammers-van der Holst HM.J Sleep Res. 2025 Aug;34(4):e14431. doi: 10.1111/jsr.14431. Epub 2024 Dec 10.PMID: 39658344

CSF3 enhances the innate immune responses to ALV-J infections via NF-κB and interferon pathways.

Xia J, Chen W, Xu C, Wang M, Mo G, Zhang X.Poult Sci. 2025 Aug 6;104(11):105648. doi: 10.1016/j.psj.2025.105648. Online ahead of print.PMID: 40812136

Essential function of the integrator complex in Kaposi's sarcoma-associated herpesvirus lytic replication.

Nguyen A, Li T, Traugot C, Paulsen K, Nelson TS, Xie M, Ma Z.J Virol. 2025 Aug 13:e0026625. doi: 10.1128/jvi.00266-25. Online ahead of print.PMID: 40801543

Long-term survival of *Babesia microti* and *Borrelia burgdorferi* in C3H/HeJ mice and their effect on Lyme arthritis and babesiosis manifestations.

Rocha SC, Moustafa MAM, Velásquez CV, Azuama OC, Zafar K, Meyer C, Araujo M, Taylor K, Parveen N.Microbiol Spectr. 2025 Aug 12:e0025225. doi: 10.1128/spectrum.00252-25. Online ahead of print.PMID: 40793757

Impact of COVID-19 vaccination on cancer patients: safety, efficacy, and long-term effects.

Alshehri S, Almutawif YA, Khan NU.Support Care Cancer. 2025 Aug 4;33(8):753. doi: 10.1007/s00520-025-09783-1.PMID: 40760361

Evaluating the burden of respiratory tract infections among mortality cases in Karachi, Pakistan: a post-pandemic surveillance analysis.

Kabir F, Allana R, Yildirim I, Hotwani A, Belgaumi SM, Aziz F, Malik FA, Jamal S, Aguolu O, Ahsan N, Hasan Z, Ariff S, Omer SB, Kazi AM.J Glob Health. 2025 Aug 4;15:04198. doi: 10.7189/jogh.15.04198.PMID: 40755024

Preconception Oral Health Is Associated with Modifiable Health Behaviors.

Bond JC, Simancas-Pallares MA, Divaris K, Garcia RI, Fox MP, Wise LA, Heaton B.J Dent Res. 2025 Aug;104(9):936-946. doi: 10.1177/00220345251325216. Epub 2025 Apr 20.PMID: 40254774

Penile human papillomavirus prevalence in circumcised sexual minority men with and without HIV.

Nampota-Nkomba N, Mohanty K, Adebiyi R, Ekeh C, Schumaker LM, Suleiman KT, Powell L, Lombardi K, Ambulos NP, Shoyemi E, Tiamiyu AB, Homan MG, Sajadi MM, Bentzen SM, Cullen KJ, Crowell TA, Nowak RG; TRUST/RV368 Study Group.AIDS. 2025 Aug 1;39(10):1431-1440. doi: 10.1097/QAD.0000000000004209. Epub 2025 Apr 14.PMID: 40239119

All-Cause and Pneumococcal Community-Acquired Pneumonia Hospitalizations Among Adults in Tennessee and Georgia.

Grijalva CG, Johnson KD, Resser JJ, Whitney CG, Baughman A, Kio M, Traenkner J, Johnson J, Miller KF, Rostad CA, Salazar LW, Tanios R, Smith VE, Cornelison SA, Zhu Y, Han JH, Yildirim I, Weiss T, Roberts CS,

Rouphael N, Self WH; PNEUMO Investigators.JAMA Netw Open. 2025 Aug 1;8(8):e2524783. doi: 10.1001/jamanetworkopen.2025.24783.PMID: 40768150

Development of selective culture media for efficient isolation of *Avibacterium paragallinarum* from chickens.

Srednik ME, Shelkamy MMS, Hashish A, R De Macedo N, Sato Y, El-Gazzar MM, Sahin O, Zhang Q.J Clin Microbiol. 2025 Aug 13;63(8):e0031125. doi: 10.1128/jcm.00311-25. Epub 2025 Jul 18.PMID: 40679850

African swine fever virus MGF505-3R facilitates ferroptosis to restrict TBK1-IRF3 pathway.

Niu S, Zhou Y, Fang C, Yang Y, Wang J, Gao S, Dai H.Microbiol Spectr. 2025 Aug 5;13(8):e0342324. doi: 10.1128/spectrum.03423-24. Epub 2025 Jun 23.PMID: 40548711

Efficacy of alternative vs. standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: A systematic review and meta-analysis.

Mohammadi I, Rajai Firouzabadi S, Aghajanian S, Aarabi A, Mohammadifard F, Sadraei S, Alinejadfard M, Etemadifar M, Salari M.Mult Scler Relat Disord. 2025 Aug 8;103:106668. doi: 10.1016/j.msard.2025.106668. Online ahead of print.PMID: 40819407

Long-term impact of oral cladribine on humoral immunity in multiple sclerosis.

Messner M, Unterhofer M, Strauss J, Mink S, Cadamuro J, Oberkofler H, Hitzl W, Wipfler P, Trinka E, Moser T.Ther Adv Neurol Disord. 2025 Aug 4;18:17562864251357275. doi: 10.1177/17562864251357275. eCollection 2025.PMID: 40766204

Identification of relevant analytical methods for adeno-associated virus stability assessment during formulation development.

Rodenstein C, Schmid E, Markova N, Seidl A.Microbiol Spectr. 2025 Aug 5;13(8):e0180624. doi: 10.1128/spectrum.01806-24. Epub 2025 Jun 30.PMID: 40586573

Unmet Need for Human Papillomavirus Vaccination Among Men Who Have Sex With Men Living With and Without Human Immunodeficiency Virus, San Francisco, 2023.

Ramirez PL, Moscatelli AAM, Suprasert B, Tate M, Wilson EC, McFarland W.Sex Transm Dis. 2025 Aug 1;52(8):482-487. doi: 10.1097/OLQ.0000000000002177. Epub 2025 Apr 24.PMID: 40273461

Emergency Department Survey of Vaccination Knowledge, Vaccination Coverage, and Willingness to Receive Vaccines in an Emergency Department Among Underserved Populations - Eight U.S. Cities, April-December, 2024.

Rodriguez RM, Torres JR, Chinnock B, Kean E, Rising KL, Conn C, Gottlieb M, Sekar S, Gomez P, Olivera L, Eucker SA, DiFulvio S, Alvarez C, Molina MF, Ge S, Kumar VA.MMWR Morb Mortal Wkly Rep. 2025 Aug 7;74(29):456-462. doi: 10.15585/mmwr.mm7429a1.PMID: 40773379

Dietary grape pomace ameliorates intestinal damage and oxidative stress by modulating MAPK-Nrf2/ARE pathways in coccidia-challenged broilers (Gallus gallus).

Sharma MK, Dugan EM, Huang MY, Jackson C, Pataki MJ, Gracey PR, McGovern CJ, Tako E.Poult Sci. 2025 Aug;104(8):105364. doi: 10.1016/j.psj.2025.105364. Epub 2025 May 28.PMID: 40451073

SARS-CoV-2 infection heightens the risk of developing HPV-related carcinoma in situ and cancer.

Shih YH, Yang CY, Lung CC.Discov Oncol. 2025 Aug 14;16(1):1552. doi: 10.1007/s12672-025-03403-4.PMID: 40813533

Comparison of two continuous cell lines BHK-21 and IB-IS2 for isolating field serotypes O and A of Foot-and-Mouth disease virus.

Khoshnood S, Azimi SM, Kafi ZZ, Najafi H, Langeroudi AG.Virus Genes. 2025 Aug;61(4):498-504. doi: 10.1007/s11262-025-02166-y. Epub 2025 Jun 13.PMID: 40512422

Genetic diversity analysis of IVM resistant Haemonchus contortus in sheep in inner Mongolia of China.

Zhang Y, Wen H, Zhang H, Liu H, Zhang L, Lu J, Luo C, Chen M, Wu W, Wang W, Wang Y, Liu C.Sci Rep. 2025 Aug 11;15(1):29344. doi: 10.1038/s41598-025-14909-w.PMID: 40790080

Hybrid and vaccination immunity against severe COVID-19 in the post-pandemic era-a retrospective cohort study.

Livne I, Ziv A, Goldberg Y, Huppert A.Clin Microbiol Infect. 2025 Aug;31(8):1371-1377. doi: 10.1016/j.cmi.2025.05.002. Epub 2025 May 9.PMID: 40349967

COVID-19 vaccination status and factors associated with deaths from the disease, Vitória, 2020-2023: cross-sectional study.

Comerio T, Cola JP, Mascarello KC, Sales CMM, Freire BS, Vasconcelos ADS, Souza MC, Maciel ELN.Epidemiol Serv Saude. 2025 Aug 8;34:e20240700. doi: 10.1590/S2237-96222025v34e20240700.en. eCollection 2025.PMID: 40802385

Hepatitis A and E Virus Seroprevalence and Water, Sanitation and Hygiene Levels in Rural Areas of Khammouane Province, Lao People's Democratic Republic: A Cross-Sectional Study.

Khounvisith V, Odermatt P, Virachith S, Innoula N, Vongphachanh B, Khenkha L, Hattendoft J, Hübschen JM, Black AP.J Med Virol. 2025 Aug;97(8):e70524. doi: 10.1002/jmv.70524.PMID: 40735963

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.

Rumyantsev A, Wang L, Wang S, Kemp T, Wriggins A, Burks A, Fisher D, Brokke K, Fix A, Hensley S, Lewis M, Zhu R, Wang K, Shasha C, Piccini G, Manenti A, Montomoli E, DeAntonio R, Saez-Llorens X, Chan M, Alberto E, Lallaine Borra MD, Jaen AM, Heppner G, Palm U, Monath TP.EClinicalMedicine. 2025 Jul 21;86:103349. doi: 10.1016/j.eclinm.2025.103349. eCollection 2025 Aug.PMID: 40727012

Long-Term Effects of COVID-19 on Cardiopulmonary Health, Muscle Strength, and Quality of Life: A Comparative Study.

Tavakoli M, Abbasi L, Rojhani-Shirazi Z, Ahmadi E.Respir Med. 2025 Aug 14:108302. doi: 10.1016/j.rmed.2025.108302. Online ahead of print.PMID: 40818761

Utilizing simulation in community health nursing education: a scoping review of current trends and applications.

Kindi ZA, Jabri WA, Zadjali MA, Muliira J.BMC Nurs. 2025 Aug 12;24(1):1055. doi: 10.1186/s12912-025-03718-1.PMID: 40796842

How did health service utilization and delivery change during the COVID-19 pandemic? Frontline healthcare workers' perceptions from the Central African Republic, the Democratic Republic of Congo, and Bangladesh.

Altare C, Bates M, Crockett H, Gankpe GF, Hasan MA, Basadia LM, Agbogan JA, Petry M, Abaradine AAA, Tonon B, Bruneau S, Antoine C, Spiegel P.BMC Health Serv Res. 2025 Aug 8;25(1):1046. doi: 10.1186/s12913-025-13255-x.PMID: 40781305

Multicentre, prospective, single-arm, non-controlled, open-label trial to evaluate the safety and efficacy of live attenuated influenza vaccine in paediatric patients with atopic dermatitis undergoing dupilumab therapy: a protocol.

Kobayashi T, Sato H, Nagasawa K, Hayata E, Tanaka S, Kurihara E, Yamamoto T, Nakano T, Ozawa Y, Yamaide F, Inoue Y, Suzuki S, Arima T, Tomiita M, Hamada H, Ishiwada N.BMJ Open. 2025 Aug 3;15(8):e101050. doi: 10.1136/bmjopen-2025-101050.PMID: 40754333

The Cleveland Clinic Post-ICU Recovery Clinic: Early Experience During the COVID-19 Pandemic.

Kommaraju K, Torbic H, Veith J, Wang X, Biehl M.J Intensive Care Med. 2025 Aug;40(8):893-901. doi: 10.1177/08850666251326551. Epub 2025 Mar 23.PMID: 40123228

Assessment of face mask use in peripartum women during the COVID-19 pandemic: an observational study.

Adusei S, Adams T, Stewart C.BMC Pregnancy Childbirth. 2025 Aug 1;25(1):804. doi: 10.1186/s12884-025-07734-6.PMID: 40751182

Nanopore sequencing reveals the genomic diversity of the variants of concern of SARS-CoV-2 during 2021 disease outbreak in Pakistan.

Hassan ZU, Park M, Park D, Amin H, Ahmed I, Badar N, Ali A, Salman M, Umair M, Mirza HA, Ahad A, Muzaffar M, Fazal F, Bibi S, Islam M, Yousafzai YM, Shah S, Zakria M, Haq ZU, Kim S.Sci Rep. 2025 Aug 1;15(1):28129. doi: 10.1038/s41598-025-12774-1.PMID: 40750817

Hybrid B- and T-Cell Immunity Associates With Protection Against Breakthrough Infection After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Avon Longitudinal Study of Parents and Children (ALSPAC) Participants.

Baum HE, Santopaolo M, Francis O, Milodowski EJ, Entwistle K, Oliver E, Hitchings B, Diamond D, Thomas AC, Mitchell RE, Kibble M, Gupta K, Di Bartolo N, Klenerman P, Brown A, Morales-Aza B, Oliver J, Berger I, Toye AM, Finn A, Goenka A, Davidson AD, Ring S, Molloy L, Lewcock M, Northstone K, Roth F, Timpson NJ, Wooldridge L, Halliday A, Rivino L.J Infect Dis. 2025 Aug 14;232(2):e327-e340. doi: 10.1093/infdis/jiaf246.PMID: 40392230

Memory T cell reactivity to a broad range of conserved SARS-CoV-2-derived ORF1ab epitopes in first wave COVID-19 convalescents.

Ahsan F, Rahmawati NY, Dachlan EG, Alditia FN, Santoso B.Vaccine. 2025 Aug 5;62:127571. doi: 10.1016/j.vaccine.2025.127571. Online ahead of print.PMID: 40768846

Differences in COVID-19 XBB.1.5 vaccination coverage: A decomposition analysis across racial and ethnic groups in a large U.S. healthcare system.

Xu S, Sy LS, Contreras R, Powers DA, Qian L, Hong V, Lewin B, Holmquist KJ, Han B, Bruxvoort KJ.Vaccine. 2025 Aug 5;62:127577. doi: 10.1016/j.vaccine.2025.127577. Online ahead of print.PMID: 40768844

Distinct features of humoral and cellular immunity against Omicron breakthrough infection among chronic liver disease patients: An experience from a follow-up cohort.

Liu Y, Shi Y, Zhan H, Wang Y, Yuan W, Xie Y, Cheng L, Guo X, Li X, Kang H, Li H, Chen Y, Sun X, Gao H, Feng F, Dai E, Li Y.Hum Vaccin Immunother. 2025 Dec;21(1):2544466. doi: 10.1080/21645515.2025.2544466. Epub 2025 Aug 15.PMID: 40814801

Isolation and characterization of avian metapneumovirus subtypes A and B associated with the 2024 disease outbreaks among poultry in the USA.

Zhang J, Tian L, Dittman J, Guo B, Kimpston-Burkgren K, Kalkwarf E, Gadu E, Gauger P, El-Gazzar M, Sato Y.J Clin Microbiol. 2025 Aug 13;63(8):e0033325. doi: 10.1128/jcm.00333-25. Epub 2025 Jul 10.PMID: 40637399

Video and Infographic Messages From Primary Care Physicians and Influenza Vaccination Rates: A Randomized Clinical Trial.

Szilagyi PG, Clark EJ, Duru OK, Casillas A, Ong MK, Vangala S, Tseng CH, Albertin C, Humiston SG, Ross MK, Evans S, Kumar A, Chakarian I, Sloyan M, Fox CR, Rand CM, Lerner C.JAMA Netw Open. 2025 Aug 1;8(8):e2526514. doi: 10.1001/jamanetworkopen.2025.26514.PMID: 40802184

Decoding the transcriptome from bulk RNA of infection-naïve versus imprinted patients with SARS-CoV-2 Omicron B.1.1.529.

Sonnleitner ST, Walder S, Hinterbichler E, Knabl L, Poernbacher R, Walder G.Microbiol Spectr. 2025 Aug 5;13(8):e0291424. doi: 10.1128/spectrum.02914-24. Epub 2025 Jul 9.PMID: 40631743

T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.

Mueller AL, Lamcaj S, Garforth S, Hiner C, Woodley D, Paraiso K, Mi T, Low S, Youngblood B, Almo SC, Goldstein H.J Virol. 2025 Aug 5:e0018825. doi: 10.1128/jvi.00188-25. Online ahead of print.PMID: 40762498

PEX7-Related Rhizomelic Chondrodysplasia Punctata.

Braverman NE, Carroll R, Fallatah W, Jain M.2001 Nov 16 [updated 2025 Aug 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.PMID: 20301447

Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022-23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study.

Nguyen-Tran H, Park SW, Vogt MR, Permaul P, Spaulding AB, Hernandez ML, Bohl JA, Godbole S, Ruckwardt TJ, Krug PW, Moss DL, Derrien-Colemyn A, Chowdhury A, Dziubla G, Wang L, Castro M, Narpala SR, Longtine ER, Henry AR, Ngo TB, Dzantiev L, Sigal GB, Metcalf CJ, Kimberlin DW, Dominguez SR, Mittelman A, McDermott AB, Serebryannyy LA, Grenfell B, Messacar K, Douek DC.Lancet Infect Dis. 2025 Aug 6:S1473-3099(25)00349-4. doi: 10.1016/S1473-3099(25)00349-4. Online ahead of print.PMID: 40782819

Live zoster vaccination and cardiovascular outcomes: a nationwide, South Korean study.

Lee S, Lee K, Oh J, Kim HJ, Son Y, Kim S, Park J, Kang J, Pizzol D, Lee J, Woo HG, Lee H, Yon DK.Eur Heart J. 2025 Aug 8;46(30):2991-3002. doi: 10.1093/eurheartj/ehaf230.PMID: 40324473

Trained ILCs confer adaptive immunity-independent protection against influenza.

Mboko WP, Wang Y, Cao W, Sayedahmed EE, Mishina M, Kumar A, Bohannon CD, Patton SK, Ray SD, Sharma SD, Kumari R, Liepkalns JS, Reber AJ, Kamal RP, McCoy J, Amoah S, Ranjan P, Burroughs M, Sheth M, Lee J, Batra D, Gangappa S, York IA, Knight PR, Pohl J, Mittal SK, Sambhara S.J Virol. 2025 Aug 4:e0053225. doi: 10.1128/jvi.00532-25. Online ahead of print.PMID: 40757858

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([01.08.2025 TO 17.08.2025]) *as the publication date 52 records.*

1.WO/2025/169951METHOD FOR DETERMINING VACCINE-INDUCED IMMUNE RESPONSE

WO - 14.08.2025

Clasificación Internacional C12Q 1/6827Nº de solicitud PCT/JP2025/003724Solicitante KEIO UNIVERSITYInventor/a NAMKOONG, Ho

The purpose of the present invention is to provide a new marker that indicates the relevance between a vaccine and the immunity of a subject inoculated with the vaccine. More specifically, the purpose of the present invention is to provide, for example, a method for determining the waning of vaccine effect using a new marker correlated with a tendency of vaccine effect to wane. The problem is solved by providing a method for determining the waning of vaccine effect, the method comprising a step for detecting a mutation in an immunoglobulin heavy-chain region in DNA contained in a sample from a subject, wherein, when the mutation is detected in the immunoglobulin heavy-chain region, the vaccine effect in the subject is determined to have a high tendency to wane.

2.WO/2025/166964METHOD FOR REDUCING OR ELIMINATING ALLOGRAFT REJECTION BY USING THYMUS VACCINE

WO - 14.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CN2024/099608Solicitante TONGJI UNIVERSITYInventor/a ZHANG, Xiaoqing

Provided is a method for reducing or eliminating allograft rejection by using a thymus vaccine. The method comprises the following steps: expressing major histocompatibility complex (MHC) from a donor and/or grafting a thymus epithelial cell from a donor in the thymus tissue of a recipient by means of the thymus vaccine. The thymus vaccine includes a thymic gene vaccine and/or a thymocyte vaccine. The thymic gene vaccine is used for expressing an MHC antigen from the donor in the thymus of the recipient, and comprises: (1) a gene expression vector; and (2) polynucleotides separately encoding MHC class I molecules and MHC class II molecules of the donor. The thymocyte vaccine is prepared by the following steps: sorting by using an anti-Epcam antibody to give thymus epithelial cells. By establishing a convenient donor source, the limitations of allograft caused by MHC mismatch are overcome, thus helping solve the clinical problem of limited donor sources.

3.WO/2025/162490PREPARATION OF NEW MRNA VACCINE, AND USE THEREOF IN PHARMACEUTICAL COMBINATION FOR TREATING HEPATITIS B VIRUS DISEASE

WO - 07.08.2025

Clasificación Internacional A61K 39/29Nº de solicitud PCT/CN2025/075833Solicitante JIANGSU CELL TECH MEDICAL RESEARCH INSTITUTE CO., LTD.Inventor/a YANG, Meijia

Provided in the present invention are a preparation of a new mRNA vaccine, and the use thereof in a pharmaceutical combination for treating the hepatitis B virus disease. Specifically, provided in the present invention is a therapeutic mRNA vaccine against chronic hepatitis B infection, which vaccine contains an mRNA encoding a large protein (L protein) region of a hepatitis B virus surface antigen, and also contains two mRNAs respectively encoding a middle protein (M protein) region of the hepatitis B virus surface antigen and encoding a small protein (S protein) region thereof, or contains an mRNA encoding the small protein (S protein) region. The therapeutic mRNA vaccine of the present invention can break the immune tolerance state in chronic hepatitis B infection, and has the potential to functionally cure chronic hepatitis B infection clinically.

4.4598953AUF DC ABZIELENDER IMPFSTOFF GEGEN NIPAH-VIRUSINFEKTION

EP - 13.08.2025

Clasificación Internacional C07K 16/28Nº de solicitud 23783875Solicitante INST NAT SANTE RECH MEDInventor/a LEVY YVES

Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus. The inventors now designed an anti-CD40 mAb associated either with the Niv G ectodomain protein (Generation-1 vaccine), or the Niv G ectodomain protein and down-selected epitopes from the Niv F and N proteins (Generation-2 vaccine). Quality controls were performed on vaccine batches. The immunogenicity of both vaccines has been tested in hCD40Tg mice. A dose- dependent IFNg T cell response to the antigen was observed. Three weeks post-boost, specific IgG were detectable in groups immunized with 10ug of vaccine. B cell responses were markedly improved 1 week post-boost. All samples at week -4 showed a neutralization with an average titer at 1:500. The inventors also demonstrated the potency of an innovative DC- targeting vaccine candidate to prevent NiV-B infection in challenge experiments in an AGM model. Responses were showed to cross-neutralize multiple strains of NiV, but also HeV. Targeting Nipah virus antigens to professional APCs can be efficiently used as a prophylactic means against a Nipah virus challenge at a lethal dose. Accordingly, the present invention relates to antibodies that are directed against a surface antigen of an antigen presenting

cell wherein the heavy chain and/or the light chain is conjugated or fused to the Nipah virus antigenic polypeptides.

5.WO/2025/170389VACCINE COMPOSITION COMPRISING NOROVIRUS GII MRNA

WO - 14.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/KR2025/001935Solicitante K-BIOCELF INC.Inventor/a OH, Myung Ryurl

The present invention relates to a vaccine composition comprising mRNA encoding structural protein VP1 of a norovirus GI genotype. An mRNA vaccine composition was prepared by deriving a consensus sequence of norovirus GI genotype VP1 antigen, and the immunogenicity of the vaccine composition was confirmed. Therefore, the vaccine composition can be effectively used to prevent and treat norovirus infection.

6.20250249087CONSTRUCTION OF NOVEL HUMAN INFLUENZA VIRUS VACCINE AND APPLICATION

US - 07.08.2025

Clasificación Internacional A61K 39/145Nº de solicitud 19002606Solicitante Wuhan JinYiTai Biological Co., Ltd.Inventor/a Yeping TAN

The present disclosure discloses a method and an application of a human influenza virus vaccine The method and a non-replicating recombinant adenovirus named Ad-JYT-CMV-recHA promoter to control E1B19K or E1B19K-E1B55K fusion protein gene, and recombinant oncolytic adenoviruses named Ad-EE1A-hTERT-recHA and Ad-HTE1A-hTERT-recHA, respectively is constructed by optimizing a nucleotide sequence for influenza virus hemagglutinin HA, and thus the recHA gene is overexpressed in mammalian cells and the recHA is anchored on the cell surface and used for preventing influenza virus cold; human TERT promoter is used to control recHA gene, and a novel influenza recHA vaccine is introduced into an oncolytic adenovirus therapy as a tumor-heterologous artificial antigen for treating a tumor; furthermore, the recHA glycoprotein is anchored on the tumor cell surface as a tumor-specific artificial target, which is expected to combine with a CART-HA cell for treating a solid tumor.

7.4598943NEUE CHIMÄRE REKOMBINANTE IMPFSTOFFANTIGENE AUF MULTIPROTEINBASIS ZUR PRÄVENTION VON LYME-KRANKHEIT BEI TIEREN UND MENSCHEN

EP - 13.08.2025

Clasificación Internacional C07K 14/20Nº de solicitud 23875683Solicitante UNIV VIRGINIA COMMONWEALTHInventor/a MARCONI RICHARD T

A vaccine formulation for humans or other mammals (including dogs, horses, and cats) is provided. The vaccine formulation includes two chimeric proteins designed to elicit antibodies that bind to several targets on the surface of Lyme disease spirochetes during their residence in ticks and in mammals, and act synergistically to kill the bacteria through both antibody-mediated complement dependent and complement-independent mechanisms.

8.WO/2025/166642HIGH-BIOACTIVITY PLASMID DNA, PREPARATION AND STORAGE THEREOF, VACCINE, KIT AND USE THEREOF

WO - 14.08.2025

Clasificación Internacional C12N 15/10Nº de solicitud PCT/CN2024/076716Solicitante CAPITAL MEDICAL UNIVERSITYInventor/a SUN, Wenzhi

The present invention relates to the field of biomedicine. Particularly provided are a high-bioactivity plasmid DNA, preparation and storage thereof, a vaccine, a kit, and a use thereof. The preparation method for the high-bioactivity plasmid DNA comprises: lysing bacterial cells after expansion culture and collecting a supernatant to obtain a crude solution containing a plasmid; purifying the crude solution by means of two-step liquid chromatography to obtain a purified plasmid DNA; precipitating the purified plasmid DNA by means of an alcohol and/or a polyol to concentrate and activate the plasmid DNA; and storing the plasmid DNA as a precipitate. The provided preparation method meets medical-grade standards, shortens the plasmid DNA purification time and reduces the material cost, improves the plasmid DNA yield and activity, and facilitates long-term storage. In addition, the plasmid DNA has higher in-vivo transfection efficiency and expression stability, thereby facilitating efficient introduction of a target gene into an organism. Thus, the plasmid DNA obtained by means of the method is suitable for use as an active component of a gene therapy drug or a DNA vaccine.

9.WO/2025/168744A VACCINE FOR PROTECTING A SWINE AGAINST AFRICAN SWINE FEVER

WO - 14.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/053180Solicitante INTERVET INTERNATIONAL B.V.Inventor/a VAN DEN BORN, Erwin

The invention pertains to a live attenuated African swine fever virus Georgia 2007 (ASFV-G) Δ9GL/ΔUK/ΔEP153R strain for use in a vaccine for protecting a swine against an infection with African swine fever virus (ASFV) by administering the vaccine comprising the live attenuated ASFV-G-Δ9GL/ΔUK/ΔEP153R strain to the swine.

10.4598588SUPERANTIGENIMPFSTOFFKONJUGAT ZUR BEHANDLUNG VON KREBS

EP - 13.08.2025

Clasificación Internacional A61K 47/68Nº de solicitud 23875747Solicitante MUSC FOUND FOR RES DEVInventor/a DOLLOFF NATHAN G

The present disclosure provides compositions comprising vaccine conjugates with a SMEZ-2 carrier. Further provided are methods for treating cancer comprising administering the vaccine conjugates provided herein.

11.20250255951VACCINES AGAINST CHLAMYDIA SP.

US - 14.08.2025

Clasificación Internacional A61K 39/118Nº de solicitud 19197254Solicitante STATENS SERUM INSTITUTInventor/a Frank Follmann

The present invention describes an efficient vaccine against a *Chlamydia trachomatis* (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

12.WO/2025/171182TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CANCER VACCINE

WO - 14.08.2025

Clasificación Internacional A61K 40/11Nº de solicitud PCT/US2025/014867Solicitante IOVANCE BIOTHERAPEUTICS, INC.Inventor/a NATARAJAN, Arvind

Provided are methods for treating cancer in a patient in need thereof with TILs in combination with a cancer vaccine.

13.20250255949STREPTOCOCCUS SUIS VACCINE COMPOSITION COMPRISING IMMUNOGENIC FUSION POLYPEPTIDES

US - 14.08.2025

Clasificación Internacional A61K 39/09Nº de solicitud 18857553Solicitante Intervacc ABInventor/a Sara Frosth

The present disclosure relates to immunogenic fusion polypeptides, immunogenic compositions and vaccine compositions comprising said fusion polypeptides and use thereof for immunization of mammals susceptible to *Streptococcus suis* infection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.

14.4593877IMPFSTOFFKONSTRUKT UND VERWENDUNGEN DAVON

EP - 06.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23801865Solicitante CEVA HAMPTON LTDInventor/a THOMPSON IAN

The present disclosure relates generally to vaccine constructs comprising a polynucleotide encoding a salmon alphavirus-like particle and uses thereof, including for inducing an immune response against salmonid alphavirus.

15.20250259721DIGITAL VACCINE SYSTEM, METHOD AND DEVICE

US - 14.08.2025

Clasificación Internacional G16H 10/60Nº de solicitud 19193575Solicitante VYDIANT, INCInventor/a James Kaput

A digital vaccine system, method and device that maintains a health knowledge base, inputs user characteristics, generates health scores based on the user characteristics and provides pathogen risk recommendations based on the user characteristics, health scores and knowledge base, wherein the recommendations are indicated by the knowledge base to be likely to improve the user's health.

16.20250255957VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT

US - 14.08.2025

Clasificación Internacional A61K 39/39Nº de solicitud 19184899Solicitante The Trustees of the University of PennsylvaniaInventor/a David B. Weiner

Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

17.WO/2025/166439ANTIGENIC PEPTIDE, IMMUNOGENIC COMPOSITION AGAINST SCHISTOSOMIASIS CONTAINING THE PEPTIDE, AND USES

WO - 14.08.2025

Clasificación Internacional C12P 21/00Nº de solicitud PCT/BR2025/050048Solicitante INSTITUTO BUTANTANInventor/a VERJOVSKI-ALMEIDA, Sergio

The present invention relates to a new vaccine candidate against schistosomiasis. This vaccine candidate is composed of peptides from different proteins of the parasite *Schistosoma mansoni*. Additionally, the present invention relates to use of the peptides for preparing a medicament for the prevention and/or treatment of schistosomiasis and to a method for preventing and/or treating schistosomiasis.

18.20250255944IMMUNOACTIVATOR, VACCINE ADJUVANT, AND METHOD FOR INDUCING IMMUNITY

US - 14.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18844599Solicitante TEIKYO UNIVERSITYInventor/a Ryo SUZUKI

Disclosed is an immunoactivator that is capable of enhancing induction of both humoral immunity and cellular immunity and contains an active ingredient derived from cell walls (derived from a natural product); a vaccine adjuvant; and a method for inducing immunity including administering the immunoactivator. Theimmunoactivator contains, as an active ingredient, particles having a maximum diameter within a range of 1 to 800 nm, wherein the particles comprise cell-wall-derived polysaccharides.

19.WO/2025/161943LIPID COMPOUND AND LIPID NANOPARTICLE FOR DELIVERY

WO - 07.08.2025

Clasificación Internacional C07C 229/16Nº de solicitud PCT/CN2025/072219Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor/a DONG, Yijie

Disclosed in the present application are a compound having a structural formula as shown in formula (I), and a pharmaceutically acceptable salt thereof or a stereoisomer thereof. Further disclosed in the present application is a nanoparticle composition containing the compound or the pharmaceutically acceptable salt thereof or the stereoisomer thereof. The nanoparticle of the present application can efficiently deliver a drug and a vaccine into a cell, thereby exerting the therapeutic or prophylactic purpose of the drug and the vaccine.

20.WO/2025/170904INJECTABLE VACCINES AGAINST CANINE RESPIRATORY DISEASES

WO - 14.08.2025

Clasificación Internacional A61K 39/02Nº de solicitud PCT/US2025/014445Solicitante ZOETIS SERVICES LLCInventor/a KLINK, Holly Annette

Provided is an injectable vaccine comprising: a heat treated purified whole cell extract of *B bronchiseptica*, wherein this extract has been heated for 10 to 60 minutes at 45°C to 65°C; and p68 pertactin protein. Methods of making and methods of using the vaccine are also provided.

21.WO/2025/168804A VACCINE FOR PROTECTING A PREGNANT SWINE AGAINST AFRICAN SWINE

WO - 14.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/EP2025/053301Solicitante INTERVET INTERNATIONAL B.V.Inventor/a VAN DEN BORN, Erwin

The present invention pertains to the use of a live attenuated African swine fever virus Georgia 2007-Δ9GL/ΔUK/ΔEP153R (ASFV-G-Δ9GL/ΔUK/ΔEP153R) strain for protecting a pregnant swine against an infection with African swine fever virus (ASFV) by administering a vaccine comprising the live attenuated ASFV-G-Δ9GL/ΔUK/ΔEP153R strain to the pregnant swine.

22.20250255952SELF-AMPLIFYING MRNA VACCINE BASED ON Z7 GENOME

US - 14.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 19050556Solicitante Fengwei BaiInventor/a Fengwei Bai

The present invention relates to a self-amplifying mRNA vaccine, including: a self-amplifying backbone comprising a live attenuated virus having a hairpin loop insert, and wherein at least one or more structural genes of the live attenuated virus have been replaced with at least one target antigen-encoding nucleic acid sequence.

23.WO/2025/171256COMPOSITIONS AND METHODS FOR TREATING MALARIA

WO - 14.08.2025

Clasificación Internacional C07K 16/20Nº de solicitud PCT/US2025/015008Solicitante CASE WESTERN RESERVE UNIVERSITYInventor/a KING, Christopher L.

An anti-PvAMA1 antibody, antibody fragment, antigen binding fragment thereof or vaccine for use in treating and/or preventing malaria as described herein.

24.4596712VERFAHREN ZUR IDENTIFIZIERUNG UND VERWENDUNG VON BIOMARKERN

EP - 06.08.2025

Clasificación Internacional C12Q 1/6806Nº de solicitud 24155636Solicitante WOBBLE GENOMICS LTDInventor/a KUO RICHARD IZEN

Methods for producing an RNA vaccine for a subject with a disease and producing a database of disease biomarkers are provided. Methods for discovering disease biomarkers and diagnosing disease are also provided. The present invention enables frequent monitoring of subjects and adjustment of treatment. The present invention also provides methods for preparing processed nucleic acid samples with a more uniform distribution of sequences, which can be more readily analysed. The methods may be combined to further improve the ability to produce RNA vaccines and discover disease biomarkers.

25.WO/2025/165727METHODS AND COMPOSITIONS FOR PROMOTING ANTI-TUMOR IMMUNITY AND ENCHANCING THE IMMUNE FUNCTION

WO - 07.08.2025

Clasificación Internacional A61K 39/39Nº de solicitud PCT/US2025/013344Solicitante NEW YORK UNIVERSITYInventor/a PACOLD, Michael

Various methods and compositions for the activating or augmenting an immune response, and for augmenting an antibody production are presented herein. Also presented herein are methods of augmenting an immune response to a vaccine. Also presented herein are methods of preventing or delaying age-related decline in physical strength or exercise tolerance. Further presented herein are methods and compositions for improving wound healing. Yet further presented herein are methods for inhibiting growth of a tumor.

26.20250255954STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE

US - 14.08.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18856345Solicitante Yuanhan WuInventor/a Yuanhan Wu

Disclosed herein is a new method referred to as Conformational Shifting by Distance and Volume Analysis (CS-DVA) which can be employed to change the dynamics of multi-state glycoproteins for altered immune responses. Also disclosed are stabilized spike antigens and methods of use thereof for SARS-COV-2 vaccines.

27.WO/2025/163087METHODS OF IDENTIFYING AND USING BIOMARKERS

WO - 07.08.2025

Clasificación Internacional C12Q 1/6806Nº de solicitud PCT/EP2025/052431Solicitante WOBBLE GENOMICS LIMITEDInventor/a KUO, Richard Izen

Methods for producing an RNA vaccine for a subject with a disease and producing a database of disease biomarkers are provided. Methods for discovering disease biomarkers and diagnosing disease are also provided. The present invention enables frequent monitoring of subjects and adjustment of treatment. The present invention also provides methods for preparing processed nucleic acid samples with a more uniform distribution of sequences, which can be more readily analysed. The methods may be combined to further improve the ability to produce RNA vaccines and discover disease biomarkers.

28.4598571GEFLÜGELIMPFSTOFFE UND VERFAHREN ZUM SCHUTZ VON GEFLÜGEL

EP - 13.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23801214Solicitante ZOETIS SERVICES LLCInventor/a AOKI SERGIO MORAES

A method of protecting an offspring of a hen against infectious bronchitis infection is provided, the method comprising administering to said hen a vaccine comprising an inactivated infectious bronchitis virus and adjuvanted with water-in-oil emulsion and an immunostimulatory oligonucleotide.

29.4598578STABILISIERUNG EINES VIRUSBASIERTEN THERAPEUTISCHEN MITTELS

EP - 13.08.2025

Clasificación Internacional A61K 47/26Nº de solicitud 23874154Solicitante ELAREX INCInventor/a IWASHKIW JEREMY ANDREW

A virus-based active agent is mixed with trehalose and water and dried. The mixture may also contain one or more of pullulan and albumin. The mixture may be dried to a moisture content of 0.1-10%. The drying may be under vacuum sufficient to produce a foam. Some or all of the drying may be at a temperature in the range of 15-40oC, or at a temperature in the range of 1-15oC, or both. The active agent may be based on a vesicular stomatitis virus (VSV) or an adenovirus (AdV). The dried mixture may be stored at a temperature in the range of 1-55oC. A composition includes a virus, which may be a derived or modified form of a virus such as VSV or AdV. The composition also includes trehalose and optionally one or more of pullulan, and albumin. The composition may be used for a virus-based vaccine.

30.2637987METHOD OF DETERMINING VACCINATIONS AND/OR MEDICATION REQUIRED BY AN INDIVIDUAL

GB - 13.08.2025

Clasificación Internacional G16H 10/60Nº de solicitud 202401808Solicitante PERSONALISED DIAGNOSTICS LTDInventor/a CLIVE MINIHAN

Computer method 300 for determining vaccinations and / or medication required by an individual. Method 300 is based on obtaining indications of the individual's: risk 301; medical history 305 and what vaccinations and/or medication are available 307. Determining what vaccinations and / or medication the individual requires 309 is based on the obtained indications 301, 305, 307. Other embodiments include making this determination by obtaining a list of all diseases present in a region and filtering it based on the individual's travel plans. Alternatively, a list of all available medication and /or vaccines is obtained and filtered based on travel plans. Further embodiments include a method for adding a new disease to a database; methods for obtaining up-to-date information by periodically crawling travel advice websites to identify any change(s). In the event of change(s) an alert is provided for assessment by a clinician to determine whether a change in medication and /or vaccination are required. Alternatively, a machine learning model may be applied to determine the nature of the change(s) and whether a change in medication and /or vaccine is required.

31.WO/2025/163760ATTENUATED BACTERIAL STRAIN, LIVE ATTENUATED VACCINE, CONTROL METHOD, AND PRODUCTION METHOD

WO - 07.08.2025

Clasificación Internacional C12N 15/09Nº de solicitud PCT/JP2024/002908Solicitante THE NATIONAL RESEARCH AND DEVELOPMENT AGENCY, JAPAN FISHERIES RESEARCH AND EDUCATION AGENCYInventor/a MATSUURA Yuta

Provided by the present invention is an attenuated bacterial strain of Nocardia seriolae, in which there is a mutation in at least a part of the MtrA gene and the amino acid 179 Val is substituted by Gly in at least part of the amino acid sequence encoded by the MtrA gene.

32.WO/2025/165132RANKL MUTANT AND VACCINE COMPOSITION COMPRISING SAME

WO - 07.08.2025

Clasificación Internacional C07K 14/705Nº de solicitud PCT/KR2025/001531Solicitante ARKGEN BIOSCIONS CO.,LTD.Inventor/a LIM, Wonbong

An RANKL protein mutant according to the present invention can inhibit RANK activity through inhibition of the ability of RANKL to bind to both OPG and RANK, thereby suppressing differentiation into osteoclasts. Therefore, the RANKL protein mutant of the present invention can be effectively used for the prevention or treatment of bone metabolic diseases.

33.WO/2025/171082PREFUSION-STABILIZED HSV2 GB PROTEINS

WO - 14.08.2025

Clasificación Internacional C07K 14/035Nº de solicitud PCT/US2025/014710Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a MCLELLAN, Jason

Provided herein are engineered HSV2 gB polypeptides. In some aspects, the engineered gB polypeptides exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered gB polypeptides as diagnostics, in screening platforms, and/or in vaccine compositions.

34.20250255828LYOPHILIZED LIPID NANOPARTICLES AND METHODS OF THEIR USE

US - 14.08.2025

Clasificación Internacional A61K 9/51Nº de solicitud 19047781Solicitante Ultragenyx Pharmaceutical Inc.Inventor/a ISAIAS PRADO

The invention is directed to the field of therapeutic formulations, in particular to lyophilization of a therapeutic cargo molecule, such as RNA. The invention provides a method for lyophilization of a molecule. The present disclosure further describes a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine, a therapeutic and a kit or kit of parts. Moreover, the disclosure herein provides a novel lyophilization excipient that protects the composition from degrading when, for example, lyophilizing RNA. The use of the inventive method further includes the manufacture of a composition that can be used after lyophilization with equivalent therapeutic effect and composition integrity.

35.WO/2025/166067SARS-COV-2 VACCINE COMPOSITIONS AND METHODS

WO - 07.08.2025

Clasificación Internacional C07K 14/32Nº de solicitud PCT/US2025/013877Solicitante HELIX NANOTECHNOLOGIES, INC.Inventor/a RAJANIEMI, Hannu

Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of SARS-CoV-2; and (ii) a complement binding polypeptide. The disclosure also provides polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.

36.20250249086PROTEIN-SACCHARIDE CONJUGATION WITH SODIUM CYANOBOROHYDRIDE

US - 07.08.2025

Clasificación Internacional A61K 39/095Nº de solicitud 18854372Solicitante Sanofi Pasteur Inc.Inventor/a Maryalice Ginley

Methods and uses of conjugating saccharides to protein carriers are disclosed herein. Exemplary conjugates prepared according to those methods and uses are also disclosed. Additionally, methods for quantifying the amount of sodium borohydride in a sodium cyanoborohydride reagent are disclosed herein. Vaccine compositions as well as related methods and uses are also disclosed herein.

37.20250255946LOW-DOSE NEOANTIGEN VACCINE THERAPY

US - 14.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 18891398Solicitante Gritstone bio, Inc.Inventor/a Karin Jooss

Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccination strategy.

38.4600256IMPFSTOFF GEGEN DAS RESPIRATORISCHE SYNZYTIALVIRUS SOWIE HERSTELLUNGSVERFAHREN DAFÜR UND VERWENDUNG DAVON

EP - 13.08.2025

Clasificación Internacional C07K 14/135Nº de solicitud 24810137Solicitante LIVERNA THERAPEUTICS INCInventor/a LI JIANGLONG

The present disclosure relates to an immunological composition comprising or encoding a human respiratory syncytial virus antigen, and the immunological composition is selected from a nucleic acid immunological composition, a polypeptide immunological composition or a viral immunological composition.

39.20250250306IMMUNOGENIC PROTEINS AND NUCLEIC ACIDS ENCODING THE SAME

US - 07.08.2025

Clasificación Internacional C07K 14/005Nº de solicitud 19061222Solicitante International AIDS Vaccine Initiative, Inc.Inventor/a Jordan WILLIS

The invention relates to proteins and nucleic acids for immunization regimens, modifications thereof, and/or development of nanoparticles, and/or development of membrane-anchored immunogens, and methods of making and using the same. The invention also encompasses cell surface trimers that bind to the broadly neutralizing antibodies and/or nucleic acids encoding the same.

40.20250257141COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING A FAS AXIS ANTAGONIST AND A T-REG CELL DEPLETING AGENT ANTAGONIST

US - 14.08.2025

Clasificación Internacional C07K 16/28Nº de solicitud 18859717Solicitante Hoffmann-La Roche Inc.Inventor/a Maria Amann

The present disclosure is directed to the combination of a Fas axis antagonist, such as an anti-FasL antibody, and a Treg cell depletion therapy, for example an anti-CD25 antibody, optionally with a cancer vaccine, for use in the treatment of cancer.

41.WO/2025/162105HUMAN PAPILLOMA VIRUS (HPV) MRNA VACCINES AND USES THEREOF

WO - 07.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud PCT/CN2025/073829Solicitante RINUAGENE BIOTECHNOLOGY CO., LTD.Inventor/a DONG, Yijie

The invention provides a HPV mRNA lipid nanoparticle vaccine, comprising an open reading frame encoding a fusion protein of E2, E6 and E7 antigens of a high-risk HPV antigen. The invention also provides a method for treating and preventing HPV infection related diseases such as cervical cancer, cervical precancerous lesions, high-grade intraepithelial lesions of the cervix, high-grade squamous intraepithelial lesions (HSIL) or cervical intraepithelial neoplasia (CIN).

42.3034089VACCINE AGAINST PORCINE PARVOVIRUS

ES - 12.08.2025

Clasificación Internacional A61K 39/23Nº de solicitud 17801619Solicitante Boehringer Ingelheim Vetmedica GmbHInventor/a VAUGHN, Eric, Martin

43.20250257102PREFUSION-STABILIZED HMPV F PROTEINS

US - 14.08.2025

Clasificación Internacional C07K 14/08Nº de solicitud 19195969Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a Jason McLellan

Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

44.20250255840HIV TREATMENT COMPOSITIONS AND METHODS

US - 14.08.2025

Clasificación Internacional A61K 31/167Nº de solicitud 19175991Solicitante NantCell, Inc.Inventor/a Kayvan Niazi

HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

45.20250249088THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-COV-2

US - 07.08.2025

Clasificación Internacional A61K 39/215Nº de solicitud 18702303Solicitante GENEONE LIFE SCIENCE, INC.Inventor/a Kar MUTHUMANI

Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and/or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.

46.4598547VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON BLASENKREBS

EP - 13.08.2025

Clasificación Internacional A61K 35/13Nº de solicitud 23875792Solicitante UNIV JEFFERSONInventor/a ANDREWS DAVID

The present disclosure relates to compositions and methods for treating bladder cancer. In some embodiments the compositions and methods involve using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of bladder cancer, including metastatic breast cancer.

47.321533METHODS OF TREATING PANCREATIC CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE

IL - 01.08.2025

Clasificación Internacional A61K 39/00Nº de solicitud 321533Solicitante GENENTECH, INC.Inventor/a

48.20250255953RECOMBINANT INFLUENZA VIRUSES WITH STABILIZED HA FOR REPLICATION IN EGGS

US - 14.08.2025

Clasificación Internacional A61K 39/145Nº de solicitud 19067428Solicitante The University of TokyoInventor/a Yoshihiro Kawaoka

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation.

49.4593874VIRUSÄHNLICHE PARTIKEL MIT SARS-COV-2-ANTIGENEN ALS BOOSTER-IMPFSTOFFE UND VERWENDUNGEN DAVON

EP - 06.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 23769188Solicitante BAVARIAN NORDIC ASInventor/a RAMBICHLER STEPHAN

The present invention relates to the use of vaccines comprising virus-like particles displaying at least one SARS-CoV-2 antigen, such as the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, as vaccine boosters. Antigens are displayed on virus-like particles (VLPs) and produce an immune response in vaccinated subjects. The invention also relates to methods of treatment using the recombinant VLPs as boosters to treat and/or prevent infection with SARS-CoV-2, and methods of preparation thereof.

50.4599067KÜNSTLICHE POLYNUKLEOTIDE ZUR EXPRESSION VON PROTEINEN

EP - 13.08.2025

Clasificación Internacional C12N 15/67Nº de solicitud 23785796Solicitante CERTEST BIOTEC S LInventor/a BROSET BLASCO ESTHER

The present invention provides a polynucleotide comprising, in the 5' to 3' direction, a 5' untranslated region (5'-UTR) and an open reading frame (ORF), wherein the 5'-UTR comprises at least two tandem repeats of sequence 5'-GCCNCC-3' operatively linked to the ORF, and wherein N is any nucleotide. The invention also provides a composition comprising a lipid nanoparticle and the polynucleotide and a pharmaceutical composition, and their use in medicine, particularly for use as a vaccine or for use in gene therapy.

51.4599846NEUE PROMOTOREN

EP - 13.08.2025

Clasificación Internacional A61K 39/12Nº de solicitud 25168096Solicitante BOEHRINGER INGELHEIM VETMEDICA GMBHInventor/a MUNDT ALICE

The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

52.20250249090NEW FELINE HERPES VIRUS VACCINE

US - 07.08.2025

Clasificación Internacional A61K 39/245Nº de solicitud 18252590Solicitante Boehringer Ingelheim Vetmedica GmbHInventor/a Callie Ann Visek

The present invention relates i.a. to an EHV (Equine Herpesvirus) comprising a Feline Herpes Virus (FHV) Antigen encoding sequence inserted into ORF70 (US4) and/or ORF1/3. Furthermore, the present invention relates to methods for immunizing a feline comprising administering to such feline an immunogenic composition of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by Feline Herpes Virus in a feline.

Patentes registradas en United States Patent and Trademark Office (USPTO)

Estrategia de búqueda: *vaccine.ti. AND @PD>="20250801"<=20250817 18 records*

Document ID	Title	Inventor	Applicant Name
US 20250255951 A1	Vaccines against Chlamydia sp.	Follmann; Frank et al.	STATENS SERUM INSTITUT

US 20250255957 A1	VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANT	Weiner; David B. et al.	The Trustees of the University of Pennsylvania,Inovio Pharmaceuticals, Inc.
US 20250257101 A1	Filovirus Consensus Antigens, Nucleic Acid Constructs and Vaccines Made Therefrom, and Methods of Using Same	Weiner; David B. et al.	The Trustees of the University of Pennsylvania,THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY,Inovio Pharmaceuticals, Inc.
US 20250259721 A1	DIGITAL VACCINE SYSTEM, METHOD AND DEVICE	Kaput; James et al.	VYDIANT, INC
US 20250255949 A1	STREPTOCOCCUS SUIS VACCINE COMPOSITION COMPRISING IMMUNOGENIC FUSION POLYPEPTIDES	Frosth; Sara et al.	Intervacc AB
US 20250255946 A1	LOW-DOSE NEOANTIGEN VACCINE THERAPY	Jooss; Karin et al.	Gritstone bio, Inc.
US 20250255954 A1	STABILIZED SPIKE PROTEIN AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE	Wu; Yuanhan et al.	Wu; Yuanhan,Walker; Susanne,Kulp; Daniel,The Wistar Institute of Anatomy and Biology
US 20250255944 A1	IMMUNOACTIVATOR, VACCINE ADJUVANT, AND METHOD FOR INDUCING IMMUNITY	SUZUKI; Ryo et al.	TEIKYO UNIVERSITY
US 20250255948 A1	PNEUMOCOCCAL CONJUGATE VACCINES AND METHODS OF USE THEREOF	Buchwald; Ulrike K. et al.	Merck Sharp & Dohme LLC
US 20250255952 A1	SELF-AMPLIFYING mRNA VACCINE BASED ON Z7 GENOME	Bai; Fengwei et al.	Bai; Fengwei,Huang; Faqing
US 12383612 B2	Vaccine to protect a pig against Actinobacillus pleuropneumoniae	Witvliet; Maarten Hendrik et al.	Intervet Inc.

US 12383609 B2	Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to	Lanzavecchia; Antonio et al.	INSTITUTE FOR RESEARCH IN BIOMEDICINE,SEATTLE CHILDREN'S HOSPITAL,SCHWEIZERISCHES TROPEN—UND PUBLIC HEALTH-INSTITUT
US 12383610 B2	Vaccine for protection against Streptococcus suis serotype 9, sequence type 16	Jacobs; Antonius Arnoldus Christiaan	Intervet Inc.
US 12383616 B2	Recombinant herpes zoster vaccine composition and application thereof	Shi; Li et al.	IMMUNE-PATH BIOTECHNOLOGY (SUZHOU) CO., LTD.
US 20250249090 A1	NEW FELINE HERPES VIRUS VACCINE	Visek; Callie Ann et al.	Boehringer Ingelheim Vetmedica GmbH
US 20250249088 A1	THERAPEUTIC AND VACCINE CANDIDATES AGAINST SARS-CoV-2	MUTHUMANI; Kar	GENEONE LIFE SCIENCE, INC.
US 20250249087 A1	CONSTRUCTION OF NOVEL HUMAN INFLUENZA VIRUS VACCINE AND APPLICATION	TAN; Yeping et al.	Wuhan JinYiTai Biological Co., Ltd.
US 12377140 B2	Multivalent pneumococcal vaccines	Besin; Gilles R. et al.	Affinivax, Inc.

Edición: Annia Ramos Rodríguez *aramos@finlay.edu.cu*
Randelys Molina Castro *rmolina@finlay.edu.*
Claudia Camejo Salas *ccamejo@finlay.edu.cu*
Yamira Puig Fernández *yamipuig@finlay.edu.cu*

FINLAY EDICIONES